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Abstract 
The introduction of combination antiretroviral therapy (cART) into clinical practice for 
the treatment of HIV in 1995-1996 has led to dramatic reductions in mortality and 
morbidity.  Factors linked to a positive response to therapy include a potent and 
tolerable regimen, good adherence and low levels of HIV drug resistance.  The aims of 
this thesis were to investigate factors potentially associated with different responses to 
cART measured using virological and immunological predictive markers, and also to 
look at the development of toxicities to a specific regimen.  The analyses were based 
on data from the EuroSIDA study, which is an observational cohort of 14,310 HIV-1 
infected patients from Europe, Israel and Argentina.  Data collected includes 
demographic history, CD4 cell counts, viral loads and details of all drugs taken.   
EuroSIDA also collects viral sequence data for its resistance database. 
 
Investigation into virological response to first-line cART across geographical regions 
found evidence of variation, which was most apparent in early-cART years.  Virological 
response improved over calendar time in all regions, especially in East Europe.   
Neither HIV-1 subtype nor transmitted drug resistance (TDR) were found to be 
associated with virological response to cART, however statistical power was limited.  A 
significantly decreased risk of virological failure was found in patients starting efavirenz 
compared with nevirapine, which did not appear to be explained by baseline drug 
resistance.  Finally, incidence of abacavir discontinuation due to a hypersensitivity 
reaction side effect of the drug appeared to be higher in patients starting abacavir as 
part of first-line therapy but decreased in recent years.  
 
In conclusion, this thesis has compared a variety of different responses to antiretroviral 
therapy across subsets of a large heterogeneous population.  It is hoped that these 
findings will contribute to research in monitoring trends in response to therapy and 
provide insight into association with the genetic variability of the virus.  
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Chapter 1. Introduction 
1.1  Current worldwide statistics 
Human immunodeficiency virus (HIV) is the virus responsible for a worldwide 
pandemic.  It is the cause of the condition acquired immune deficiency syndrome 
(AIDS), which has killed more than 25 million people since the first diagnosis in 1981 
[1].  According to the latest statistics from the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) and the World Health Organisation (WHO) as of December 2007, 
33.2 million (range: 30.6-36.1 million) individuals worldwide are estimated to be living 
with HIV, of which 15.4 million (46%) are women and 2.5 million (8%) are children 
under the age of 15 years [2].  This total is over 10 million more than 10 years ago and 
has been rising steadily each year (Figure 1.1) [2].  In 2007 alone, there were 2.5 
million (range: 1.8-4.1 million) new infections of HIV and 2.1 million (range: 1.9-2.4 
million) deaths from AIDS worldwide [2]. 
 
Figure 1.1: Estimated number of people living with HIV globally, 1990-2007.   
 
 
 
 
Figure not available due to copyright restrictions. 
 
Source: UNAIDS/WHO. AIDS epidemic update December 2007 [2]. 
 
A global view of the prevalence of HIV infection in 2007 is illustrated in the AIDS 
epidemic update December 2007 (UNAIDS/WHO) below (Figure 1.2) [2].  This 
highlights the concentrated epidemic in Africa, particularly in Southern parts, but also 
the relatively high prevalence in Eastern Europe, compared to Western and Central 
Europe. 
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Figure 1.2: Adults and children estimated to be living with HIV, 2007.     
 
 
 
 
Figure not available due to copyright restrictions. 
 
Source: UNAIDS/WHO. AIDS epidemic update December 2007 [2]. 
 
The data analysed in this thesis are from the large observational study, EuroSIDA, 
which collects data from HIV infected patients across Europe and from a minority in 
Argentina and Israel.  UNAIDS/WHO report that in Western and Central Europe, in 
2007, there were an estimated 760,000 individuals living with HIV.  In Eastern Europe 
and Central Asia, where nearly 90% of HIV infections are in the Russian Federation 
and Ukraine, there were 1.6 million HIV infected individuals in 2007.  During this year, a 
total of 31,000 new infections and 12,000 deaths occurred in Western and Central 
Europe, and 150,000 new infections and 55,000 deaths occurred in Eastern Europe 
and Central Asia.  Eastern Europe has experienced one of the steepest increases in 
the number of people living with HIV over the past six years; this figure rose by over 
150% from 630,000 in 2001 to 1.6 million in 2007 [2].   
 
To understand how HIV has spread so rapidly worldwide, it is important to understand 
how the virus infects the human immune system and uses it to replicate. 
 
1.2 Immunology  and  virology 
1.2.1 The  immune  system 
Infection with HIV leads to the progressive breakdown of the immune system in 
humans [3,4].  The immune system protects the body from potentially harmful 
substances by activating an immune response.  Cells invading the body such as 
viruses and bacteria carry proteins called antigens that are recognised by white blood 
cells in the immune system.  The white blood cells act by either directly attacking the 
foreign cells or by helping other cells in the immune response to destroy them [5].  This 
response is co-ordinated by a certain type of white blood cell called a CD4+ “T-helper” 
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lymphocyte [6].  HIV infected (HIV positive) individuals experience a significant 
depletion of these CD4 cells, which means that the body is left without defence and is 
vulnerable to infection [7,8].  CD4 cells die naturally as a consequence of immune 
activation but in healthy individuals the body produces more to take their place.  How 
the vast depletion caused by HIV occurs is still unclear and could be caused directly or 
indirectly by the virus [7-9]. 
 
1.2.2 HIV  replication 
HIV infection is characterised by a very high turnover of virus, as many as one billion 
new virions produced per day (and over 10
 million newly infected host cells a day) [10].  
This occurs through the process of reverse transcription.  HIV is a human retrovirus, 
which is defined by its capability to produce an enzyme called reverse transcriptase, 
and this enzyme catalyses the transformation of the viral genetic material, single-
stranded RNA (ribonucleic acid), into double-stranded DNA (deoxyribonucleic acid) 
[11-13].  The virus contains two strands of RNA, which stores the genetic code for 
manufacturing viral proteins [14].   
 
RNA is made up of a string of chemical units called nucleotide bases, of which there 
are four types: adenine (A), uracil (U), cytosine (C) and guanine (G).  The specific 
position of a single base is referred to as a site [15].  There are approximately 9200 
bases in HIV RNA [16] and the order in which they appear defines the genetic 
sequence.  Much of the sequence has no function, however, certain triplets of bases 
(codons) encode for the production of one of 20 different amino acids, which are the 
building blocks of proteins [17].  An RNA gene comprises a section of RNA that 
encodes for one protein, for example the RT gene is responsible for the production of 
reverse transcriptase.  The complete set of genes is called the genome [15]. 
 
In a similar way, DNA, which is contained in every cell of every organism, stores the 
genetic code for manufacturing proteins to allow the organism to grow and function 
[15].  When an individual is infected with HIV, the virus invades human cells by fusing 
with the cell surface.  HIV RNA enters the human cell and the process of reverse 
transcription follows.  The resulting HIV DNA is then able to enter the central nucleus of 
the host cell [4,13,18,19].  A further viral enzyme called integrase [20] allows 
integration of the viral DNA with the host cell’s DNA [13,18] leading to the production of 
viral proteins including the enzyme protease, which is needed to convert other HIV 
proteins into functional forms.  Together the proteins form new HIVs (virions) that leave 
the cell, free to invade others [4,13,18,19].  This is the way in which the virus replicates 
itself and multiplies in the body.  Sometimes the host cell can remain in a resting state 
17 
during which time the cell is not producing any new virus or exhibiting signs of infection, 
i.e. it is latently infected.  Thus HIV is able to remain undetected by the immune system 
that would normally destroy it [9,13].   
 
1.2.3 Target  host  cells 
CD4 cells are the major (but not exclusive) targets for HIV as the virus carries a 
glycoprotein (gp120) that can bind with the CD4 receptors present on the surface of 
these cells [21,22] in the presence of a co-receptor, usually either CCR5 or CXCR4 
[23,24].  If the infected cells are active then viral replication is effective, however, the 
majority of CD4 cells in the body are in a resting state.  Studies have shown that 
reverse transcription can still occur in these cells [25,26].  This provides a lifelong 
reservoir of latently infected CD4 cells, which makes the virus impossible to eradicate 
completely by the anti-HIV (antiretroviral) drugs that are currently available [27,28].   
The HIV replication process is illustrated in Figure 1.3. 
 
Figure 1.3: Replication cycle of HIV.   
 
 
 
 
 
 
Figure not available due to copyright restrictions. 
 
Source: Weiss (2001) [19]. 
 
1.2.4  Monitoring HIV progression 
Quantitative measurements of the amount of circulating virus, i.e. how much of the 
virus is in the blood, as well as counts of CD4 cells, are the main predictive markers 
used to indicate the clinical progression of HIV infection [29-32].  The CD4 count is the 
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measurement of the number of CD4 cells detected in a cubic millimetre of blood 
(cells/mm
3).  A healthy HIV negative individual can be expected to have a CD4 count of 
between 540 and 1120 cells/mm
3 (mean: 830 cells/mm
3) [33], although this can vary 
depending on factors such as age, gender and smoking status [34,35].  In untreated 
HIV positive individuals the CD4 count gradually declines over a number of years at a 
rate of around 50-80 cells/mm
3 per year [36-39] and if the CD4 count drops below 500 
cells/mm
3 this indicates that the immune system is beginning to fail.  The risk of AIDS 
related illness greatly increases if the CD4 count drops below 200 cells/mm
3 and   
individuals are advised to start antiretroviral therapy (ART) and disease specific 
prophylaxis (preventative treatment) [40-42].   
 
Independent from this, another prognostic marker of HIV progression is the viral load, 
which refers to the amount of HIV genetic material (RNA) present in the blood plasma 
(the liquid part of the blood) and is measured in copies of RNA per millilitre (mL) 
[30,43,44].  The first assay used to measure this was the Amplicor HIV-1 Monitor Test 
approved by the United States Food and Drug Administration (US FDA) in 1996 
[45,46].  This was used in clinical practice and could quantify HIV RNA to as low as 
1000 copies/mL [47].  The most widely used ultra-sensitive viral load assays at present 
use one of three different methods to quantify HIV RNA in blood plasma, namely, 
reverse transcriptase-polymerase chain reaction (RT-PCR), nucleic acid sequence-
based amplification (NASBA) and the branched DNA (bDNA) signal amplification 
technique.  These have been found to give broadly consistent results and limits of 
detection are as low as 40 copies/mL [48,49].  
 
1.3 HIV  transmission 
HIV can be transmitted via blood, semen, cervical secretions and breast milk, which 
puts individuals engaging in unprotected sexual intercourse, injecting drug users and 
babies born to HIV positive mothers at risk.  Before 1985, when HIV testing became 
available, HIV was also transmitted via the donation of blood products, organs and 
tissue, which accounted for approximately 2% of AIDS cases in the USA [50,51].  This 
put individuals with haemophilia particularly at risk.  For example, in the UK, between 
1979 and 1985, 1227 of the 6278 haemophilic individuals (19.5%) were infected with 
HIV [52]. 
 
1.3.1 Sexual  transmission 
The most common mode of transmission worldwide is sexual intercourse [53,54], even 
though the probability of infection per contact is lower than that through other routes of 
exposure, as low as one in a thousand for female-to-male exposure [53,55].   
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Transmission susceptibility varies greatly according to a number of factors.  It is 
increased when the infected partner’s viral load is particularly high.  This occurs when 
the individuals are in the primary stage or the late stage of infection in the absence of 
ART [55-57].  The presence of other sexually transmitted diseases (STDs), especially 
local infections and ulcerations in the genital region, has also been found to be a strong 
predictor of transmission [53,57-59].  A review of the scientific data investigating the 
relationship between the presence of STDs in HIV infected individuals to the risk of HIV 
transmission found that STDs increased the risk by two to five times, but ranging up to 
as much as 23.5 times [58].  This review included studies looking at ulcerative and non-
ulcerative STDs, male-to-female, female-to-male and male-to-male transmission.   
Other factors associated with the risk of transmission (either positively or negatively) 
have been found to be genetic factors, ART, cervical ectopy (condition where cells 
extend beyond uterus into cervix), male circumcision, contraception and menstruation 
[54,55,59,60].  
 
1.3.1.1 Heterosexual transmission 
The per-contact risk of being infected with HIV through heterosexual intercourse with 
an HIV infected person has been estimated to be between 0.01% and 0.14% from 
studies of discordant couples (where one partner is infected with HIV and the other is 
not) in the USA and Europe [55,61-63].  For example, a ten-year study in northern 
California found that the per-contact risk of male-to-female transmission was 0.0009 
(95% confidence interval (CI): 0.0005-0.001) and that male-to-female transmission was 
eight times more efficient than female-to-male [63].     
 
1.3.1.2 Homosexual transmission 
Estimates for the per-contact risk of transmission through male-to-male intercourse 
have been found to vary greatly.  A study in the USA estimated the risk of anal 
transmission (with ejaculation) in men who have sex with men (MSM) during the 
asymptomatic phase of infection to be between 0.5% and 3.0% [64].  Another study 
found that during primary infection the risk was as high as 10-30% per contact [65].  
Risk through orogenital contact (oral sex) was estimated in a cohort study of MSM 
predicting a 0.04% chance of infection through receptive oral sex with ejaculation [66].  
This however included men whose HIV infection status was unknown.  Factors likely to 
be associated with an increased risk of HIV transmission through oral sex are oral 
trauma, sores, inflammation, allergy, concomitant sexually transmitted infections, 
ejaculation in the mouth and systemic immune suppression [67]. 
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1.3.2  Transmission via blood 
The most efficient mode of transmission is through the transfer of blood.  Intravenous 
drug users (IDUs) are particularly at risk if they regularly share or reuse needles and 
estimates of the risk of infection per injection with a contaminated syringe are between 
0.7% and 0.8% [68,69].  Health care workers who come into contact with HIV infected 
blood and body fluids are also at risk.  Transmission through needle stick injury has 
been estimated to be 0.3% per injury [70].   
  
1.3.3 Mother-to-child  transmission 
HIV can also be passed on from mother to child (vertical transmission) either in the 
womb, at birth or through breastfeeding.  The risk of transmission in the absence of any 
interventions has been estimated to be 15-25% in non-breastfeeding populations and 
25-40% in breastfeeding populations, depending on a number of risk factors [71].  A 
systematic review of five placebo-controlled trials showed that the use of the drug 
zidovudine as prophylactic antiretroviral treatment reduced the risk of transmission by 
43% [72].  In the same review, it was found that compared to a zidovudine regimen 
during labour and after delivery, nevirapine monotherapy given to mothers and babies 
as a single dose resulted in a 40% lower risk of transmission.  Current guidelines by 
the WHO recommend the use of combination antiretroviral therapy (cART) to help 
prevent vertical transmission [73], which is a potent and effective combination of drugs, 
detailed later in section 1.6.  However, a single dose of the drug nevirapine during and 
after delivery is advised as the absolute minimum in the absence of adequate 
resources to provide cART [74].   
 
If the mother does not breastfeed, takes prophylactic ART during pregnancy and opts 
for a caesarean section delivery, the risk may be reduced to less than 1% [75-77].  Risk 
of vertical transmission has been shown to increase with maternal viral load [78,79].  
The odds of vertical transmission, adjusted for significant covariates such as use of 
ART, were almost twice as high for mothers with a maternal viral load of 10,000-50,000 
copies/mL compared to 1000-10,000 copies/mL, and almost four times as high for 
those with a viral load of more than 50,000 copies/mL [78].   
 
A study investigating infection through breastfeeding estimated the risk to be 29% 
(95% CI: 16-42%) in mothers infected during or after delivery, and 14% (95% CI: 7-
22%) in mothers with established infection [80]. 
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1.3.4  Modes of transmission across Europe 
Epidemics of HIV have arisen in populations throughout Europe with changing trends in 
the routes of HIV transmission.  Figures from 2005 reported by the EuroHIV 
surveillance network showed that in the European Union, heterosexual contact 
accounted for 55% of all HIV transmissions, homo-/bisexual contact accounted for 34% 
and injecting drug use (IDU) for 10% [81].  These figures exclude Italy and Spain where 
surveillance data were not available.  Together with Portugal, these were previously 
sites of epidemics amongst IDUs, however recent data from certain regions of Italy and 
Spain show a decline in HIV in this exposure group and an increase in heterosexual 
contact as the major mode of transmission [81,82].  The predominant mode of 
transmission varies between countries within Europe, for example in Germany, Greece, 
Iceland and the Netherlands, the prevailing transmission group is homo-/bisexual men 
[82].  In Eastern Europe, the major exposure group is IDUs [81].  A major increase in 
IDU followed the collapse of the Soviet Union during the 1990s when Afghanistan was 
the world’s largest opium producer [83].  However this appears to have declined over 
the past few years, especially in the Russian Federation.  In 2001, the number of new 
diagnoses amongst IDUs reached a peak of over 55,000, whereas in 2005 it had 
decreased to less than 20,000 [81]. 
 
1.4 Stages  of  infection 
Although the course of HIV infection can vary widely between individuals, there are 
generally three main stages that occur in HIV positive individuals in the absence of 
antiretroviral treatment, characterised by virological and immunological events.  [3,84-
86].  These are described over the next few paragraphs.  A typical plasma viral load 
and CD4 count over the duration of infection are shown in an illustration in Figure 1.4.  
However, recent studies have found evidence that examination of viral load and CD4 
count from peripheral blood alone may be misleading to understanding the course of 
infection.  The major sites of HIV infection are in the gut and mucosal tissues where 
CD4 cells are selectively infected and destroyed within days [87,88].  This could have 
major implications for treatment strategies, as to preserve these intestinal CD4 cells, 
therapy needs to be started immediately after infection.  One study provided a historical 
comparison to compare viral load three years after HIV infection between individuals 
who did not start therapy and those who started cART in the first stage of HIV infection 
(primary HIV infection detailed below) [89].  Subjects in the CASCADE (Concerted 
Action on SeroConversion to AIDS and Death in Europe) study who had viral load 
measurements available before starting ART were compared to subjects from the 
Quest trial who received cART for an average of two and a half years.  The results 
showed that cART taken during primary HIV infection might increase the probability of 
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a low viral load after treatment discontinuation, but the difference appeared modest and 
could represent a delay of natural history of the virus rather than a long-term benefit of 
treatment. 
 
Figure 1.4: Typical course of HIV infection.  
 
 
 
 
 
Figure not available due to copyright restrictions. 
 
Source: Pantaleo (1993) [86]. 
 
1.4.1 Primary  HIV  infection 
The first stage of HIV infection is known as primary or acute HIV infection (PHI), lasting 
approximately two to twelve weeks.  During this time, the patient experiences a sharp 
rise in plasma viral load to as much as 10
7 copies/mL [90,91], before declining rapidly 
to a ‘set point’ [3,85].  This can differ greatly from person to person but in most people it 
is between 10
3 and 10
5 copies/mL [29,43,92].  At the same time, the CD4 count (in the 
blood) experiences an acute drop by as much as 50% [3,84-86].  This rises back 
towards normal levels (540-1120 cells/mm
3 [33]) within four to five months [3].   
 
During this immune response, antibodies are produced that help to fight the virus and it 
is the presence of these antibodies that is detected in tests used to determine whether 
or not an individual has HIV.  Antibody tests were traditionally carried out on blood 
samples but now saliva or urine samples may also be used [93].  The time when the 
body starts producing antibodies is called seroconversion, which follows the primary 
infection period.  Antibodies can be detected in a sample one to six months following 
seroconversion depending on the sensitivity of the test used [94,95]. 
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Individuals in the PHI stage are particularly infectious because of the initial high viral 
load [96].  Clinical symptoms have been estimated to emerge two to four weeks after 
exposure in 40-90% of individuals [97,98] and include fever, lethargy and malaise, 
anorexia, sore throat, myalgias (muscular pain), headaches, arthralgias (pain in the 
joints), weight loss, swollen glands, retro-orbital pain (behind the eye), dehydration, 
nausea, lymphadenopathy (abnormal enlargement of the lymph glands) and diarrhoea 
[98-100].  Findings indicate that those who develop illness in this early stage have a 
more rapid decline in CD4 count and may progress to AIDS more rapidly than those 
who do not show symptoms [101,102].      
 
1.4.2 Asymptomatic  HIV  infection 
The second stage is known as asymptomatic infection due to the general lack of 
clinical symptoms.  This can last a number of years but in the continued absence of 
ART, the median time to development of AIDS from initial HIV infection is ten to eleven 
years [3,84-86].  During this stage the CD4 count generally remains within a healthy 
range but slowly decreases over time, eventually reaching borderline dangerously low 
levels around 200-250 cells/mm
3 [3,84-86,103].  It is reported that over this period, the 
plasma viral load stays at a fairly steady level around the individual’s set point, mostly 
between 10
3 and 10
5 copies/mL [29,43,92,104].  However there is some evidence from 
observational studies that the plasma viral load may gradually increase over this 
period, as opposed to remaining stable [103,105,106].  Longitudinal studies have 
shown gradual increases of 0.08 log10copies/mL [105] and 0.11 log10copies/mL per 
year [103].  This supports an inverse relationship between the two variables.     
 
1.4.3  Symptomatic HIV infection 
If an HIV infected individual still does not receive ART, it is likely the individual will 
progress into the last stage of infection, the symptomatic phase.  Over potentially a 
period of some years, the CD4 count diminishes towards zero leaving the body with 
little immune defence, at the same time as the viral load gradually rises back up above 
the set point [85].  Early symptoms to appear include skin rashes, fatigue, weight loss, 
night sweats and oral candidiasis (thrush in the mouth) [107].  As the immune system 
breaks down, more severe opportunistic infections that would not be normally seen in 
patients with a preserved immune function start to occur.  In HIV positive individuals, 
the contraction of one of these diseases defines the condition known as AIDS, which 
ultimately results in the death of the individual [108].   
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1.4.4 AIDS  defining  illnesses 
AIDS is signified by the contraction of one or more of a list of AIDS defining illnesses 
(ADIs).  The Centers for Disease Control and Prevention (CDC) in the USA, with the 
support of the WHO, describe a staging system for HIV infection, which is based 
primarily on clinical criteria but also allows a subdivision of clinical stages to incorporate 
laboratory markers if available (total lymphocyte counts or CD4 counts) [109,110].  In 
Europe, this staging system has not been adopted but the list of AIDS defining 
illnesses, as defined by the CDC/WHO (Table 1.1), is used to diagnose patients with 
AIDS [111,112].  Factors associated with faster progression to AIDS include a high viral 
load set point at the end of the first stage [113,114] and older age at time of infection 
[115]. 
 
1.4.5  Prevention of opportunistic infections 
In 1995, the United States Public Health Service (USPHS) and the Infectious Diseases 
Society of America (IDSA) developed guidelines for the use of prophylaxis against 
opportunistic infections, including AIDS defining illnesses, defining thresholds of CD4 
counts below which people were recommended to start treatment [116].  Both primary 
prophylaxis (to prevent initial episodes) and secondary prophylaxis (to prevent 
subsequent episodes) for opportunistic infections such as Pneumocystis jiroveci 
pneumonia (PCP; formerly classified as Pneumocystis carinii), Mycobacterium avium 
complex (MAC) (affecting the lungs) and cytomegalovirus (a herpes virus) had already 
become standard of care at this time [117].  However the introduction in 1995-1996 of 
cART (detailed in section 1.6) reduced the incidence of opportunistic infections and 
lengthened survival time for patients considerably [118-121].  Updated guidelines 
therefore advised that it was safe to stop prophylaxis if cART led to an increase in CD4 
count to above the defined thresholds, which were based on randomised controlled trial 
and observational data [116,122].  For example, it was concluded that it was safe to 
discontinue primary and secondary PCP prophylaxis after the CD4 count had remained 
above 200 cells/mm
3 for at least three months [123,124].  For Mycobacterium avium 
complex disease, a threshold of at least 100 CD4 cells/mm
3 was set [125,126]. 
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Table 1.1: Definitive and presumptive diagnosis of AIDS defining illnesses. 
AIDS defining illness  Definitive, autopsy or 
presumptive 
Definitive diagnostic method or presumptive 
diagnostic criteria 
    
Definitive  Disabling cognitive and/or motor dysfunction, or 
milestone loss in a child, and no other causes by 
CSF exam and brain imaging or by autopsy. 
AIDS dementia complex 
Presumptive  Same as above but no CSF and brain imaging 
performed. 
 
Definitive  New X-ray evidence not present earlier and 
culture of pathogen that typically causes 
pneumonia (other than P. jiroveci or M. 
tuberculosis). 
Bacterial pneumonia, 
recurrent (> 2 episodes 
within 1 year) 
Presumptive  Acute radiological findings (new X-ray evidence 
not present earlier) and acute clinical findings. 
 
Candidiasis (tracheal, 
bronchial, lung) 
Definitive/autopsy  Gross inspection at endoscopy/autopsy or by 
microscopic evaluation of tissue, not only culture. 
 
Definitive/autopsy  Gross inspection by endoscopy/autopsy or by 
microscopy (histology). 
Candidiasis 
(oesophageal) 
Presumptive  Recent onset retrosternal pain on swallowing 
and confirmed oral or pharyngeal candidiasis. 
 
Cervical cancer (only 
females) 
Definitive/autopsy Histology. 
 
 
Coccidioidomycosis, 
disseminated or 
extrapulmonary 
Definitive/autopsy  Microscopy, culture or detection of antigen in 
tissue/fluid from affected organ. 
 
 
Cryptococcosis, 
extrapulm. 
Definitive/autopsy  Microscopy, culture of, or antigen detection in 
affected tissue. 
 
Cryptosporidiosis, > 1 
month 
Definitive/autopsy  Microscopy.  Duration of diarrhoea for more then 
1 month. 
 
Cytomegalovirus retinitis  Presumptive  Loss of vision and characteristic appearance on 
serial ophtalmoscopy, progressing over serial 
months. 
 
Cytomegalovirus 
(pneumonia, oesophagitis, 
colitis, adrenalitis, other 
organs) 
 
Definitive/autopsy  Microscopy (histology or cytology). 
Herpes simplex ulcers 
(duration > 1 month) or 
pneumonia/oesophagitis 
Definitive/autopsy  Microscopy, culture of, or antigen detection in 
affected tissue. 
 
 
Histoplasmosis 
(extrapulm.) 
Definitive/autopsy  Microscopy, culture of, or antigen detection in 
affected tissue. 
 
HIV wasting syndrome 
 
Definitive  Weight loss (over 10% of baseline) with no other 
cause, and 30 days or more of either diarrhoea 
or weakness with fever 
 
Isosporiasis, duration > 1 
month 
 
Definitive/autopsy  Microscopy (histology or cytology).  Duration of 
diarrhoea for more than 1 month. 
 
Definitive/autopsy Histology. 
 
Kaposi’s sarcoma 
 
Presumptive Characteristic  erythematous/violaceous  plaque-
like lesion on skin or mucous membranes. 
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AIDS defining illness  Definitive, autopsy or 
presumptive 
Definitive diagnostic method or presumptive 
diagnostic criteria 
    
Definitive/autopsy Histology.  Malignant lymphoma 
  Presumptive  (Only primary brain lymphoma).  Recent onset of 
focal neurological symptoms and signs or 
reduced level of consciousness, CT/MR scan 
evidence of a lesion or lesions having mass 
effect, no response to toxo therapy, no evidence 
of lymphoma outside the brain. 
 
Mycobacterium 
tuberculosis and 
MAC/Kansasii (pulmonary 
and/or extrapulm.) 
(Pulmonary 
MAC/Kansassii not AIDS 
defining) 
 
Definitive Culture. 
 
Definitive Culture  (indicate  type).  Mycobacterium other type 
(extrapulm.) 
 
Presumptive  Acid fast bacteria (species not identified by 
culture) on microscopy of normally sterile body 
fluid/tissue. 
 
Definitive  Microscopy (histology or cytology)  Pneumocystis jiroveci 
pneumonia (PCP)  Presumptive  Recent onset of dyspnoea on exertion or dry 
cough, and diffuse bilateral infiltrates on chest X-
ray and pO2 <70 mmHg and no evidence of 
bacterial pneumonia. 
 
Definitive/autopsy  Microscopy (histology or cytology).  Progressive multifocal 
leukoencephalopathy 
(PML) 
 
Presumptive  Progressive deterioration in neurological function 
and CT/MR scan evidence. 
 
Salmonella (non typhoid) 
bacteriaemia (> 2 
episodes) 
 
Definitive Culture. 
Definitive Microscopy  (histology/cytology).  Toxoplasmosis, brain 
  Presumptive  Recent onset focal neurological abnormalities or 
reduced level of consciousness, and mass effect 
lesion on scan, and specific therapy response. 
 
Source: EuroHIV. 1993 Revision of the European and surveillance case definition [111,112]. 

1.4.6 Survival  time 
1.4.6.1 Pre-cART era 
In the absence of any antiretroviral treatment, the average survival time following 
diagnosis of AIDS is approximately two years [85,86].  Factors associated with a longer 
period of survival following an AIDS diagnosis have been investigated in a number of 
studies.  Younger age, more recent date of diagnosis and a higher CD4 count at time 
of diagnosis were consistently found to be associated with longer survival time [127-
136].  However other findings were less consistent, most likely due to differences in 
analytical methods and the presence of confounding variables, for example, 
associations found between survival time and gender, transmission risk group, and 
ethnicity [127,129,130,132,135].  Survival time has also been shown to vary 
considerably depending upon which AIDS defining illness is diagnosed 
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[129,130,132,137,138].  Results from the AIDS in Europe study found that median 
survival time varied from 2-19 months with diseases such as progressive multifocal 
leukoencephalopathy (affecting central nervous system), malignant lymphoma (tumour 
of lymphoid tissue) and AIDS dementia complex having the shortest survival time and 
PCP, Kaposi’s sarcoma and tuberculosis (extrapulmonary) having the longest survival 
time [137]. 
 
1.4.6.2 Post- introduction of cART 
Since the introduction of cART the incidence of AIDS and death in HIV positive 
individuals has decreased significantly [119,120,139,140].  The risk of death for 
infected individuals in the era of cART has been estimated to be more than 85% lower 
than the risk before cART [139].  In patients receiving cART, the strongest predictor of 
clinical progression to AIDS or death has been found to be a lower CD4 count 
measured at the start of treatment [139,141-144].  Viral load [142,144], haemoglobin 
level (an iron-containing respiratory pigment of red blood cells) [144] and a diagnosis of 
severe AIDS before starting cART have also been independently linked to the risk of 
clinical progression [142].  In 2002, the EuroSIDA study incorporated these three 
factors, together with CD4 count, into a clinically prognostic scoring system for patients 
receiving cART, which aimed to assess the risk of clinical progression according to a 
patient’s current clinical status.  The system was validated against data from two other 
cohorts and was found to be highly predictive [141].  This risk score was updated in 
2007 and included all predictive factors of short-term clinical disease progression. 
These factors were: lower current CD4 cell count, higher viral load, presence of 
anaemia, body mass index outside normal range, older age, steeper CD4 cell slope, 
ART experience prior to cART, not presently receiving ART and HIV infection via IDU 
[145].  It is planned that the score will be made publicly available via online calculation 
tools so that it can be implemented into clinical practice.  
 
Age has been found to be another independent predictor of disease progression in 
patients starting cART with no previous treatment experience (ART-naïve) [142].  The 
association between survival and both gender and transmission risk group is less clear 
[142,146-149] with suggestion of interactions with calendar time [150].   
 
1.5  History of AIDS and HIV 
1.5.1  Origin of HIV 
The origin of HIV is now accepted to be the simian immunodeficiency virus (SIV) that 
infects monkeys [18,151].  Evidence was found in 1999 that showed that a strain of SIV 
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in chimpanzees was almost identical to the most infectious and predominant strain of 
HIV, HIV-1 [152].  Co-infection of three different strains of SIV may have led to a 
recombinant form capable of infecting humans [18,153,154].  Recombination occurs 
when the genetic material from more than one viral strain is accidentally swapped 
during viral replication resulting in a strain that incorporates genetic code from both [18-
20,155].  It is likely that cross-species transmission occurred through the hunting and 
butchering of monkeys [156].  The earliest recorded case of HIV-1 was in an African 
plasma sample from 1959 and it is estimated that the first human infection may have 
taken place not long before this [157].  A second genetically different strain of HIV, HIV-
2, which is largely confined to West Africa and Asia, is thought to originate from the 
sooty mangabey monkey [18].   
 
1.5.2  First cases of AIDS 
The first documented cases of AIDS occurred in the USA in 1981.  Deaths began to 
take place amongst homosexual men with reduced immune systems who had 
contracted the illnesses, Kaposi's sarcoma and/or PCP [158,159].  By the end of the 
year, it was recognised that this immune deficiency was caused by a new disease 
[160,161].  Cases of PCP also started occurring in IDUs and so it was apparent that the 
disease was not confined to just one population and could be transmitted via blood 
[162].  In July 1982, the CDC, gay-community leaders and federal bureaucrats met in 
Washington and agreed to name the disease acquired immune deficiency syndrome or 
AIDS to recognise the weakening of the immune system, characteristic of this condition 
[163].  Within the year, the first incidences of AIDS had occurred in haemophiliacs, 
which raised concerns with possible transmission via the transfusion of blood products 
[164,165].  Immune dysfunctions accompanied by opportunistic infections were also 
observed in infants and it was suggested that transmission of an ‘AIDS agent’ from 
mother to child, in utero or shortly after birth, could account for the early onset [166].  
 
1.5.3  AIDS virus  
It was not until 1983 that the virus believed to be the cause of AIDS was first 
discovered and at the time named LAV (lymphadenopathy-associated virus) [167].   
However, in 1984, an independent laboratory similarly identified a virus designated 
HTLV-III (human t-cell leukaemia) and also provided convincing evidence that it was 
the virus behind AIDS [168].  By 1985 it was recognised that these viruses were 
actually the same [169].  In this same year, an antibody test using patients’ blood 
serum to detect the presence of LAV/HTLV-III called ELISA (enzyme linked 
immunosorbent assay), was approved by the FDA [170], which led to the 
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recommendation that blood or serum from donors of organs, tissues or semen should 
be routinely screened for the virus [171].   
 
In May 1986, a subcommittee commissioned by the International Committee on the 
Taxonomy of Viruses determined a definitive name for the AIDS virus.  The names LAV 
and HTLV-III were dropped in favour of HIV (later to be called HIV-1 [172]) to settle the 
dispute over the two names [173-175].  Also this year, a genetically distinct strain of the 
virus was discovered in two AIDS patients in West Africa [176] (later to be designated 
HIV-2 [172]).  The following year, the first antiretroviral drug was approved, which at the 
time was believed to be an important step towards bringing significant relief to those 
infected with the virus [177] (see section 1.7 on treatment strategies). 
 
1.5.4  AIDS definition  
The first formal definition of AIDS was in 1985 by the CDC/WHO as described in 
section 1.4.4.  They defined it as an illness characterised by one of a list of 
opportunistic infections in the absence of all known underlying causes of 
immunodeficiency, other than the virus, HIV (at the time still called LAV/HTLV-III) [108].  
This was first revised in 1987 to specify definitions of AIDS defining illnesses for those 
with laboratory evidence of HIV, those without and those with laboratory evidence 
against HIV [178].  In 1993 the definition was further extended to include extra 
diagnoses, i.e. pulmonary tuberculosis, recurrent pneumonia and invasive cervical 
carcinoma (malignant tumour of cellular tissue), and those who were severely 
immunosuppressed with a CD4 lymphocyte count less than 200 cells/mm
3 [109].  The 
1993 European AIDS definition differs from this CDC definition (used in the USA) in 
that it does not include the CD4 count criteria [111].  
 
1.6 Antiretroviral  therapy 
The use of combinations of antiretroviral drugs to treat HIV positive individuals has 
drastically reduced mortality and morbidity since its introduction into clinical practice in 
developed countries in 1995-1996 [118-121,139,140,179].  These drugs are designed 
to prevent the virus from successfully replicating, thereby preventing further damage to 
the immune system and allowing restoration of CD4 cells [40,180-186].  This protects 
the body from opportunistic infections, which could result in the development of AIDS 
or death [187].  However, the efficacy of antiretroviral drugs to achieve a successful 
response is restricted by a number of factors including drug absorption and distribution 
[188,189], the emergence of drug-resistant viral strains (which are discussed later) 
[172,190] and patient adherence to the regimen [191-196].  The HAART Observational 
Medical Evaluation and Research (HOMER) study run through the British Columbia 
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Centre for Excellence in HIV/AIDS Drug Treatment Program suggested that patients 
should be more than 95% adherent to conserve long-term CD4 count responses [192].  
Factors affecting adherence include the severity of side effects experienced, 
convenience of the regimen, confidence in ability to take the medication correctly and 
amount of social support [197-201].  The side effects associated with the use of 
antiretroviral drugs can be severe and often result in treatment switches or 
discontinuation.  Studies have shown that up to 50% of both ART-naïve and 
experienced patients who start a cART regimen discontinue one or more of the drugs 
within a year of starting, mostly due to toxicities or patient choice [202-205].  The risk of 
serious life threatening events such as liver failure [206] and myocardial infarction is 
also increased in patients receiving therapy, for example, the D:A:D study showed that 
cART was independently associated with a 16% relative increase in the rate of 
myocardial infarction per year of exposure to a class of antiretroviral drugs called 
protease inhibitors (detailed in section 1.6.2.3) during the first four to six years of use 
[207]. 
 
1.6.1  Studying the effects of antiretroviral drugs 
The effects of antiretroviral drugs are studied in HIV research in a variety of ways.  
Randomised controlled trials (RCTs) are the gold standard for investigating the safety 
and efficacy of drug interventions due to the fact that randomisation ensures that 
comparisons between patients are unbiased.  The allocation of patients to intervention 
arms is determined by chance and so any other factors that may affect the outcome 
should be balanced between the groups.  However RCTs are not always possible for 
ethical or practical reasons and are often not powered for clinical endpoints and so 
there is a strong argument in favour of using the findings from large-scale cohort 
studies as a supplement to RCTs [208,209].  Cohort studies follow a group of 
individuals over time and the effects of exposure to factors are observed without any 
interventions. 
 
When ART was first introduced, the rate of clinical events, i.e. AIDS defining illnesses 
and deaths, was high and so conclusions from RCTs could be reached within a few 
years [210-212], which is relatively short compared to the number of years that would 
be needed now.  As more drugs were developed and treatment strategies changed, a 
problem of the long-term RCTs became that the data were irrelevant by the time the 
trial had finished and the results were published.  Surrogate marker endpoints, e.g. 
proportion of patients with viral loads less than 400 copies/mL, were designed instead 
to draw conclusions about the efficacy of treatment more quickly, typically within 48 
weeks [213,214].  However these short-term trials cannot assess the long-term effects 
31 
and toxicities of ART, especially those that rarely occur.  Further problems with RCTs 
are that patients are almost always not representative of the general HIV infected 
population due to the strict inclusion/exclusion criteria set, for example limitations in 
CD4 count, viral load, previous drug experience.  Patients are usually motivated and 
therefore more adherent than the general population and patients visit their clinics 
more frequently [208,209].  Since observational cohort studies can include a much 
more heterogeneous population and follow up patients over a long period of time, this 
allows all stages of treatment including salvage therapy to be observed. 
 
Although observational studies have the disadvantage that comparisons of patients 
may be biased due to differences in baseline characteristics, statistical analyses can 
take into account the known, measured differences and produce adjusted results [208].  
Thus observational cohorts are important for studying areas that are not feasible in an 
RCT, to support findings from RCTs in a more representative sample of the HIV 
infected population and to identify areas of research for which an RCT would be useful.  
 
1.6.2 Available  antiretroviral  drugs 
Before drugs become available for public use, they need to be given marketing 
authorisation by a governing public health agency, i.e. the FDA in the USA and the 
European Medicines Agency (EMEA) in Europe.  There are three main classes of 
antiretroviral drug to treat HIV, classified according to the way in which they act to 
prevent replication: nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs 
or nucs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease 
inhibitors (PIs).  There are also three more drugs from new classes that have been 
more recently licensed: a fusion inhibitor, an entry inhibitor (CCR5 co-receptor 
antagonist) and an integrase inhibitor [215,216]. 
 
1.6.2.1 Nucleoside (and nucleotide) reverse transcriptase inhibitors 
One strategy to prevent HIV replication is to inhibit the viral enzyme reverse 
transcriptase.  HIV RNA binds to the active site of reverse transcriptase, which allows 
the enzyme to catalyse the production of a copy of the viral RNA called HIV proviral 
DNA.  The class of antiretroviral drugs called nucleoside reverse transcriptase 
inhibitors (NRTIs) work by competitively binding to this active site during reverse 
transcription so that the NRTI is incorporated into the HIV proviral DNA chain.  This 
results in termination of the chain and thus the prevention of viral DNA production.  The 
remaining viral RNA is then likely to be destroyed by cellular enzymes [217,218].   
Nucleotide reverse transcriptase inhibitors (sometimes called NtRTIs) work in the same 
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way but because of their chemical structure, they bind more easily to the active site 
[219]. 
 
The first antiretroviral drug to be developed was an NRTI called zidovudine (ZDV), 
authorised in the USA in 1987 [177].  Since then, a further six NRTIs have been 
approved: didanosine (ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), 
abacavir (ABC) and emtricitabine (FTC), and one NtRTI: tenofovir disoproxil fumarate 
(TDF) [215,216,220].  There are a number of toxicities associated with the use of 
NRTIs that can be severe [221,222].  Cohort studies have shown that asymptomatic 
hyperlactaemia (mild to moderate elevations of lactic acid in the circulating blood) has 
an estimated prevalence of 15-35% in HIV infected patients on NRTIs and symptomatic 
hyperlactaemia and lactic acidosis (a persistently high elevation of lactic acid in the 
circulating blood) have an incidence ranging from 1.7-25.2 cases per 1000 person-
years of treatment [223].  Risk factors linked to these illnesses are long duration of 
NRTI therapy, female sex, pregnancy and high body mass index [223].  Hepatotoxicity 
(liver damage) with hepatic steatosis (fatty degeneration of the liver) is another 
complication of NRTI treatment [224].  Studies have shown incidence rates of severe 
hepatotoxicity (defined by elevation of liver enzymes) ranging from 8.5-17% [225-230] 
and patients co-infected with hepatitis B and C were found to be at considerably 
(approximately three times) higher risk [226,227,230].  Severe or life threatening 
hepatic events were observed in a cohort of 2947 patients receiving ART regimens at a 
rate of 2.6 per 100 person-years of follow-up over a five-year period [206].   
Lipodystrophy and lipoatrophy (metabolic disorders involving the loss or gain of fat 
deposition in tissue) have also been linked to NRTI use [231,232], especially with use 
of stavudine, which is why this drug is no longer a preferred option for first-line therapy 
[233].  Of patients on a cART regimen, the prevalence of lipodystrophy has been 
estimated to be 25-50% with NRTI use as a risk factor [231,232].  Hypersensitivity 
(symptomised by rash with or without fever) is a further problem that occurs in about 4-
8% of patients taking ABC [234-236].  This particular toxicity is investigated in Chapter 
7.  Table 1.2 lists all NRTIs and NtRTIs licensed in the USA and Europe with possible 
associated toxicities. 
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Table 1.2: Currently licensed nucleoside and nucleotide reverse transcriptase 
inhibitors. 
Brand 
name 
Generic 
name 
Manufacturer 
name 
FDA 
approval 
date [220] 
EMEA 
approval 
date [216] 
Possible side effects [215,216] 
          
Atripla Tenofovir/ 
emtricitabine
/efavirenz 
(NNRTI) 
Gilead Sciences 
and Bristol-Myers 
Squibb 
12 Jul  
2006 
13 Dec 
2007 
See Emtriva, Viread and 
Stocrin. 
Combivir Zidovudine/ 
lamivudine 
GlaxoSmithKline 27  Sep 
1997 
18 Mar 
1998 
See Retrovir and Epivir. 
Emtriva  Emtricitabine  Gilead Sciences  2 Jul  
2003 
24 Oct 
2003 
Headache, dizziness, 
insomnia, nausea, diarrhoea, 
abdominal pain, rash, 
neutropenia (low white blood 
cell count), hyperglycaemia 
(excess of sugar in blood), 
elevated liver enzymes, 
hyperbilirubinaemia (excess of 
pigment bilirubin in blood). 
Epivir Lamivudine  GlaxoSmithKline  17  Nov 
1995 
8 Aug 
1996 
Headache, insomnia, nausea, 
vomiting, abdominal pain, 
diarrhoea, rash, fatigue, 
malaise, fever, arthralgia (pain 
in joints), muscle disorders.  
More rarely: hepatitis, 
pancreatitis, rhabdomyolysis 
(destruction of skeletal muscle 
tissue). 
Epzicom Abacavir/ 
lamivudine 
GlaxoSmithKline  2 Aug  
2004 
*  See Epivir and Ziagen. 
Hivid Zalcitabine Hoffmann-La 
Roche 
19 Jun 
1992 
*  Peripheral neuropathy (pain, 
tingling, numbness, or burning 
in the hands and/or feet).  
More rarely: lactic acidosis (an 
increase of lactic acid in the 
blood), pancreatitis 
(inflammation of the pancreas). 
Kivexa Abacavir/ 
lamivudine 
GlaxoSmithKline *  17  Dec 
2004 
See Epivir and Ziagen. 
Retrovir Zidovudine  GlaxoSmithKline 19  Mar 
1987 
* Headache,  insomnia,  nausea, 
stomach discomfort.  More 
rarely: muscle wasting, 
anaemia (low red blood cell 
count), neutropenia. 
Trizivir Zidovudine/ 
lamivudine/ 
abacavir 
GlaxoSmithKline 14  Nov 
2000 
28 Dec 
2000 
See Retrovir, Epivir and 
Ziagen. 
Truvada Tenofovir/ 
lamivudine 
Gilead Sciences  2 Aug  
2004 
21 Feb 
2005 
See Viread and Emtriva. 
Videx Didanosine 
(buffered 
version) 
Bristol-Myers 
Squibb 
9 Oct  
1991 
*  Numbness, tingling, or pain in 
the hands or feet, nausea, 
diarrhoea, vomiting, headache, 
rash.  More rarely: pancreatitis.
Possible increased side effects 
if taken with Viread. 
Notes: *Not licensed by agency. 
FDA = Food and Drug Administration; European Medicines Agency. 
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Brand 
name 
Generic 
name 
Manufacturer 
name 
FDA 
approval 
date [220] 
EMEA 
approval 
date [216] 
Possible side effects [215,216] 
Videx EC  Didanosine 
(delayed 
release 
capsules) 
Bristol-Myers 
Squibb 
31 Oct 
2000 
* See  Videx. 
Viread  Tenofovir  Gilead Sciences  26 Oct 
2001 
5 Feb 
2002 
Nausea, vomiting, diarrhoea, 
flatulence.  More rarely: 
osteopenia (thinning bones). 
Zerit Stavudine  Bristol-Myers 
Squibb 
24 Jun 
1994 
8 May 
1996 
Numbness, tingling, or pain in 
the hands or feet, nausea, 
diarrhoea, vomiting, headache, 
rash.  More rarely: pancreatitis 
or lactic acidosis. 
Ziagen Abacavir  GlaxoSmithKline  17  Dec 
1998 
8 Jul  
1999 
Headache, nausea, vomiting, 
diarrhoea, loss of appetite, 
insomnia, fever, fatigue, rash, 
serious allergic reactions. 
Notes: *Not licensed by agency. 
FDA = Food and Drug Administration; European Medicines Agency. 
 
 
1.6.2.2 Non-nucleoside reverse transcriptase inhibitors 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) work in a different way to 
NRTIs but with the same outcome.  NNRTIs bind to another site on the reverse 
transcriptase enzyme, which results in changes to the active site that prevents HIV 
RNA from binding to it [218,237].   
 
Four NNRTIs are currently approved by public health agencies: nevirapine (NVP), 
efavirenz (EFV), etravirine (TMC-125) and in the USA, delavirdine (DLV) [215,220].  
Two further NNRTIs loviride and caprivirine reached development stages but were 
discontinued due to disappointing results in clinical trials [238,239].  The newest 
NNRTI, etravirine, was very recently approved by the FDA and is designed to work 
against HIV that is resistant to NVP and EFV, therefore this drug will be ideal for use in 
second-line therapy after initial failure on either of these NNRTIs [240]. 
 
The rate of toxicities occurring is relatively low in this class but symptoms include rash, 
headaches, fatigue, stomach upset, dizziness, vivid dreams and insomnia [215,241].  
The most severe adverse effect of this drug class is hepatotoxicity.  Studies have found 
incidences of severe hepatic events ranging from 7.8-15.6% in NNRTI-treated patients 
[242].  Hypersensitivity reactions may also occur after starting NNRTI treatment with 
research showing incidences of 10-17% in NNRTI-treated patients [241].  Table 1.3 
lists all licensed NNRTIs and toxicities. 
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Table 1.3: Currently licensed non-nucleoside reverse transcriptase inhibitors. 
Brand 
name 
Generic 
name 
Manufacturer 
name 
FDA 
approval 
date [220] 
EMEA 
approval 
date [216] 
Possible side effects [215,216] 
Atripla Tenofovir/ 
emtricitabin
e/efavirenz 
Gilead Sciences 
and Bristol-Myers 
Squibb 
12 Jul  
2006 
13 Dec 
2007 
See Emtriva, Viread and 
Stocrin. 
Intelence Etravirine  Tibotec 
Therapeutics 
18 Jan 
2008 
* Rash,  nausea,  diarrhoea, 
vomiting, abdominal pain, 
tiredness, tingling or pain in 
hands and feet, numbness, 
headache, high blood 
pressure. 
Rescriptor Delavirdine  Pfizer  4  Apr 
1997 
* Rash,  headache,  fatigue, 
stomach upset, elevated liver 
enzymes. 
Stocrin Efavirenz  Merck  *  28  May 
1999 
Rash, drowsiness, insomnia, 
confusion, inability to 
concentrate, dizziness, vivid 
dreams, nausea, stomach 
discomfort, fever, insomnia, 
elevated liver enzymes. 
Sustiva Efavirenz Bristol  Myers-
Squibb 
17 Sep 
1998 
28 May 
1999 
See Stocrin. 
Viramune Nevirapine  Boehringer 
Ingelheim 
21 Jun 
1996 
5 Feb 
1998 
Rash, stomach upset, 
headaches, increased liver 
enzyme levels.  More rarely: 
hepatitis. 
Notes: *Not licensed by agency. 
FDA = Food and Drug Administration; European Medicines Agency. 
 
 
1.6.2.3 Protease inhibitors 
Protease inhibitors (PIs) work by competitively binding to the active site of the HIV 
enzyme protease.  This prevents the enzyme from processing and cleaving HIV 
proteins into functional forms and as a result, the new virions produced are immature 
and unable to function properly [243,244].  
 
There are nine currently approved PIs: saquinavir (hard and soft gel formulations) 
(SQV), ritonavir (RTV), indinavir (IDV), nelfinavir (NFV), amprenavir (APV) (and newer 
version, fosamprenavir), lopinavir (LPV), atazanavir (ATV), tipranavir (TPV) and 
darunavir (DRV) [215,220].  RTV is now only used in low-dose to boost other PIs by 
inhibiting their metabolism and therefore boosting the levels in the blood [40-42].   
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Table 1.4: Currently licensed protease inhibitors. 
Brand 
name 
Generic 
name 
Manufacturer 
name 
FDA 
approval 
date [220] 
EMEA 
approval 
date [216] 
Possible side effects [215,216] 
Agenerase Amprenavir GlaxoSmithKline  15  Apr 
1999 
20 Oct 
2000 
Rash, appetite loss, 
headaches, malaise, 
diarrhoea, nausea, vomiting, 
numbness/tingling around the 
mouth.  More rarely: 
lipodystrophy, diabetes. 
Aptivus Tipranavir  Boehringer 
Ingelheim 
22 Jun 
2005 
25 Oct 
2005 
Rash, nausea, vomiting, 
diarrhoea, stomach pain, 
tiredness, headache.  More 
rarely: liver damage. 
Crixivan Indinavir  Merck  13  Mar 
1996 
4 Oct 
1996 
Kidney stones, nausea, 
vomiting, diarrhoea, stomach 
discomfort, headache, 
insomnia, rash, back pain. 
Fortovase Saquinavir 
(soft gel 
capsules) 
Hoffmann- 
La Roche 
7 Nov 
1997 
20 Aug 
1998 
Nausea, diarrhoea, stomach 
discomfort, insomnia, 
headache, increased liver 
enzyme levels. 
Invirase Saquinavir  Hoffmann- 
La Roche 
6 Dec 
1995 
4 Oct 
1996 
See Fortovase. 
Kaletra Lopinavir/ 
Ritonavir 
Abbott 
Laboratories 
15 Sep 
2000 
20 Mar 
2001 
Diarrhoea, nausea, feeling 
weak/tired, headache.  More 
rarely: pancreatitis. 
Lexiva Fos-
amprenavir 
GlaxoSmithKline 20  Oct 
2003 
* Rash,  diarrhoea,  nausea, 
vomiting, abdominal pain, 
fatigue, dizziness, headache. 
Norvir Ritonavir  Abbott 
Laboratories 
1 Mar 
1996 
26 Aug 
1996 
Nausea, vomiting, diarrhoea, 
loss of appetite, stomach 
discomfort, oral tingling and 
numbness, increased liver 
enzyme levels. 
Prezista Darunavir  Tibotec  23  Jun 
2006 
12 Feb 
2007 
 
Reyataz Atazanavir  Bristol-Myers 
Squibb 
20 Jun 
2003 
2 Mar 
2004 
Increased levels of bilirubin (a 
pigment found in the liver), 
headaches, pain/tingling in the 
arms and legs, nausea, 
diarrhoea, rash.  More rarely: 
changes in the way your heart 
beats. 
Telzir Fos-
amprenavir 
GlaxoSmithKline *  12  Jul 
2004 
See Lexiva. 
Viracept Nelfinavir  Agouron 
Pharmaceuticals 
14 Mar 
1997 
22 Jan 
1998 
Diarrhoea, nausea, stomach 
discomfort, gas, rash, 
increased liver enzyme levels. 
Notes: *Not licensed by agency. 
FDA = Food and Drug Administration; European Medicines Agency. 
 
 
Common to all the PIs are the side effects, nausea, diarrhoea and vomiting [215].   
Body fat and metabolic disorders have also been linked to PIs including lypodystrophy, 
high lipid levels, insulin resistance, diabetes mellitus, hyperglycaemia (increased blood 
levels of sugar), hypercholesterolaemia (increased cholesterol), hypertriglyceridaemia 
(increased levels of triglycerides) and increased bleeding in haemophiliacs 
[231,241,245,246].  For example, 7% of patients treated with LPV for 60 weeks had 
developed body fat changes, as had those on NFV [247].  In another study 35% of 
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patients experienced body fat changes after four years on LPV and RTV [248].  Table 
1.4 displays all licensed PIs and associated toxicities. 
 
1.6.2.4 Fusion, entry and integrase inhibitors 
The most recent developments are three new drugs, which all work differently to the 
standard drug classes available.  The fusion inhibitor enfuvirtide (T-20) works by 
interacting with sites on the virion that bind to the CD4 cells and so blocks entry into the 
potential host cells [249,250].  The entry inhibitor maraviroc is similar in that it prevents 
the virus from entering cells.  This is only effective for certain strains of virus (R5) that 
bind with a CCR5 co-receptor on the surface of CD4 cells [251].  Finally, the most 
recent new drug is raltegravir, which is an inhibitor of the viral enzyme integrase and 
prevents integration of the viral DNA into the host DNA [252].  Table 1.5 shows the 
licensed drugs and associated side effects.   
 
Table 1.5: Currently licensed fusion, entry and integrase inhibitors. 
Brand name  Generic 
name 
Manufacturer 
name 
FDA 
approval 
date [220] 
EMEA 
approval 
date [216] 
Possible side effects [215,216] 
Celsentri Maraviroc  Pfizer  *  18  Sep 
2007 
Cough, fever, colds, rash, 
muscle and joint pain, stomach 
pain and dizziness. Less 
common side effects include 
cardiovascular problems and 
liver toxicity. 
Fuzeon Enfuvirtide  Hoffman-La 
Roche and 
Trimeris 
13 Mar 
2003 
27 May 
2003 
Injection site reactions 
including itching, swelling, 
redness, pain or tenderness, 
hardened skin or bumps.  
More rarely: serious allergic 
reactions. 
Isentress  Raltegravir  Merck & Co.  12 Oct 
2007 
* Diarrhoea,  nausea  and 
headache. In some patients, 
blood tests showed abnormally 
elevated levels of a muscle 
enzyme, creatine kinase. 
Selzentry Maraviroc  Pfizer  6  Aug 
2007 
* See  Celsentri. 
Notes: *Not licensed by agency. 
FDA = Food and Drug Administration; European Medicines Agency. 
 
1.7 Treatment  strategies 
1.7.1 Monotherapy  (1987-1993) 
When antiretroviral drugs first started to be developed, there were very limited options 
for patients and the long-term effects were unknown.  For the first four years, there was 
only one drug available therefore if the patient found it to be ineffective or intolerable, 
there were no alternatives to switch to.  This first antiretroviral drug was an NRTI called 
azidothymidine (AZT), now more commonly known as zidovudine (ZDV) [177].  The 
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FDA approved ZDV in 1987 after a clinical trial demonstrated its ability to increase CD4 
count, to decrease incidence of mortality and to reduce the frequency of opportunistic 
infections amongst patients with AIDS or advanced AIDS related complex (ARC) 
[210,253] (now defined as CDC/WHO category B [109]).  Further trials showed that the 
drug was also effective in asymptomatic patients with CD4 counts of less than 500 
cells/mm
3 and could delay progression to symptomatic disease or AIDS in the short-
term [211,254].  However, the largest study of ZDV monotherapy in asymptomatic HIV 
infection, called the Concorde study, published results that suggested that over the 
long-term, starting ZDV before symptoms developed did not increase the chances of 
AIDS-free survival [212,255].   
 
The second NRTI, didanosine (dideoxyinosine or ddI), was authorised by the FDA in 
1991 [256] based on data from clinical trials that showed its efficacy in increasing CD4 
count [257,258].  This provided an alternative for patients who had not responded to 
ZDV treatment or had not been able to tolerate its side effects.  However no survival 
benefits over continuing ZDV were found [259,260]. 
 
In 1992, a third drug, zalcitabine (ddC or dideoxycytidine), was given accelerated 
approval by the FDA (allowing marketing approval before the drug’s clinical efficacy 
had been established) for use in the first combination therapy with ZDV for patients 
who had advanced HIV infection with signs of clinical or immunological deterioration 
[261].  Although there were no study results to indicate a higher rate of survival, a lower 
incidence of opportunistic infections or decreased progression to AIDS, there was 
evidence that the combination appeared to increase and sustain CD4 cell count more 
than ZDV alone [262].  This approval, however, was withdrawn a year later after it was 
concluded that there were insufficient data to support the efficacy of this treatment 
[263].  At the same meeting ddC monotherapy was approved based on preliminary 
results from clinical trials showing that ddC was as effective as ddI in delaying 
progression to death [264].  No difference was found in survival between ddC and 
continuing ZDV [265].  Table 1.6 displays some of these findings from the major clinical 
trials investigating the use of a single antiretroviral drug. 
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Table 1.6: Major clinical trials in antiretroviral monotherapy. 
Study Clinical  trial  Authors,  year  Main  outcomes  Conclusions 
ZDV vs 
placebo 
ZDVCG 
studies 
Fischl et al. 
1987 [210] 
Fischl et al. 
1989 [253] 
Progression to death or 
opportunistic infection 
and increase in CD4 
count in patients with 
AIDS and ARC. 
ZDV decreases mortality and 
frequency of opportunistic 
infections in subjects with 
AIDS/ARC over 8-24 weeks of 
observation.   Continued survival 
benefits with long-term ZDV 
therapy. 
ZDV vs 
placebo 
ACTG 019  Volberding et 
al. 1990 [211] 
Volberding et 
al. 1994 [254] 
Progression to AIDS, 
ARC or death and 
increase in CD4 count 
in asymptomatic HIV 
infected patients. 
ZDV delays disease progression 
in asymptomatic patients and 
CD4 <500 cells/mm
3, but there is 
no survival benefit.  Earlier use 
was not associated with longer 
survival compared with delayed 
initiation of ZDV. 
ZDV: 
Early vs 
deferred 
Concorde Concorde 
Coordinating 
committee 
1994 [212] 
1998 [255] 
Progression to AIDS, 
ARC or death and 
increase in CD4 count 
in asymptomatic HIV 
infected patients. 
Early use of ZDV in 
asymptomatic patients is not 
encouraged. 
ddI vs 
continued 
ZDV 
ACTG 116B  Kahn et al. 
1992 [259] 
Progression to 
disease/death and 
increase in CD4 count 
in ZDV-experienced 
patients. 
Changing treatment from ZDV to 
ddI appears to slow progression 
of HIV disease but there was no 
survival benefit with change to 
ddI. 
ddI vs 
continued 
ZDV 
ISS 901  Vella et al. 
1996 [260] 
Kaplan-Meier 
estimates of survival 
and time to AIDS-
defining event in ZDV-
experienced patients 
with AIDS. 
In patients with advanced 
disease, switching from ZDV to 
ddI does not produce apparent 
benefits. 
ddC vs 
continued 
ZDV 
ACTG 119  Fischl et al. 
1993 [265] 
Estimated 12-month 
event-free probabilities 
and survival, rate of 
CD4 count decline and 
progression to 
AIDS/death in ZDV-
experienced patients. 
No differences in survival and 
clinical endpoints were found.  
Slower rates of CD4 count 
decline were found in the ddC 
group. 
ddI  vs 
ddC 
CPCRA Abrams  et al. 
1994 [264] 
Disease progression or 
death rates and CD4 
count decline in ZDV-
experienced patients. 
ddC is at least as efficacious as 
ddI in delaying disease 
progression and death with 
similar CD4 count decline. 
Notes: ZDV = zidovudine; ddI = didanosine; ddC = zalcitabine; ARC = AIDS related complex. 
 
1.7.2 Dual  therapy  (1992-1996) 
Over the following few years, the use of two NRTIs in dual combination therapy 
gradually replaced monotherapy as the standard of treatment.  Three major trials, 
ACTG 175, DELTA and CPCRA compared treatments of ZDV/ddC, ZDV/ddI and ZDV 
monotherapy.  The first two found that both dual therapies were superior to ZDV alone 
in preventing a significant reduction of CD4 counts, progression to AIDS or death 
[266,267].  The third, CPCRA, did not find the combinations to be superior than ZDV 
alone in patients with advanced HIV infection, however suggested that they might be 
more effective in patients with little or no previous ZDV experience [268].  
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Two more NRTIs were introduced during this period: stavudine (d4T) in 1994 [269] and 
lamivudine (3TC) in 1995 [270].  A study looking at patients on a 3TC/ZDV combination 
compared to either drug alone found more improvements in immunological and 
virological measures in patients on the dual therapy than those on monotherapy [271].  
Table 1.7 displays the outcomes of some of the major clinical trials investigating dual 
therapy versus monotherapy. 
 
Table 1.7: Major clinical trials in antiretroviral dual versus monotherapy. 
Study  Clinical trial  Authors, year  Main outcomes  Conclusions 
ZDV vs 
ZDV/ddI 
vs 
ZDV/ddC 
vs ddI 
ACTG 175  Hammer et al. 
1996 [266] 
Progression to 50% 
CD4 drop, AIDS or 
death in ZDV-naïve (no 
previous experience of 
ZDV) or -experienced 
patients with CD4 200-
500 cells/mm
3. 
Treatment with ZDV/ddI, ZDV/ddC 
or ddI alone slows the progression 
of HIV disease more than ZDV 
alone. 
ZDV vs 
ZDV /ddI 
vs 
ZDV/ddC 
DELTA 1 
and 2 
Delta 
Coordinating 
Committee 
1996 [267] 
Progression to AIDS or 
death, relative 
reduction in mortality 
and change in CD4 
median at week 8 in 
ZDV-naïve (DELTA 1) 
and ZDV-experienced 
(DELTA 2) patients. 
Treatment with ZDV/ddI or 
ZDV/ddC prolongs life and delays 
disease progression compared 
with ZDV alone.  The addition of 
ddI to ZDV-experienced patients 
also improves survival, although 
benefit appears less. 
ZDV vs 
ZDV/ddI 
vs 
ZDV/ddC 
CPCRA Saravolatz  et 
al. 1996 [268] 
Progression to disease 
or death in ZDV-naïve 
or -experienced 
patients with CD4 <200 
cells/mm
3. 
In patients with advanced HIV 
infection, combination therapy 
with ZDV and either ddI or ddC is 
not superior to ZDV alone.  They 
may be more effective in patients 
with little or no previous ZDV 
treatment. 
ZDV vs 
3TC vs 
ZDV/3TC 
NUCA 3001  Eron et al. 
1996 [271] 
Change in CD4 count 
and viral load at 24 
weeks in ZDV-naïve 
patients with CD4 200-
500 cells/mm
3. 
ZDV/3TC produce more 
improvement in immunological 
and virological response than 
either alone. 
Notes: ZDV = zidovudine; ddI = didanosine; ddC = zalcitabine; 3TC = lamivudine. 
 
1.7.3  Combination antiretroviral therapy (1995-current) 
The major breakthrough in HIV therapy came with the advent of cART defined as a 
regimen consisting of at least three antiretroviral drugs from two different drug classes.  
This is also widely known as highly active antiretroviral therapy (HAART).   
 
1.7.3.1 PI-containing regimens 
The era of cART started with the development of the new drug class, PIs, which proved 
to be highly potent when combined with NRTIs.  Compared with a dual NRTI regimen, 
combinations of two NRTIs and one PI were found to be significantly superior in 
reducing the number of patients progressing to AIDS or death [180,182], as well as in 
antiviral activity and CD4 cell increase in subjects with and without previous ART 
experience both in early and late stages of infection [184,213,272-275].  Table 1.8 
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summarises some of the major trials looking at PI-containing cART regimens compared 
to dual NRTI therapy. 
 
Table 1.8: Major clinical trials in PI-containing cART versus dual NRTI therapy. 
Study  Clinical trial  Authors, year  Main outcomes  Conclusions 
IDV/ZDV/3TC 
vs ZDV/3TC 
ACTG 320  Hammer et al. 
1997 [180] 
Progression to 
AIDS/death, CD4 
increase and viral 
load decrease in ZDV-
experienced subjects 
with CD4 ≤200 
cells/mm
3.  
Treatment with three-drug 
therapy containing IDV, ZDV 
and 3TC compared to ZDV and 
3TC significantly slows the 
progression of HIV disease. 
RTV/2 NRTIs 
vs 2 NRTIs 
Advanced 
HIV disease 
Ritonavir 
Study Group 
Cameron et 
al. 1998 [182] 
Progression to 
AIDS/death in NRTI-
experienced, PI-naïve 
subjects with CD4 
≤100 cells/mm
3. 
RTV in combination therapy for 
patients with advanced disease 
and extensive previous 
antiretroviral use lowers risk of 
AIDS and prolongs survival 
more than two NRTIs alone. 
SQV/ZDV/ddC 
vs SQV/ZDV 
vs ZDV/ddC 
ACTG 229  Collier et al. 
1996 [184] 
CD4 increase and 
reduction in viral load 
in ZDV-experienced 
subjects with CD4 50-
300 cells/mm
3. 
SQV/ddC/ZDV reduced viral 
load and increased CD4 count 
more than ZDV with either 
SQV or ddC alone. 
RTV/d4T/3TC 
vs d4T/ddI vs 
ZDV/ddI vs 
ZDV/ddC vs 
no treatment 
Spanish 
Earth-1 
Study 
Garcia et al. 
1999 [272] 
Change in CD4 count 
and viral load in ART-
naïve subjects with 
CD4 >500 cells/mm
3 
and viral load >10000 
copies/mL. 
Three-drug therapy is the 
treatment of choice in very 
early stages of HIV infection. 
IDV/ZDV/3TC 
vs ZDV/3TC 
vs IDV 
MSD 
Protocol 039 
Hirsch et al. 
1999 [273] 
CD4 increase and 
reduction in viral load 
in PI-naïve and 
extensively ZDV-
experienced subjects 
with CD4 ≤50 
cells/mm
3. 
Patients with advanced HIV 
infection benefit from three-
drug therapy with 
IDV/ZDV/3TC more than two 
NRTIs or IDV alone. 
APV/ZDV/3TC 
vs ZDV/3TC 
PROAB3001 Goodgame  et 
al. 2000 [213] 
Proportion reaching 
viral load <400 
copies/mL at 48 
weeks in ART-naïve 
subjects with CD4 
≥200 cells/mm
3 and 
viral load ≥10000 
copies/mL. 
APV/ZDV/3TC significantly 
better in terms of antiviral 
activity than ZDV/3TC in ART-
naïve subjects.  
IDV/ZDV/3TC 
vs ZDV/3TC 
AVANTI 2  AVANTI study 
group 2000 
[274] 
CD4 increase and 
reduction in viral load 
in ART-naïve subjects 
with CD4 150-300 
cells/mm
3. 
IDV/ZDV/3TC results in 
considerable improvement 
compared with ZDV/3TC. 
NFV/ZDV/3TC 
vs ZDV/3TC 
AVANTI 3  Gartland on 
behalf of the 
AVANTI study 
group 2001 
[275] 
CD4 increase and 
reduction in viral load 
in ART-naïve subjects 
with CD4 150-300 
cells/mm
3. 
NFV/ZDV/3TC has significantly 
better benefits than ZDV/3TC. 
Notes: IDV = indinavir; ZDV = zidovudine; 3TC = lamivudine; RTV = ritonavir; SQV = saquinavir; ddC = 
zalcitabine; d4T = stavudine; APV = amprenavir; NFV = nelfinavir. 
 
 
42 
The first PI was approved in late 1995 [276].  Saquinavir (SQV), a hard gel formulation, 
when combined with both ZDV and ddC was shown to increase CD4 counts and 
decrease viral loads more than SQV/ZDV or ZDV/ddC in a randomised double-blind 
trial consisting of patients with previous exposure to NRTIs, despite SQV hard gel’s low 
bioavailability (rate of absorption) [184].  In 1996, two more PIs were licensed for use 
either alone or in combination with NRTIs: ritonavir (RTV) [277] and indinavir (IDV) 
[278].  A randomised placebo-controlled trial investigating the efficacy of RTV in 
combination with up to two NRTIs, in patients previously on NRTIs only and with 
advanced HIV disease, found that the combination including RTV lowered the risk of 
AIDS complications and prolonged survival [182].  In NRTI-experienced patients with 
less than 200 CD4 cells/mm
3, IDV with ZDV and 3TC was found to be significantly 
more effective at slowing progression to HIV disease than ZDV and 3TC alone [180].   
 
Two new PIs were introduced over the next couple of years: nelfinavir (NFV) [279] and 
amprenavir (APV) [280], as was a new formulation of SQV as a soft gel to improve the 
degree and rate at which the drug was absorbed [281].  NFV, as part of a cART 
regimen, was found to have more virological and immunological benefit than dual NRTI 
therapy [275].  APV with ZDV/3TC was also found to have a significantly higher rate of 
viral suppression than the two NRTIs alone [213].  A new version of this drug was 
licensed in 2003: fosamprenavir (fAPV), which had a slower release and resulted in 
higher blood levels of the active drug [282].   
 
Lopinavir (LPV) was licensed in 2000 for use in a combined drug called Kaletra that 
contained a low dose of RTV [283].  Low dose RTV inhibits the metabolism of LPV and 
therefore enhances the concentration of the PI in the blood to above the levels needed 
to inhibit HIV replication.  Trials have since been carried out to compare the antiviral 
efficacy of different RTV-boosted PIs to each other and to non-boosted PIs.  These are 
displayed in Table 1.9.  In the M98-863 phase III clinical trial, regimens containing 
either the RTV-boosted LPV (LPV/r) or NFV, together with d4T and 3TC, were 
compared in patients with no more than 14 days previous ART experience at any time 
[284].  The LPV/r arm was found to have superior antiviral activity and hence is 
currently recommended for first-line therapy [40-42].  The KLEAN study found similar 
virological efficacy between a fAPV/r containing regimen and one containing LPV/r in 
ART-naïve patients [285], and results from the CASTLE study showed similar 
virological responses in ART-naïve patients starting ATV/r and LPV/r [286]. 
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Table 1.9: Major clinical trials in ritonavir-boosted versus non-boosted PI-containing 
regimens and comparisons of ritonavir-boosted PI-containing regimens. 
Study  Clinical trial  Authors, year  Main outcomes  Conclusions 
LPV/r/ d4T/3TC 
vs d4T/3TC/NFV 
M98-863 Walmsley  et al. 
2002 [284] 
Proportion with viral 
load <400 copies/mL at 
week 24 and time to 
loss of virological 
response at week 48 in 
subjects with no 
previous ART 
experience of more than 
14 days at a time. 
A combination regimen 
including LPV/r has 
superior virological 
efficacy than a NFV-
containing regimen. 
fAPV/r (once 
daily)/ABC/ 
3TC vs  
NFV (twice 
daily)/ABC/3TC 
SOLO Gathe  et al. 
2004 [287] 
Proportion with viral 
load <400 copies/mL 
and <50 copies/mL, and 
change in CD4 count at 
week 48 in ART-naïve 
subjects. 
fAPV/r (once daily) was 
well-tolerated and 
provided potent, durable 
virological suppression. 
LPV/r plus >1 
NRTI vs SQV/r 
plus >1 NRTI 
MaxCMin2 Dragsted  et al. 
2005 [288] 
Proportion with 
treatment failure, 
defined as composite of 
virological failure, 
withdrawal of consent to 
participate, loss to 
follow-up, and death. 
Less patients on the 
LPV/r regimen 
experienced virological 
failure than on SQV/r, 
which could be due to 
patient adherence 
rather than potency of 
drugs. 
 fAPV/r/ABC/ 
3TC vs 
LPV/r/ABC/ 
3TC 
KLEAN Eron  et al. 
2006 [285] 
Proportion with viral 
load <400 copies/mL at 
week 48 in ART-naïve 
subjects. 
A regimen containing 
fAPV/r provides similar 
virological efficacy as 
LPV/r, when each is 
combined with 
ABC/3TC. 
ATV/r/TDF/FTC 
vs 
LPV/r/TDF/FTC 
CASTLE Molina  et al. 
2008 [286] 
Proportion with viral 
load <50 copies/mL and 
<400 copies/mL, and 
change in CD4 count 
and viral load at week 
48 in ART-naïve 
subjects. 
ATV/r has similar 
virological efficacy to 
LPV/r. 
Notes: LPV/r = ritonavir-boosted lopinavir; d4T = stavudine; 3TC = lamivudine; NFV = nelfinavir; fAPV/r = 
ritonavir-boosted fosamprenavir; ABC = abacavir; SQV/r = ritonavir-boosted saquinavir; ATV/r = ritonavir-
boosted atazanavir; TDF = tenofovir; FTC = emtricitabine. 
 
 
1.7.3.2 NNRTI-containing regimens 
Alternative treatment options became available with the introduction of a third drug 
class.  In combination with NRTIs, NNRTIs were found to be at least as effective as PI-
containing regimens at suppressing the virus [289-291], although it was uncertain at 
first as to whether this was the case in patients starting therapy with low CD4 counts 
and high viral loads [292].  NNRTI regimens were particularly beneficial for those who 
could not tolerate the toxicities associated with PIs.  Table 1.10 displays some of the 
major clinical trials comparing the efficacy of NNRTI-containing regimens to dual NRTI 
and PI-containing cART regimens.   
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Table 1.10: Major clinical trials in NNRTI-containing cART versus dual therapy and PI-
containing cART. 
Study  Clinical trial  Authors, year  Main outcomes  Conclusions 
NVP/ZDV/ddI vs 
ZDV/ddI 
ACTG 241  D’Aquila et al. 
1996 [293] 
Change in CD4 count 
and viral load at 48 
weeks in NRTI-
experienced subjects 
with CD4 ≤350 
cells/mm
3. 
Adding NVP to ZDV/ddI 
improved long-term 
immunological and 
virological effects of 
therapy. 
NVP/ZDV/ddI vs 
ZDV/ddI 
ISS 047  Floridia et al. 
1999 [214] 
Change in CD4 count 
and viral load and 
proportion with viral 
load <400 copies/mL at 
24 and 48 weeks in 
ART-naïve subjects with 
AIDS or CD4 <200 
cells/mm
3. 
Three-drug combination 
more effective at 
sustaining 
immunological and 
virological response. 
NVP/ZDV/ddI vs 
NVP/ZDV vs 
ZDV/ddI 
INCAS Montaner  et al. 
1998 [294] 
Change in CD4 count 
and viral load (average 
of measures from 
weeks 40, 44, 48 and 
52) and proportion with 
viral load <20 
copies/mL at week 52 in 
ART-naïve subjects free 
from AIDS and with 
CD4 200-600 
cells/mm
3.  Rate of 
disease progression or 
death. 
Three-drug combination 
led to significantly 
greater and sustained 
decrease in plasma viral 
load than the two-drug 
regimens. 
NVP/ZDV/3TC vs 
NFV/ZDV/3TC 
COMBINE Podzamczer  et 
al. 2002 [289] 
Change in CD4 count 
and viral load and 
proportion with viral 
load <200 and <20 
copies/mL at 12 months 
in ART-naïve subjects. 
NVP/ZDV/3TC is at 
least as effective as 
NFV/ZDV/3TC as first-
line therapy for HIV 
disease. 
DLV/ZDV/ddI vs 
DLV/ZDV vs 
DLV/ddI vs 
ZDV/ddI 
ACTG 261  Friedland et al. 
1999 [295] 
Change in CD4 count 
and viral load at 4-12 
and 40-48 weeks in 
ZDV- or ddI-
experienced subjects 
with CD4 200-500 
cells/mm
3. 
Therapy with 
DLV/ZDV/ddI showed 
modest, but not always 
significant, antiviral 
activity and CD4 count 
benefit compare to two-
drug regimens. 
EFV/ZDV/3TC vs 
EFV/IDV vs 
IDV/ZDV/3TC 
DMP 266-
006 
Staszewski et 
al. 1999 [290] 
Change in CD4 count 
and proportion with viral 
load <400 and <50 
copies/mL at 48,72 and 
144 weeks in PI-, 
NNRTI- and 3TC-naïve 
subjects with CD4 ≥50 
cells/mm
3 and viral load 
> 10000 copies/mL. 
EFV/ZDV/3TC has 
superior efficacy with 
durability of response 
than IDV/ZDV/3TC. 
Initial regimens: 
EFV/ddI/d4T vs 
NFV/ddI/d4T vs 
EFV/ZDV/3TC vs 
NFV/ZDV/3TC vs 
EFV/NFV/ddI/ 
d4T vs 
EFV/NFV/ZDV/ 
3TC 
ACTG 384  Shafer et al. 
2003 [291] 
Comparison of time to 
regimen failure between 
four-drug regimens and 
three-drug regimens 
followed sequentially by 
further three-drug 
regimen with same 
NRTIs and opposite 
third drug in ART-naïve 
subjects. 
There was no significant 
difference in the 
duration of successful 
treatment between a 
single four-drug 
regimen and two 
consecutive three-drug 
regimens.  Initiating 
therapy with 
EFV/ZDV/3TC was the 
optimal choice. 
Notes: NVP = nevirapine; ZDV = zidovudine; ddI = didanosine; 3TC = lamivudine; DLV = delavirdine; EFV 
= efavirenz; IDV = indinavir; d4T = stavudine; NFV = nelfinavir. 
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The first NNRTI was licensed in 1996: nevirapine (NVP) [296].  NVP in combination 
with ZDV and ddI was found to improve the long-term virological and immunological 
effects of the treatment compared to the NRTIs alone [214,293].  It was also found to 
be at least as effective as NFV in a three-drug regimen as first-line therapy [289]. 
 
The FDA licensed another NNRTI, delavirdine (DLV), in 1997 [220].  However the 
following year, an application for licensing this drug in Europe was rejected by the 
European pharmaceutical licensing board, as it was not considered to offer any unique 
benefits when compared to other NNRTIs [297].  A randomised trial found that a three-
drug combination of DLV, ZDV and ddI resulted in moderately improved antiviral 
activity and CD4 count increase compared to each of the two-drug combinations of the 
same drugs, however these differences were not all statistically significant [295].   
 
In 1998, efavirenz (EFV) was given approval [298].  In one trial, NNRTI-, PI- and 3TC-
naïve patients were randomised to either EFV or IDV in combination with ZDV and 
3TC.  It was found that patients in the EFV arm were significantly more likely to 
suppress their viral loads to less than 400 copies/mL (undetectable by standard RNA 
assays at that time) than those in the IDV arm and that this combination was better 
tolerated [290].  Another trial compared time to regimen failure between EFV-and NFV-
containing regimens [291].  Four-drug regimens containing two NRTIs and both EFV 
and NFV were compared to initial three-drug regimens containing two NRTIs plus 
either EFV or NFV sequentially followed by the same NRTIs plus the opposite third 
drug.  The optimal choice was found to be EFV/ZDV/3TC. 
 
EFV and NVP were compared in the 2NN study (2004) in a randomised trial of first-line 
ART.  No difference was found in virological efficacy between regimens containing 
d4T/3TC and either EFV or NVP [299].  However a number of cohort studies found an 
increased risk of virological failure in those starting NVP [300-304].  This is investigated 
further in Chapter 6. 
 
1.7.3.3 Triple NRTI regimens 
With the increasing development of NRTIs, clinical trials were carried out to investigate 
the potential advantages of triple NRTI regimens.  These would not only reduce and 
simplify pill burden leading to possible improvements in adherence, but also would 
avoid the risks of the severe toxicities associated with PIs.  Furthermore, starting a 
triple NRTI regimen as first-line treatment (with no previous use of ART) would keep 
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the efficacy of other drug classes optimal for use in later therapy options if the NRTI 
regimen started to fail [305].   
 
However, the results from clinical trials looking at ART-naïve patients showed no 
benefits in terms of antiviral efficacy in comparison to both PI- and NNRTI-containing 
cART regimens [185,306-308].  Staszewski et al. (2001) found that similar proportions 
of patients starting regimens containing a combination pill of ZDV and 3TC (Combivir) 
and either abacavir (ABC) (an NRTI that was approved in 1998 [309]) or IDV, achieved 
virological suppression at 48 weeks [307].  Gulick et al. in 2004 found that the triple 
NRTI regimen ZDV/3TC/ABC was virologically inferior to ZDV/3TC/EFV [185].  Due to 
the suboptimal virological response observed in trials, current guidelines do not 
recommend triple NRTI regimens for ART-naïve patients starting first-line therapy [40-
42]. 
 
In ART-experienced patients, the use of triple NRTI regimens was in the past 
suggested as a simplification strategy.  In a number of trials, in patients with a high 
level of viral suppression, switching to a triple NRTI combination from PI- and NNRTI-
containing regimen was found to maintain suppression at least as well as continuing on 
a PI regimen and improved lipid profiles in some patients (reducing cardiovascular 
risks) [310-312].  This could be attributed to the increased number of adverse side 
effects associated with the PI, withdrawals of consent and a desire to simplify 
treatment.  They are now only recommended in highly selected circumstances due to 
their low potency and the ease of resistant strains emerging.  There is evidence that in 
patients with undetectable viral load (i.e. suppressed to a level undetectable by RNA 
assays) before switching, the emergence of NRTI-resistant strains may result in 
subsequent virological failure, therefore using this as a simplification strategy may need 
careful monitoring [313].  Indeed, evidence from the I.Co.N.A. (Italian Cohort of 
Antiretroviral Naïve Patients) study showed that patients who achieved virological 
suppression whilst receiving ABC-containing cART were more likely to experience viral 
rebound (i.e. if the viral load increases and remains above the level of detection) than 
those receiving EFV instead [314].  Table 1.11 provides the results from major clinical 
trials looking at triple NRTI regimens compared to PI- and NNRTI-containing cART 
regimens. 
 
A number of combination drugs were approved over this period with the aim of 
reducing pill burden.  Following Combivir in 1997 were Trizivir in 2000 (ZDV/3TC/ABC), 
Epzicom (USA) and Kivexa (Europe) (both 3TC/ABC) in 2004, Truvada in 2004 
(FTC/TDF) and most recently Atripla (FTC/TDF/EFV) in 2006 [215,216,220].  
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Table 1.11: Major clinical trials in triple NRTI therapy versus PI-/NNRTI-containing 
cART. 
Study  Clinical trial  Authors, year  Main outcomes  Conclusions 
ZDV/3TC/ABC vs 
ZDV/3TC/EFV vs 
ZDV/3TC/ABC/EFV 
ACTG 5095  Gulick et al. 
2004 [185] 
Virological failure 
(two consecutive 
viral loads >200 
copies/mL) at 32 
weeks and time to 
virological failure in 
ART-naïve subjects. 
The triple NRTI combination 
was virologically inferior to 
both EFV-containing 
regimens. 
ddI/d4T/3TC vs 
ddI/d4T/IDV vs 
ddI/d4T/NVP 
Atlantic 
study 
Van Leeuwen 
et al. 2003 
[306] 
% with viral load 
<500 copies/mL and 
<50 copies/mL at 48 
weeks and 96 
weeks in ART-naïve 
subjects with CD4 
>200 cell/mm
3, viral 
load >500 
copies/mL. 
A smaller percentage of 
subjects randomised to 
receive 3TC as third drug 
reached a viral load <50 
copies at 48 and 98 weeks 
in an on-treatment analysis. 
ZDV/3TC/ABC vs 
ZDV/3TC/IDV 
CNAAB3005 Staszewski  et 
al. 2001 [307] 
% with viral load 
<400 copies/mL at 
48 weeks in ART-
naïve subjects with 
CD4 >100 cell/mm
3, 
viral load >10000 
copies/mL. 
Triple NRTI regimen was 
equivalent to IDV-containing 
one in achieving virological 
suppression. 
Continuation of two 
NRTIs/PI vs 
switching PI to 
ABC 
CNA30017 Clumeck  et 
al. 1999 [310] 
Time to virological 
failure (two 
consecutive viral 
loads >400 
copies/mL or 
premature 
discontinuation of 
treatment) subjects 
with viral load <50 
copies/mL. 
The replacement of a PI 
with ABC in a triple 
combination regimen 
following prolonged 
suppression of viral load 
provides continued 
virological suppression. 
Continuation of 
three NRTIs vs 
continuation of two 
NRTIs/PI vs 
continuation of two 
NRTIs/NNRTI vs 
switching to 
ZDV/3TC/ABC 
(Trizivir) 
AZL30002 Katlama  et al. 
2002 [311] 
Time to virological 
failure (two 
consecutive viral 
loads >400 
copies/mL) in 
subjects with CD4 
≥100 cells/mm
3 and 
viral load <400 
copies/mL 
throughout therapy. 
Switching to Trizivir had 
equivalent efficacy to triple 
therapy. 
Continuation of PI-
based regimen vs 
switching to ABC or 
EFV from PI 
 Maggiolo  et 
al. 2003 [312] 
% with viral load <50 
copies/mL at 52 
weeks in ABC- and 
NNRTI-naïve 
subjects with viral 
load <50 copies/mL. 
Switching from a PI-based 
regimen to ABC or EFV 
maintains optimal levels of 
virological suppression. 
Notes: ZDV = zidovudine; 3TC = lamivudine; ABC = abacavir; EFV = efavirenz; ddI = didanosine; d4T = 
stavudine; IDV = indinavir; NVP = nevirapine. 
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1.7.4  Current aims of cART 
The primary aim of cART for initial treatment of HIV infection is to suppress viral 
replication for as long as possible, as measured by the viral load [40-42].  Virological 
suppression enables recovery of the immune system, which is indicated by the CD4 
lymphocyte count and hence reduces the risk of opportunistic infections and death 
[186,187]. 
 
Treatment guidelines offer advice to physicians providing HIV care with regards to 
when to start therapy, what drugs to start with, when to change regimens and what 
regimens to switch to after therapy fails [40-42].  Current guidelines recommend that 
patients should start ART if they are symptomatic or severely immunocompromised, 
i.e. with a CD4 count less than 350 cells/mm
3.  The recommended initial antiretroviral 
treatment is currently an EFV-containing regimen with a dual NRTI backbone when 
good adherence is expected, due to the convenience, superior virological suppression, 
lower rates of toxic effects and fewer drug interactions [40-42].  Alternatively, if a PI-
containing regimen is prescribed, it should be boosted with RTV to increase blood 
levels of the other PI.  Triple NRTI regimens are no longer recommended as initial 
therapy due to the inferior potency compared to an EFV-containing regimen. 
 
Patients may change regimens or switch components of a regimen due to toxic effects, 
intolerance, inconvenience or failure of treatment to suppress the viral load.  Causes of 
treatment failure include inadequate adherence [191-196], emergence or pre-existence 
of drug resistance [172,190] or low drug absorption  [188,189].  If a patient experiences 
failure, the patient’s immunological condition and remaining treatment options, 
determined by how much resistance the virus has built up to specific drugs or drug 
classes, are both considered when determining the recommended course of action.   
 
In early treatment failure, when the patient still has many treatment options available, 
the aim is to achieve re-suppression of viral replication by substituting one or more 
drugs in the regimen or by completely switching regimen, depending upon the cause of 
failure [41,315].  In late treatment failure, in patients who still have high CD4 counts but 
with limited treatment options, it is reasonable to continue with the same regimen but 
with close monitoring of CD4 count.  CD4 count can remain high for prolonged periods, 
even when the viral load is detectable, therefore keeping the risk of opportunistic 
infections low [316].  In late treatment failure, in patients with low CD4 counts, it is 
recommended that the patient continue treatment with the hope that new drug classes 
will become available [41,315]. 
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The introduction of ART has drastically improved the outlook for HIV patients both in 
the short-term and long-term.  However, the development of drug-resistant strains 
remains a major barrier to successful treatment.  This is discussed next. 
 
1.8  Antiretroviral drug resistance 
Drug-resistant strains of HIV develop due to the high frequency of genetic errors during 
viral replication.  These errors can result in survival benefits in the viral copies over the 
original virus, e.g. resistance to antiretroviral drugs.  Treatment with antiretroviral drugs 
may then fail to suppress this new strain of drug-resistant virus and consequently the 
viral load may increase [16,317-323].  To understand how this happens, the process by 
which these changes occur is detailed. 
 
1.8.1 Genetic  mutations 
As detailed earlier, HIV infection is characterised by a very high turnover of virus 
production.  Replication of the virus is highly error-prone and results in a high 
frequency of genetic mutations in the replicated copies of the virus [4,10,13,324].  A 
genetic mutation is defined as an alteration or mistake in the genetic code [15].  If a 
mutation occurs in the specific code needed to manufacture the viral proteins, reverse 
transcriptase or protease, this may affect whether or not the antiretroviral drugs 
designed to target these proteins are able to inhibit replication of this virus.   
 
1.8.2 Selection 
The concept of natural selection (introduced by Charles Darwin [325]) highlights that 
species with characteristics advantageous to survival are more likely to reproduce than 
those without, meaning that the genes responsible for these characteristics are more 
likely to be passed on.  In a viral population, a strain with mutations conferring 
resistance to antiretroviral drugs has a survival benefit in the presence of ART 
compared to drug-sensitive HIV (wild-type), i.e. it has a higher level of fitness, which is 
the ability to replicate in a well-defined environment.  However in drug-resistant strains 
the efficiency of the target enzymes (e.g. reverse transcriptase, protease) is lowered, 
which results in inefficient replication (a reduced replicative capacity) in comparison to 
wild-type [38,326-330].  In the absence of ART, wild-type virus has a higher level of 
fitness and thus produces more successful replicated copies than drug-resistant HIV 
and remains the dominant viral strain.  If therapy is stopped after drug resistance has 
developed, the wild-type may again become the dominant strain [331-334], for 
example, if 3TC is stopped, the HIV variants with the M184I/V mutation rapidly 
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disappear [335].  Figure 1.5 shows in a diagram how drug-resistant virus populations 
are selected. 
 
Figure 1.5: Resistance and viral load.   
 
 
 
 
 
Figure not available due to copyright restrictions. 
 
Source: www.aidsmap.com. 
 
1.8.3  Reducing the risk of drug resistance 
Drug-resistant strains of HIV may emerge when treatment fails to suppress viral 
replication effectively either through suboptimal treatment, e.g. monotherapy, or 
moderately high but incomplete adherence [16,317-323].  In suboptimal concentrations 
of antiretroviral drugs, the virus has more chance to replicate and therefore it is more 
likely that resistance-associated mutations will occur.  The most effective strategy to 
prevent the development of drug resistance is to completely suppress viral replication 
and sustain an undetectable viral load with the initial cART regimen [336,337]. 
 
In addition, the use of more than one drug class in cART means that viruses that 
develop resistance to one drug class may still be sensitive to the others and so with a 
rapid switch of drugs virological suppression may be sustained.  Current guidelines 
recommend that single drug substitutions should generally be avoided to ensure that 
minor resistant strains do not emerge [338,339].  Different drugs or drug classes have 
different genetic barriers to resistance, that is thresholds of evolving a sufficient number 
of resistance mutations in the viral population to overcome the efficacy of the drugs in 
keeping the viral load suppressed.  For example, NNRTIs have a low genetic barrier 
and only one critical resistance mutation needs to occur for NNRTI-resistant strains to 
emerge, therefore in an NNRTI-containing cART regimen it is vital to keep the viral load 
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undetectable.  RTV-boosted PI regimens have high genetic barriers and drug 
resistance appears to be limited if virological failure occurs [340]. 
 
1.8.4 Resistance  testing 
HIV infected individuals may have resistance tests carried out in routine clinical 
practice to see if their dominant HIV strain has drug resistance.  There are two types of 
resistance testing: phenotypic and genotypic [338,339,341,342].  Phenotypic tests 
measure the concentration of a drug required to reduce viral replication by a set 
amount compared to wild-type virus.  Genotypic tests extract and sequence HIV RNA 
to look for specific mutations thought to be associated with drug resistance.  Currently 
only RT and PR genes can be sequenced by commonly available assays.  Both types 
of tests have strengths and weaknesses.  Phenotypic tests detect actual drug 
resistance rather than simply listing mutations and are therefore easier to interpret.  
However they take longer to do and are twice as expensive as genotypic tests.   
Genotypic tests report the specific mutations rather than just low, medium or high-level 
resistance, which can be an advantage, but the presence of mutations might not 
necessarily mean the virus has full resistance to a drug [343].  This is why 
interpretation systems have been developed to improve the understanding of 
mutational interactions.  These are discussed further below. 
 
1.8.4.1 Genetic sequencing   
To establish the presence of drug resistance mutations, the genetic sequence from the 
test HIV RNA is compared to a reference or consensus sequence, obtained from the 
RNA of wild-type HIV [344].  A consensus sequence is a sequence of the most 
common nucleotide bases.  The reference sequence generally used in HIV research is 
from the HIV-1 strain HXB2 [344,345].  Comparison of the test RNA sequence against 
this reference sequence highlights the positions where there are differences, that is, 
where mutations have occurred and certain mutations or combinations of mutations 
have been found to be associated with phenotypic resistance to certain antiretroviral 
drugs [346].  Drug resistance can be interpreted using one of the established 
interpretation systems.  These have either been devised by experts in the field based 
on literature looking at correlations between genotypic and phenotypic data or between 
treatment history and clinical response (rule-based system), or have been based on 
statistical modelling on databases of genotypes and phenotypes [347,348]. 
 
1.8.4.2 Genotypic resistance and interpretation systems   
The International AIDS Society (IAS-USA) publishes updated lists of point mutations, 
i.e. specific positions on the RT and PR RNA genes thought to be related to resistance 
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[346].  Each position relates to a codon that encodes an amino acid.  The amino acids 
expected in the wild-type virus are specified, together with the amino acid substitutions 
resulting from mutations that would indicate antiretroviral resistance.  Using this, 
researchers can specify how many NRTI-, NNRTI-, major PI- and minor PI-associated 
mutations a virus has from the RNA sequence extracted from a plasma sample of the 
infected individual’s blood.  See Appendix I for the current IAS-USA list of drug 
resistance mutations from Spring 2008 [346]. 
 
However, the aim of conducting a genotypic resistance test is to predict how a patient 
will respond to therapy.  Interpreting how drug resistance will impact on this is more 
complicated than merely reporting the number of resistance-associated mutations.   
Certain combinations of mutations can increase or decrease viral susceptibility to drugs 
and so a number of algorithms to interpret resistance have been developed to try and 
take these into account.  In particular they define sets of drug-specific rules that identify 
combinations of mutations that confer resistance to each drug.  Each algorithm then 
outputs a genotypic sensitivity score (GSS), which tries to predict how sensitive or how 
resistant the virus is to the drug regimen the patient is starting [347].  Three of the main 
algorithms presently used are the Rega algorithm [349] (Appendix II), the ANRS 
(Agence Nationale de Recherche sur le SIDA) algorithm [350] and the Stanford 
University algorithm (HIVdb) [351] (both found at http://hivdb.stanford.edu/pages/asi/). 
 
1.8.4.3 Guidelines   
The most recent guidelines for the clinical use of drug resistance testing from the IAS-
USA and from the British HIV Association (BHIVA) recommend resistance testing at 
the time of HIV diagnosis where possible, as well as in all cases of virological failure 
[42,338].  It is now accepted that identifying the presence of resistance is an important 
addition in the management of patients in order to provide optimal treatment.   
Genotypic tests are not favoured over phenotypic but are more commonly used due to 
their lower cost and faster turnaround time. 
 
1.8.5  Transmitted drug resistance 
Drug-resistant strains can be transmitted to other individuals therefore it is possible for 
HIV infected individuals who have never received ART to have viral drug resistance 
[337,352,353].  As drug-resistant HIV variants tend to have a reduced replicative 
capacity compared to wild-type, in ART-naïve patients they remain in the minority and 
so transmitted drug resistance (TDR) may be difficult to pick up by routine resistance 
tests [339].  Prevalence of TDR has been reported in numerous studies and is 
discussed in detail in Chapter 5.  However a problem with comparing estimates of 
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prevalence is that different definitions of resistance are used.  Shafer et al. (2007) 
suggested a standardised list of mutations to define TDR [345]. 
 
1.9  HIV genetic diversity 
Within both types of HIV, HIV-1 and HIV-2, there are further subtypes based on 
clustering of genetically similar strains.  The HIV-1 subtypes are discussed in Chapter 
4.  Phylogenetic analysis, which is the method used to recognise different HIV strains, 
is discussed below. 
 
1.9.1 Phylogenetic  analysis 
Phylogenetic analysis identifies clusters of genetically similar viral strains and uses a 
hierarchical model to construct the most likely evolutionary history [354].  A 
phylogenetic tree resembles a family tree diagram in appearance, mapping a sample of 
RNA sequences back in time to the nearest point in history at which they all share a 
common ancestor.  This point is where all the branches in the tree merge and is called 
the most recent common ancestor.  Each branch represents an event (mutation or 
recombination) that has led to a change in the nucleotide base.  The genetic distance 
between two sequences is measured by the expected number of nucleotide 
substitutions that have occurred over time between them and their most recent 
common ancestor and can be represented by branch lengths in the tree.  A statistical 
method can then be applied to determine the most likely tree topology and branch 
lengths.   
 
Phylogenetic analysis can be used to determine the HIV-1 subtype an individual is 
infected with.  Viral RNA strands extracted from a patient’s blood plasma are 
sequenced and aligned to make a site-by-site comparison.  If the person is only 
infected with one strain of HIV, all of the HIV RNA will have an ancestral sequence in 
common.  These ancestral sequences can be compared against consensus sequences 
that have been identified for each subtype [344]. 
 
1.9.2  The HIV genome 
Maps of the HIV-1 and HIV-2 genomes have been constructed to display the different 
regions that code for different functions.  These are displayed in Figure 1.6 [18].  Three 
of the major regions are known as env, pol and gag [344,355,356].  The env (envelope) 
region encodes the glycoproteins, which interact with host cell surface receptors and 
are needed to allow the virus to enter the cell.  The pol (polymerase) region contains 
the genetic code for producing the enzymes essential for viral replication, i.e. HIV 
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reverse transcriptase for converting viral RNA into DNA, integrase for incorporating the 
viral DNA into the cell DNA and protease for processing other HIV proteins into 
functional forms.  The gag region encodes the structural proteins of the virus [18]. 
 
Figure 1.6: Genomic organisation of HIV-1 and HIV-2.   
 
 
 
 
Figure not available due to copyright restrictions. 
 
Source: Weiss (2000) [18]. 
 
1.9.3  Implications for vaccine development 
The vast genetic variability of HIV, together with the complex viral biology and a limited 
understanding of the immune responses that protect against HIV infection, pose major 
challenges in the development of potential HIV vaccines.  So far, these obstacles have 
not been overcome but finding a vaccine is essential for prevention of the continuing 
worldwide spread.  In 1987, President Bill Clinton set a ten-year goal for developing an 
HIV/AIDS vaccine, however this has not been accomplished.  Nevertheless, clinical 
trials continue to evaluate new vaccination strategies in the hope of developing a safe, 
effective and affordable vaccine.  Phase I and II trials of candidate vaccines are being 
conducted [357-359]. 
 
1.10  Aims and objectives of this thesis 
The broad aim of this thesis was to investigate the factors potentially associated with 
different responses to cART measured using virological and immunological endpoints, 
as well as the development of toxicities to a specific regimen.  The analyses were 
based on data from the EuroSIDA study, which is a large, prospective, observational 
cohort study that includes patients from all across Europe and a minority from Israel 
and Argentina.  Details of the study and of the EuroSIDA patients are described in 
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Chapter 2, which then goes on to detail the statistical methods employed in the 
analysis of endpoints throughout this thesis. 
 
Chapter 3 investigates both regional differences and changes over calendar time in the 
rate of virological response to first-line cART.  The motivation for this was to see if the 
ongoing clinical success of cART due to an increasing availability of new antiretroviral 
drugs and improvements in clinical support and the management of associated 
toxicities, was also reflected in an improving rate of virological success over time, and if 
so, in which regions.  Three time periods were compared: early-cART years (1996-
1997), mid-cART years (1998-1999) and late-cART years (2000-2004).  The analysis 
was stratified by geographical region within EuroSIDA, which was split into South, 
Central West, North and East.  Response to cART in these four regions was also 
investigated within each time period to see if regional variability had decreased over 
the years since ART became more widely available.   
 
Chapter 4 compares virological and immunological response to cART across patients 
infected with different HIV-1 subtypes in a population where subtype B is prevalent.  
The aim of this was to investigate whether or not the genetic differences that define 
different subtypes appear to affect the efficacy of antiretroviral drugs.  Emerging 
differences in genetic mutations and selection of resistance pathways have been 
observed between subtypes in other studies that could affect drug susceptibility and 
response.   
 
Chapter 5 investigates trends in transmitted drug resistance (TDR) across ART-naïve 
patients in different geographical regions, patients infected with different HIV-1 
subtypes and over calendar time.  It also looks at the factors associated with detection 
of TDR and goes on to investigate whether or not the presence of baseline TDR has a 
negative impact on virological and immunological response rates following initiation of 
cART.  The findings from analyses such as these are important for assessing the value 
of resistance testing in ART-naïve patients.   
 
Chapter 6 specifically compares two NNRTIs in terms of virological response following 
initiation of treatment.  A previous EuroSIDA analysis compared NVP-containing 
regimens with EFV-containing regimens and found that patients starting NVP were 
twice as likely to experience virological failure than patients starting EFV [300].  The 
analyses in this chapter aimed to re-investigate this difference and see if ART 
resistance present at the start of treatment could explain this finding.  Resistance 
profiles at the time of virological failure were also compared between the two groups. 
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Chapter 7 looks at the toxic effects of cART.  It investigates reasons for discontinuation 
of the NRTI, ABC, in particular the potentially fatal toxicity, hypersensitivity reaction 
(HSR).  The incidence of ABC related HSR was investigated according to the line of 
therapy within which ABC was received, geographical region, calendar time, and co-
formulation of ABC (as part of Kivexa or as part of either Trizivir or as a single tablet).  
The rate of death associated with ABC HSR was also determined.  This is important to 
identify patients most at risk and to monitor trends.   
 
Chapter 8 summarises the findings and conclusions of this thesis with a discussion of 
the overall limitations, implications and applications of these results. 
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Chapter 2. Patients and methodology 
2.1 Patients 
2.1.1  EuroSIDA and AIDS in Europe 
The data analysed in this thesis are from the EuroSIDA study, which is a prospective 
observational cohort of 14,310 patients with HIV-1 infection.  The project is one of the 
largest international cohort studies, so far spanning 95 centres across 31 European 
countries, Israel and Argentina.  EuroSIDA began in May 1994 to continue the work 
generated by its predecessor, the AIDS in Europe study [360].  AIDS in Europe 
gathered retrospective data on every patient with AIDS diagnosed between 1979 and 
1989 in 52 centres across 17 European countries, giving a total of 6572 patients 
enrolled into the study.  It collected data from patient case-notes on demographics, HIV 
antibody status, CD4 lymphocyte counts, use of zidovudine, PCP (now known as 
Pneumocystis jiroveci pneumonia) prophylaxis, details of AIDS defining illnesses and 
opportunistic infections.  Like EuroSIDA, the study was coordinated in Copenhagen by 
the project leader, Professor Jens Lundgren, director of the Copenhagen HIV 
Programme (CHIP) at Panum Institute in Copenhagen, Denmark.  Details of CHIP can 
be found at http://www.cphiv.dk.  EuroSIDA evolved from this initial study with the aim 
of collecting more detailed prospective data.  
 
Primary support for EuroSIDA is provided by the European Commission BIOMED 1 
(CT94-1637), BIOMED 2 (CT97-2713), the fifth Framework (QLK2-2000-00773) and 
the sixth Framework (LSHP-CT-2006-018632) programmes.   Current support also 
includes unrestricted grants by Bristol-Myers Squibb, GlaxoSmithKline, Roche, Gilead, 
Pfizer, Merck and Co.,  Tibotec and Boehringer-Ingelheim, and the participation of 
centres from Switzerland was supported by a grant from the Swiss Federal Office for 
Education and Science.  The study is guided by the steering committee, which consists 
of regional representatives from across Europe and is led by the chair, Bruno 
Ledergerber from Zürich in Switzerland.  Regular elections are held for positions on the 
steering committee.  Appendix III provides a full list of the members of the EuroSIDA 
study group.  The study receives statistical contribution and support from the statistical 
centre in the Royal Free and University College Medical School, London and also data 
input relating to genotypic resistance and subtype diversity from the virology laboratory 
group, based in the central virology centres in London, UK (up to 2004) and in 
Badalona, Spain.  Both the statistical centre and the virology coordinators are also 
involved in the proposal and development of new EuroSIDA projects.  
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EuroSIDA is also one of the major contributors of data to the D:A:D study (Data 
collection on Adverse events of anti-HIV Drugs), which has the primary purpose of 
assessing the risk of myocardial infarction in HIV infected patients and is looking at 
cardiovascular risk factors associated with ART [361,362]. 
 
2.1.2 Data  collection 
The EuroSIDA study has so far enrolled seven cohorts of consecutive HIV-1 infected 
patients with a pre-booked clinic appointment, aged 16 or over, for which data were 
collected at their clinical centres.  This ensures that the selection of patients under 
current follow-up is not based on any characteristics or background and so is unbiased 
to gain a representative sample from each clinic.  Patients were enrolled until a 
predefined number was attained from each centre, starting with Cohort I in May 1994 
(Figure 2.1).  For Cohort I-III, eligible patients were those with a CD4 lymphocyte count 
of below 500 cells/mm
3 in the previous four months. This restriction was removed for 
Cohorts IV-VII.  A further specification for Cohorts VI and VII were that half of the 
patients enrolled should be from East European countries.  The reason for this was to 
boost the numbers in East Europe in order to gain a more comprehensive view of the 
epidemic in this region.  To date, EuroSIDA has collected 74,581 person years of 
patient follow-up.     
 
Information is provided on a standardised data collection form at baseline and every six 
months thereafter with follow-up to (median date of last visit) January 2007 at present.  
Examples of the current forms can be found in Appendix IV.  At each follow-up visit, 
details on all CD4 counts and viral loads measured since the last follow-up, including 
methods used and the lower limits of detection, are collected.  A total of 310,503 CD4 
counts from 14,118 patients and 257,749 viral load measurements from 12,094 
patients have been collected so far (including retrospective and prospective data), with 
a median average of 18 (interquartile range (IQR): 8-34) CD4 counts per patient 
(median 3.0 months (IQR: 2.0-4.1 months) between each measurement) and 19 (IQR: 
9-32) viral load measurements per patient (median 3.0 months (IQR: 2.0-4.0 months) 
between each measurement).  The dates of starting and stopping each antiretroviral 
drug, reasons for discontinuation of drugs, and the use of drugs for prophylaxis against 
opportunistic infections are also recorded, as are dates of diagnosis of all AIDS 
defining illnesses, including those diagnoses made subsequent to the initial diagnosis, 
using the 1993 clinical definition of AIDS from the CDC [109].  Information on dosing 
levels of drugs is not collected in EuroSIDA, however it is assumed that if patients start 
ritonavir (RTV) plus another PI at the same time, then this is likely to be a boosted PI 
regimen with low-dose RTV. 
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Figure 2.1: Patients, enrolment dates and number of follow-up forms available according to cohort in EuroSIDA. 
 
 
Cohort I
n=3116
Spring 1994
26 follow-up forms
Cohort II
n=1365
Winter 1995/1996
23 follow-up forms
Cohort III
n=2841
Spring 1997
20 follow-up forms
Cohort IV
n=1225
Spring 1999
16 follow-up forms
Cohort V
n=1223
Autumn 2001
11 follow-up forms
Cohort VI
n=2121
Spring 2004
8 follow-up forms
Cohort VII
n=2419
Winter 2005/2006
4 follow-up forms
EuroSIDA patients
n=14310
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Members of the coordinating centre visit all centres participating in EuroSIDA to ensure 
correct patient selection and to verify that accurate data are supplied by checking the 
information provided against case-notes for all patients with clinical events and 10% 
randomly selected patients per year.  Centres have ethical approval according to their 
own local and national requirements and as part of the new contract with the European 
Commission, the coordinating centre is required to have copies on file of the approvals.  
The data collected in EuroSIDA is summarised in Table 2.1, which also indicates when 
new items were added to the follow-up forms. 
 
Table 2.1: Summary of EuroSIDA data collected. 
Demographics  Last HIV-subtyping ADDED Jun 1999 
Date of birth  Last HCV-subtyping ADDED Jun 2005 
Gender  Last resistance test ADDED Jun 2001 
Mode of infection  Hepatitis virology/serology results and dates  
ADDED Jan 1997 
Country of origin    HBV antibody test 
Race   HBVsAg 
Basic clinical information   HBV-DNA 
Height    HCV antibody test 
Weight   HCV-RNA 
Blood pressure ADDED Jun 2000  Antiretroviral treatment within the last 5 years 
Smoking ADDED Jun 2000  History of antiretrovirals taken: 
Family history of MI ADDED Jun 2000    Starting and stopping dates 
Pregnancy in women ADDED Jan 1997    If discontinued, reason for discontinuation 
ADDED Jan 1999 
Clinical events ADDED Jun 1998  Adherence rating ADDED Jan 2005 
Diagnosed since last follow-up of (with date of 
diagnosis):  Treatment against infections 
  Cardiovascular events  Drugs to prevent or treat opportunistic infection: 
  Metabolic events    Starting and stopping dates 
 Other  organ  events  Treatment related to risk of cardiovascular 
disease 
Laboratory values (and dates of measurement)  Medication related to risk of cardiovascular disease: 
Serum total and HDL cholesterol  
ADDED Jun 1999    Starting and stopping dates  
ADDED Jun 2000 
Serum triglycerides ADDED Jun 1999  Severe opportunistic infections 
Plasma glucose ADDED Jun 2004  Dates and diagnosis (definitive, presumptive, 
autopsy) 
S-creatinine ADDED Jun 2004  Other severe infections 
Haemoglobin  Dates and diagnosis (definitive, presumptive, 
autopsy) ADDED Jan 2006 
Platelet count ADDED Jun 2005  AIDS defining malignancies 
ALT ADDED Jun 2000  Dates and diagnosis (definitive, presumptive, 
autopsy) 
AST ADDED Jun 2000  Non-AIDS defining cancers 
INR ADDED Jun 2000  Dates and diagnosis (definitive, presumptive, 
autopsy) 
Bilirubin ADDED Jun 2005  For patients who died 
S-lactate (not LDH) ADDED Jun 2000  Date of death 
S-amylase ADDED Jun 2002  Autopsy performed 
CD4 counts  Presumed cause 
HIV RNA ADDED Jan 1997  CoDe case report form ADDED Jan 2005 
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All deaths and causes of death are collected in EuroSIDA.  Due to the lack of a uniform 
classification of deaths in HIV patients, especially in the increasing number of non-
AIDS deaths, in July 2004 the CoDe (Coding of Death in HIV) project was initiated to 
provide a standardised approach to collecting and reviewing data on causes of death in 
HIV.  A pilot study was carried out to test the CoDe case report forms and guidelines at 
clinics in the D:A:D study and a revised version was released in February 2005. 
 
2.1.3 Resistance  database 
EuroSIDA also requests that plasma samples from patients are collected every six 
months and shipped intermittently for storage in the central repository at the 
coordinating centre.  This repository currently holds 59,590 plasma samples from 8349 
patients.  Samples are then selected based on patient inclusion criteria for a number of 
ongoing projects and viral RNA is extracted for sequence analysis.  Genotypic 
resistance mutations can then be identified.  This process is conducted retrospectively, 
even though the collection of plasma samples is done prospectively, and so resistance 
test results are not communicated to clinicians at the time of storing the sample.  At 
present, the genotypic resistance database contains 4427 partial or full sequences of 
the HIV-1 RT (reverse transcriptase) and PR (protease) genes from 2535 patients.  
Sequence analysis of RT and PR reading frames is performed using the Trugene HIV-
1 genotyping Kit and OpenGene DNA Sequencing System according to the 
manufacturer's recommendations (Bayer, Barcelona, Spain) and mutations are 
identified by comparison against a reference sequence of the subtype B isolate, HXB2.  
The database also holds information on mutations identified in resistance tests 
performed at the clinical sites, as requested on the follow-up forms.  A total of 2143 
paper copies of resistance test results from 1417 patients have been collected.   
 
HIV-1 subtypes in EuroSIDA are primarily ascertained using the plasma samples 
analysed in the central virology laboratories.  Phylogenetic analysis of the RT and PR 
genes is used to determine subtype.  So far, 634 subtypes have been identified in this 
way.  When sequences have been incomplete, serology methods have previously been 
used to determine subtype, which do not give as reliable results as phylogenetic 
analysis.  The database holds 564 subtypes determined using a serology method.  In 
the absence of plasma samples, clinics can provide information on subtypes based on 
the results of genetic sequencing conducted in the local laboratories.  A total of 183 
have been provided so far.  If these are also not available, any subtype assignment in 
the patients’ case-notes reported on the follow-up forms is taken.  At present there are 
2348 patients with HIV-1 subtype determined on the forms.  This gives an overall total 
of 3729 subtypes identified in EuroSIDA. 
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2.1.4 Publications 
As of April 2008, 92 publications have appeared in peer-reviewed journals, which have 
described analyses investigating a wide range of predictive markers for survival and 
response rates following initiation of ART.  Analyses have used virological, 
immunological and clinical endpoints [147] and include looking at trends over time 
[140], response according to specific regimens [300], triple class failure [363], influence 
of hepatitis B [364] and C [365] on disease progression, drug resistance [366] and 
incidence of AIDS defining illnesses [367]. 
 
2.1.5  Patient characteristics in EuroSIDA at January 2007 
To give a recent overview of the patients in EuroSIDA, the characteristics of 7932 
patients who were under prospective follow-up at 1st January 2007 are summarised in 
Table 2.2.  Three quarters of the study population were male and the majority were of 
white ethnicity.  A total of 40.6% of individuals were exposed to HIV via homo/bisexual 
contact (men who have sex with men (MSM)), 21.0% were injecting drug users (IDUs) 
and 31.3% were heterosexual.  Almost a third had been previously diagnosed with an 
AIDS defining illness, 6.0% were co-infected with hepatitis B and 24.5% were co-
infected with hepatitis C.  The median date of enrolment into EuroSIDA was June 2000 
(interquartile range (IQR): March 1997-March 2004) and the median age was 44 (IQR: 
38-51) years.  Median CD4 count and viral load at the date 1st January 2007 were 480 
(IQR: 330-661) cells/mm
3 and 1.7 (IQR: 1.6-2.1) log10copies/mL respectively. 
 
EuroSIDA is divided into broad geographical regions based on the location of the 
clinical centres, the borders of which were chosen arbitrarily early on in the study in 
order to make comparisons between areas of Europe.  These are defined as South 
(Argentina, Greece, Israel, Italy, Portugal, Spain), Central West (Austria, Belgium, 
France, south Germany, Luxembourg and Switzerland), North (Denmark, Ireland, north 
Germany, Netherlands, Norway, Sweden, UK, Finland), and the newly established East 
region (Belarus, Russia, Ukraine, Serbia, Croatia, Poland, Hungary, Romania, 
Slovakia, Czech Republic, Bulgaria, Estonia, Latvia and Lithuania).  Although not in 
Europe, Argentina and Israel were included after links were established with centres 
that offered to provide data and were added into the South region due to similarities in 
characteristics.  The East region has further been split into Central East (Serbia, 
Croatia, Poland, Hungary, Romania, Slovakia, Czech Republic, Bulgaria) and East 
(Belarus, Russia, Ukraine, Estonia, Latvia and Lithuania), however numbers are still 
limited at present in both groups and therefore the aggregated East region is used in 
many analyses.  At January 2007, 31.4% of patients were from the South region, 
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24.8% were from the Central West, 23.8% were from the North and 20.0% from the 
East. 
 
Table 2.2: Demographics and laboratory data of 7932 EuroSIDA patients under follow-
up at 1st January 2007. 
  n %     Median  Interquartile  range
All 7932  100   Date of enrolment  Jun 00  Mar 97-Mar 04 
Male 5843  73.7   Age (years)  44  38-51 
HIV exposure group    CD4 count (cells/mm
3)    
 MSM  3183  40.1    At  Jan  2007
(1)  480 330-661 
 IDU  1665  21.0    Nadir
(2)  260 135-409 
 Heterosexual  2481  31.3   Time from nadir (years)  9  5-11 
 Other  603  7.6   Viral load (log10copies/mL)    
Ethnicity        At  Jan  2007
 (3)  1.7 1.6-2.1 
 White  7007  88.3    Maximum  ever
(4)  4.9 4.1-5.4 
 Asian  153  1.9   Time from HIV+ve diagnosis (years)  12  7-16 
 Black  420  5.3   Note: Median CD4 counts and viral loads based on measurements 
 Unknown  352  4.4
 
from 
(1)6849, 
(2)7668, 
(3)6260 and 
(4)7566 patients.  
MSM = men who have sex with men ; IDU = injecting drug use.
 
EuroSIDA region*         
 South  2493  31.4   *EuroSIDA geographical regions 
 Central  West  1968  24.8  
 North  1886  23.8  
 East  1585  20.0  
Origin      
 Same  country  as 
centre 
5758 72.6
 
 Other  European  409  5.2  
 Africa  435  5.5  
 America  341  4.3  
 Asia  114  1.4  
 Unknown  875 11.0  
Prior AIDS  2422  30.5  
Hepatitis B status       
 Negative  6729  84.8  
 Positive  479  6.0  
 Unknown  724  9.1  
Hepatitis C status       
 Negative  5347  67.4  
 Positive  1943  24.5  
   Unknown  642  8.1  
 
 
Table 2.3 summarises ART history and current regimens.  At January 2007, 1117 
(14.1%) of the 7932 patients were not receiving any ART, of which 639 (57.2% or 8.1% 
of all patients under follow-up) were ART-naïve.  The remaining 478 (42.8% or 6.0% of 
all under follow-up) had discontinued therapy sometime before this date.  The vast 
majority (90.4%) had previously received at least three different drugs and nearly two 
thirds had received at least six (not necessarily in the same regimen).  Just over half 
had previously received all three drug classes (NRTIs, PIs and NNRTIs) and 84.1% 
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had received a cART regimen defined as at least three drugs including a PI, an NNRTI 
or abacavir (ABC).  Current regimens mostly consisted of three or four drugs and 
approximately a third of patients were taking a ritonavir (RTV)-boosted regimen and 
another third, a single NNRTI regimen.   
 
Table 2.3: History of ART and current regimens of 7932 EuroSIDA patients under 
follow-up at 1st January 2007. 
   n %       n % 
All 7932  100    Current ART at Jan 07    
Previous ART at Jan 07       Number of drugs     
ART-naïve 639  8.1     0  1117 14.1 
Number of different drugs         1  42 0.5 
 0-2  760 9.6     2  184 2.3 
 3-5  2033 25.6    3  3456 43.6 
 6-8  2244 28.3    4  2443 30.8 
 9-11  1791 22.6    5+  690 8.7 
 12+  1104 13.9   Number of NRTIs     
Number of NRTIs         0  1382 17.4 
 0-1  726 9.2     1  451 5.7 
 2-3  2500 31.5    2  5187 65.4 
 4-5  2773 35.0    3+  912 11.5 
 6+  1933 24.4   Number of PIs     
Number of PIs         0  4059 51.2 
 0-1  3008 37.9    1  696 8.8 
 2-3  2861 36.1    2  2887 36.4 
 4-5  1596 20.1    3+  290 3.7 
 6+  467 5.9    Number of NNRTIs     
Number of NNRTIs         0  4959 62.5 
 0  2513 31.7    1-2  2973 37.5 
 1  4233 53.4   On cART regimen  6528 82.3 
 2+  1186 15.0    Single  PI  573 8.8 
Received NRTIs, PIs and  4388 55.3    RTV-boosted  PI  2206 33.8 
NNRTIs        Single  NNRTI  2390 36.6 
Received cART  6671 84.1    Triple  NRTI  299 4.6 
          Other  1060 16.2 
Note: RTV = ritonavir. 
 
2.2 Statistical  methods 
To analyse the data in this thesis a number of statistical tests and modelling techniques 
were used, which are described below.  SAS software version 9.1 (SAS Institute, Cary, 
NC, USA, 2002-2003) was used to carry out all analyses.   
 
2.2.1 Initial  analyses 
For initial exploratory purposes, descriptive methods and tests of significance were 
used to compare subsets or groups of patients for a number of variables.  Pearson’s 
chi-squared and Fisher’s exact tests were used for categorical data and non-parametric 
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Wilcoxon rank sum and Kruskal-Wallis tests for continuous data, which all compare 
independent groups of data.  The Fisher’s exact test was used when more than 5% of 
the events had expected frequencies of less than five, which causes problems when 
using the chi-squared test as the approximation to the chi-squared distribution breaks 
down.  The Wilcoxon rank sum test is used when there are just two groups (with 
unpaired data) and the Kruskal-Wallis is an extension of this for more than two groups.  
Non-parametric tests do not make any assumptions about the underlying probability 
distribution of the data, which is useful when it is impossible to assess this or when the 
data are clearly not normally distributed [368].  All tests were two-sided and a p value 
of less than 0.05 was taken to be statistically significant, i.e. to indicate that there is 
enough evidence to reject the null hypothesis of no difference between subsets of the 
data. 
 
To obtain 95% confidence intervals (CIs) of proportions, p, with sample size, n, for np 
and n(1-p) greater than five, normal approximations with continuity corrections (using 
the simple asymptotic method) were used [369].  Otherwise, exact binomial CIs were 
calculated. 
 
2.2.2 Statistical  models 
Statistical models aim to provide an understanding of the relationships between 
variables and can be applied for both descriptive and predictive purposes.  They 
provide a mathematical representation of how the variability of a response can be 
explained in terms of explanatory variables.  They also incorporate a random 
component to account for the deviation of the observed response values from the 
predicted values.  In HIV epidemiology research, models are used to look at a number 
of virological, immunological and clinical outcomes.  Univariable models contain only 
one explanatory variable and are used to investigate what effect this variable alone has 
on the response.  However, there may be additional factors that have associations with 
both the response variable and the explanatory variable that confound their 
relationship.  For example, a univariable analysis may find that IDUs have a higher risk 
of death, but IDUs also typically have a lower CD4 cell count due to lifestyle factors, 
which is also associated with a higher risk of death.  Therefore it is possible that the 
relationship between IDU and death could be due to CD4 cell count instead.  To 
prevent bias of potentially confounding factors, multivariable analyses are used that 
contain more than one variable and adjust the effects of each variable to take account 
of the others in the model.  Unfortunately in observational studies, there may still be 
unknown or unmeasured confounding variables, which is a limitation of analyses such 
as these. 
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Statistical interactions may also be adjusted for in multivariable analyses.  These occur 
when the relationship between the explanatory and the response variable is stronger in 
some groups than in others, e.g. the cumulative effect of treatment exposure on 
cholesterol is worse in men than in women meaning that there is a statistical interaction 
between gender and length of time on treatment.  As a general rule, statistical 
interactions between all variables are not routinely tested, because of the possibility of 
a false positive result due to repeated statistical testing.  Interactions of interest are 
normally decided a priori based upon clinical suspicion. 
 
Three main methods of statistical modelling were used in this thesis: logistic 
regression, survival analysis and Poisson regression.  Linear regression is also used in 
some sensitivity analyses.  Formal descriptions can be found in Appendix V.   
Overviews of what the models are used for and the reasons for choosing these 
particular methods are briefly outlined below. 
 
2.2.2.1 Logistic regression 
Logistic regression models are used when the response variable under investigation is 
of a binary form, i.e. with only two different outcomes [370,371].  These are often 
labelled ‘success’ and ‘failure’ usually corresponding to a positive and negative 
outcome, for example, a successful reduction of viral load to an undetectable level 
following ART as opposed to failure to reach an undetectable level.  For simple 
analyses, the proportion of successes can be compared between groups.  However, 
this probability of a success, p, is a number between 0 and 1 and in order to use 
regression methods for analysis, this has to be mathematically transformed into 
something that takes a number between minus infinity (-∞) and infinity (∞).  Hence, 
logistic regression models predict the log odds of observing a ‘success’, which can take 
values in (-∞,∞), based on observed explanatory variables.  The odds of observing a 
success are defined as the ratio of the probability of success to the probability of 
failure, i.e. p/(1-p).  This number is similar to the probability of a success when the 
outcome is rare.   
 
This type of model is called a linear logistic model and assumes a linear relationship 
between the explanatory variables and the log odds of a ‘success’.  It can be used to 
estimate odds ratios (and 95% CIs) that compare the outcomes from two groups of 
patients.  An odds ratio is defined as the ratio of the odds in one group to the odds in a 
second group.  When the value is greater than one, this indicates that the first group 
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has greater odds of a success than the second.  When it is less than one, the second 
has greater odds.   
 
2.2.2.2 Survival analysis 
Survival analysis methods are used to investigate time to an event from a well-defined 
time origin [372].  If the event is death, the data are literally survival times.  Survival 
data are often highly skewed and have a non-normal distribution.  However, their main 
feature is that they can be censored when the event has not been observed for an 
individual, for example, if for the duration of patient follow-up, the event has not been 
observed the patient can be censored at their last visit, which indicates that from that 
point in time onwards there was no information available.  The assumption of this is 
that the actual survival time is independent of any mechanism that causes the 
censoring.  Censoring that occurs after the last known survival time is called right 
censoring (as it is to the right when plotted on a graph) and gives a right censored 
survival time that is less than the unknown actual survival time.  Data can also be left 
censored when the actual survival time is less than that observed. 
 
A mathematical function that summarises a distribution of survival times is called the 
survivor function.  This can be estimated using a Kaplan-Meier estimate, which can be 
displayed visually as a plot showing the cumulative rates of those experiencing an 
event.  The median survival time (and other percentiles) can be read from this plot.  
The log-rank test is a non-parametric test that can be used to compare survival times in 
independent groups. 
 
To assess the effects of explanatory variables on survival times, a proportional hazards 
regression model can be used.  This models a hazard function that predicts the 
instantaneous risk or hazard of the event occurring at a given time point after the time 
origin and is conditional on the individual having survived up to that point.  The model 
can estimate hazard ratios or relative hazards (and 95% CIs) to compare the risk of an 
event between groups of patients, which are comparable to odds ratios in a logistic 
regression model. 
 
A proportional hazards model assumes that for different values of an explanatory 
variable, the relative hazards are proportional over time.  This can be checked by 
including in the model an interaction term between the log survival time and the 
variable of interest.  If the model fits significantly better after including this term, there is 
evidence of non-proportionality.  It also assumes a log-linear relationship between the 
hazard and the explanatory variables.  In this thesis, the Cox proportional hazards 
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regression model is used that makes no assumption about the shape of the distribution 
of the hazard function.   
 
2.2.2.3 Poisson regression 
Poisson regression models are used for count data to predict rates of an event and 
hence can be used to calculate rate ratios (and 95% CIs) [373].  As with a logistic 
regression model, a function is needed to transform the data into a form that can take 
values in (-∞,∞) and the appropriate function for this is log-linear.   
 
2.2.2.4 Linear regression 
Linear regression is the most straightforward of the linear models, used when the data 
are continuous with a normal distribution and assuming a linear relationship with the 
explanatory variables [374].  Differences in the response can be compared between 
values of an explanatory variable.  
 
2.2.3  Choice of statistical methods 
All of the above methods are used in this thesis.  Survival analysis is the most 
appropriate method to use for time-to-event data as it takes into account the proportion 
of patients at risk at each time point.  However, the results may be biased when there 
are varying time intervals between measurements as patients who have a higher 
frequency of measurements have a higher chance of the analysis registering an event.  
Most of the main analyses investigate virological and immunological response to 
therapy and due to differences in the frequency of viral load measurements and CD4 
counts between analysis subgroups, logistic regression is used in most of the main 
analyses.  Unlike survival analysis, it is relatively robust to the number of 
measurements available.   
 
In one particular analysis in Chapter 5, generalised estimating equations are used to fit 
the parameters of the logistic regression model due to the inclusion of repeated 
measurements on patients.  This method takes into account the within-subject 
correlation between measurements from the same patient by using weighted 
combinations of observations and is detailed by Hanley et al. (2003) [375].   
 
2.2.3.1 Choice of endpoint 
Treatment guidelines indicate that successful therapy will result in an undetectable viral 
load within 16-24 weeks and suggest that viral suppression leads to a CD4 cell 
increase of 100-150 cells/mm
3 per year with an accelerated response in the first three 
months [40].  Throughout this thesis, the logistic regression models estimate the odds 
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that the first viral load measurement within the period six to twelve months after the 
defined baseline is at an undetectable level.  As EuroSIDA data have been collected 
for a number of years and some early viral load assays only measured as low as 500 
copies/mL [376], this is defined as the undetectable level for the main analyses.  The 
study population was limited to patients with an unsuppressed baseline viral load of at 
least 500 copies/mL, measured within the six-month period prior to the defined 
baseline.  To analyse immunological response, the first CD4 count within six to twelve 
months after the defined baseline was examined to estimate the odds that this was at 
least 100 cells/mm
3 more than at baseline so patients were required to have a baseline 
CD4 count.  These endpoints were chosen to be consistent with previous EuroSIDA 
analyses [147,377], however different endpoints were investigated in sensitivity 
analyses.   
 
2.2.3.2 Missing measurements 
Two conventional approaches were investigated for patients with missing 
measurements in this six-month period: patients were either defined to be 
virological/immunological failures or they were excluded [378].  The first approach, 
‘missing = failure’, was used in the main analysis in all chapters to maximise the 
number of patients included.  This gives a conservative estimate of the failure rate, as 
the assumption is that measurements are missing due to patients being too ill to visit 
the clinic (and hence having a worse response to treatment).  The second approach, 
‘missing = excluded’, was used in a sensitivity analysis.  These were intent-to-treat 
analyses in the sense that no adjustments were made for stopping or changing any 
component of the regimen.   
 
2.2.3.3 Alternative methods used  
Cox proportional hazards models were used in this thesis to conduct sensitivity 
analyses to check how robust the findings are to the statistical method used.  They 
were also used in Chapter 6 as the main analysis.  This was due to the frequency of 
viral load measurements being similar between the two groups being studied and also 
due to the fact that this chapter was following up a previous EuroSIDA analysis that 
used this method.  For comparison with these previous results, it was most suitable to 
use the same method, however both logistic regression and linear regression were 
used to check the robustness of findings.  The censoring used is defined in each 
chapter where appropriate. 
 
Poisson regression was used in the final chapter as this was investigating a different 
aspect of the effects of ART.  Incidence of discontinuation of the drug abacavir was 
70 
 
calculated and was compared between subsets of patients in a multivariable Poisson 
regression model.   
 
2.2.4 Model  building  strategies 
Multivariable models were generally developed throughout this thesis including all 
variables of interest in addition to any potentially confounding variables.  Potentially 
confounding variables were chosen a priori to be those which had been found in 
previous studies or analyses to be associated with the outcome or where there was a 
valid reason to believe that there could be an association.  Those found to be 
significantly associated with the outcome with a p value of less than 0.1 (to be 
conservative) were included in the multivariable model.  A stepwise selection method 
was then used to confirm whether or not after adjustment for these variables, any 
further variables might also be explanatory.  Any found to be significant significantly 
associated with the outcome (with a p value of less than 0.1) were added in.  This 
meant that all variables that were associated with the outcome and therefore could 
potentially confound the findings related to the variables of interest, were adjusted for in 
the models. 
 
2.2.5 Summary 
The statistical methods described in this chapter have been employed throughout this 
thesis.  Further details of the patients selected, the assumptions made and the specific 
details of endpoints analysed are described in each chapter.  Sensitivity analyses have 
been used to check the robustness of the results to different assumptions. 
71 
 
Chapter 3. Virological response to first-line 
combination antiretroviral therapy across geographical 
regions and over calendar time 
3.1 Introduction 
The introduction of cART into clinical practice in 1995-1996 in developed countries 
such as North America and Western Europe resulted in dramatic reductions in mortality 
and morbidity rates in HIV infected individuals [118-121,139,140,179].  These have 
been sustained into recent years despite the long-term adverse effects potentially 
associated with treatment, such as liver damage, lactic acidosis, increased risk of 
cardiovascular disease and selection of drug resistance [172,223,224,361].  The 
increasing availability of new, more potent antiretroviral drugs, improvements in clinical 
support, management of associated toxicities, as well as a greater understanding of 
issues relating to non-adherence, all appear to be increasing the clinical success of 
cART over time [139,140].  This is also reflected in improvements in virological 
response rate [379-382]. 
 
Regional differences across Europe in the use of antiretroviral drugs, death rates and 
virological failure following the initiation of cART have been highlighted in EuroSIDA 
reports [383-385].  With the increasing widespread use of antiretroviral drugs across 
Europe, it is speculated that virological response rates may be more similar between 
different regions in later years as compared to periods closer to the time of the first 
introduction of cART.  There may also be different temporal trends in response to cART 
across regions, according to when cART was introduced.  This chapter investigates 
both of these hypotheses in patients starting cART for the first time with no previous 
ART experience. 
 
3.1.1  Regional differences in use of ART and virological failure 
Kirk et al. (1998) found a decrease over time in regional variation in the use of ART 
over the period 1994-1997 [383].  The odds of being on triple ART including a protease 
inhibitor in March 1996 were approximately double in patients visiting a clinic in Central 
and North Europe, compared to patients in South Europe, but by September 1997 
these differences had diminished.  These results indicated a quicker introduction of 
new treatments in Central and North Europe compared to South, which could be due to 
varying availability of drugs after marketing approval between countries and also socio-
economic factors such as income and education.  Another EuroSIDA study compared 
virological failure across South, Central and North regions and found significantly 
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higher failure rates in the South region at week 16 after starting cART [384].  This could 
be due to differences in treatment strategies and availability of new drugs. 
 
3.1.2  Changes over time in use of ART and virological failure 
Virological response rates have increased over calendar time since the introduction of 
cART [379-382].  Risk of virological failure following initiation of first-line cART was 
investigated in a large multi-cohort analysis over a seven-year period in Europe and 
Canada including 3825 patients from five HIV clinic cohorts [379].  The results of this 
analysis indicated a significant decrease in virological failure over calendar time, which 
appeared to be partly due to improvements in cART regimens.  It could also be 
explained by factors such as increased clinical experience, improved toxicity profile of 
drugs and better patient adherence due to more effective clinical management and 
knowledge of treatment.   
 
3.1.2.1 Guidelines for first-line cART regimens 
Improvements in cART regimens have been achieved through increased knowledge of 
the combinations of drugs that are most effective from clinical trial and observational 
data.  This is reflected in the changing guidelines for what drugs to start as first-line 
therapy.  Guidelines published in 1996 suggested NRTI combinations as an initial 
regimen, reserving PIs for patients at higher progression risk [386].  In 1998, a PI and 
two NRTIs was the preferred initial option [387].  By 2000, with the wider variety of 
antiretroviral drugs available, guidelines recognised the need to individualise regimens 
based on factors such as tolerability, convenience and adherence likelihood, and 
possibly baseline resistance test results, but recommended regimens containing two 
NRTIs and either a PI (or two PIs) or an NNRTI [292].  As discussed in Chapter 1 
(section 1.7.4), current treatment guidelines recommend that patients should start a 
combination of two NRTIs and either a single NNRTI (efavirenz (EFV)) or a ritonavir 
(RTV)-boosted PI (atazanavir (ATV), fosamprenavir (fAPV) or lopinavir (LPV)) [40,41].  
The EFV-containing regimen is the preferred option for first-line cART recommended 
by the British HIV Association (BHIVA) guidelines [42].   
 
3.1.2.2 Transmitted drug resistance 
Another factor that may influence the rate of virological response in ART-naïve patients 
over calendar time is the prevalence of transmitted (or primary) drug resistance (TDR).  
ART-naïve patients do not have drug pressure encouraging the selection of drug-
resistant viral strains but may acquire a drug-resistant HIV strain through transmission 
[337,352,353].  As detailed in Chapter 1 (section 1.8), viral drug resistance reduces the 
efficacy of antiretroviral drugs and limits future treatment options [172,338].   
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It is unclear from research as to whether TDR is increasing or decreasing over 
calendar time.  An increase could be due to more people in the HIV infected population 
developing drug resistance as a result of exposure to ART, hence increasing the 
probability that it is transmitted [388-393].  The UK Group on Transmitted HIV Drug 
Resistance found an increase in prevalence of TDR over the period 1996-2003 [389].  
However, the latest data from this group between 1996 and 2004 showed a decrease 
in TDR in later years [394].  These results could be explained by the fact that there is 
more accessibility to regimens that suppress the viral load, which reduces transmission 
rates.   
 
3.1.3  Motivation and aims for chapter 
Virological response to first-line cART has not previously been compared across the 
current four geographical regions defined in EuroSIDA (South, North, Central West and 
East).  As EuroSIDA has longitudinal data spanning a period of over 13 years it is also 
the ideal dataset in which to monitor trends over calendar time.  Few cohort studies 
have the capacity to look at both aspects in the same analysis.  Therefore the aims of 
this analysis were to examine both temporal changes within the four regions, and also 
regional differences within calendar time periods (corresponding to treatment initiation 
in early-, mid- and late-cART years, i.e. 1996-1997, 1998-1999 and 2000-2004) in rates 
of virological suppression following initiation of cART in previously ART-naïve patients.   
 
3.2 Methods 
3.2.1 Inclusion  criteria 
The EuroSIDA dataset used for the analyses in this chapter was the update completed 
in December 2005.  It included data on 11,928 patients with follow-up to (median date 
of last visit) May 2005.  Patients were included who started cART, defined as at least 
three antiretroviral drugs including a PI, an NNRTI, or abacavir (ABC), between 
January 1996 and May 2004.  This allowed patients to have the potential for at least 
one year’s follow-up providing a suitable length of time to analyse response to cART.  
They were also required to have no previous ART experience and to have a viral load 
of at least 500 copies/mL measured in the six months before starting cART.   
 
3.2.2 Statistical  methods 
3.2.2.1 Definitions 
EuroSIDA geographical regions were defined similarly to Chapter 2 (section 2.1.5), 
except that there were less clinical centres involved in EuroSIDA at the time of this 
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earlier dataset.  Data was included from 83 centres across 26 European countries, 
Israel and Argentina: South (26 centres in Spain, Portugal, Italy, Greece, Serbia-
Montenegro, Israel, and Argentina), Central West (20 centres in France, Belgium, 
south Germany, Luxembourg, Switzerland, and Austria), North (18 centres in the UK, 
Ireland, Netherlands, north Germany, Denmark, Sweden, and Norway) and East (19 
centres in Poland, Czech Republic, Slovakia, Hungary, Romania, Estonia, Latvia, 
Lithuania, Belarus, Ukraine, and Russia).  Calendar time periods were defined 
according to the starting date of cART: early-cART  (1996-1997), mid-cART (1998-
1999) and late-cART (2000-2004).  These were consistent with previous EuroSIDA 
analyses [140,179].  Baseline was defined as the date of starting cART and treatment 
discontinuation was defined as the date of the first drug in the initial regimen to be 
discontinued. 
 
For patients with blood plasma samples taken within a year before the date of cART 
initiation that were subsequently tested for genotypic HIV drug resistance, resistance 
was defined as at least one NRTI, NNRTI or major PI resistance mutation according to 
the IAS-USA 2005 figures of HIV-1 drug resistance mutations [395].   
 
3.2.2.2 Virological response to cART 
Logistic regression was used to investigate the odds of a successful virological 
response to cART (defined as a viral load less than 500 copies/mL) at the first viral 
load measurement six to twelve months after initiation of the cART regimen, as 
discussed in Chapter 2 (section 2.2.3).  Patients were required to have a baseline viral 
load of at least 500 copies/mL and baseline measurements were defined as those 
taken within the six-month period prior to starting cART.  A ‘missing = failure’ approach 
was used in the main analysis.   
 
Stratified multivariable models were developed to investigate the effects of calendar 
time periods within regions and regions within time periods on virological response.  
Time period was fitted in different ways: as a categorical variable (with two dummy 
variables) and as an ordered categorical variable.  A further model was developed 
including time as a continuous variable instead of as a categorical variable.   
 
Explanatory variables were identified as those significantly associated with the odds of 
a virological response in univariable analysis (p<0.1) or in a stepwise selection 
procedure.  These were included in the multivariable model to ensure that any that 
could potentially confound the relationship between calendar time or region and the 
outcome were adjusted for.  Factors investigated were: gender, age, HIV exposure 
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group (defined as ‘men who have sex with men (MSM)’, ‘injecting drug use (IDU)’, 
‘heterosexual’ or ‘other’), country of origin (defined as ‘same as clinical centre’, ‘another 
European country’, ‘Africa’, ‘America’, ‘Asia’ or ‘other’), ethnicity (defined as ‘white’ or 
‘other’), viral load measurements (baseline and maximum ever at baseline), CD4 
counts (baseline and nadir), time from CD4 nadir, hepatitis B/C co-infection status, 
prior AIDS diagnosis, time from HIV diagnosis, type of regimen (defined as containing 
‘a single PI: not saquinavir (SQV) hard gel’, ‘a single PI: SQV hard gel’, ‘a RTV-boosted 
PI’, ‘a single NNRTI’, ‘triple NRTI’ or ‘other’) and number of drugs in regimen.  For 
pairwise comparisons, the pre-chosen reference categories were mid-cART years and 
the North region due to having the largest number of patients.   
 
3.2.2.3 Sensitivity analyses 
A sensitivity analysis was carried out using a ‘missing = excluded’ approach.  Further 
sensitivity analyses were conducted, using both approaches to missing data, on the 
subset of patients who started cART after enrolment into EuroSIDA, excluding patients 
whose treatment data were collected retrospectively.  These excluded patients who 
had already survived for a period up to enrolment implying that their treatment was 
successful enough to keep them alive, therefore the observed proportion of virological 
suppression in this group could have been greater than that of those starting cART 
after enrolment. 
 
Virological response, measured as a viral load less than 50 copies/mL rather than 500 
copies/mL, was also investigated.  This analysis was conducted on a subset of patients 
whose first viral load measurements in the six to twelve month period after starting 
cART were measured using an assay with a level of detection as low as at most 50 
copies/mL.  This required all those with missing values to be excluded. 
 
Survival analysis using Kaplan-Meier estimates and Cox proportional hazards models 
was used to check that the findings were consistent using a different statistical method.  
Time to virological suppression (a viral load less than 500 copies/mL), with right 
censoring at the date of patients’ last viral load measurement was investigated.  Left 
censoring at date of enrolment into EuroSIDA was also investigated, again to exclude 
retrospective treatment data from patients.   
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3.3 Results 
3.3.1 Patient  numbers 
A total of 2102 (17.6%) patients met the inclusion criteria, shown in Figure 3.1.  Of 
these, 560 (26.6%) were from the South region (48 (8.6%) of which were from Israel 
and 88 (15.7%) of which were from Argentina), 466 (22.2%) were from the Central 
West, 606 (28.8%) were from the North and 470 (22.4%) were from the East.  A total of 
645 (30.7%) patients started cART in the early-cART years, 601 (28.6%) in the mid-
cART years and 856 (40.7%) in the late-cART years. 
 
Figure 3.1: Patient numbers in analyses according to inclusion criteria. 
 
 
 
3.3.2  Patient characteristics at date of starting cART 
3.3.2.1 Comparison of regions 
Table 3.1 demonstrates the considerable heterogeneity in characteristics between 
regions.  A significant difference was found in the dates of starting cART: April 1999 
(median) in the South compared to January 1998 in the Central West, May 1998 in the 
North and March 2001 in the East (p<0.001).  Median baseline CD4 counts ranged 
Missing viral loads
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between 200 and 244 cells/mm
3 ( p=0.005) and viral loads between 4.8 and 5.1 
log10copies/mL (p<0.001).  HIV transmission exposure groups differed significantly 
between regions (p<0.001).  MSM were the main group in Central West and North 
regions (45.9% and 59.7% respectively), followed by heterosexuals (29.4% and 23.9% 
respectively).  These groups were more evenly distributed in the South region (38.8% 
MSM and 36.6% heterosexual).  In the East, there were similar proportions of patients 
exposed via IDU (31.9%) as MSM (28.7%) and heterosexual (31.3%) groups.   
 
A total of 249 (11.9%) patients had plasma samples available within a year before 
starting cART that had been successfully tested for drug-resistant HIV: 23 (4.1%) in the 
South region, 34 (7.3%) in the Central West, 142 (23.4%) in the North and 50 (10.6%) 
in the East (p<0.001).  Only 1 (4.4%) patient in the South had HIV with drug resistance 
(to NRTIs), 3 (8.8%) patients in the Central West (all with NRTI resistance), 9 (6.3%) in 
the North (6 of which had NRTI resistance, 2 of which had NNRTI resistance and 3 of 
which had PI resistance) and 4 (8.0%) in the East (3 with NRTI resistance, 1 with 
NNRTI resistance). 
 
Time to treatment discontinuation or switches were compared across regions.  Kaplan-
Meier estimates of the median times to first treatment discontinuation were 25 months 
(95% CI: 23-30 months) in the South region, 19 months (95% CI: 16-21 months) in 
Central West and North, and 41 months in East (95% CI: 36-44 months) (p<0.001). 
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Table 3.1: Patient characteristics at start of cART according to geographical region within EuroSIDA. 
  Total South  Central  West  North  East  p 
n %                 
All  2102  100 560 26.6 466 22.2 606 28.8 470  22.4  - 
Male  1590  75.9 407 72.7 350 75.1 496 81.8 337  71.7  <0.001 
HIV  exposure  group                <0.001 
  MSM  928  44.1 217 38.8 214 45.9 362 59.7 135  28.7  - 
  IDU  387  18.4 112 20.0  57  12.2  68  11.2 150  31.9  - 
  Heterosexual  634  30.2 205 36.6 137 29.4 145 23.9 147  31.3  - 
  Other  153  7.3 26 4.6 58  12.4  31 5.1  38  8.1 - 
White  ethnicity  1819  86.5 489 87.3 372 79.8 504 83.2 454  96.6  <0.001 
Previous  AIDS  413  19.6 145 25.9  80  17.2 118 19.5 70  14.9  <0.001 
H e p a t i t i s   B   s t a t u s                 < 0 . 0 0 1  
  Negative  1299  61.8 293 52.3 289 62.0 435 71.8 282  60.0  - 
  Positive  103  4.9 26 4.6 15 3.2 41 6.8  21  4.5 - 
  Unknown  700  33.3 241 43.0 162 34.8 130 21.5 167  35.5  - 
H e p a t i t i s   C   s t a t u s                 < 0 . 0 0 1  
  Negative  949  45.1 247 44.1 230 49.4 301 49.7 171  36.4  - 
  Positive  313  14.9 76 13.6 46  9.9  52  8.6 139  29.6 - 
  Unknown  840  40.0 237 42.3 190 40.8 253 41.7 160  34.0  - 
Genotypic resistance test 
results available  249 11.8  23 4.1 34 7.3  142  23.4  50  10.6  <0.001 
Median (IQR)                 
Date started cART  Mar 99  (Sep 97-May 01) Apr 99 (Jan 98-May 01) Jan 98 (Mar 97-Mar 00)  May 98 (May 97-Apr 00) Mar 01 (Dec 99-Dec  <0.001 
Age  (years)  36  (30-43) 36 (30-42) 37 (31-44) 38 (33-46)  33  (27-40)  <0.001 
CD4 count (cells/mm
3)                  
 Baseline
(1)  214 (98-345)  233  (99-374)  244  (103-368) 200 (101-300)  206  (84-346)  0.005 
 Nadir
  193 (90-310)  205  (93-358)  220  (100-330) 177  (88-260) 183  (81-303)  <0.001 
Viral load (log10c o p i e s / m L )                
 Baseline
(2)  5.0  (4.5-5.5) 4.8 (4.3-5.3) 5.0 (4.5-5.5) 5.1 (4.6-5.5)  5.0  (4.5-5.6)  <0.001 
 Max  ever
  5.1  (4.6-5.5) 4.9 (4.4-5.4) 5.1 (4.6-5.6) 5.2 (4.8-5.5)  5.1  (4.6-5.7)  <0.001 
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests.  
Median CD4 counts and viral loads based on measurements from 
(1)2022 patients and 
(2)2046 patients.   
MSM = men who have sex with men; IDU = injecting drug use; IQR = interquartile range. 
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There was also significant variation in types of cART regimen started (p<0.001), 
illustrated in Figure 3.2.  Single PI-containing regimens were started by 57.9% of South 
patients, 63.5% of Central West, 52.5% of North and 35.5% of East patients.  The next 
most widely used regimen contained an NNRTI and was started by 24.5% of South 
patients, 19.7% of Central West, 22.6% of North and 30.0% of East patients.   
 
Figure 3.2: Type of cART regimen started according to geographical region within 
EuroSIDA. 
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Single PI (non SQV-h) Single PI (SQV-h)
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Notes: SQV-h = saquinavir hard gel; RTV = ritonavir; ABC = abacavir. 
 
3.3.2.2 Comparison of cART initiation periods 
Table 3.2 summarises the characteristics of patients starting cART in the three defined 
time periods, early-, mid- and late-cART years.  There was no evidence of a significant 
difference in median baseline CD4 counts across the three periods (p=0.170).  Median 
baseline viral loads were between 4.9 and 5.0 log10copies/mL (p=0.005).  Over time, 
the proportion of patients in the MSM exposure group decreased and IDUs and 
heterosexuals increased (p<0.001), which could be confounded by the increased 
number of East Europeans enrolled into EuroSIDA in later years.  The percentage of 
patients with a previous AIDS diagnosis was reduced from 21.1% in early-cART to 
17.9% in late-cART years (p<0.001).   
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Table 3.2: Patient characteristics at date of starting cART according to cART initiation period. 
    Total  Early-cART 1996-1997  Mid-cART 1997-1998  Late-cART 2000-2004  p 
n %             
All    2102 100 645 30.7 601 28.6 856  40.7  - 
Male  1590  75.9 529 82.0 469 78.0 592  69.2  <0.001
HIV  exposure  group            <0.001
  MSM  928 44.1 345 53.5 277 46.1 306  35.7  - 
  IDU  387 18.4  99  15.3 122 20.3 166  19.4  - 
  Heterosexual  634 30.2 147 22.8 172 28.6 315  36.8  - 
  Other  153  7.3 54 8.4 30 5.0 69  8.1 - 
Ethnicity            0.107 
  White  1819  86.5 543 84.2 528 87.9 748  87.4  - 
  Other  283 13.5 102 15.8  73  12.1 108  12.6  - 
Previous  AIDS  413 19.6 136 21.1 124 20.6 153  17.9  <0.001
Hepatitis  B  status            0.232 
  Negative  1299  61.8 409 63.4 358 59.6 532  62.1  - 
  Positive  103  4.9 36 5.6 24 4.0 43  5.0 - 
  Unknown  700 33.3 200 31.0 219 36.4 281  32.8  - 
Hepatitis  C  status            0.261 
  Negative  949 45.1 282 43.7 245 40.8 422  49.3  - 
  Positive  313  14.9 67 10.4 91 15.1  155  18.1 - 
  Unknown  840 40.0 296 45.9 265 44.1 279  32.6  - 
Genotypic resistance test results available  249  11.8 99 15.3 76 12.6 74 8.6  <0.001
Median (IQR)             
Age  (years)  36 (30-43) 36 (31-43) 35 (30-43) 37  (30-44)  0.236 
CD4 count (cells/mm
3)              
 Baseline
(1)  214 (98-345) 220 (98-339) 230  (100-370) 205 (93-336)  0.170 
  Nadir  193 (90-310) 208 (90-315) 190 (91-332) 187  (86-296)  0.239 
Viral load (log10copies/mL)             
 Baseline
(2)  5.0 (4.5-5.5) 5.0 (4.5-5.5) 4.9 (4.4-5.4) 5.0  (4.5-5.5)  0.005 
  Max  ever  5.1 (4.6-5.5) 5.1 (4.6-5.5) 5.0 (4.5-5.5) 5.1  (4.7-5.6)  <0.001
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
Median CD4 counts and viral loads based on measurements from 
(1)2022 patients and 
(2)2046 patients. 
MSM = men who have sex with men; IDU = injecting drug use; IQR = interquartile range. 
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The proportion of patients with plasma samples available within a year before starting 
cART, which had been tested for HIV drug resistance, decreased over time: 99 (15.3%) 
patients in early-cART years, 76 (12.7%) in mid-cART years and 74 (8.6%) in late-
cART years (p<0.001).  A total of 7 (7.1%) patients in the early-cART period had HIV 
with drug resistance (6 of which had NRTI resistance, 2 of which had NNRTI resistance 
and 1 of which had PI resistance), 5 (6.6%) patients in mid-cART years (3 of which had 
NRTI resistance, 1 of which had NNRTI resistance and 1 of which had PI resistance) 
and 5 (6.8%) in late-cART years (4 of which had NRTI resistance and 1 of which had PI 
resistance). 
 
Kaplan-Meier estimates of the median times to first treatment discontinuation were 18 
months (95% CI: 16-20 months) in early-cART, 22 months (95% CI: 19-26 months) in 
mid-cART and 37 months (95% CI: 33-40 months) in late-cART years (p<0.001). 
 
The types of cART regimen started also changed significantly over time (p<0.001), 
shown in Figure 3.3.  Single PI regimens decreased from 89.8% in the early-cART 
period to 16.6% in late-cART, in favour of those containing a RTV-boosted PI and more 
commonly, an NNRTI.  Single NNRTI regimens were started by 43.0% of patients in 
the late-cART period.  The use of SQV hard gel, without low-dose RTV, as part of a 
single PI regimen was phased out over time.  Triple NRTI regimens containing ABC 
were started by comparatively few patients in all three periods. 
 
Figure 3.3: Type of cART regimen started according to cART initiation period. 
0%
20%
40%
60%
80%
100%
Early-cART Mid-cART Late-cART
Single PI (non SQV-h) Single PI (SQV-h)
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Triple NRTI incl ABC Other
 
Notes: SQV-h = saquinavir hard gel; RTV = ritonavir; ABC = abacavir. 
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3.3.2.3 cART regimens over time within regions 
Figure 3.4 illustrates how cART regimens have changed over time within each region.  
Similar patterns emerged in each region with single PI regimens decreasing in favour 
of RTV-boosted PI and single NNRTI regimens.  However significant regional 
differences in type of cART regimen were found in early-, mid- and late-cART years 
(p<0.001 in each period). 
 
Figure 3.4: Type of cART regimen started in each cART initiation period according to 
geographical region within EuroSIDA. 
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Notes: SQV-h = saquinavir hard gel; RTV = ritonavir; ABC = abacavir. 
 
3.3.3  Virological response to cART: viral load less than 500 copies/mL at 
months six to twelve 
3.3.3.1 Main analysis: missing viral load = failure 
A total of 1256 (59.8%) out of the 2102 patients included achieved virological 
suppression (less than 500 copies/mL) at the first measurement during the six to twelve 
month period after starting cART.  In this same time window, 503 (23.9%) of the 2102 
patients included had no viral load measurement available and so were counted as 
virological failures, although 432 (85.9%) of these had a subsequent measurement 
recorded a median of 19 months (IQR: 15-28 months) after starting cART.  Median 
times to first viral load measurement in the six to twelve month period in each region 
were 33 weeks (IQR: 28-39 weeks), 31 weeks (IQR: 27-35 weeks), 32 weeks (IQR: 27-
37 weeks) and 35 weeks (IQR: 26-40 weeks), in the South, Central West, North and 
East, respectively.  In each time period, median times were 31 weeks (IQR: 28-37 
83 
 
weeks), 32 weeks (IQR: 26-39 weeks) and 33 weeks (IQR: 28-39 weeks), in patients 
starting in early-cART years, mid-cART years and late-cART years, respectively. 
 
Response rates were found to be similar across regions: 317 (56.6%; 95% CI: 52.7-
80.6%) of 560 South patients, 283 (60.7%; 95% CI: 56.5-65.4%) of 466 Central West 
patients, 384 (63.4%; 95% CI: 59.7-67.4%) of 606 North patients and 272 (57.9%; 95% 
CI: 53.6-62.5%) of 470 East patients (p=0.091).  Over time, an increase in response 
rate was observed: 332 (51.5%; 95% CI: 47.8-55.5%) of 645 patients starting in early-
cART years, 338 (56.2%; 95% CI: 52.4-60.4%) of 601 mid-cART patients and 586 
(68.5%; 95% CI: 65.5-71.7%) of 856 late-cART patients (p<0.001).  This increase was 
also reflected within each region (Figure 3.5), most noticeably in the East, rising from 
20.0% in early-cART to 63.1% in late-cART years.   
 
Figure 3.5: Virological response rates (less than 500 copies/mL) after starting cART 
over time within regions (missing = failure). 
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Variables significantly associated with the odds of a virological response were identified 
as: gender, age, HIV exposure group, origin, baseline CD4 count and viral load, 
hepatitis B/C co-infection, previous AIDS diagnosis, type of cART regimen and number 
of drugs in regimen.  A multivariable logistic regression model adjusting for these 
variables was developed to look at the effects of region and time period (of cART 
initiation) on virological response.  After adjustment for time period, region was found to 
have a significant effect (p=0.025 when time period was fitted as categorical, p=0.026 
when it was fitted as ordered categorical, and p=0.037 when time was fitted as a 
continuous variable).  Time period was also significant after adjustment for region 
(p<0.001).  Although the interaction between time period and region was not found to 
be highly significant, possibly due to the low power for this test (p=0.088) stratified 
analyses were carried out as decided a priori.  
 
To compare virological response in different regions within time periods, models 
stratified by time period and containing region were developed.  Before adjustment for 
potential confounders, there were significant regional differences in the odds of 
achieving virological suppression in early-, mid- and late-cART periods with global p 
values p=0.001, p=0.054 and p<0.001 respectively.  However, after adjustment for the 
variables identified above, these differences between odds of virological response by 
region were not observed in mid- or late-cART years (p=0.291 and p=0.163 
respectively) and in early-cART the difference was borderline significant (p=0.068).  
Pairwise comparisons of regions with the North region within time periods showed one 
significant difference in the odds of a virological response in the East in mid-cART 
years (multivariable odds ratio (OR): 0.50; 95% CI: 0.29-0.86; p=0.013).  However 
there was a tendency for a poorer response rate in the East within all time periods.  
These comparisons should be treated with caution due to multiple testing over time.  
Figure 3.6 displays these multivariable ORs with 95% CIs. 
 
85 
 
Figure 3.6: Multivariable odds ratios and 95% confidence intervals of virological 
response (less than 500 copies/mL) after starting cART in each cART initiation period 
according to region (missing = failure). 
 
Note: Analysis adjusted for gender, HIV exposure group, previous AIDS diagnosis, origin, hepatitis B/C co-
infection, baseline CD4 count and viral load, age, type of cART regimen and number of drugs in regimen. 
 
To compare virological response in time periods within each region, models stratified 
by region and containing time period (ordered categorical) were developed.  Before 
adjustment, there were significant differences over time between the odds of virological 
suppression in South, North and East regions, with global p values p<0.001 in each 
case (no significant difference in Central West, p=0.150).  After adjustment, these 
differences were borderline significant in South and North regions (p=0.061 and 
p=0.070 respectively) and significant in Central West and East (p<0.001 and p=0.001 
respectively).  Pairwise comparisons between mid-cART and early-/late-cART showed 
that North and East regions had significantly higher odds of virological suppression in 
the late-cART period (OR: 1.96; 95% CI: 1.10-3.49; p=0.023; and OR: 2.14; 95% CI: 
1.23-3.73; p=0.007 respectively).  These are displayed in Figure 3.7. 
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Figure 3.7: Multivariable odds ratios and 95% confidence intervals of virological 
response (less than 500 copies/mL) after starting cART in each region according to 
treatment initiation period (missing = failure). 
 
Note: Analysis adjusted for gender, HIV exposure group, previous AIDS diagnosis, origin, hepatitis B/C co-
infection, baseline CD4 count and viral load, age, type of cART regimen and number of drugs in regimen. 
 
 
3.3.3.2 Sensitivity analysis: missing viral load = excluded 
Excluding patients with missing viral load measurements at six to twelve months 
provided mostly similar findings to those of the main analysis (Table 3.3).  The number 
of eligible patients in this analysis was reduced from 2102 to 1599 patients and 
response rates were higher as expected.  Virological suppression was achieved by 
78.5% overall: 74.4% (95% CI: 47.8-55.5%) of 426 South, 80.6% (95% CI: 76.8-85.0%) 
of 351 Central West, 77.4% (95% CI: 73.9-81.3%) of 496 North and 83.4% (95% CI: 
79.7-87.8%) of 326 East patients (p=0.017).  Response rates increased over time with 
67.8% (95% CI: 63.8-72.1%) of 490 early-cART patients, 78.6% (95% CI: 75.0-82.7%) 
of 430 mid-cART patients and 86.3% (95% CI: 83.9-89.0%) of 679 late-cART patients 
achieving viral load suppression (p<0.001).  These rates remained almost identical 
when including patients with missing viral loads between months six to twelve who had 
a subsequent measurement after this time; overall 1578 (78.1%) of 2031 patients had a 
positive virological response. 
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Table 3.3: Multivariable odds ratios and 95% confidence intervals of virological 
response (less than 500 copies/mL) after starting cART (missing = excluded). 
      Total 
patients
No. VL 
responders 
% VL 
responders 
Multivariable
OR  95% CI  p 
South 102  57  56%  0.83  (0.46-1.47) 0.514 
Central West 173  135  78%  2.14  (1.28-3.59) 0.004 
North 206  137  67%  1.00  -  -   
Early 1996-97 
(n=490) 
East 9  3  33%  0.51  (0.10-2.60) 0.416 
South 139  107  77%  0.97  (0.48-1.95) 0.934 
Central West 79  64  81%  1.38  (0.63-3.01) 0.419 
North 147  115  78%  1.00  -  -   
Mid 1998-99 
(n=430) 
East 65  52  80%  1.90  (0.78-4.62) 0.158 
South 185  153  83%  0.73  (0.30-1.76) 0.481 
Central West 99  84  85%  0.93  (0.35-2.46) 0.876 
North 143  132  92%  1.00  -  -   
Late 2000-04 
(n=679) 
East 252  217  86%  0.88  (0.37-2.10) 0.773 
Early 102  57  56%  0.46  (0.23-0.92) 0.028 
Mid 139  107  77%  1.00  -  -    South (n=426) 
Late 185  153  83%  0.93  (0.42-2.08) 0.864 
Early 173  135  78%  1.01  (0.47-2.18) 0.983 
Mid 79  64  81%  1.00  -  -   
Central West 
(n=351) 
Late 99  84  85%  1.38  (0.48-4.00) 0.556 
Early 206  137  67%  0.62  (0.34-1.12) 0.111 
Mid 147  115  78%  1.00  -  -    North (n=496) 
Late 143  132  92%  2.24  (0.94-5.32) 0.069 
Early 9  3  33%  0.06  (0.01-0.40) 0.004 
Mid 65  52  80%  1.00  -  -    East (n=326) 
Late 252  217  86%  2.69  (0.99-7.30) 0.053 
Total     1599  1256  79%       
Notes: Multivariable analysis adjusted for gender, HIV exposure group, previous AIDS diagnosis, origin, 
hepatitis B/C co-infection, baseline CD4 cell count and viral load, age, type of cART regimen and number 
of drugs in regimen. 
VL = viral load; OR = odds ratio; CI = confidence interval. 
 
After adjustment for the variables previously identified as significantly associated with 
the response, in addition to time period (ordered categorical), region was found to have 
a significant effect on virological response (p=0.028) as was time period after 
adjustment for region (p<0.001).  This corresponds to the findings from the main 
analysis.  Testing for an interaction between time period and region gave a significant 
result (p=0.039). 
 
Within mid- and late-cART periods after adjustment, there were no significant regional 
differences in the odds of a virological response (p=0.447 and p=0.644 respectively) 
but within the early-cART period, there was a significant difference (p=0.016).  This 
was borderline significant in the main analysis.  Pairwise comparisons with the odds of 
virological suppression in the North region showed one significant difference with the 
odds in the Central West in the early-cART period (OR: 2.14; 95% CI: 1.28-3.59; 
p=0.004). 
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Significant differences were found over time in North and East regions after adjustment 
(p=0.008 and p=0.006 respectively).  No significant differences were found in the South 
(p=0.134) or Central West (p=0.751).  This differed from the main analysis that found a 
significant temporal trend in the Central West.  Compared to the odds of a virological 
response in mid-cART years, the odds in early-cART years were significantly lower in 
the South region (OR: 0.46; 95% CI: 0.23-0.92; p=0.028) and particularly in the East 
(OR: 0.06; 95% CI: 0.01-0.40; p=0.004).  Borderline significant differences were 
observed between the odds in mid- and late-cART years in North and East regions 
(p=0.069 and p=0.053 respectively).   
 
3.3.3.3 Sensitivity analysis: subset of patients with prospective treatment data  
Analyses with the same endpoint as the main analyses, but excluding patients who 
started cART before enrolment into EuroSIDA, were carried out.  Using a ‘missing = 
failure’ approach, a total of 607 patients were included, of which 64.1% experienced a 
virological response.  The proportion of virological responders across regions differed 
significantly in this subset: 47.2% (95% CI: 39.7-56.1%) of 144 South patients, 72.4% 
(95% CI: 64.6-82.3%) of 98 Central West, 71.2% (95% CI: 66.2-77.0%) of 271 North 
and 60.6% (95% CI: 51.8-71.6%) of 94 East patients (p<0.001).  However the 
proportion of virological responders over time did not change significantly: 60.6% (95% 
CI: 54.6-67.6%) of 216 early-cART patients, 62.1% (95% CI: 55.4-69.8%) of 174 mid-
cART and 69.1% (95% CI: 63.4-75.7%) of 217 late-cART patients (p=0.149).  Adjusting 
for the previously identified potentially confounding variables, as well as time period 
(ordered categorical) and region, there was again an overall significant regional 
difference (p=0.023) but unlike in the main analysis there was no significant temporal 
difference (p=0.635).  As there were no patients in the East region who started cART 
before enrolment into EuroSIDA in early-cART years, stratified analyses were carried 
out in the remaining regions and time periods.  There was no significant regional 
difference found in mid-cART years (p=0.580) but a borderline difference in late-cART 
years (p=0.073).  Stratified by region, there was one borderline significant temporal 
difference in the North (p=0.083).   
 
Using a ‘missing = excluded’ approach left a total of 506 patients to be included, with a 
higher response rate of 76.9%.  The global p  values after adjustment for potential 
confounders were p=0.044 for the regional difference and p=0.407 for the temporal 
difference.  
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3.3.4  Virological response to cART: viral load less than 50 copies/mL at 
months six to twelve 
Taking the subset of patients whose first viral loads in the period six to twelve months 
after initiation of the cART regimen were measured using an assay with a lower limit of 
detection of 50 copies/mL or less, gave a total of 1408 patients.  The overall virological 
response rate was found to be 48.7%.  Across regions, a significant difference was 
found: 44.7% (95% CI: 40.0-50.0%) of 380 patients in the South, 42.9% (95% CI: 37.9-
48.4%) of 336 Central West patients, 48.6% (95% CI: 44.3-53.2%) of 484 North 
patients and 65.9% (95% CI: 59.9-72.8%) of 208 East patients (p<0.001).  There was 
also a significant difference between time periods: 15.9% (95% CI: 12.8-19.4%) of 471 
patients starting in early-cART, 52.3% (95% CI: 47.6-57.6%) of 384 patients starting in 
mid-cART and 74.1% (95% CI: 70.7-78.0%) of 553 patients in late-cART years 
(p<0.001).  After adjustment for potential confounders, there appeared to be an overall 
borderline significant regional difference (p=0.062) and a significant temporal difference 
(p<0.001) in virological response to cART.  Stratified analyses showed no significant 
regional differences in virological response in mid- and late-cART years (p=0.655 and 
p=0.205 respectively).  No patients in the East in early-cART years achieved virological 
suppression, most likely due to the small number and the lack of more sensitive viral 
load assays.  However there were significant temporal differences in South, Central 
West and North regions (p<0.001 for all).     
 
3.3.5  Virological response to cART: time to viral load less than 500 
copies/mL 
Binary endpoints were investigated in the main analyses due to potential differences in 
the frequency of viral load measurements between regions or time periods.  Survival 
analysis techniques were used as an alternative method to see how robust the findings 
were.  The same inclusion criteria applied and so 2102 patients were included in these 
analyses.   
 
3.3.5.1 Frequency of measurements  
A significant difference was found between regions in the median frequency of viral 
load measurements in the first year following the start of cART.  Median frequencies of 
viral load measurements were 2 (IQR: 1-4) in the South region, 4 (2-5) in the Central 
West, 4 (2-5) in the North and 2 (1-3) in the East region (p<0.001).     
 
There was also a statistically significant difference in the median numbers of viral load 
measurements in the first year of cART comparing people who started in different 
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calendar time periods.  Median numbers of viral load measurements were 3 (IQR: 1-5) 
in early-cART years, 3 (1-4) in mid-cART and 3 (2-5) in late-cART years (p<0.001).   
 
3.3.5.2 Kaplan-Meier estimates  
Figure 3.8 displays Kaplan-Meier estimates of the percentage of patients achieving 
virological suppression from date of starting a cART regimen, according to region and 
stratified by time period.  The log rank tests showed significant regional differences in 
each of the time periods (p<0.001 in early- and late-cART years, p=0.002 in mid-cART 
years).  Kaplan-Meier estimates according to time period and stratified by region 
showed significant temporal differences in all regions (all p<0.001). 
 
3.3.5.3 Cox proportional hazards models 
Cox proportional hazards models, adjusted for the same potential confounders as in 
the main logistic regression analysis, revealed overall that both region adjusted for time 
period, and time period adjusted for region had significant effects on the risk of 
virological response (p<0.001 for both). 
 
Stratified by time periods, and again after adjustment, there was a significant regional 
difference in the risk of virological response in early-cART years (p=0.013).  In mid- 
and late-cART years, there were no regional differences (p=0.104 and p=0.154 
respectively).  Pairwise regional comparisons of the relative hazards (RHs) of 
virological response (with 95% CIs) are displayed in Figure 3.9.  
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Figure 3.8: Kaplan-Meier estimates of the percentage of patients achieving a virological response (less than 500 copies/mL) by date from start of 
cART regimen, according to region in (a) early-cART years, (b) mid-cART years and (c) late-cART years. 
 
(a) Early-cART  (b) Mid-cART  (c) Late-cART 
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Figure 3.9: Multivariable relative hazards and 95% confidence intervals of virological 
response (less than 500 copies/mL) after starting cART in each cART initiation period 
according to region. 
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Note: Analysis adjusted for gender, HIV exposure group, previous AIDS diagnosis, origin, hepatitis B/C co-
infection, baseline CD4 count and viral load, age, type of cART regimen and number of drugs in regimen. 
 
 
Stratified by regions, and after adjustment, there were significant temporal differences 
in all regions in the risk of virological response (South, p=0.040, Central West, p<0.001, 
North, p=0.019 and East, p=0.001).  Pairwise comparisons of the RHs of virological 
response over time are displayed in Figure 3.10.  
 
Both stratifying by clinical centre and left censoring at date of enrolment resulted in 
similar findings (results not shown).   
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Figure 3.10: Multivariable relative hazards and 95% confidence intervals of virological 
response (less than 500 copies/mL) after starting cART in each region according to 
cART initiation period. 
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Note: Analysis adjusted for gender, HIV exposure group, previous AIDS diagnosis, origin, hepatitis B/C co-
infection, baseline CD4 count and viral load, age, type of cART regimen and number of drugs in regimen. 
 
3.4 Discussion 
The focus of this chapter was to assess two potential predictors of virological response 
to first-line cART: geographical region and calendar time period of initiation of cART.  
The findings showed that overall there was some indication of regional differences in 
initial virological response to cART that cannot be explained by differences in cART 
regimen started.  These were most evident in early-cART years, 1996-1997.   
Improvements in virological response rates over time were also clearly observed, most 
noticeably in the East region.  
 
3.4.1  Regional differences in virological response 
3.4.1.1 Interpretation of findings 
An overall significant regional difference in initial virological response to cART was 
found, after adjustment for potentially confounding variables including the type of cART 
regimen, suggesting that the difference could be linked to unmeasured factors such as 
differing levels of patient care and management of associated toxicities that may affect 
patient adherence.  In the main analysis, there was a borderline significant regional 
difference in early-cART years and no regional differences in mid- or late-cART years, 
which could indicate that these factors have become more uniform throughout Europe 
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in more recent years.  This finding was more pronounced in the ‘missing = excluded’ 
analysis implying that there was more variability between regions in the proportion with 
missing viral load measurements in early-cART years.  The East region was found to 
have the lowest odds of achieving virological suppression in all three calendar time 
periods, however this did increase over time to become more consistent with other 
regions.  The Central West region appeared to have the highest odds of virological 
response in early-cART years compared to the North but the lowest in late-cART years.  
This may be an indication of comparatively higher improvements in treatment 
strategies and adherence and increased access to new antiretroviral drugs in the other 
regions.  It could also indicate increasing drug resistance in Central West.  However, 
these trends were not statistically significant and so may be explained by a chance 
result. 
 
3.4.1.2 Previous research  
As expected, these findings are broadly consistent with previous regional comparisons 
in EuroSIDA, however the chosen endpoint of a successful virological response to 
cART has not been compared between EuroSIDA regions before.  In an analysis 
comparing South, Central and North Europe (before the addition of East European 
countries into EuroSIDA), Chiesi et al. (1999) found that rate of mortality following a low 
CD4 cell count was significantly lower in Central Europe than in North and South 
Europe over the period 1994-1999 [179].  Mocroft et al. (2000) showed that in patients 
mostly starting cART before 1996-1997, Central and North Europe had significantly 
lower odds of virological failure at 16 and 48 weeks following initiation of cART than 
South Europe [384].  These studies both found evidence of a better response to cART 
in Central Europe in early years, which, as mentioned above was found in the analyses 
in this chapter albeit that the effects observed were not statistically significant.   
 
Another EuroSIDA analysis by Kirk et al. (1998) examined the use of ART over the 
period 1994-1997 and found a decrease in regional variation over time [383].  The 
findings in this chapter indicated a significant regional variation in the type of cART 
regimen started in all three time periods, however the magnitude of differences did 
decrease over time, which supports these previous results.  The decreasing regional 
differences could be due to treatment policies becoming more consistent throughout 
Europe, resulting from the increasing widespread availability of antiretroviral drugs.   
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3.4.2  Changes over time in virological response 
3.4.2.1 Interpretation of findings 
The improvements in initial virological response to cART over time observed in this 
analysis could be attributed to changes in clinical support, patients’ attitude towards 
therapy, management of toxicities linked to improved adherence, a better 
understanding of drug resistance and an increased availability of new antiretroviral 
drugs [40-42].  The analyses were adjusted for type of cART regimen, suggesting that 
changes in first-line regimens are not solely responsible for the improvements in 
response.  Increases in virological response rates were observed in all four regions.  
These were only statistically significant in the Central West and East regions in the 
main analysis, although they were borderline significant in the South and North.  The 
analysis excluding patients with missing viral loads gave somewhat different results 
with no significant changes over time in virological response in South or Central West 
regions.  This indicates that the proportion with missing values declined over time in 
these regions, possibly due to improved clinical management.  This finding was also 
true in the analyses excluding patients with retrospective treatment data, possibly due 
to those with retrospective data being more likely to have missing measurements.  The 
number of patients included in this analysis was reduced to just over a quarter and so 
had reduced power to detect true differences.  As East European countries were 
enrolled into EuroSIDA relatively recently, the proportion with retrospective data was 
highest in this region and all patients who started cART in early-cART years were 
excluded.   
 
3.4.2.2 Previous research  
Few studies have quantified trends over calendar time in virological response to cART.  
The ART Cohort Collaboration 2006 found a steady improvement in the odds of a 
virological response (viral load less than 500 copies/mL) six months after starting cART 
in ART-naïve patients over the years 1995 to 2003 [382].  Moore et al. (2005) found 
significant improvements in virological suppression (viral load less than 400 copies/mL) 
to cART: 43.8% in 1996 compared to 72.4% in 2001-2002 by six months and 60.1% in 
1996 compared to 79.9% in 2001-2002 by twelve months [380].  Ledergerber et al. 
(1999) looked at virological suppression and progression to AIDS or death in the Swiss 
HIV Cohort Study and found that patients starting PI-containing cART regimens in 
1997-1998 were 30% more likely to reach virological suppression than those starting in 
1995-1996 [381].  Lampe et al. (2006) investigated risk of initial virological failure after 
starting cART whilst ART-naïve in a multi-cohort analysis over a seven-year period in 
Europe and Canada and found a significant decrease over time (results shown in 
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Figure 3.11) [379].  The results in this chapter support the conclusions of improvements 
over time in treatment success of initial cART regimens.  
 
Figure 3.11: Unadjusted and adjusted risk ratios (with 95% confidence intervals) of 
virological failure by year of starting triple-combination therapy (missing = failure).   
 
 
 
 
 
 
 
 
Figure not available due to copyright restrictions. 
 
Source: Lampe et al. (2006) [379]. 
 
Since an increase in odds of virological response to cART over time was observed and 
the majority of patients’ regimens were not chosen according to their resistance profiles 
(only 12% of patients had plasma samples available within a year before starting cART 
that had been successfully tested for HIV drug resistance), this indicates that the 
transmission of drug-resistant HIV may not have had a great impact or may be 
decreasing over time, which supports recent data from the UK [394].  However, it is 
possible that if TDR was increasing, it may have reduced the rate of improvement in 
virological success rates.  This is investigated further in Chapter 5 that specifically 
investigates the prevalence of TDR in EuroSIDA. 
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3.4.3 Limitations  of  analysis 
The limitations of this analysis should be recognised when interpreting these results.  
The clinics involved in EuroSIDA were not selected at random and could differ from 
others in terms of clinician experience and availability of ART.  However due to the 
large number of clinics in the study, the sample should be broadly representative of 
centres across Europe.  Regions were defined according to the grouping of countries 
historically used by EuroSIDA [179]  as there was not enough power to compare 
countries or clinical centres.  Countries were allocated into regions at the initiation of 
EuroSIDA in 1994 according to geographical location and the same groupings have 
been maintained in all analyses.  There may be variation in virological response 
between countries within regions however this analysis aims to compare broad regions 
of Europe to gain an overview of any existing differences. 
 
Pairwise comparisons of regions within time intervals should be treated with caution as 
multiple testing over time carries an increased risk that significant results could be due 
to chance.  Adjustments can be made to the p  values (such as the Bonferroni 
correction) to compensate for this.  The pairwise comparisons made in this analysis 
were conducted to illustrate regional differences in more detail and conclusions were 
not drawn from these p values.  
 
The sensitivity analysis using the subset of patients including only those who started 
cART after enrolment into EuroSIDA showed different results to the main analysis as 
no significant trend over time was found in virological response.  This is likely to be due 
to the fact that no patients from the East region started cART before enrolment into 
EuroSIDA in the early-cART years.  As this was the subset of patients with the lowest 
virological response rate in the main analysis, this could account for the difference.  
The alternative is that the validity of the retrospective data could be questioned as 
patients who started cART before enrolment have already proved that treatment was 
successful enough to allow them to survive a period up to enrolment and therefore they 
may be more likely to have a successful virological response.  Retrospective data are 
also more likely to contain missing information, such as viral load measurements.  In a 
‘missing = failure’ analysis, this would bias the findings in favour of virological failure.  
In order to increase numbers in this sensitivity analysis, patients could only be 
excluded who started cART more than six months before enrolment so that they had 
the potential for a prospective viral load measurement in the six to twelve month period 
after starting cART. 
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The frequency of viral load measurements in the year after starting cART was 
significantly different across regions and time periods, which could account for missing 
values during months six to twelve, although it cannot be ruled out that missing values 
may be related to the outcome of treatment, e.g. patients being too ill to visit a clinic.  
Most patients with missing values during this time had a subsequent one after.  The 
difference in frequency of measurements was the reason for choosing a binary 
endpoint rather than a time-to-event endpoint for the main analyses.  However to 
compare the results found from using an alternative statistical method, survival analysis 
was also applied and even though there was potential for bias the conclusions were the 
same.   
 
3.4.4 Implications  of  findings 
The findings of this analysis show that the differences in virological response rate 
following initiation of first-line therapy between regions that existed when cART was 
first introduced have now diminished, which suggests that the standard of patient care, 
toxicity management, the level of information available to patients and availability of 
new antiretroviral drugs have become more uniform across Europe.  Increasing 
virological response rates were observed in all regions, which indicate that 
improvements in clinical management have made an important difference over the 
years.  The analysis was carried out on ART-naïve patients as they do not have a 
history of ART use that would confound the results due to the accumulation of HIV drug 
resistance.  Nowadays, patients generally start cART for the first time from ART-naïve 
and so these results are applicable to the population of newly diagnosed HIV infected 
individuals across Europe.   
 
3.4.5 Further  research 
The continued expansion of EuroSIDA will increase the number of patients eligible for 
inclusion in analyses such as this.  As more clinical centres in East European countries 
join EuroSIDA, this will provide a better picture of the impact of cART in this region.  
Ideally it would be interesting to compare response to cART across individual countries 
rather than regions, as well as using a year-by-year stratification.   
 
Immunological response could also be investigated across regions and over time using 
logistic regression to analyse endpoints such as a 100 cells/mm
3 or 50% increase in 
CD4 count from initiation of cART at the first measurement six to twelve months after 
starting cART in those with CD4 counts available.  To study the long-term effects of 
cART, the risk of clinical outcomes (new AIDS or death) should be compared using 
survival analysis methods.  A previous EuroSIDA analysis compared pre-cART (1994-
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1995), early-cART (1996-1997) and late-cART years (1998-2002) in terms of mortality 
and morbidity, finding that there was a significantly higher risk of AIDS and death in the 
pre-cART years compared to the early-cART years and a significantly lower risk in the 
late-cART years [140].  This showed that the initial drop following the introduction of 
cART was sustained in later years.  A EuroSIDA analysis comparing death rates 
between regions in EuroSIDA was mentioned earlier, which found Central Europe to 
have a significantly lower death rate than South and North [179].  EuroSIDA has 
already grown extensively since these analyses were carried out and in the future the 
dataset may be large enough to compare clinical outcomes across regions within time 
periods and over time within regions.  
 
3.4.6 Conclusions 
Some regional variation in initial virological response to cART was observed in this 
analysis, which was most apparent in early-cART years.  Virological response appears 
to have improved over calendar time in all regions, especially in East Europe.  These 
findings could be a consequence of better adherence to regimens due to improved 
management of toxicities, more clinical support and increased access to new 
antiretroviral drugs that are virologically more potent and have better tolerability 
profiles.  There was no evidence to support a clinically significant increasing 
emergence of TDR and so this may be yet to have a significant impact.  This will be 
investigated further in Chapter 5. 
 
A manuscript of this analysis was published by the Journal of Acquired Immune 
Deficiency Syndrome in June 2006 and can be found in Appendix VI. 
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Chapter 4. HIV-1 subtypes and virological and 
immunological response to combination antiretroviral 
therapy 
4.1 Introduction 
HIV infection is characterised by a very high turnover of virus [10].  Viral replication is 
highly error-prone and results in a high frequency of genetic mutations, consequently 
HIV has evolved into numerous different strains and has become a genetically diverse 
group of retroviruses [18,344,396,397].   
 
4.1.1 Classification  of  HIV-1 
HIV-1 is the predominant form of the virus worldwide, classified into three groups 
according to its genetic structure: ‘M’ the main or major group, ‘O’ the outliers and ‘N’ 
the new or non-M/O group [344,355,398,399].  Group ‘O’ is currently restricted to 
countries in West Central Africa and ‘N’ has only been identified in a few individuals 
from Cameroon [396,400].  The ‘M’ group represents the vast majority of all infections 
and currently nine distinct subtypes within this group have been identified: A-D, F-H, J 
and K, with further sub-subtypes A1, A2, A3, F1 and F2 [344,355,399,401].  Infection 
with two or more different HIV strains has led to the evolution of circulating recombinant 
forms (CRFs) [402-404], which incorporate genetic material from more than one 
subtype through the process of recombination during replication (recombination is 
described in Chapter 1, section 1.5.1).  There are currently 43 known CRFs (CRF01-
CRF43) [405], of which CRF01_AE and CRF02_AG are the most common, 
predominant in South East Asia and Western/Central Africa respectively [344,396,406].  
Subtype E was originally identified as one of the two major strains causing epidemics in 
Thailand [407,408] but in more recent years it has been found that all representatives 
of this subtype are actually the recombinant or mosaic form, CRF01_AE, made up of 
subtypes E and A [344,403,404].  The non-recombinant form, E, is no longer thought to 
exist.  Likewise subtype I has now been recognised as a complex mosaic form.  It was 
first reclassified as a CRF comprising A, G and I [409], however it is now recognised 
that CRF04_cpx, as it is now known, additionally comprises subtypes H and K [410]. 
 
4.1.2 Genetic  sequencing 
As discussed in Chapter 1 (section 1.9.1), HIV-1 subtypes can be determined via the 
method of phylogenetic analysis.  Each subtype has a consensus sequence, which is 
the sequence of the most common nucleotide bases.  To determine the HIV strain an 
individual is infected with, viral RNA is extracted from a plasma sample, sequences are 
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aligned and by constructing a phylogenetic tree, the most recent common ancestor can 
be compared against consensus sequences to find out to which one it is most closely 
matched [344,354].  For most accurate results, the entire HIV genome should be 
sequenced and compared [344,355,396].  However, the major regions of the genome 
that are often focused upon are known as env, pol and gag [344,355,356].  As it is 
essential for the functions of these proteins to be preserved, the variation that can 
occur between subtypes is limited in these genetic regions, but is sufficient to allow 
phylogenetic identification of subtypes.  HIV-1 subtypes have been found to differ by 
approximately 20-30% in the env region, 10-12% in the pol region and 15-22% in the 
gag region [399,411]. 
 
4.1.3 Antiretroviral  resistance 
Mutations in the reverse transcriptase (RT) and protease (PR) genes in the pol region 
have been shown to be associated with resistance to inhibitors of these enzymes 
[412,413].  These resistance mutations are defined according to subtype B consensus 
sequences but are also selected by ART in non-B subtypes.  Although drug resistance 
evolution appears to be fairly comparable between B and non-B subtypes according to 
current research, emerging differences in drug susceptibilities have been observed that 
may result in difficulties interpreting genotypic resistance in non-B subtypes 
[399,406,411,413-417].  These differences could be driven by different patterns of 
nucleotide changes existing before therapy initiation or by selection of resistance along 
different pathways, which could affect drug susceptibility and therapy response.  For 
example, the selection of the K65R mutation by tenofovir (TDF) appears to be more 
rapid in subtype C than subtype B [418].  Another example is that greater genetic 
variability at NNRTI resistance sites, e.g. mutations V106M and A98S, has been 
observed in subtype C strains than in subtype B [419,420].  This indicates that 
differences in resistance to different regimens may exist between subtypes, i.e. there 
could be an interaction between HIV-1 subtype and type of cART regimen in terms of 
response to therapy. 
 
4.1.4  Global distribution of HIV-1 subtypes and response to ART 
Historically, antiretroviral drugs have mostly been developed in North America and 
Western Europe where subtype B is the most prevalent strain [416].  In 2004, 
Hemelaar et al. estimated the global distribution and regional spread of HIV-1 subtypes 
by combining molecular epidemiological data on subtype distribution in individual 
countries with country-specific estimates of the number of individuals living with HIV 
from UNAIDS and the WHO [401].  This is displayed in Figure 4.1.  It was estimated 
that 98% of individuals living with HIV in North America and 88% in Western Europe 
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were infected with subtype B [401].  Consequently drugs have been developed based 
on the biological and clinical findings of their effects on patients largely infected with 
this strain [13,25], even though in 2004, subtype B was estimated to contribute to just 
10% of the worldwide epidemic [401].  As non-B subtypes are genetically different and 
as already mentioned, may develop different patterns of resistance, there is reason to 
hypothesise that patients infected with different subtypes will have different response 
rates to therapy.   
 
Figure 4.1: Global distribution of HIV-1 subtypes and recombinants in 2004. 
 
 
 
 
 
 
 
Figure not available due to copyright restrictions. 
 
Source: Hemelaar et al. (2004) [401]. 
 
Non-B subtypes are widespread in Africa (subtypes A, C, D, G, CRF02_AG and other 
CRFs and recombinants), Asia (subtypes A, CRF01_AE and other CRFs and 
recombinants) and much of East Europe (subtype A) [401,415].  However, as travel 
and migration are on the increase, non-B subtypes are spreading worldwide [421].   
Previous studies researching response to therapy across HIV-1 subtypes have 
generally so far been small-scale and have not found any striking differences, although 
most have only been able to compare subtype B with an aggregated group of non-B 
subtypes [399,422-429].   
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4.1.5  Motivation and aims for chapter   
EuroSIDA represents an ideal setting for comparing response to therapy across HIV-1 
subtypes in an area where B is most prevalent.  The study prospectively collects 
plasma samples from patients all across Europe from which viral RNA can be 
sequenced to determine subtype.  Whether or not cART is as effective at reducing viral 
load and promoting immune regeneration in patients infected with non-B subtypes as it 
is in those with subtype B remains an important, yet unresolved question in HIV 
research.    Therefore the aim of this analysis was to compare both virological and 
immunological response to cART between patients infected with different HIV-1 
subtypes.   
 
4.2 Methods 
4.2.1 Inclusion  criteria 
The EuroSIDA dataset used for the analyses in this chapter, as in Chapter 3, was the 
update completed in December 2005 including data on 11,928 patients with follow-up 
to (median date of last visit) May 2005.  Patients were eligible for analyses if they 
started cART, defined as at least three antiretroviral drugs including a PI, an NNRTI, or 
abacavir (ABC), with no previous PI/NNRTI/ABC experience and had the potential for 
at least one year’s follow-up after starting cART (i.e. started cART at least one year 
before May 2005).  They were also required to have pre-cART blood plasma samples 
stored, upon which genotypic sequencing and phylogenetic analysis were 
retrospectively performed to determine the HIV-1 subtype they were infected with.   
Alternatively, if this was not available, pre-cART subtype test results provided by the 
clinical centres were used.  Plasma samples or genotypic sequence data may have 
been obtained when a patient was tested for drug resistance therefore patients with 
subtype test results after starting cART may be more likely to have been failing their 
regimen.  This was the reason for selecting only those with samples obtained before 
starting cART, to prevent a biased selection of patients for the analysis who may be 
more likely to fail. 
 
4.2.1.1 Identification of HIV-1 subtype 
As detailed in Chapter 2 (section 2.1.3), HIV-1 subtypes in EuroSIDA are primarily 
ascertained using phylogenetic analysis on viral RNA extracted from plasma samples 
analysed in central virology laboratories.  In some cases when sequences were 
incomplete, serology methods were used instead to determine subtype, which are not 
as accurate as phylogenetic analysis.  In the absence of plasma samples, the results of 
genetic sequencing conducted in the local laboratories were used if available and as 
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long as they were dated before the patient started cART.  If these were also not 
available, any subtype assignment in the patients’ case-notes reported on the follow-up 
forms was taken, again, as long as this was before the patient started cART.  
 
4.2.2 Statistical  methods 
4.2.2.1 Definitions 
Patients infected with HIV-1 subtypes A, B, C and ‘other’ were compared, where ‘other’ 
included all other HIV-1 subtypes and CRFs.  For the main analysis, A, C and ‘other’ 
subtypes were aggregated into a non-B subtype group due to lack of statistical power 
to compare the four groups.  Baseline was defined as the date of starting cART. 
 
For patients with blood plasma samples taken within a year before the date of cART 
initiation that were subsequently tested for genotypic HIV drug resistance, resistance 
was defined as at least one NRTI, NNRTI or major PI resistance mutation according to 
the IAS-USA 2005 figures of HIV-1 drug resistance mutations [395].   
  
4.2.2.2 Infection with an HIV-1 B or non-B subtype 
Multivariable logistic regression models were developed to investigate the factors 
affecting whether or not patients were infected with an HIV-1 non-B subtype, as 
opposed to subtype B.  Explanatory variables were identified as those significantly 
associated with the odds of being infected with subtype B in univariable analysis 
(p<0.1) and those investigated were: gender, age, HIV exposure group (defined as 
‘men who have sex with men (MSM)’, ‘injecting drug use (IDU)’, ‘heterosexual’ or 
‘other’), country of origin (defined as ‘Africa’ or ‘non-Africa’), geographical region 
(defined in Chapter 2, section 2.1.5), ethnicity (defined as ‘white’ or ‘other’), hepatitis 
B/C co-infection status and how subtype was determined (‘phylogenetic analysis’ or 
‘other’).   
 
4.2.2.3 Virological and immunological response to cART 
Logistic regression was also used to compare the odds of a virological and 
immunological response to cART at the first viral load measurement and CD4 count 
respectively, six to twelve months after initiation of the cART regimen, between patients 
infected with B and non-B subtypes.  A virological response was defined as a viral load 
less than 500 copies/mL.  An immunological response was defined as a CD4 count 
increase of at least 100 cells/mm
3 from baseline.  For analyses of virological response, 
patients were required to have a baseline viral load of at least 500 copies/mL and for 
analyses of immunological response, patients needed to have a baseline CD4 count 
available.  Baseline measurements were defined as those taken within the six-month 
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period prior to starting cART.  A ‘missing = failure’ approach was taken as the main 
analysis. 
 
Multivariable models were developed to investigate the effects of HIV-1 subtype on 
virological and immunological response.  Variables were identified that were 
significantly associated with the response (p<0.1 in univariable analyses or using a 
stepwise selection procedure) and therefore potentially could confound the relationship 
between subtype and the outcome.  Variables investigated were as in section 4.2.2.2 
with additions of: viral load measurements (baseline and maximum ever at baseline), 
CD4 counts (baseline and nadir), time from CD4 nadir, prior AIDS diagnosis, time from 
HIV diagnosis, calendar year of starting cART regimen, type of regimen (defined as 
containing ‘a single PI: not saquinavir (SQV) hard gel’, ‘a single PI: SQV hard gel’, ‘a 
ritonavir (RTV)-boosted PI’, ‘a single NNRTI’ or ‘other’), number of new drugs in 
regimen (according to the patient inclusion criteria any previous drugs would have been 
taken as monotherapy or dual therapy, not cART), whether or not ART-naïve at 
baseline and whether or not the patient had genotypic resistance test results available 
within a year before starting cART. 
 
4.2.2.4 Sensitivity analyses 
A sensitivity analysis was carried out using a ‘missing = excluded’ approach.  Further 
sensitivity analyses using a ‘missing = failure’ approach were conducted on subsets of 
(i) ART-naïve patients, to minimise any differences in drug resistance caused by 
previous NRTI experience; (ii) patients with subtypes determined by phylogenetic 
analysis as opposed to other less reliable methods; (iii) patients who had their subtypes 
identified post-1999, in order to exclude from the analysis potentially less reliable 
measures of viral load due to subtype-specific problems of viral load assays commonly 
used before then [430-432] (for virological response only); and (iv) patients who started 
cART after enrolment into EuroSIDA to exclude retrospective data.  Another sensitivity 
analysis looking at immunological response was carried out on a subset of only 
patients who had achieved virological suppression.   
 
A further endpoint for the virological response analysis was also investigated: a viral 
load less than 50 copies/mL.  This analysis was conducted on a subset of patients 
whose first viral load measurements in the six to twelve month period after starting 
cART were measured using an assay with a level of detection as low as at most 50 
copies/mL.  This required all those with missing values to be excluded.  In addition, an 
alternative immunological response was investigated: a CD4 count increase of 25% 
from baseline.  A ‘missing = failure’ approach was used for this.  
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Survival analysis using Kaplan-Meier estimates and Cox proportional hazards models 
was used to check the consistency of results.  Time to virological suppression (a viral 
load less than 500 copies/mL) and time to a CD4 cell increase of 100 cells/mm
3, with 
right censoring at the date of patients’ last viral load measurement or CD4 cell count 
respectively were investigated.  Stratifying by clinical centre was investigated to adjust 
for potential differences between centres.  Left censoring at date of enrolment into 
EuroSIDA was also investigated. 
 
4.3 Results 
4.3.1 Patient  numbers 
A total of 8200 (68.7%) patients met the inclusion criteria, displayed in Figure 4.2.  Pre-
cART HIV-1 subtype results were available for 939 (11.4%) patients, therefore 7261 
(88.5%) patients were excluded for having unknown subtypes.   
 
Figure 4.2: Patient numbers in analyses according to inclusion criteria.  
 
 
Missing viral loads
6-12 months after
cART = excluded
n=721
Missing viral loads
6-12 months after cART
= virological failures
n=791
Virological response:
baseline viral load of
at least 500 copies/mL
n=791
Missing CD4 counts
6-12 months after
cART = excluded
n=796
Missing CD4 counts
6-12 months after cART
= immunological failures
n=867
Immunological response:
baseline CD4 count
n=867
Subtype determined before
starting cART
n=939
Potential for one year's
follow-up after starting cART
n=8200
Started cART with no previous
 experience of NNRTIs/PIs/abacavir
n=8330
EuroSIDA patients
(December 2005 dataset)
n=11928
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4.3.2  Patient characteristics at date of starting cART 
4.3.2.1 Patients with HIV-1 subtypes known versus unknown 
Table 4.1 compares the characteristics of patients with HIV-1 subtype test results 
available to those without.  Due to the large sample size, there were a number of 
statistically significant differences.  Those with known subtypes on average started 
cART later than those with unknown subtypes (median: January 1998 versus July 
1997;  p<0.001).  They had higher median baseline CD4 counts (228 versus 185 
cells/mm
3;  p<0.001) and slightly higher median viral loads (4.7 versus 4.5 
log10copies/mL; p<0.001).  There was also a lower proportion with a previous AIDS 
diagnoses (21.9% versus 29.5%; p<0.001) and a higher proportion of patients who 
were ART-naïve at baseline (44.6% versus 36.5%; p<0.001).   
 
4.3.2.2 Regional distribution of HIV-1 subtypes 
Figure 4.3 illustrates the distribution of the subtypes identified in the 939 patients 
included in the analyses across geographical regions within EuroSIDA.  These patients 
were widespread across Europe with the addition of 16 (1.7%) patients from Israel (no 
patients from Argentina).  The large majority of patients who met the inclusion criteria in 
all the regions (South, Central West, North and East) were infected with HIV-1 subtype 
B (89.1%, 82.5%, 86.4% and 94.2% respectively), however there were also non-B 
subtypes found in all regions.  Overall the analyses included 812 (86.5%) patients 
infected with subtype B, 23 (2.4%) with A, 42 (4.5%) with C and 127 (6.6%) with any 
other subtype, including 16 (1.7%) with CRF01_AE and 14 (1.5%) with CRF02_AG.  Of 
all patients who started a cART regimen (n=8200), those visiting clinical centres in the 
North region were over twice as likely to have pre-cART subtype test results available 
than those in the South, Central West or East (22.2% compared to 4.0%, 10.6% and 
8.8% respectively).   
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Table 4.1: Patient characteristics at date of starting cART according to whether or not 
pre-cART HIV-1 subtype test results were available. 
  
                               Total  Pre-cART subtype test 
results  No subtype test results p 
n %           
All  8200 100.0  939  11.5  7261  88.5  - 
Male  6318 77.0  725  77.2  5593  77.0  0.901 
HIV exposure group          0.001 
 MSM  3601 43.9  467  49.7  3134  43.2  - 
 IDU  1820 22.2  179  19.1  1641  22.6  - 
 Heterosexual  2180 26.6  223  23.7  1957  27.0  - 
 Other  599  7.3  70  7.5 529 7.3 - 
Ethnicity          0.007 
 White  7073 86.3  783  83.4  6290  86.6  - 
 Other  1127  13.7 156 16.6 971 13.4 - 
Region          <0.001
 South  2740 33.4  110  11.7  2630  36.2  - 
 Central  West  2166 26.4  229  24.4  1937  26.7  - 
 North  2316 28.2  514  54.7  1802  24.8  - 
 East  978  11.9 86  9.2 892  12.3  - 
Previous AIDS  2348 28.6  206  21.9  2142  29.5  <0.001
Hepatitis B status          <0.001
 Negative  4524 55.2  662  70.5  3862  53.2  - 
 Positive  409  5.0  68  7.2 341 4.7 - 
 Unknown  3267 39.8  209  22.3  3058  42.1  - 
Hepatitis C status          <0.001
 Negative  2525 30.8  418  44.5  2107  29.0  - 
 Positive  1168 14.2  153  16.3  1015  14.0  - 
 Unknown  4507 55.0  368  39.2  4139  57.0  - 
Type of cART regimen          <0.001
 
Single PI (non-SQV 
hard gel) 
4461 54.4  465  49.5  3996  55.0  - 
 
Single PI (SQV hard 
gel) 
1118 13.6  67  7.1  1051  14.5  - 
 RTV-boosted  PI  447  5.5  78  8.3 369 5.1 - 
 Single  NNRTI  1188 14.5  185  19.7  1003  13.8  - 
  Triple NRTI incl ABC  155  1.9  27  2.9 128 1.8 - 
 Other  155  1.9  27  2.9 128 1.8 - 
ART-naïve  3069 37.4  419  44.6  2650  36.5  <0.001
Median (IQR)           
Date started cART 
regimen 
Jul 97  (Nov 96-
Mar 99)  Jan-98  (Apr 97-
Dec 99)  Jul 97  (Nov 96-
Feb 99)  <0.001
Age (years)  37  (32-44) 37 (32-45) 37 (32-44)  0.208 
CD4 count (cells/mm
3)           
 Baseline
(1)  191  (81-323) 228  (113-333) 185 (78-321)  <0.001
 Nadir
(2)  150  (60-254) 172 (87-260) 148 (59-253)  <0.001
Viral load (log10copies/mL)           
 Baseline
(3)  4.6  (3.8-5.2) 4.7 (4.0-5.2) 4.5 (3.7-5.2)  <0.001
 Max  ever
(4)  4.8  (4.2-5.3) 5.0 (4.5-5.4) 4.8 (4.1-5.3)  <0.001
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
Median CD4 counts and viral loads based on measurements from 
(1)7974 patients, 
(2)8122 patients, 
(3)5391 patients and 
(4)5711 patients. 
MSM = men who have sex with men; IDU = injecting drug use; SQV = saquinavir; RTV = ritonavir; ABC = 
abacavir; IQR = interquartile range. 
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Figure 4.3: HIV-1 subtypes identified in patients with pre-cART HIV-1 subtype test results available according to geographical region within 
EuroSIDA. 
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4.3.2.3 Patients with HIV-1 B versus non-B subtypes 
Table 4.2 compares the characteristics between the 812 (86.5%) patients infected with 
B and the 127 (13.5%) infected with a non-B virus at the date of starting cART.  Dates 
of starting cART were similar for patients infected with B and non-B subtypes (medians: 
February 1998 and November 1997 respectively), as were dates of subtype tests 
(medians: May 1997 and April 1997 respectively).  A total of 656 (80.8%) of the 
patients infected with B had their subtype determined by phylogenetic analysis 
compared to 73 (57.5%) of the non-B infected patients (p<0.001).  There was a 
significant difference in country of origin between B and non-B infected patients 
(p<0.001), for example 52.8% of patients with a non-B subtype originated from Africa 
(15 patients with subtype A, 28 with C, 24 with another subtype) compared to just 1.7% 
of patients with subtype B and these were mostly infected through heterosexual contact 
(78.5%).  The majority of the remaining patients originated from the same country as 
the clinical centre they visited.  Significant differences were also found between groups 
in gender, HIV exposure group and ethnicity (all p<0.001).  For those with baseline 
CD4 cell counts (n=923), medians were found to be similar between B and non-B 
infected patients (230 versus 210 cells/mm
3; p=0.881).  Baseline viral loads (for the 
637 patients with measurements) were slightly higher for B infected patients (medians: 
5.0 versus 4.9 log10copies/mL; p=0.017).     
 
A total of 533 (56.8%) patients had genotypic resistance test results available from 
tests carried out on plasma samples collected within one year before starting cART.  
Amongst these patients, 466 (87.4%) were infected with subtype B.  Overall, 218 
patients (40.9% of those with test results) had at least one IAS-USA NRTI resistance 
mutation (41.2% of B infected versus 38.8% of non-B infected patients; p=0.709), of 
whom 193 (88.5%) patients had previous NRTI experience.  Major PI resistance 
mutations were found in 35 (3.7%) patients and NNRTI resistance mutations in 24 
(2.6%) patients. 
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Table 4.2: Patient characteristics at date of starting cART according to HIV-1 subtype 
B versus non-B. 
   Total B  Non-B  p 
n %         
All  939  100.0 812 86.5 127 13.5  - 
Source of subtype identification            - 
  Phylogenetic  analysis  729 77.6 656 80.8  73  57.5  <0.001 
  Other:  210 22.4 156 19.2  54  42.5  - 
    Serology  methods  6 0.6 6 0.7 0 0.0 - 
    Local  lab  results  30 3.2 21 2.6  9  7.1  - 
    EuroSIDA  forms  174 18.5 129 15.9  45  35.4  - 
Male  725 77.2 666 82.0  59  46.5  <0.001 
HIV  exposure  group         <0.001 
  MSM  467 49.7 457 56.3  10  7.9  - 
  IDU  179 19.1 170 20.9  9  7.1  - 
  Heterosexual  223 23.7 128 15.8  95  74.8  - 
  Other  70 7.5 57 7.0 13  10.2  - 
E t h n i c i t y          < 0 . 0 0 1  
  White  783 83.4 725 89.3  58  45.7  - 
  Other  156  16.6 87 10.7 69 54.3  - 
Region         0.045 
  South  110  11.7 98 12.1 12 9.4  - 
  Central  West  229 24.4 189 23.3  40  31.5  - 
  North  514 54.7 444 54.7  70  55.1  - 
  East  86 9.2 81  10.0 5 3.9  - 
Previous  AIDS  206 21.9 184 22.7  22  17.3  0.177 
Hepatitis  B  status         0.582 
  Negative  662 70.5 574 70.7  88  69.3  - 
  Positive  68 7.2 56 6.9 12 9.4  - 
  Unknown  209 22.3 182 22.4  27  21.3  - 
Hepatitis  C  status         0.013 
  Negative  418 44.5 351 43.2  67  52.8  - 
  Positive  153 16.3 143 17.6  10  7.9  - 
  Unknown  368 39.2 318 39.2  50  39.4  - 
ART-naïve  419 44.6 366 45.1  53  41.7  0.481 
Genotypic resistance test 
results available  533 56.8 466 57.4  67  52.8  0.327 
  NRTI resistance
(1)  218 40.9 192 41.2  26  38.8  0.709 
  PI resistance
(1)  35 3.7 26 5.6  8 11.9  0.022 
  NNRTI resistance
(1)  24 2.6 17 3.6  7 10.4  0.059 
Median (IQR)         
Date started cART regimen  Jan 98 (Apr 97-
Dec-99)  Feb 98  (Apr 97-
Dec 99)  Nov 97  (Mar 97-
Mar 00)  0.607 
Date pre-cART subtype test  May 97 (Jul 96-
Dec-98)  May 97 (Jul 96-
Dec 98)  Apr 97  (Jul 96-
Sep 98)  0.752 
Age  (years)  37 (32-45) 37 (32-45) 35 (32-43)  0.124 
CD4 count (cells/mm
3)         
 Baseline
(2)  228 (113-333) 230 (113-333) 210 (116-330)  0.881 
 Nadir
(3)  172 (87-260) 171 (87-260) 176 (84-257)  0.843 
Viral load (log10c o p i e s / m L )          
 Baseline
(4)  4.7 (4.0-5.2) 4.7 (4.0-5.2) 4.5 (3.8-5.0)  0.045 
 Max  ever
(5)  5.0 (4.5-5.4) 5.0 (4.5-5.4) 4.9 (4.4-5.2)  0.017 
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
 (1)In subset of patients with a successful genotypic resistance test within one year pre-cART. 
Median CD4 counts and viral loads based on measurements from 
(2)923 patients, 
(3)936 patients, 
(4)637 
patients and 
(5)659 patients. 
MSM = men who have sex with men; IDU = injecting drug use; IQR = interquartile range. 
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A total of 366 (45.1%) B infected patients and 53 (41.7%) non-B infected patients were 
ART-naïve at initiation of cART (p=0.481).  The types of regimen started by the two 
groups were also similar, displayed in Figure 4.4 (p=0.786).  Amongst patients infected 
with subtype B, single PI-containing regimens were started by 56.8%, RTV-boosted PI 
regimens were started by 8.3% and single NNRTI regimens were started by 19.3%.  
Amongst patients infected with a non-B subtype, single PI-containing regimens were 
started by 55.9%, RTV-boosted PI regimens were started by 8.7% and single NNRTI 
regimens were started by 22.0%. 
 
Figure 4.4: Type of cART regimen started according to HIV-1 subtype B versus non-B. 
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Notes: SQV = saquinavir; RTV = ritonavir; ABC = abacavir. 
 
Figure 4.5 displays the specific antiretroviral drugs started as part of the cART regimen.  
The proportions of patients starting each drug were similar between B and non-B 
infected patients for all drugs (p>0.1).  The most widely used NRTIs were zidovudine 
(ZDV), stavudine (d4T) and lamivudine (3TC) with 50.9%, 41.4% and 80.8% of patients 
starting each respectively.  Indinavir (IDV) and RTV were the most common PIs 
started: 30.7% and 22.4% respectively.  Slightly more patients started nevirapine 
(NVP) than efavirenz (EFV) (15.9% compared to 11.5%). 
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Figure 4.5: Antiretroviral drugs in cART regimen according to HIV-1 subtype B versus 
non-B. 
p=0.411
p=0.980
p=0.755
p=0.933
p=0.445
p=0.597
p=0.787
p=0.436
p=0.992
p=0.553
p=0.968
p=0.631
0% 20% 40% 60% 80% 100%
Efavirenz
Nevirapine
Saquinavir
Indinavir
Ritonavir
Nelfinavir
Lopinavir
Abacavir
Lamivudine
Stavudine
Didanosine
Zalcitabine
Zidovudine
N
N
R
T
I
s
P
I
s
N
R
T
I
s
B
Non-B
p=0.406
 
 
4.3.2.4 Factors associated with infection with an HIV-1 non-B subtype 
Factors associated with being infected with a non-B subtype, as opposed to subtype B 
virus, were investigated further and those found to be significant (p<0.1) in univariable 
analyses are displayed in Table 4.3.  Before adjustment for other variables, 
determination of subtype by a non-phylogenetic analysis method, female gender, HIV 
exposure group other than MSM, non-white ethnicity and African origin were all 
associated with higher odds of infection with non-B virus.  The East region and positive 
hepatitis C status were associated with lower odds of infection with a non-B subtype.  
In a multivariable model containing these variables, significant differences in odds of 
infection with a non-B subtype remained between different methods of subtype 
determination, HIV transmission exposure groups, country of origin and hepatitis C 
status.  Subtype determination by non-phylogenetic analysis methods, non-MSM 
transmission exposure groups and African origin were independently associated with 
higher odds of infection with a non-B subtype and positive hepatitis C status was 
associated with lower odds (borderline significant). 
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Table 4.3: Odds ratios and 95% confidence intervals of infection with an HIV-1 non-B 
subtype. 
    Univariable OR 
(95% CI)  p  Multivariable OR 
(95% CI)  p 
Source of subtype id         
 Phylogenetic  analysis  1.00    1.00   
  Other  3.11 (2.10-4.61)  <0.001  2.22 (1.26-3.91)  0.006 
Gender      
 Male  1.00    1.00   
  Female  5.26 (3.55-7.78)  <0.001  1.12 (0.62-2.01)  0.710 
HIV  exposure  group      
 MSM  1.00    1.00   
 IDU  2.42  (0.97-6.06)  0.059  4.69  (1.58-13.97)  0.006 
 Heterosexual  33.92  (17.18-66.98) <0.001  16.70  (7.39-37.70)  <0.001 
 Other  10.42  (4.37-24.86)  <0.001  6.90  (2.46-19.36)  <0.001 
Ethnicity      
 White  1.00    1.00   
 Other  9.91  (6.55-15.00)  <0.001  1.33  (0.59-2.96)  0.491 
Region      
 North  1.00    1.00   
  South  0.78 (0.41-1.49)  0.446  1.37 (0.62-3.02)  0.441 
  Central West  1.34 (0.88-2.05)  0.174  1.50 (0.81-2.77)  0.198 
  East  0.39 (0.15-1.00)  0.050  0.85 (0.30-2.43)  0.762 
Origin      
 Non-Africa  1.00    1.00   
 Africa  63.65  (33.80-19.85) <0.001  23.02  (9.12-58.10)  <0.001 
Hepatitis C status         
 Negative  1.00    1.00   
  Positive  0.37 (0.18-0.73)  0.005  0.38 (0.14-1.05)  0.061 
  Unknown  0.82 (0.55-1.23)  0.338  0.84 (0.48-1.47)  0.537 
Notes: MSM = men who have sex with men; IDU = injecting drug use; OR = odds ratio; CI = confidence 
interval. 
 
 
4.3.3  Virological response to cART: viral load less than 500 copies/mL at 
months six to twelve 
4.3.3.1 Main analysis: missing viral load = failure 
A total of 791 (84.2%) of the 939 patients with subtype test results available had 
baseline viral loads of at least 500 copies/mL.  Of these 469 (59.3%) achieved 
virological suppression (viral load less than 500 copies/mL) at the first measurement 
during the six to twelve month period after starting cART: 402 (58.3%; 95% CI: 54.8-
62.2%) of 689 B infected compared to 67 (65.7%; 95% CI: 57.4-75.9%) of 102 non-B 
infected patients (p=0.159).  Median time to first measurement was 7 months (IQR: 6-8 
months) for both B infected and non-B infected patients (p=0.779).  During months six 
to twelve, 70 (8.8%) of the 791 patients included had no viral load measurement 
available and so were counted as virological failures, although 47 (67.1%) of these had 
a subsequent measurement recorded a median of 15 months (IQR: 13-19 months) 
after starting cART, 28 (59.6%) of whom had a viral load less than 500 copies/mL.  
Within the non-B subtypes, 8 (47.1%; 95% CI: 29.1-76.6%) of 17 patients infected with 
subtype A, 25 (65.8%; 95% CI: 53.3-83.5%) of 38 patients with C and 34 (72.3%; 95% 
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CI: 61.6-87.2%) of 47 patients with ‘other’ achieved virological suppression (p=0.152).  
Response rates are displayed in Figure 4.6. 
 
Figure 4.6: Virological response rates (less than 500 copies/mL) after starting cART 
and 95% confidence intervals according to HIV-1 subtype (missing = failure). 
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The odds of achieving virological suppression were investigated in patients infected 
with a non-B subtype compared to B subtype.  Before adjustment for potentially 
confounding variables, the data showed no evidence of a significant difference 
between them (odds ratio (OR): 1.37; 95% CI: 0.88-2.11; p=0.160).  Further analysis of 
the non-B subtypes, A, C, and ‘other’ compared to B resulted in ORs of 0.64 (95% CI: 
0.24-1.67; p=0.355), 1.37 (95% CI: 0.69-2.73; p=0.366) and 1.87 (95% CI: 0.97-3.60; 
p=0.063) respectively.  
 
A multivariable model was developed adjusting for baseline maximum ever viral load, 
CD4 nadir, time from CD4 nadir, hepatitis B and C co-infection status, calendar year of 
starting cART, type of regimen, number of new drugs in regimen, whether or not ART-
naïve at baseline, age, HIV exposure group, geographical region and ethnicity.  After 
adjustment, there remained no significant difference in the odds of achieving virological 
suppression (OR: 1.05; 95% CI: 0.58-1.93; p=0.866).  Further investigation into A, C 
and ‘other’ subtypes showed a borderline significantly lower odds in patients infected 
with subtype A compared to B (multivariable OR: 0.32; 95% CI: 0.10-1.00; p=0.051).  
There was no significant difference in C or ‘other’ compared to B (multivariable ORs: 
1.07; 95% CI: 0.45-2.54; p=0.879; and 1.64; 95% CI: 0.73-3.67; p=0.233, respectively).  
Univariable and multivariable ORs are displayed in Figure 4.7.   
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Figure 4.7: Odds ratios and 95% confidence intervals of virological response (less than 
500 copies/mL) after starting cART according to HIV-1 subtype (missing = failure). 
 
Notes: Multivariable analysis adjusted for baseline maximum ever viral load, baseline CD4 nadir, time from 
CD4 nadir, hepatitis B and C co-infection status, calendar year of starting cART regimen, type of regimen, 
number of new drugs in regimen, whether or not ART-naïve at baseline, age, HIV exposure group, 
EuroSIDA region and ethnicity. 
 
 
Interactions between type of cART regimen and HIV-1 subtype were also considered.  
The power for this was limited, however interactions between PI-containing versus 
other regimens and subtype (A, B, C or ‘other’) were not found to be significant 
(p=0.841).   
 
4.3.3.2 Sensitivity analysis: missing viral load = excluded 
Excluding patients with missing viral load measurements at six to twelve months 
provided similar findings to those of the main analysis.  The number of eligible patients 
in this analysis was reduced from 791 (84.2%) to 721 (76.8%) patients and response 
rates were higher as expected.  Virological suppression was achieved by 469 (65.0%) 
patients: 63.9% (95% CI: 60.3-67.8%) of 629 infected with B and 72.8% (95% CI: 64.8-
83.0%) of 92 infected with non-B (p=0.094).  Within the non-B subtypes, 57.1% (95% 
CI: 38.2-90.1%) of 14 patients infected with subtype A, 69.4% (95% CI: 57.1-87.2%) of 
36 patients with C and 81.0% (95% CI: 71.4-95.2%) of 42 patients with ‘other’ 
experienced a virological response. 
 
No significant difference was found in the odds of achieving virological suppression in 
patients infected with a non-B subtype compared to B, after adjustment for the 
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potentially confounding variables identified in the main analysis (OR: 1.37; 95% CI: 
0.69-2.70; p=0.367).  These results are included in Table 4.4, which compares the 
results of all sensitivity analyses (non-B versus B), to those of the main analysis.   
 
Looking at non-B subtypes A, C and ‘other’ compared to B gave multivariable ORs of 
0.42 (95% CI: 0.11-1.57; p=0.198), 1.00 (95% CI: 0.39-2.57; p=0.997) and 2.38 (95% 
CI: 0.90-6.31; p=0.081) respectively.   
 
Table 4.4: Odds ratios and 95% confidence intervals of virological response (less than 
500 copies/mL) after starting cART for HIV-1 subtype B versus non-B. 
  B  Non-B  Non-B versus B 
  n  % VL 
responders n  % VL 
responders
Univariable 
OR (95% CI) p  Multivariable 
OR (95% CI) p 
               
Main analysis,  
missing = failure  689 58% 102 66%  1.37 
(0.88-2.11)  0.160  1.05 
(0.58-1.93)  0.866
Missing = excluded  629  64%  92  73%  1.51 
(0.93-2.46)  0.096  1.28 
(0.65-2.54)  0.476
Sensitivity analyses,  
missing = failure:              
ART-naïve   326  71%  46  72%  1.04 
(0.53-2.07)  0.903  1.09 
(0.44-2.70)  0.849
Subtypes by 
phylogenetic analysis  573 59%  58  62%  1.15 
(0.66-2.01)  0.613  1.22 
(0.58-2.56)  0.597
Subtypes post-1999  139  63%  35  83%  2.80 
(1.09-7.20)  0.033  3.51 
(0.80-15.47)  0.098
Excluding 
retrospective data  565 62%  72  67%  1.23 
(0.73-2.06)  0.437  1.13 
(0.56-2.29)  0.730
Endpoint viral load 
<50 copies/mL  689 29% 102 42%  1.76 
(1.15-2.69)  0.010  1.39 
(0.72-2.67)  0.330
Notes: Multivariable analysis adjusted for baseline maximum ever viral load, baseline CD4 nadir, time from 
CD4 nadir, hepatitis B and C co-infection status, calendar year of starting cART regimen, type of regimen, 
number of new drugs in regimen, whether or not ART-naïve at baseline, age, HIV exposure group, 
EuroSIDA region and ethnicity. 
VL = viral load; OR = odds ratio; CI = confidence interval. 
 
4.3.3.3 Further sensitivity analyses  
Repeating the main analysis in a subset of ART-naïve patients, of patients with 
subtypes determined by phylogenetic analysis only and excluding patients with 
retrospective data gave consistent results as those from the main analyses.  There 
were no significant differences in the odds of a virological response in patients infected 
with non-B compared to B after adjustment for potential confounders, ORs: 1.09 (95% 
CI: 0.44-2.70; p=0.849), 1.22 (95% CI: 0.58-2.56; p=0.597), and 1.13 (95% CI: 0.56-
2.29; p=0.730) respectively.  Within the subset of patients with subtypes determined 
post-1999, there was a much greater odds of virological suppression (although not 
significant at the 5% level) in patients infected with non-B compared to B (multivariable 
OR: 3.51; 95% CI: 0.80-15.47; p=0.098).  However the number of non-B patients in this 
subset was small (n=35), as reflected by the large confidence interval.   
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The alternative endpoint of a viral load less than 50 copies/mL instead of 500 
copies/mL at six to twelve months also gave consistent results in the multivariable 
analysis of all patients with a viral load measurement during this time (OR: 1.39; 95% 
CI: 0.72-2.67; p=0.330). 
 
4.3.4  Immunological response to cART: 100 CD4 cells/mm
3 increase at 
months six to twelve 
4.3.4.1 Main analysis: missing CD4 count = failure 
A total of 867 (92.3%) of the 939 patients with pre-cART subtype test results had 
baseline CD4 counts available.  Of these 382 (44.1%) experienced a successful 
immunological response (CD4 count increase of at least 100 cells/mm
3) at the first 
measurement during the six to twelve month period after starting cART: 327 (43.4%; 
95% CI: 38.4-49.1%) of 753 B infected compared to 55 (48.2%; 95% CI: 36.8-63.2%) 
of 114 non-B infected patients (p=0.334).  Median time to first measurement was 7 
months (IQR: 6-8 months) for both B infected and non-B infected patients (p=0.973).  
During months six to twelve, 71 (8.2%) of the 867 patients included had no CD4 count 
available and so were counted as immunological failures, although 47 (66.2%) of these 
had a subsequent measurement recorded a median of 14 months (IQR: 13-17 months) 
after starting cART, 27 (57.5%) of whom had a CD4 count increase of at least 100 
cells/mm
3.  Within the non-B subtypes, 8 (47.1%; 95% CI: 29.1-76.6%) of 17 patients 
infected with subtype A, 25 (65.8%; 95% CI: 53.3-83.5%) of 38 patients with C and 34 
(72.3%; 95% CI: 61.6-87.2%) of 47 patients with ‘other’ experienced an immunological 
response (p=0.476,) displayed in Figure 4.8. 
 
Comparing the odds of experiencing an immunological response in non-B to B infected 
patients, before adjustment for potentially confounding variables, showed there was no 
evidence of a significant difference (OR: 1.21; 95% CI: 0.82-1.80; p=0.335).  Analysis 
of A, C, and ‘other’ subtypes also showed no significant differences with ORs of 0.70 
(95% CI: 0.28-1.78; p=0.455), 1.12 (95% CI: 0.59-2.13; p=0.738) and 1.56 (95% CI: 
0.90-2.71; p=0.111) respectively. 
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Figure 4.8: Immunological response rates (at least 100 CD4 cells/mm
3 increase) after 
starting cART and 95% confidence intervals according to HIV-1 subtype (missing = 
failure). 
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A multivariable model was developed adjusting for baseline viral load (less than 500 
copies/mL, 500-10000 copies/mL, more than 10000 copies/mL or missing), baseline 
CD4 nadir, time from CD4 nadir, calendar year of starting cART, type of regimen, 
number of new drugs in regimen, whether or not ART-naïve at baseline and 
transmission exposure group.  After adjustment, there was no significant difference in 
the odds of an immunological response (non-B compared to B) (OR: 1.17; 95% CI: 
0.73-1.87; p=0.524).  Multivariable ORs for A, C and ‘other’ subtypes compared to B 
were 0.64 (95% CI: 0.24-1.72; p=0.375), 1.06 (95% CI: 0.52-2.18; p=0.871) and 1.54 
(95% CI: 0.83-2.86; p=0.168) respectively, which are displayed in Figure 4.9.   
 
Interactions between type of cART regimen (PI-containing versus other) and subtype 
(A, B, C or ‘other’) were again considered, however these were not found to be 
significant (p=0.506). 
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Figure 4.9: Odds ratios and 95% confidence intervals of immunological response (at 
least 100 CD4 cells/mm
3 increase) after starting cART according to HIV-1 (missing = 
failure). 
 
Notes: Multivariable analysis adjusted for baseline viral load, baseline CD4 nadir, time from CD4 nadir, 
calendar year of starting cART regimen, type of regimen, number of new drugs in regimen, whether or not 
ART-naïve and HIV exposure group. 
 
4.3.4.2 Sensitivity analysis: missing CD4 count = excluded 
Excluding patients with missing CD4 counts at six to twelve months resulted in 
consistent findings to those in the main analysis.  The number of eligible patients was 
reduced from 867 (92.3%) to 796 (84.8%) patients.  A successful immunological 
response was achieved by 382 (48.0%) patients: 47.3% (95% CI: 43.7-51.2%) of 691 B 
patients and 52.4% (95% CI: 43.8-62.9%) of 105 non-B patients (p=0.334).  Within the 
non-B subtypes, 38.9% (95% CI: 21.8-66.9%) of 18 with subtype A, 51.4% (95% CI: 
37.7-70.8%) of 35 with subtype C and 57.7% (95% CI: 46.1-73.0%) of 52 with ‘other’ 
experienced an immunological response. 
 
Before adjustment, there were no significant differences in the odds of experiencing an 
increase of 100 CD4 cells/mm
3 between non-B subtypes compared to B (OR: 1.23; 
95% CI: 0.81-1.85; p=0.334).  In the multivariable analysis, the results were very 
similar (OR: 1.17; 95% CI: 0.72-1.90; p=0.537).  Comparing the odds of an 
immunological response in non-B subtypes A, C and ‘other’ compared to B subtype 
resulted in ORs of 0.68 (95% CI: 0.25-1.88; p=0.457), 1.14 (95% CI: 0.53-2.43; 
p=0.738) and 1.44 (95% CI: 0.76-2.72; p=0.265) respectively.  Table 4.5 displays the 
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results of this analysis and those from other sensitivity analyses, compared to the main 
results.   
 
Table 4.5: Odds ratios and 95% confidence intervals of immunological response (at 
least 100 CD4 cells/mm
3 increase) for HIV-1 subtype B versus non-B. 
  B  Non-B  Non-B versus B 
  n  %  CD4 
responders n  % CD4 
responders
Univariable 
OR (95% CI) p  Multivariable 
OR (95% CI) p 
               
Main analysis,  
missing = failure  753 43% 114 48%  1.21 
(0.82-1.80)  0.335  1.17 
(0.73-1.87)  0.524
Missing = excluded  691 47% 105 52%  1.23 
(0.81-1.85)  0.334  1.17 
(0.72-1.90)  0.537
Sensitivity analyses,  
missing = failure:              
ART-naïve  353 48%  49  55%  1.31 
(0.72-2.38)  0.383  1.35 
(0.67-2.75)  0.401
Subtypes by 
phylogenetic analysis  623 43%  65  48%  1.21 
(0.72-2.02)  0.470  1.27 
(0.70-2.31)  0.425
Excluding 
retrospective data  614 44%  85  49%  1.26 
(0.80-1.99)  0.317  1.34 
(0.78-2.31)  0.285
Excluding non VL 
responders  434 54%  72  58%  1.20 
(0.72-1.98)  0.486  1.02 
(0.56-1.86)  0.953
Endpoint 25% CD4 
cell increase  753 57% 114 61%  1.20 
(0.80-1.79)  0.387  1.28 
(0.78-2.09)  0.333
Notes: Multivariable analysis adjusted for baseline viral load, baseline CD4 nadir, time from CD4 nadir, 
calendar year of starting cART regimen, type of regimen, number of new drugs in regimen, whether or not 
ART-naïve and HIV exposure group. 
VL = viral load; OR = odds ratio; CI = confidence interval. 
  
4.3.4.3 Further sensitivity analyses  
Further sensitivity analyses using subsets of patients also gave results consistent with 
those from the main analyses (results shown in Table 4.5).  The alternative endpoint of 
a 25% CD4 cell increase from baseline also showed no significant difference in the 
odds of an immunological response between patients infected with non-B compared to 
B (multivariable OR: 1.28; 95% CI: 0.78-2.09; p=0.333). 
 
4.3.5  Response to cART: time to viral load less than 500 copies/mL or 
100 CD4 cells/mm
3 increase 
Survival analysis techniques investigating time to virological suppression and time to 
immunological response, as defined in the main analysis, were used to check the 
robustness of these findings.  The frequencies of viral load measurements and CD4 
counts were compared between patients infected with B and non-B subtypes before 
adopting this alternative approach as a difference between the groups could bias the 
results.  
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4.3.5.1 Frequency of measurements  
Median numbers of viral load measurements in the first year following the start of cART 
were 4 (IQR: 3-5) for both patients infected with subtype B and with non-B subtypes 
(p=0.095).  Median numbers of CD4 counts were 4 (IQR: 3-5) for B infected patients 
and 4 (IQR: 3-4) for non-B infected patients (p=0.365).  The median times between 
measurements in this first year also did not differ significantly.  Median times between 
viral loads were 3.0 months (IQR: 1.9-4.0 months) for both B and non-B infected 
patients (p=0.729) and between CD4 counts were 3.0 months (IQR: 2.0-5.0 months) 
for B and non-B infected patients (p=0.195).  As there were similar frequencies of 
measurements in each group, survival analysis methods could make an unbiased 
comparison between groups.  
 
4.3.5.2 Kaplan-Meier estimates  
Figure 4.10 (a) displays a Kaplan-Meier estimate of the percentage of patients 
achieving virological suppression from date of starting a cART regimen.  The log rank 
test showed no significant difference between B and non-B infected patients (p=0.860).  
Estimates of median time to virological suppression were 3.0 months (95% CI: 3.0-3.0 
months) in those infected with B compared to 3.0 months (95% CI: 2.6-4.0 months) in 
those infected with non-B.  Figure 4.10 (b) displays a Kaplan-Meier estimate of the 
percentage of patients achieving an immunological response (CD4 cell increase of 100 
cells/mm
3) from date of starting cART.  The log rank test showed no significant 
difference between B and non-B infected patients (p=0.384) and estimates of median 
time to immunological response were 8.0 months (95% CI: 7.0-8.9 months) in B 
infected patients compared to 6.0 months (95% CI: 5.0-7.6 months) in non-B infected 
patients.   
 
4.3.5.3 Cox proportional hazards models  
Both univariable and multivariable (adjusted for same potential confounders as in main 
analysis) Cox proportional hazards models revealed no significant effect of B versus 
non-B subtype on time to virological response.  Univariable relative hazards (RH) were 
1.02 (95% CI: 0.82-1.26; p=0.862) and multivariable RH were 0.96 (95% CI: 0.72-1.29; 
p=0.799) shown in Figure 4.11.  Both stratifying by clinical centre and left censoring at 
date of enrolment into EuroSIDA resulted in very similar findings (multivariable RH: 
0.89; 95% CI: 0.63-1.24; p=0.485 and RH: 0.96; 95% CI: 0.70-1.31; p=0.795 
respectively).   
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Figure 4.10: Kaplan-Meier estimates of the percentage of patients achieving (a) a 
virological response (less than 500 copies/mL) and (b) an immunological response (at 
least 100 CD4 cells/mm
3 increase) by time from cART initiation for HIV-1 subtype B 
versus non-B. 
(a) Virological response  (b) Immunological response 
 
For immunological response, univariable RH were 1.10 (95% CI: 0.89-1.35; p=0.388) 
and multivariable RH were 1.20 (95% CI: 0.94-1.53; p=0.148) indicating no significant 
difference between B and non-B infected patients.  These are also illustrated in Figure 
4.11.  Stratifying by clinical centre gave consistent results (multivariable RH: 1.12; 95% 
CI: 0.85-1.49; p=0.412) however the multivariable analysis with left censoring at date of 
enrolment showed a significantly higher chance of achieving an immunological 
response in the non-B infected patients (multivariable RH: 1.37; 95% CI: 1.06-1.78; 
p=0.015).  The median time between CD4 counts in the first year from baseline in the 
analysis (if patient started cART before enrolment, time of enrolment was taken as 
baseline) was investigated to see if this could explain the difference in response in this 
sensitivity analysis.  A difference was found between B and non-B infected patients 
(3.0 months (IQR: 2.0-4.0 months) versus 2.9 months (IQR: 1.9-3.9 months); p=0.003), 
which could account for the significant difference observed.  
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Figure 4.11: Relative hazards and 95% confidence intervals of virological response 
(less than 500 copies/mL) and immunological response (at least 100 CD4 cells/mm
3 
increase) after starting cART for HIV-1 subtype B versus non-B.  
 
Notes: For virological response, multivariable analysis adjusted for baseline maximum ever viral load, 
baseline CD4 nadir, time from CD4 nadir, hepatitis B and C co-infection status, calendar year of starting 
cART regimen, type of regimen, number of new drugs in regimen, whether or not ART-naïve at baseline, 
age, HIV exposure group, EuroSIDA region and ethnicity. 
For immunological response, multivariable analysis adjusted for baseline viral load, baseline CD4 nadir, 
time from CD4 nadir, calendar year of starting cART regimen, type of regimen, number of new drugs in 
regimen, whether or not ART-naïve and HIV exposure group. 
 
 
 
4.4 Discussion 
This chapter investigated potential differences in virological and immunological 
response to cART between patients infected with HIV-1 B and non-B subtypes.  No 
significant differences between the two groups were found in this dataset and no 
interaction between HIV-1 subtype and type of cART regimen (PI-containing versus 
other) were found either.  There were relatively few non-B subtypes but further 
investigation suggested that there were no significant differences in virological or 
immunological response between patients infected with C or ‘other’ subtypes, 
compared to those with B, although response rates were slightly higher than in patients 
infected with B subtype.  There were borderline significantly lower odds of a virological 
response in patients infected with subtype A.  These varied responses in patients 
infected with non-B subtypes suggests that they should not be aggregated together 
and shows that the overall response rate in non-B infected patients was averaged out, 
which could be responsible for the similar response rate to B infected patients.  Due to 
the small numbers, the analysis lacked the statistical power to be able to draw firm 
conclusions.  
 
125 
4.4.1  Interpretation of findings 
4.4.1.1 Factors associated with infection with an HIV-1 non-B subtype 
The method by which HIV subtype was determined, HIV transmission exposure group 
and African origin were found to be associated with the odds of infection with a non-B 
subtype in this analysis.  Patients who were enrolled into EuroSIDA more recently were 
less likely to have plasma samples stored in the EuroSIDA central laboratories and so 
were less likely to have had their HIV subtypes determined by phylogenetic analysis.  
Cohorts VI and VII included many patients from East Europe where subtype A is known 
to be prevalent [401] and the most common route of transmission is IDU [81].  This 
could explain the association of non-B subtypes with these variables.  Non-B subtypes 
are also widespread across Africa so it was expected that patients with African origin 
would also mostly be infected with non-B virus [401,415]. 
 
4.4.1.2 Virological response to cART 
No significant differences in virological response to cART were found between patients 
infected with B or non-B subtypes, except for a borderline significant difference in 
patients whose subtypes were determined after 1999 due to less reliable viral load 
assays potentially measuring low in patients infected with non-B subtypes before then 
[430-432].  Even though the potential bias was expected to be over-estimating the 
virological response rate in these patients, patients infected with non-B subtypes 
appeared to have higher odds of virological suppression in this analysis.  However the 
sample size was small and the finding could be due to chance.  Investigation into 
differences between A, B, C and ‘other’ subtypes showed a borderline significantly 
lower virological response rate in patients infected with A.  The analysis would need 
more statistical power to determine if this was a true difference.  ‘Other’ subtypes 
including CRFs appeared to have a slightly higher response rate but this was not 
statistically significant.  This could account for the similar virological response rates 
between B infected patients and the aggregated group infected with non-B subtypes.  
 
4.4.1.3 Immunological response to cART 
There were also no significant differences in immunological response to cART between 
B and non-B subtypes.  There was a similar trend for patients infected with subtype A 
to have a lower response rate than those with subtype B and for those with ‘other’ 
subtypes to have a higher response rate, but neither of the differences were significant.  
A significant difference was found in a sensitivity analysis using a Cox proportional 
hazards model with left censoring at the date of enrolment into EuroSIDA.  This was 
conducted to exclude retrospective data from patients.  This may be explained by a 
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difference that was found in the median time between CD4 count measurements when 
CD4 count data before enrolment was excluded between B and non-B subtypes. 
 
No interaction between HIV-1 subtype and type of cART regimen started was found.  
However again, the number of patients infected with non-B subtypes that started each 
type of cART regimen was small. 
  
Although the statistical power for these analyses was limited, these results suggest that 
the HIV genetic diversity and potential differences in drug resistance between HIV-1 
subtypes do not appear to have affected patients’ response to therapy so far.     
 
4.4.2 Previous  research   
The findings are consistent with previous research, summarised in Table 4.6 [422-429].  
Comparisons between patients infected with B and non-B subtypes generally found no 
significant differences in virological response, both short- and long-term.  Bocket et al. 
(2005) [423] compared time to virological suppression between 317 B and 99 non-B 
infected ART-naïve patients starting ART in a French cohort and found no significant 
difference.  A retrospective, case-control study of 50 B infected and 50 non-B infected 
UK patients starting cART looked at both initial and long-term virological response, 
finding no significant differences [428].  However, De Wit et al. (2004) [422] did find a 
significantly lower median CD4 cell increase 24 months after starting a PI-containing 
regimen in non-B infected patients, which they suggested could be due to viral or host 
characteristics and should be explored further.  A comparison of patients seen at a UK 
clinic whose country of origin was either ‘European’ or ‘African’ was carried out by 
Frater  et al. (2002) [429], with ‘European’ representing B subtype and ‘African’ 
representing non-B subtypes.  The longer-term virological response was found to be 
poorer in the African cohort, which they suggested could be related to cultural and 
language barriers leading to non-adherence.  In studies looking at specific non-B 
subtypes, no associations were found between subtype and virological response or 
incidence of disease progression [399,424-426]. 
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Table 4.6: Previous research investigating the effect of HIV-1 subtypes on response to 
ART. 
Authors, year 
Patient numbers 
with each 
subtype 
Main outcomes  Conclusions 
      
Lawrence et 
al. 2006[399] 
45 B, 22 
CRF02_AG 
Changes in viral load and CD4 
cell count at 1, 3, 6, 12 and 24 
months after starting ART. % with 
therapeutic failure defined as a 
rebound in viral load of at least 
5000 copies/mL over 24 month 
period. 
No significant differences in 
short or longer term 
response.  No difference in 
therapeutic failure over 
study period. 
Atlas et al. 
2005 [424] 
32 A, 44 B, 34 C, 
18 D, 5 G, 19 
CRF01_AE 
% with undetectable viral loads 
six months after starting cART. 
In univariable analyses, no 
evidence of association 
between subtype and short-
term virological response. 
Bocket et al. 
2005 [423] 
317 B, 99 non-B  Time to viral load <400 copies/mL 
after starting ART for first time.  
Incidence of clinical progression 
(AIDS or death), changes in CD4 
cell count from baseline and % 
achieving viral load <400 
copies/mL at 3, 6 and 12 months. 
No significant differences in 
virological response or 
clinical progression. 
De Wit et al. 
2004 [422] 
56 B, 119 non-B  % with viral loads <400 
copies/mL and median CD4 cell 
increase 24 months after starting 
PI-containing cART for first time.   
No significant difference in 
virological response but 
significant difference in 
immunological response. 
Pillay et al. 
2002 [425] 
Children: 16 A, 
44 B, 17 C, 10 D, 
8 F, G, and H, 13 
CRF01_AE and 
CRF02_AG 
Change in viral load from starting 
dual ART to 24 and 48 weeks. 
No evidence of association 
between subtype and 
virological response.   
Alexander et 
al. 2002 [427] 
459 B, 19 non-B  Virological response after up to 
18 months after starting ART for 
first time. 
No significant difference in 
virological response. 
Frater et al. 
2002 [429] 
265 ‘European’, 
97 ‘African’ 
(random % 
sequenced to 
check ‘European’ 
= B, ‘African’ = 
non-B) 
Kaplan-Meier survival analysis on 
time to viral load <500 copies/mL 
after starting cART and changes 
in CD4 cell count and viral load 
from baseline. 
Initial virological and 
immunological responses 
similar between European 
and African cohorts.  
Longer-term virological 
response was poorer in 
African cohort. 
Loveday et al. 
2001 [428] 
50 B, 50 non-B  Retrospective case-controlled 
comparison of time to a viral load 
<400 copies/mL and <50 
copies/mL, and mean minimum 
duration of response <400 
copies/mL after starting cART. 
No significant differences in 
initial or long-term virological 
response. 
Alaeus et al. 
1999 [426] 
28 A, 59 B, 21 C, 
18 D 
Rate of CD4 cell decline from 
date of diagnosis, incidence of 
clinical disease progression, viral 
load (latest in follow-up period) 
over a mean follow-up period of 
44 months. 
No evidence of association 
between subtype and 
disease progression. 
 
4.4.3 Limitations  of  analysis 
The main limitation of the analyses in this chapter was the limited statistical power to 
detect true differences in response to therapy between HIV-1 subtypes due to the 
relatively small number of patients infected with a non-B subtype.  For example, with 
the 689 subtype B infected patients and 102 non-B infected patients included in the 
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virological response analysis, there was 80% power (with alpha = 0.05) to detect a true 
difference in virological response rate of 15%.  For the group of 38 patients infected 
with subtype C, there would only be 41% power to detect a difference with subtype B 
patients and for the 17 patients infected with subtype A, there would be only 19% 
power.  This means that it is not yet possible to draw any firm conclusions of no real 
difference in response to therapy between B subtypes and specific non-B subtypes. 
 
4.4.4 Implications  of  findings 
Analyses such as this address whether or not ART results in better rates of virological 
and immunological response in patients infected with certain subtypes, which has 
implications for increasing the availability of drugs in developing countries (where non-
B subtypes dominate) and for future drug development [356,396,406,411].  Current 
treatment guidelines do not make any specific recommendations according to HIV-1 
subtype [40-42] and to date, clinical trials investigating antiretroviral drugs also do not 
report on subtype, therefore it is unknown whether or not newer therapies are equally 
effective for all subtypes.  Although this analysis did not find any differences in 
response to cART between subtypes nor any interaction with type of cART regimen, it 
is important for research to continue to investigate potential differences as evidence of 
variation would support the use of subtype testing as a standard procedure before 
starting therapy to optimise a patient’s subsequent treatment strategy.   
 
4.4.5 Further  research 
As the EuroSIDA resistance database continues to expand, all available patient plasma 
samples will be used to obtain HIV RT and PR gene sequences.  Consequently, these 
sequences will allow determination of HIV-1 subtypes by phylogenetic analysis and the 
use of other sources of subtype identification can eventually be eliminated.  This will 
ensure the highest standard of subtype determination for future analyses.  It will also 
increase the number of patients who will be eligible for inclusion in these analyses.  
With more patients included, it may be possible to make specific comparisons between 
subtypes instead of grouping them into B versus non-B.  As non-B subtypes are 
genetically very different from each other, the effect of grouping them together may 
have concealed true differences in response.  It may also be possible to focus on 
exclusively ART-naïve patients for the main analyses, which minimises the effects of 
drug resistance mutations that may have been acquired from previous NRTI 
experience.  In addition, an increased number of patients could provide the power to 
stratify analyses by type of cART regimen. 
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Investigating virological and immunological response provides insight into the short-
term outcome of ART.  However, ultimately it is the long-term clinical outcome that is 
important.  Due to lack of power it was not possible to analyse clinical endpoints (AIDS 
or death), however other studies have so far not found any significant difference 
between patients infected with different HIV-1 subtypes [422-429].  More data could 
provide enough power to conduct multivariable analyses looking at clinical endpoints.  
Collaborations of studies are an ideal way to pool data in order to maximise power to 
answer specific research questions.  This analysis is a project that could be addressed 
in such a way.      
 
4.4.6 Conclusions 
The findings from these analyses showed no evidence of significant differences in 
virological or immunological response to cART between patients infected with HIV-1 B 
and non-B subtypes.  Patients infected with non-B subtypes did not show a detrimental 
outcome compared to those with B as suggested by differences both in HIV diversity 
(in untreated patients), and in resistance development on treatment, found in other 
research.  The continued expansion of the EuroSIDA resistance database and the 
exclusive use of phylogenetic analysis to determine subtypes will allow more sensitive 
analyses in the future with increased power to detect any true differences.  Increasingly 
it will be possible to focus on individual non-B subtypes and on responses to particular 
regimens.  A collaborative study may be needed in order to fully address this important 
research question. 
 
A manuscript of this analysis was published by Antiviral Therapy in September 2006 
and can be found in Appendix VII. 
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Chapter 5. Transmitted drug-resistant HIV-1 and 
association with virological and immunological 
response to first-line combination antiretroviral therapy 
5.1 Introduction 
Resistance of HIV-1 to antiretroviral drugs is a major challenge for the continued 
efficacy of ART and emerges when treatment fails to suppress viral replication 
effectively, either through suboptimal treatment or incomplete adherence.  It is 
associated with virological failure in patients undergoing treatment and limits 
subsequent therapy options [16,317-320].   
 
5.1.1  Transmission of drug-resistant HIV 
As discussed in Chapter 1 (section 1.8.5), individuals may acquire a drug-resistant HIV 
strain through infection [337,352,353].  In the absence of therapy, wild-type HIV will 
rapidly become dominant due to its increased replicative capacity (efficiency in 
replication) compared to resistant HIV, and the resistant virus will become negligible, 
although still “archived”.  Under selective drug pressure, the resistant strain could once 
again emerge rapidly [336,339].  However, if only the resistant strain is transmitted, 
reversion to wild-type virus can only occur through back mutations, i.e. mutations that 
occur at the site of the resistance-associated mutations, which result in a viral copy 
closer to wild-type.  This takes a much longer period of time to happen [433].   
 
It has been suggested that drug-resistant HIV is less transmissible than wild-type HIV 
[434,435].  A number of reasons have been proposed for this.  Patients who have 
developed resistance whilst on therapy may have lower viral loads than untreated 
individuals, lowering the transmission risk.  In addition, patients regularly attending a 
clinic to receive ART may engage in less “risky” behaviour than those who do not 
attend a clinic.  Resistant HIV also has a reduced level of fitness in patients not on 
therapy (the ability to replicate in a well-defined environment), which could lower the 
probability of transmission [434].  Despite this, transmission of many different resistant 
strains has been observed over the past few years [435,436]. 
 
5.1.2  Prevalence of transmitted drug resistance in Europe 
The prevalence of transmitted drug-resistant HIV (TDR) in ART-naïve patients has 
been estimated to range from as little as 2.1% to 51.5% across Europe [437,438].   
Recent data from the CATCH (The Combined Analysis of Resistance Transmission 
over Time of Chronically and Acute Infected HIV Patients) study, a substudy of the 
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European scientific surveillance programme, SPREAD (Strategy to Control Spread of 
HIV Drug Resistance) [436], showed a mean prevalence of TDR of 10.4% across 
recently and chronically infected ART-naïve patients in 19 European countries and 
gives an estimate close to the majority of smaller studies performed across Europe  
[348,435,439-444].  There are many reasons to explain this wide range of estimates of 
TDR prevalence including varying time periods of study, populations, designs, methods 
and definitions of resistance.  The rates may also be affected by the distribution of HIV-
1 subtypes in the population.  Non-B subtypes are likely to have originated from 
countries where ART is not readily available resulting in a population that is likely to 
have a lower prevalence of TDR.  Therefore, HIV-1 subtype may be a marker for 
exposure to ART [337]. 
 
As mentioned in Chapter 3 (section 3.1.2.2), temporal trends in prevalence of TDR 
appear to vary across cohorts.  More HIV infected individuals may be developing drug 
resistance as a result of the wider access to ART, use of treatment interruptions or 
increasing high-risk behaviour, which could lead to an increase in transmission rates 
[388-393,445-448].  The UK Group on Transmitted HIV Drug Resistance found an 
increase in prevalence of TDR in a sample of 2357 UK HIV infected patients (high or 
medium level according to the Stanford genotypic resistance algorithm (Version 
2004.04)) over the period 1996-2003 from 11.0% to 19.2%, most noticeably in NNRTI 
resistance [389].  However, the latest data from this group between 1996 and 2004 
showed a decrease in TDR in later years.  TDR was defined as at least one major 
mutation from the 2005 IAS-USA guidelines plus selected additional mutations, and 
reached a peak of approximately 14% in 2001-2002, falling to 8% by the end of 2004, 
mostly driven by NRTI resistance [394].  Improved virological control in patients 
receiving ART, management of treatment failure and the fact that most infectious 
people are not receiving ART could explain this latest trend.  Blower et al. (2003) used 
a mathematical model to predict that the percentage of new drug-resistant HIV 
infections would increase over the years 1996 to 2001, with only very slight increases 
over 2001 to 2005 [449].  Estimates matched well with data from Grant et al. (2002) 
who found increasing TDR over 1996 to 2001 in California [392]. 
 
5.1.3  Resistance testing and response to first-line ART 
If an ART-naïve patient who has acquired a drug-resistant strain through transmission 
is prescribed an initial regimen without knowledge of the resistance-associated 
mutations present, the selection of drugs may not be optimal, which could potentially 
lead to an increased risk of virological failure.  Little et al. (2002) found that those 
infected with a drug-resistant virus in a sample of 202 ART-naïve North American 
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patients, experienced a longer time to viral suppression after initiation of therapy than 
in those with no TDR (p=0.05) [393].  Grant et al. (2002) also found a similar result in 
225 patients in California [392].  Chaix et al. (2007) found that the presence of TDR led 
to a significantly inferior virological outcome in patients from the French ANRS PRIMO 
Cohort or ANRS Resistance Group who started cART during primary HIV infection 
[448].  This reasoning supports the implementation of resistance testing in patients 
starting therapy whilst ART-naïve [338,436,450,451].  Current guidelines recommend 
the clinical use of drug resistance testing in all newly diagnosed ART-naïve patients 
due to suboptimal virological responses found to be associated with TDR [42,338].   
 
5.1.4  Motivation and aims for chapter   
The question of whether or not TDR has a significant effect on the ability of cART to 
suppress viral load and to boost immune regeneration is yet unresolved, although 
some evidence has suggested that its presence leads to a suboptimal virological 
response to cART [348,392,393,448,452].  As EuroSIDA captures a geographically 
diverse population, it is in a position to monitor trends in TDR and to study its impact on 
the short-term outcomes of ART.  Therefore, the aims of these analyses were to 
investigate the prevalence of TDR in the EuroSIDA cohort, the factors associated with 
its detection and to compare virological and immunological response to cART between 
patients infected with HIV with resistance to at least one drug prescribed in their 
regimens and patients infected with fully susceptible HIV.   
 
5.2 Methods 
5.2.1 Inclusion  criteria 
The EuroSIDA dataset used for the analyses in this chapter was the update completed 
in February 2008.  It included data on 14,310 patients with follow-up to (median date of 
last visit) January 2007.  The patients included in this analysis were those who had 
blood plasma samples taken whilst ART-naïve from which viral RNA was subsequently 
extracted and analysed for genotypic resistance.  Samples selected for analysis were 
not based on suspicion of resistance and the results of these tests were not used to 
guide future treatment nor communicated to clinicians at the time of storing the sample.  
As mentioned in Chapter 2 (section 2.1.3), EuroSIDA also collects information on 
mutations identified in resistance tests performed by the clinical centres.  It is possible 
that patients who received a resistance test in the clinic may have had suspected 
resistance, therefore to eliminate any potential selection bias, these resistance test 
results were excluded from the analyses.   
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To investigate virological and immunological response to cART, a subset of the ART-
naïve patients who later started a cART regimen (defined as at least three antiretroviral 
drugs including a PI, an NNRTI, or abacavir (ABC)), without starting mono-/dual ART 
first, were selected.  Patients were also required to have the potential for at least one 
year’s follow-up time after starting cART (i.e. started cART at least one year before 
January 2007) to provide a suitable length of time to analyse response. 
 
5.2.2 Statistical  methods 
5.2.2.1 Definitions 
The results from genotypic resistance tests performed on HIV RNA from plasma 
samples taken whilst the patient was ART-naïve were used to estimate prevalence of 
TDR in the EuroSIDA population.  If the patient had more than one sample available 
before starting ART, results were cumulated.  TDR was defined as the detection of at 
least one HIV-1 mutation from a list proposed for genotypic TDR surveillance by Shafer 
et al. (2007) [345], which included 31 PI resistance mutations at 14 PR positions, 31 
NRTI resistance mutations at 15 RT positions and 18 NNRTI resistance mutations at 
10 RT positions.  For comparison purposes, the IAS-USA 2008 figures of HIV-1 drug 
resistance mutations [346] (which include naturally occurring polymorphisms that may 
not have been present at transmission), the Stanford University algorithm (HIVdb) 
Version 4.3.4 [351], the Rega algorithm Version 7.1 [349] and the ANRS algorithm July 
2006 [350] were also used to interpret resistance and to obtain estimates of TDR 
prevalence.   
 
Date of HIV infection was estimated in patients who had dates for HIV negative and 
HIV positive serostatus as the midpoint of the two.  Chronic HIV infection was defined 
as HIV infection longer than a year (similarly to the CATCH Study [436]). 
 
As in previous chapters, a cART regimen was defined as at least three drugs including 
a PI, an NNRTI or abacavir (ABC).  Baseline was defined as the date of starting cART.   
 
5.2.2.2 Availability of resistance test results whilst ART-naïve 
Multivariable logistic regression models were developed to investigate the factors 
affecting whether or not patients had plasma samples available whilst ART-naïve that 
were subsequently tested retrospectively for genotypic resistance.  Variables 
investigated (at date of enrolment) were gender, age, HIV exposure group (defined as 
‘men who have sex with men (MSM)’, ‘injecting drug use (IDU)’, ‘heterosexual’ or 
‘other’), geographical region (defined in Chapter 2, section 2.1.5), country of origin 
(defined as ‘same as clinical centre’, ‘another European country’, ‘Africa’, ‘America’, 
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‘Asia’ or ‘other’), ethnicity (defined as ‘white’ or ‘other’), CD4 count and viral load, 
hepatitis B/C coinfection status, prior AIDS diagnosis and date of enrolment.   
 
5.2.2.3 Detection of transmitted drug resistance 
Multivariable logistic regression was also used to assess the effect of calendar time 
(divided into 1994-1995, 1996-1997, 1998-1999, 2000-2001 and 2002-2004), HIV-1 
subtype (A, B and ‘other’) and geographical region (South, Central West, North and 
East), on the detection of TDR after adjustment for potentially confounding factors.  All 
resistance test results were included until the first detection of TDR for each patient 
and the analysis was adjusted for repeated tests per patient using generalised 
estimating equations.  Potential confounders investigated were as above but at the 
date of the plasma sample analysed, instead of at date of enrolment.  Those that were 
significantly associated with the detection of TDR in univariable analyses (p<0.1) were 
included in the multivariable model. 
 
5.2.2.4 Virological and immunological response to cART 
Response to cART was analysed via multivariable logistic regression models taking the 
first measurements six to twelve months after initiation of cART.  Patients infected with 
HIV with full/intermediate resistance to at least one drug started according to genotypic 
sensitivity scores calculated using the Stanford algorithm (the ‘resistant group’) were 
compared to those with HIV susceptible to all drugs started (the ‘susceptible group’), 
after adjustment for potentially confounding factors.  These were identified as those 
significantly associated with the odds of a response in univariable analysis (p<0.1) and 
any additional variables identified using a stepwise selection procedure.  Variables 
investigated were similar to above but at date started cART.   
 
A successful virological response was defined as a viral load less than 500 copies/mL 
and immunological response as a 100 CD4 cells/mm
3 or more increase from the start 
of cART.  For analyses of virological response, patients were required to have a 
baseline viral load of at least 500 copies/mL and for immunological response patients 
needed a baseline CD4 count available measured within six months prior to starting 
cART.  A ‘missing = failure’ approach was taken as the main analysis.   
 
5.2.2.5 Sensitivity analyses 
A sensitivity analysis was carried out using a ‘missing = excluded’ approach.  Further 
sensitivity analyses using the ‘missing = failure’ approach were conducted on the 
subset of patients who started cART after enrolment into EuroSIDA (excluding patients 
whose treatment data were collected retrospectively), using the Rega algorithm to 
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calculate genotypic sensitivity scores instead of Stanford, and using the definition of 
TDR by Shafer et al. (2007) to define groups based on whether or not patients had 
TDR mutations regardless of the drugs they were starting.  
 
For the analysis of immunological response, a sensitivity analysis was carried out 
adjusting for the change in viral load from baseline to the first measurement six to 
twelve months after starting cART.  This excluded any patients with missing viral load 
measurements during this time. 
 
Alternative endpoints were also investigated.  A virological endpoint of a viral load less 
than 50 copies/mL was analysed on a subset of patients whose first viral load 
measurements in the six to twelve month period after starting cART were measured 
using an assay with a level of detection as low as 50 copies/mL.  This required all 
those with missing values to be excluded.  A further immunological endpoint of a 50% 
CD4 cells/mm
3 increase
 or more from baseline was also analysed. 
 
5.3 Results 
5.3.1  Patient numbers  
The patient numbers according to the inclusion criteria are displayed in Figure 5.1.  
Amongst 14,310 patients, 525 (3.7%) were included who had plasma samples 
available whilst ART-naïve, which were subsequently tested retrospectively for 
genotypic HIV drug resistance.   
   
Date of HIV infection could be estimated for 118 (22.5%) of the 525 ART-naïve patients 
tested for resistance.  The median time between estimated date of infection and 
earliest resistance test was 51.0 months (IQR: 24.6-83.5 months) for these patients 
and was more than one year for 105 (89.0%) patients.  In 395 (75.2%) patients whose 
date of infection could not be estimated but the date of HIV positive diagnosis was 
known, the median time between HIV positive diagnosis and earliest resistance test 
was 48.4 months (IQR: 17.5-97.1 months) and was more than one year for 325 
(82.3%) patients.  Therefore the majority of this study population (at least n=430, 
81.9%) were chronically infected patients.  
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Figure 5.1: Patient numbers in analyses according to inclusion criteria. 
 
 
5.3.2  Patient characteristics at date of enrolment 
5.3.2.1 Resistance test results available versus not 
Table 5.1 shows the differences between these 525 patients who met the inclusion 
criteria compared to those excluded at the date of enrolment into EuroSIDA.  Over half 
of the patients included with resistance test results were from the North region, 
whereas amongst those excluded, patients were more evenly distributed between all 
regions (p<0.001).  Patients with resistance test results available were less likely to 
have a previous AIDS diagnosis (10.7% versus 29.1%; p<0.001), more likely to be co-
infected with hepatitis B (68.2% versus 60.0%; p<0.001) and were diagnosed with HIV 
more recently (33 versus 52 months; p<0.001).  They also had a higher median CD4 
count (370 versus 284 cells/mm
3; p<0.001) and a higher median viral load (4.4 versus 
2.7 log10copies/mL; p<0.001).   
  
No genotypic resistance test
results available whilst
ART-naive
n=13785
Started cART with
previous ART experience
n=66
Missing viral loads
6-12 months after
cART = excluded
n=255
Missing viral loads
6-12 months after cART
= virological failures
n=277
Virological response:
baseline viral load of
at least 500 copies/mL
n=277
Missing CD4 counts
6-12 months after
cART = excluded
n=277
Missing CD4 counts
6-12 months after cART
= immunological failures
n=299
Immunological response:
baseline CD4 count
n=299
Potential for at least
one year's follow-up
n=308
Started cART from
ART-naive
n=322
Never started
cART
n=137
Plasma samples available whilst
ART-naive from which HIV RNA
tested for genotypic resistance
n=525
EuroSIDA patients
(February 2008 dataset)
n=14310
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Table 5.1: Patient characteristics at date of enrolment according to whether or not 
patients had plasma samples available whilst ART-naïve that were subsequently tested 
retrospectively for genotypic HIV drug resistance.  
                                  Total    Tested for 
resistance 
No resistance  
test  p 
All   n %  14310 100.0   525  3.7  13785  96.3  - 
Male 10840 75.8    395  75.2  10445  75.8  0.780 
HIV exposure group                0.021 
 MSM  5809  40.6    239  45.5  5570  40.4  - 
 IDU  3641  25.4    140  26.7  3501  25.4  - 
 Heterosexual  3848  26.9    117  22.3  3731  27.1  - 
 Other  1012  7.1    29  5.5 983 7.1 - 
Ethnicity               0.588 
 White  12678 88.6    469  89.3  12209  88.6  - 
 Other  1632  11.4    56  10.7  1576  11.4  - 
Region               <0.001
 South  4562  31.9    52  9.9  4510  32.7   
 Central  West  3481  24.3    84  16.0  3397  24.6  - 
 North  3707  25.9    282  53.7  3425  24.9  - 
 East  2560  17.9    107  20.4  2453  17.8  - 
Origin               0.003 
  Same as EuroSIDA centre 10893 76.1    429  81.7  10464  75.9  - 
  Other European country  793  5.5    26  5.0  767  5.6  - 
 Africa  771  5.4    29  5.5 742 5.4 - 
 Other/unknown  1853  13.0    41  7.8  1812  13.1  - 
Previous AIDS  4068  28.4    56  10.7  4012  29.1  <0.001
Hepatitis B status                <0.001
 Negative  8628  60.3    358  68.2  8270  60.0  - 
 Positive  706  4.9    33  6.3 673 4.9 - 
 Unknown  4976  34.8    134  25.5  4842  35.1  - 
Hepatitis C status                0.241 
 Negative  5762  40.3    224  42.7  5538  40.2  - 
 Positive  2780  19.4    108  20.6  2672  19.4  - 
 Unknown  5768  40.3    193  36.8  5575  40.4  - 
Median (IQR)                
Date of enrolment  Aug 97 (Dec 95-
Nov 03)   Apr  97 (Jan 96-
May 99) Sep 97  (Dec 95-
Nov 03) <0.001
Age (years)  36 (31-44)    35  (29-41)  36  (31-44)  <0.001
CD4 count (cells/mm
3)               
 At  enrolment
(1)  289 (144-440)  370  (256-475) 284  (140-439) <0.001
 Nadir
(2)  176 (67-300)   320  (220-415) 170  (63-294) <0.001
Time from nadir (months)  5 (1-16)    3 (0-8)  5  (1-17)  <0.001
Viral load (log10copies/mL)               
 At  enrolment
(3)  2.7 (1.8-4.2)   4.4  (3.8-5.0) 2.7  (1.7-4.1) <0.001
 Maximum  ever
(4)   4.6 (3.6-5.2)   4.6  (4.1-5.1) 4.6  (3.6-5.2) 0.016 
Time from HIV positive diagnosis 
(months)  51 (20-96)    33  (11-78)  52  (21-96)  <0.001
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
Median CD4 counts and viral loads based on measurements from 
(1)13552 patients, 
(2)13918 patients, 
(3)8129 patients, 
(4)8725 patients. 
MSM = men who have sex with men; IDU = injecting drug use; IQR = interquartile range. 
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5.3.2.2 Factors affecting availability of resistance test results 
A multivariable logistic regression model was developed to investigate further factors 
that may have affected whether or not patients had plasma samples available whilst 
ART-naïve that were subsequently tested retrospectively for genotypic HIV drug 
resistance.  Odds ratios (ORs) of all factors investigated are displayed in Table 5.2.  
The multivariable odds of having resistance test results available were significantly 
higher in: IDUs versus MSM (OR: 1.39; 95% CI: 1.01-1.91; p=0.044), patients from 
East versus North Europe (OR: 1.47; 95% CI: 1.02-2.12; p=0.039), patients with higher 
CD4 counts at date of enrolment compared to less than or equal to 200 cells/mm
3 (OR 
for 201-350 cells/mm
3: 3.08; 95% CI: 2.30-4.13; p<0.001; OR for higher than 350 
cells/mm
3: 6.39; 95% CI: 4.81-8.50; p<0.001; and OR for missing CD4 count: 2.85; 
95% CI: 1.46-5.57; p=0.002) and patients with a viral load at time of enrolment of more 
than 10,000 copies/mL versus less than or equal to this amount (OR: 5.70; 95% CI: 
1.02-2.12; p=0.039).   
 
The multivariable odds of having resistance test results available were significantly 
lower in: patients from South and Central West versus North Europe (OR for South: 
0.13; 95% CI: 0.09-0.18; p<0.001 and OR for Central West: 0.31; 95% CI: 0.24-0.41; 
p<0.001), patients with a prior AIDS diagnosis (OR: 0.43; 95% CI: 0.32-0.57; p<0.001) 
and patients with positive or unknown hepatitis C coinfection status versus a negative 
status (OR for hepatitis C positive: 0.69; 95% CI: 0.49-0.97; p=0.032 and OR for 
unknown status: 0.71; 95% CI: 0.54-0.92; p=0.011). 
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Table 5.2: Odds ratios and 95% confidence intervals of patients having plasma 
samples available whilst ART-naïve that were subsequently tested retrospectively for 
genotypic HIV drug resistance. 
   Univariable Multivariable 
   OR  95%  CI  p  OR 95%  CI p 
Gender        
 Male  1.00             
 Female  1.03  (0.84,  1.26)  0.778  1.17  (0.90,  1.52) 0.229 
HIV exposure group               
 MSM  1.00        1.00    
 IDU  0.93  (0.75,  1.15)  0.516  1.39  (1.01,  1.91) 0.044 
 Heterosexual  0.73  (0.58,  0.92)  0.006  0.95  (0.70,  1.28) 0.722 
 Other  0.69  (0.47,  1.02)  0.061  0.93  (0.60,  1.45) 0.759 
Ethnicity                  
 White  1.00        1.00    
 Other  0.93  (0.70,  1.23)  0.588  0.85  (0.56,  1.30) 0.449 
Region                  
 North  1.00        1.00    
 South  0.14  (0.10,  0.19)  <0.001 0.13  (0.09,  0.18) <0.001
  Central West  0.30  (0.23, 0.39)  <0.001 0.31  (0.24, 0.41) <0.001
 East  0.53  (0.42,  0.67)  <0.001 1.47  (1.02,  2.12) 0.039 
Origin                  
  Same as EuroSIDA centre  1.00       1.00     
  Other European country  0.83  (0.55, 1.24)  0.355  0.67  (0.44, 1.04) 0.072 
 Africa  0.95  (0.65,  1.40)  0.807  1.02  (0.58,  1.79) 0.941 
 Other/unknown  0.55  (0.40,  0.76)  <0.001 1.01  (0.68,  1.49) 0.961 
Prior AIDS  0.29  (0.22, 0.39)  <0.001 0.43  (0.32, 0.57) <0.001
Hepatitis B status               
 Negative  1.00        1.00    
 Positive  1.13  (0.79,  1.63)  0.504  1.22  (0.83,  1.80) 0.318 
 Unknown  0.64  (0.52,  0.78)  <0.001 0.97  (0.74,  1.27) 0.804 
Hepatitis C status               
 Negative  1.00        1.00    
 Positive  1.00  (0.79,  1.26)  0.995  0.69  (0.49,  0.97) 0.032 
 Unknown  0.86  (0.70,  1.04)  0.120  0.71  (0.54,  0.92) 0.011 
CD4 count at time of enrolment (cells/mm3)          
  ≤200 1.00        1.00     
 201-350  2.69  (2.04,  3.54)  <0.001 3.08  (2.30,  4.13) <0.001
 >350  3.34  (2.59,  4.31)  <0.001 6.39  (4.81,  8.50) <0.001
 Missing  0.88  (0.46,  1.66)  0.685  2.85  (1.46,  5.57) 0.002 
Viral load at time of enrolment (copies/mL)          
  ≤10000 1.00        1.00     
 >10000  5.91  (4.65,  7.52)  <0.001 5.70  (4.41,  7.36) <0.001
 Missing  1.87  (1.46,  2.38)  <0.001 0.92  (0.69,  1.25) 0.601 
Date of enrolment (per year increase)  0.91 (0.88,  0.93)  <0.001 0.73  (0.70,  0.77) <0.001
Age (per 10 year increase)  0.75  (0.68, 0.82)  <0.001 0.83  (0.74, 0.93) 0.001 
Notes: MSM = men who have sex with men; IDU = injecting drug use; OR = odds ratio; CI = confidence 
interval. 
 
 
5.3.3  Prevalence of transmitted drug resistance 
5.3.3.1 Resistance profiles in ART-naïve patients  
TDR defined according to Shafer et al. (2007) was detected in 60 of the 525 patients 
(11.4%; 95% CI: 8.9-14.3%).  A total of 49 (9.3%; 95% CI: 7.0-12.0%) had HIV with 
one or more mutations associated with NRTI resistance, 5 (1.0%; 95% CI: 0.3-2.2%) 
had NNRTI resistance mutations and 16 (3.0%; 95% CI: 1.8-4.7%) had PI resistance 
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mutations.  A total of 9 patients (1.7%; 95% CI: 0.8-3.0%) were infected with multi-class 
drug-resistant HIV.  The specific TDR mutations that were detected are displayed in 
Figure 5.2. 
 
Figure 5.2: HIV-1 drug resistance mutations identified for surveillance of transmitted 
drug resistance in 525 ART-naïve patients. 
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Table 5.3 compares the prevalence of TDR estimated by Shafer et al.’s list of 
mutations to other interpretation systems.  Using the IAS-USA list of HIV-1 mutations to 
interpret resistance, at least one NRTI, NNRTI or major PI mutation linked to drug 
resistance was detected in HIV from 71 patients (13.5%; 95% CI: 12.7-18.9%).  A total 
of 53 (10.1%; 95% CI: 7.7-12.9%) had NRTI resistance mutations, 21 (4.0%; 95% CI: 
2.5-5.9%) had NNRTI resistance mutations and 17 (3.2%; 95% CI: 1.9-4.9%) had 
major PI resistance mutations.  Using the Stanford algorithm to interpret genotypic 
resistance gave the highest estimate: 84 patients (16.0%; 95% CI: 13.1-19.3%) were 
infected with HIV with full or intermediate drug resistance.  The Rega algorithm resulted 
in a similar estimate to that found using Shafer et al.’s list (9.9%; 95% CI: 7.5-12.6%) 
and the ANRS algorithm gave the lowest estimate of TDR prevalence (6.3%; 95% CI: 
4.4-8.5%).   
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Table 5.3: Prevalence of transmitted drug resistance and 95% confidence intervals in 
525 ART-naïve patients according to various interpretation systems. 
Prevalence of TDR (95% CI)  Resistance interpretation system  Any NRTI  NNRTI PI 
Shafer et al. 2007 [345]  11.4% 
(8.9-14.3%) 
9.3% 
(7.0-12.0%) 
1.0% 
(0.3-2.2%) 
3.0% 
(1.8-4.7%) 
IAS-USA 2008 [346]
 (1)  13.5% 
(12.7-18.9%) 
10.1% 
(7.7-12.9%) 
4.0% 
(2.5-5.9%) 
3.2% 
(1.9-4.9%)
(1) 
Stanford algorithm Version 4.3.4[351]
(2)  16.0% 
(13.1-19.3%) 
9.5% 
(7.2-12.2%) 
4.8% 
(3.1-6.8%) 
4.0% 
(2.5-5.9%) 
Rega algorithm Version 7.1 [349]
(2)  9.9% 
(7.5-12.6%) 
6.7% 
(4.7-9.0%) 
1.0% 
(0.3-2.2%) 
3.8% 
(2.4-5.6%) 
ANRS algorithm July 2006 [350]
(2)  6.3% 
(4.4-8.5%) 
3.4% 
(2.1-5.2%) 
1.0% 
(0.3-2.2%) 
3.6% 
(2.2-5.4%) 
Notes: 
(1)Major PI mutations only. 
(2)Full or intermediate resistance. 
TDR = transmitted drug resistance; CI = confidence interval. 
 
As an alternative to cumulating all resistance test results up to the date of starting 
therapy, only the results from the resistance test performed on each patient’s earliest 
plasma sample were taken to obtain a further estimate of TDR prevalence.  This gave 
a very similar estimate (using Shafer et al.’s definition) of 10.9% (95% CI: 8.4-13.7%).  
NRTI resistance was detected in 9.1% (95% CI: 6.9-11.8%), NNRTI resistance was 
detected in 0.6% (95% CI: 0.1-1.7%) and PI resistance was detected in 2.7% (95% CI: 
1.5-4.2%). 
  
5.3.3.2 Resistance profiles over calendar time  
Figure 5.3 displays TDR according to calendar year of resistance test.  Over calendar 
time, the difference in overall prevalence of detected TDR between two-year periods 
between 1994 and 2004 was borderline significant (p=0.050).  After an initial relatively 
high TDR prevalence of 20.3% (95% CI: 12.0-31.7%) in 64 patients with plasma 
samples available for genotypic resistance testing in 1994-1995, the prevalence 
remained fairly stable.  TDR prevalence was 10.5% (95% CI: 6.9-15.0%) in 219 
patients in 1996-1997, 6.8% (95% CI: 3.4-11.5%) in 147 patients in 1998-1999, 6.5% 
(95% CI: 2.5-12.5%) in 93 patients in 2000-2001 and 9.1% (95% CI: 4.4-15.7%) in 99 
patients in 2002-2004.  No resistance test results were available in 2005 onwards.   
NRTI resistance ranged from 4.8% to 20.3%, NNRTI resistance from 0.0% to 2.0% and 
PI resistance from 1.6% to 3.9%.  
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Figure 5.3: Prevalence of transmitted drug resistance and 95% confidence intervals 
according to calendar year. 
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5.3.3.3 Resistance profiles according to HIV-1 subtype 
A total of 31 (5.9%) patients were infected with HIV-1 subtype A, 432 (82.3%) with 
subtype B, 14 (2.7%) with subtype C and 48 (9.1%) were infected with another subtype 
or circulating recombinant form.  TDR was highest in those infected with subtype B, 
12.5% (95% CI: 9.6-15.8%), followed by 7.1% (95% CI: 0.1-33.9%) of those with 
subtype C, 6.5% (95% CI: 0.8-21.4%) of the subtype A group and 6.3% (95% CI: 1.3-
17.2%) of patients in the ‘other’ subtype group, displayed in Figure 5.4.  The overall 
prevalence of TDR in non-B subtypes was 6.5% (95% CI: 2.5-12.5%) (6 out of 93 
patients), which did not differ significantly compared to patients infected with subtype B 
(p=0.096).  Resistance was predominantly NRTI-associated in patients infected across 
all subtypes, except for those with HIV-1 subtype C where the one patient with 
resistance had PI resistance mutations only.  NNRTI resistance was only observed in 
patients infected with subtype B. 
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Figure 5.4: Prevalence of transmitted drug resistance and 95% confidence intervals 
according to HIV-1 subtype. 
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5.3.3.4 Resistance profiles according to geographical region within EuroSIDA 
Amongst the 525 patients, 52 (9.9%) visited clinics in the South region, 84 (16.0%) in 
the Central West, 282 (53.7%) in the North and 107 (20.4%) in the East.  There was no 
significant overall difference in TDR prevalence between regions (p=0.550).  The South 
region had the largest prevalence of TDR, 17.3% (95% CI: 8.9-29.5%), followed by the 
Central West with 11.9% (95% CI: 6.1-20.0%), the North with 10.6% (95% CI: 7.4-
14.6%) and the East region with 10.3% (95% CI: 5.4-17.0%).  These are displayed in 
Figure 5.5.  NRTI resistance was lowest in the East (6.5%) and highest in the South 
(13.5%).  NNRTI resistance was similarly low across regions.  PI resistance ranged 
from 2.4% to 5.8%. 
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Figure 5.5: Prevalence of transmitted drug resistance and 95% confidence intervals 
according to geographical region within EuroSIDA. 
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5.3.3.5 Multivariable model of detection of transmitted drug resistance 
A total of 622 genotypic resistance test results for the 525 ART-naïve patients were 
included in a multivariable logistic regression analysis (using generalised estimating 
equations to adjust for repeated tests per patient), to investigate the effect of calendar 
time, HIV-1 subtype and geographical region on the detection of TDR.  TDR was 
detected in 61 (9.8%) resistance tests and multivariable odds ratios are displayed in 
Figure 5.6.  After adjustment for viral load at the date of the plasma sample analysed 
and hepatitis C status that were found to be significantly associated with detection of 
TDR in univariable analyses (p<0.1), no statistically significant differences could be 
demonstrated in the detection of TDR between any two-year time periods compared to 
1996-1997.  There was also no significant difference in the odds of detection of TDR in 
patients infected with subtype A compared to subtype B (p=0.243) and a borderline 
significantly lower odds in patients infected with ‘other’ subtypes compared to B (OR: 
0.35; 95% CI: 0.11-1.07; p=0.066).  In the South region, there were significantly higher 
odds of detection of TDR than in the North region (OR: 2.47; 95% CI: 1.02-5.95; 
p=0.044).  The wide confidence intervals indicate the limited power of these analyses 
due to small patient numbers. 
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Figure 5.6: Multivariable odds ratios and 95% confidence intervals of detection of transmitted drug-resistant HIV in 622 genotypic resistance tests 
performed on plasma samples from 525 ART-naïve patients. 
Factor in multivariable model  No. of 
tests 
No. (%) 
detecting TDR  
        
Total   622  61  (9.8)   
    
1994-1995 64  13  (20.3) 
1996-1997 219  23  (10.5) 
1998-1999 147  10  (6.8) 
2000-2002 93  6  (6.5) 
Calendar year 
2002-2004 99  9  (9.1) 
      
A 34  2  (5.9) 
B 516  55  (10.7) 
HIV-1 subtype 
Other 72  4  (5.7) 
      
South 57  9  (15.8) 
Central West  101  10 (9.9) 
North 352  31  (8.8) 
Region 
East 112  11  (9.8) 
      
Negative 258  18  (7.0) 
Positive 108  14  (13.0) 
Unknown 256  29  (11.3) 
Hepatitis C 
status  
    
500-10000 117  14  (12.0) 
>10000 344  22  (6.4) 
Missing 161  25  (15.5) 
    
Viral load at date 
of plasma 
sample analysed 
(copies/mL) 
      
Notes: TDR = transmitted drug resistance; OR = odds ratio;  
CI = confidence interval.   
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5.3.4  Transmitted drug resistance at initiation of cART 
5.3.4.1 Genotypic sensitivity scores 
Out of the 525 patients with resistance test results, 308 (58.7%) then initiated a cART 
regimen whilst they were still ART-naïve with the potential for one year’s follow-up.  
TDR mutations (defined according to Shafer et al. (2007)) were detected in 29 (9.4%; 
95% CI: 6.5-13.0%) patients in this subset.  Genotypic sensitivity scores calculated 
using the Stanford algorithm showed that 13 (4.2%; 95% CI: 2.3-6.8%) patients had 
HIV with full resistance to at least one drug prescribed in their regimens at the time of 
starting cART (baseline) or intermediate resistance to at least two drugs started and 24 
(7.8%; 95% CI: 5.1-11.1%) had HIV with intermediate resistance to just one drug 
started.  A total of 23 (7.5%; 95% CI: 4.8-10.7%) had NRTI resistance mutations to an 
NRTI started including M41L, D67G/N/deletion, K70R, F77L, M184I/V, L210W, T215Y 
/D/E/S/I and K219Q, 5 (1.6%; 95% CI: 0.5-3.7%) had NNRTI resistance including 
V106M and 11 (3.6%; 95% CI: 1.8-6.0%) had PI resistance including L24I, M46I and 
V82A.   
 
Alternatively, using the Rega algorithm, 14 (4.6%; 95% CI: 2.5-7.2%) patients had HIV 
with full or intermediate resistance to at least one drug started.  Using the ANRS 
algorithm, 5 (1.6%; 95% CI: 0.5-3.7%) patients had HIV with full or intermediate 
resistance to at least one drug started.   
 
5.3.4.2 Patient characteristics at date of starting cART  
Table 5.4 shows that the patient characteristics were mostly similar between these 37 
patients with resistant HIV interpreted using the Stanford algorithm (the ‘resistant’ 
group) and the 271 patients with HIV susceptible to all drugs started (the ‘susceptible’ 
group).  Both groups had a similar median time between their most recent resistance 
test whilst ART-naïve and starting cART: 8 months (IQR: 4-23 months) for the resistant 
group and 7 months (IQR: 3-19 months) for the susceptible group (p=0.482). 
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Table 5.4: Patient characteristics at date of starting cART according to whether 
patients had HIV with full or intermediate resistance to at least one drug started 
(‘resistant’) or HIV susceptible to all drugs started (‘susceptible’). 
                                  Total     Resistant  Susceptible  p 
All   n, %  308 100.0   37  12.0  271  88.0  - 
Male 230  74.7    30  81.1  200  73.8  0.340
HIV exposure group                0.071
 MSM  154  50.0    26  70.3  128  47.2  - 
 IDU  63  20.5    5  13.5 58 21.4  - 
 Heterosexual  71  23.1    5  13.5 66 24.4  - 
 Other  20  6.5    1  2.7  19  7.0 - 
Ethnicity               0.149
 White  278  90.3    36  97.3  242  89.3  - 
 Other  30  9.7    1  2.7  29 10.7  - 
Region               0.135
 South/East  92  29.9    15  40.5 77 28.4  - 
 Central  West  36  11.7    6  16.2 30 11.1  - 
 North  180  58.4    16  43.2  164  60.5  - 
Previous AIDS  35  11.4    3  8.1  32  11.8  0.782
Hepatitis B status                0.959
 Negative  246  79.9    30  81.1  216  79.7  - 
 Positive  20  6.5    2  5.4  18  6.6 - 
 Unknown  42  13.6    5  13.5 37 13.7  - 
Hepatitis C status                0.977
 Negative  176  57.1    21  56.8  155  57.2  - 
 Positive  61  19.8    7  18.9 54 19.9  - 
 Unknown  71  23.1    9  24.3 62 22.9  - 
cART regimen  
(including ≥ 2 NRTIs)                0.134
 Single  PI  128  41.6    13  35.1  115  42.4  - 
 RTV-boosted  PI  38  12.3    9  24.3 29 10.7  - 
 Single  NNRTI  81  26.3    7  18.9 74 27.3  - 
 Triple  NRTI  including  ABC 15  4.9    1  2.7  14  5.2 - 
 Other  46  14.9    7  18.9 39 14.4  - 
Median (IQR)              
Date of starting cART  Jul 99 (Oct 97-
Feb 02)   Oct  00 (Jan 98-
Jul 02)  Jun 99  (Oct 97-
Dec 01) 0.148
Date of enrolment  Apr 97 (Feb 97-
May 99)  Mar  99 (Mar 97-
Nov 00)  Apr 97  (Nov 96-
Mar 99) 0.052
Age (years)  37  (31-44)    36  (30-43)  37  (31-44)  0.735
CD4 count (cells/mm
3)                
 Baseline
(1)  251 (147-330)   261 (164-314) 250  (140-331) 0.785
 Nadir
(2)  207 (122-283)   222 (144-273) 205  (110-288) 0.470
Time from nadir (months)  2  (1-7)  1  (1-3)  2  (1-8)  0.004
Viral load (log10copies/mL)               
 Baseline
(3)  4.9 (4.4-5.3)   4.8 (4.5-5.3) 4.9  (4.3-5.3) 0.978
 Maximum  ever
(4)  5.1 (4.7-5.5)   5.1 (4.6-5.5) 5.1  (4.7-5.5) 0.719
Time from HIV positive diagnosis 
(months)  61 (34-113)   64 (32-113) 60  (35-113) 0.877
Time from most recent resistance 
test (months)  7 (3-19)   8 (4-23)  7  (3-19)  0.482
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
Resistance interpreted by the Stanford algorithm Version 4.3.4. 
Median CD4 counts and viral loads based on measurements from 
(1)299 patients, 
(2)308 patients, 
(3)289 
patients, 
(4)296 patients. 
MSM = men who have sex with men; IDU = injecting drug use; RTV = ritonavir; ABC = abacavir;  
IQR = interquartile range. 
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5.3.5  Virological response to cART: viral load less than 500 copies/mL at 
months six to twelve 
5.3.5.1 Main analysis: missing viral load = failure 
Virological response was analysed in 277 (89.9%) patients who had baseline viral 
loads measured of at least 500 copies/mL, of which 34 (12.3%) patients had HIV with 
full or intermediate resistance to at least one drug started (using the Stanford 
algorithm).  Of these 277 patients, 22 (7.9%) had no viral load measurement in the 
period six to twelve months after starting cART and so were counted as virological 
failures in the main analysis.  A total of 211 (76.2%) patients achieved virological 
suppression (viral load less than 500 copies/mL) at the first measurement six to twelve 
months after starting cART.  Response rates between patients in the resistant and the 
susceptible groups were similar: 25 (73.5%; 95% CI: 61.6-91.2%) of 34 patients 
compared to 186 (76.5%; 95% CI: 71.6-82.3%) of 243 patients respectively (p=0.699).   
 
In a univariable logistic regression model, the odds of virological suppression were 
lower but not significantly in the resistant group compared to the susceptible group 
(OR: 0.85; 95% CI: 0.38-1.93; p=0.700).  After adjustment for potential confounders, 
namely: gender, geographical region, baseline CD4 count and viral load, date started 
cART, type of cART regimen and time from most recent resistance test, the findings 
were similar (OR: 0.68; 95% CI: 0.27-1.71; p=0.408).  Table 5.5 displays these results, 
as well as those from sensitivity analyses.  Results were similar in those starting PI- 
and those starting NNRTI-containing regimens; no interaction was found between type 
of cART regimen and resistance (p=0.222).  However, the power of this analysis to 
detect true differences was limited by the small numbers. 
 
5.3.5.2 Sensitivity analysis: missing = excluded 
In a sensitivity analysis, patients with missing viral load measurements at six to twelve 
months were excluded with results were similar to those of the main analysis.   
Virological suppression was achieved by 83.3%: (95% CI: 73.3-99.9%) of 30 patients in 
the resistant group and 82.7% (95% CI: 78.2-88.0%) of 225 patients in the susceptible 
group (p=0.928).  After adjustment for the same potentially confounding variables as in 
the main analysis, there was again no significant difference in the odds of virological 
suppression in the resistant group compared to the susceptible group (OR: 0.71; 95% 
CI: 0.22-2.35; p=0.580).  
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Table 5.5: Odds ratios and 95% confidence intervals for virological response (less than 
500 copies/mL) to cART according to whether patients had HIV with full or intermediate 
resistance to at least one drug started (‘resistant’) or HIV susceptible to all drugs 
started (‘susceptible’). 
  Resistant Susceptible  Resistant  versus  susceptible 
  n  % VL 
respond n  % VL 
respond
Univariable 
OR (95% CI) p  Multivariable 
OR (95% CI) p 
Main analysis:               
Missing = failure
*  34 73.5% 243 76.5%  0.85 
(0.38-1.93)
0.700  0.68 
(0.27-1.71)
0.408
Sensitivity analyses:                
Missing = excluded
*  30 83.3% 225 82.7%  1.05 
(0.38-2.91)  0.928  0.71 
(0.22-2.35)  0.580
Excluding retrospective 
treatment data (missing = 
failure)
* 
31 74.2% 220 75.9%  0.91 
(0.39-2.16)  0.835  0.83 
(0.32-2.19)  0.712
Resistance interpreted by 
Rega Version 7.1 
(missing = failure) 
12 66.7% 265 76.6%  0.61 
(0.18-2.10)  0.433  0.72 
(0.18-2.86)  0.645
Resistance defined by 
Shafer et al. (missing = 
failure) 
24 70.8% 253 76.7%  0.74 
(0.29-1.87)  0.522  0.65 
(0.23-1.82)  0.415
Endpoint viral load <50 
copies/mL  
(missing = excluded)
* 
25 68.0% 206 61.2%  1.35 
(0.56-3.27)  0.508  1.55 
(0.52-4.62)  0.430
Notes: *Resistance interpreted by the Stanford algorithm Version 4.3.4. 
Multivariable analyses adjusted for gender, EuroSIDA region, date started cART, type of cART regimen, 
baseline CD4 count and viral load, and time from most recent resistance test. 
VL respond = virological responders; OR = odds ratio; CI = confidence interval. 
 
5.3.5.3 Further sensitivity analyses 
As shown in Table 5.5, the results from the four other sensitivity analyses carried out 
gave mostly similar findings to the main analysis.  Analysing the alternative endpoint of 
a viral load of less than 50 copies/mL instead of 500 copies/mL found a result in the 
opposite direction to the other analyses, in that patients in the resistant group had 
increased odds of a successful virological response (multivariable OR: 1.55; 95% CI: 
0.52-4.62; p=0.430).  However this was also not statistically significant.  
 
5.3.6  Immunological response to cART: at least 100 CD4 cells/mm
3 
increase 
5.3.6.1 Main analysis: missing CD4 count = failure 
Immunological response was analysed in 299 (97.1%) patients with baseline CD4 
counts, of which 36 (12.0%) had HIV with full or intermediate resistance to at least one 
drug started.  Of these 299 patients, 22 (7.4%) had no CD4 count measured six to 
twelve months after starting cART and so were counted as immunological failures in 
the main analysis.  In total, 130 (43.5%) patients had an immunological response (of at 
least 100 cells/mm
3 from baseline) at the first measurement six to twelve months after 
starting cART.  The response rate of patients in the resistant group was significantly 
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higher than patients in the susceptible group: 25 (69.4%; 95% CI: 57.1-87.2%) of 36 
patients compared to 119 (45.3%; 95% CI: 39.6-51.6%) of 263 patients (p=0.006). 
 
In a univariable logistic regression model, it was found that patients in the resistant 
group were over two and a half times more likely to have an immunological response 
compared to those in the susceptible group, which was significant (OR: 2.75; 95% CI: 
1.30-5.82; p=0.008).  After adjustment for baseline CD4 count and viral load, time from 
HIV positive diagnosis, type of cART regimen and time from most recent resistance 
test, the results were similar (multivariable OR: 2.56; 95% CI: 1.11-5.86; p=0.027).  
Table 5.6 displays these results, as well as those from sensitivity analyses.  No 
interaction was found between type of cART regimen and resistance (p=0.391), 
although as in the virological response analysis, the power to detect a true difference 
was very limited.   
 
Table 5.6: Odds ratios and 95% confidence intervals for immunological (at least 100 
CD4 cells/mm
3 increase) response to cART according to whether patients had HIV with 
full or intermediate resistance to at least one drug started (‘resistant’) or HIV 
susceptible to all drugs started (‘susceptible’). 
  Resistant Susceptible  Resistant  versus  susceptible 
  n  % CD4 
respond n  % CD4 
respond
Univariable 
OR (95% CI) p  Multivariable 
OR (95% CI) p 
Main analysis:               
Missing = failure
*  36 69.4%  263 45.3%  2.75 
(1.30-5.82)
0.008  2.56 
(1.11-5.86)
0.027 
Sensitivity analyses:               
Missing = excluded
*  34 73.5%  243 49.0%  2.89 
(1.30-6.46)  0.009  2.75 
(1.16-6.51)  0.021 
Excluding retrospective 
treatment data (missing = 
failure)
* 
33 69.7%  238 44.1%  2.91 
(1.33-6.39)  0.008  3.06 
(1.23-7.60)  0.016 
Resistance interpreted by 
Rega Version 7.1 
(missing = failure) 
14 78.6%  285 46.7%  4.19 
(1.15-15.34)  0.031  6.25 
(1.50-25.99)  0.012 
Resistance defined by 
Shafer et al. (missing = 
failure) 
28 67.9%  271 46.1%  2.47 
(1.08-5.64)  0.033  3.25 
(1.31-8.02)  0.011 
Endpoint 50% CD4 
cells/mm
3 increase
*  36 55.6%  263 41.8%  1.74 
(0.86-3.51)  0.122  1.65 
(0.73-3.73)  0.231 
Notes: 
*Resistance interpreted by the Stanford algorithm Version 4.3.4. 
Multivariable analyses adjusted for type of cART regimen, baseline CD4 count and viral load, time from HIV 
positive diagnosis and time from most recent resistance test. 
CD4 respond = immunological responders; OR = odds ratio; CI = confidence interval. 
 
To see if the results could be explained by the change in viral load after starting cART, 
the model was adjusted for this in patients with viral load measurements available at 
baseline and at six to twelve months.  This analysis included 262 patients, of which 31 
(11.8%) were in the resistant group.  After adjustment for the same variables as in the 
main analysis as well as change in viral load, similar results were obtained (OR: 3.09; 
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95% CI: 1.20-7.92; p=0.019).  To take account of variability in CD4 counts, average 
CD4 cell measurements at baseline (average of most recent two measurements within 
a year before starting cART) and during months six to twelve (average of first two 
measurements within this time window) were analysed.  The odds of an immunological 
response were more similar between the resistant and susceptible groups in this 
analysis than in the main analysis and the multivariable OR was not significant (OR: 
1.61; 95% CI: 0.74-3.53; p=0.232). 
 
5.3.6.2 Sensitivity analysis: missing = excluded 
Excluding patients with missing CD4 counts at six to twelve months resulted in very 
similar findings to those of the main analysis.  An immunological response was 
achieved by 52.0% of 243 patients: 73.5% (95% CI: 61.6-91.2%) of 34 patients in the 
resistant group and 49.0% (95% CI: 43.1-55.7%) of 243 patients in the susceptible 
group (p=0.007).  As in the main analysis, the odds of an immunological response in 
the resistant group were over two and a half times that of patients in the susceptible 
group (multivariable OR: 2.75; 95% CI: 1.16-6.51; p=0.021).  
 
5.3.6.3 Further sensitivity analyses 
The results from the other sensitivity analyses are shown in Table 5.6.  The analyses 
excluding patients with retrospective treatment data and comparing patients with and 
without TDR mutations (defined by Shafer et al.) gave consistent results to the main 
analysis.  Use of the Rega algorithm to interpret resistance showed the odds of an 
immunological response in the resistant group to be six times that of the odds in the 
susceptible group (multivariable OR: 6.25; 95% CI: 1.50-25.99; p=0.012), but with a 
very large confidence interval.  Only 14 patients were included in the resistant group for 
this analysis.  The alternative endpoint of a 50% or more CD4 count increase from 
baseline also showed higher odds of an immunological response in the resistant group 
but the effect was less pronounced and non-significant (multivariable OR: 1.65; 95% 
CI: 0.73-3.73; p=0.231). 
 
5.4 Discussion 
The analyses in this chapter found that the overall prevalence of TDR in chronically 
infected, ART-naïve patients in EuroSIDA was 11.4%.  The prevalence of TDR was 
found to be fairly stable over time, after an initially high level in 1994-1995, and no 
significant differences were found in the odds of TDR between two-year time periods in 
a multivariable model adjusting for potentially confounding factors.  Furthermore, no 
significant differences were found in the odds of TDR between patients infected with 
HIV-1 B and non-B subtypes or between Central West and East geographical regions 
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compared to the North region within EuroSIDA.  However there were significant higher 
odds of TDR in the South region compared to the North. 
 
No significant difference could be demonstrated in the odds of having a successful 
virological response to first-line cART in patients infected with HIV with full/intermediate 
resistance to at least one drug started compared to those with HIV susceptible to all 
drugs started, after adjustment for potentially confounding factors, although the 
response rate was slightly lower in the resistant group.  The number of patients with 
resistant HIV was small so the power of the analyses to detect true differences was 
limited.  An unexpected significantly higher immunological response rate was observed 
in the resistant group.   
 
5.4.1  Interpretation of findings and previous research 
5.4.1.1 Factors affecting availability of resistance test results 
Amongst the 14,310 EuroSIDA patients, 3.7% had plasma samples available whilst 
ART-naïve that were subsequently tested retrospectively for genotypic resistance.  As 
detailed in Chapter 2 (section 2.1.3), EuroSIDA requests that plasma samples are 
collected from patients every six months and shipped intermittently to the coordinating 
centre.  Samples were then selected according to patient inclusion criteria from a 
number of EuroSIDA projects, including this project, and genotypic resistance testing 
was carried out retrospectively on viral RNA.  Suspicion of having resistance was not 
one of the criteria and therefore these patients should not be more likely to have 
resistant HIV than patients whose samples were not analysed.  The factors associated 
with having resistance test results available from a plasma sample taken whilst ART-
naïve were investigated to examine how representative this subset of EuroSIDA 
patients was. 
 
IDU compared to MSM, visiting a clinical centre in the East region as opposed to the 
North, higher or missing CD4 counts at date of enrolment compared to a CD4 count of 
less than 200 cells/mm
3 and a viral load at date of enrolment of more than 10,000 
copies/mL compared to less than or equal to 10,000 copies/mL, were positively 
associated with having resistance test results available.  Visiting a clinical centre in the 
South or Central West regions, as opposed to the North, having a prior AIDS diagnosis 
and positive or unknown hepatitis C status compared to negative status, were less 
likely to have test results available.  This is likely to reflect the inclusion criteria for the 
EuroSIDA projects that determined which samples were selected for analysis.  One 
particular project was ‘HIV-1 subtypes and response to cART’ (Chapter 4) where 
samples were required that were collected prior to starting cART from those suspected 
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of being infected with a non-B HIV-1 subtype, i.e. those of non-white ethnicity, 
originating from non-European countries or living in East Europe, in order to gain power 
for more detailed comparisons in this study.  Samples were also prioritised where the 
patient’s viral load was more than 10,000 copies/mL to increase the likelihood of the 
test being successful.   
 
These results could also partly reflect the characteristics of patients who visit clinics 
more frequently and hence have more chance of a plasma sample being taken.  For 
example, unknown hepatitis C status was negatively associated with having test results 
available; if patients visit the clinic less frequently they are less likely to be tested for 
hepatitis C. 
 
5.4.1.2 Prevalence of transmitted drug resistance 
Amongst 525 patients, the prevalence of TDR was found to be 11.4%.  NRTI 
resistance was found in 9.3% of patients, NNRTI resistance in 1.0% and PI resistance 
in 3.0%.  This overall prevalence of TDR was found to be in line with the majority of 
studies investigating TDR across Europe [348,435,436,439-444].   
 
Tables 5.7 summarises the prevalence of TDR found in this analysis compared to other 
studies in ART-naïve patients across Europe.  Most of the studies used IAS-USA 
figures of drug resistance mutations to define TDR, although some modified the list to 
exclude minor protease mutations and polymorphisms that may occur naturally.  The 
CATCH study, similarly to EuroSIDA, analysed sequences from recently and 
chronically infected patients across Europe [436].  A total of 2208 sequences were 
analysed from patients in 19 different countries in a consistent way and an overall 
prevalence of 10.4% was found.  NRTI resistance was found in 7.6%, NNRTI 
resistance in 2.9% and major PI resistance in 2.5%.   
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Table 5.7: Prevalence of transmitted drug resistance in ART-naïve patients across Europe as reported in this analysis compared to published 
research (listed in descending order of number of patients included). 
TDR mutations (%)  Country Recruitment  period No. of 
patients 
Selected patients 
Any NRTI  NNRTI    PI 
Name of study  Authors, year 
Europe 1994-2005  525  Recently and 
chronically infected  11.4  9.3 1.0 3.0  EuroSIDA  - 
Europe 1996-2002  2208  Recently and 
chronically infected  10.4  7.6 2.9 2.5  CATCH Wensing  et al. 2005 [436] 
Italy  1997 onwards  415  Chronically infected  10.1  -  -  -  I.Co.N.A.  De Luca et al. 2004 [348] 
Italy  Up to 2000  347  Chronically infected  -  7.8  4.9  1.4  I.Co.N.A.  Perno et al. 2002 [453] 
France  2001  363  Chronically  infected  12.0  4.3 0.8 6.1  Odyssee 
France  2001-2002  303  With acute infection  14.0  10.3  3.3  4.3  PRIMO 
Descamps et al. 2005 [443] 
UK  2004-2006  239  Newly  diagnosed  7.1 4.2 1.7 1.7  -  Booth  et al. 2006 [446] 
1995 45  26.7  15.6  17.6  4.4  - 
1997 75  26.7  14.7  13.3  8.0    Belgium 
1998 111 
Newly diagnosed 
31.5 10.8 16.5  9.9   
Van Vaerenbergh et al. 2001 
[454] 
Switzerland  1999-2001  220  Recently  infected 10.5  8.6 2.3 0.9  Swiss HIV 
Cohort Study  Yerly et al. 2004 [435] 
France  1996-1997  204  With acute infection  8.8  7.8  3.9  ANRS 053/ 
PRIMO  Harzic et al. 2001 [444] 
Germany 2000-2001  184  Chronically  infected  14.0  10.5  2.8  2.1  -  Oette  et al. 2004 [440] 
Spain  2004  182  Newly diagnosed  -  2.2  1.1  0.5  -  Martinez-Picado 2005 [455] 
UK  2000-2004  140  With acute infection  6.0  -  -  -  - 
UK Collaborative Group on 
Monitoring the Transmission of 
HIV Drug Resistance 2001 [394] 
Luxembourg 1992-1997  135    11.9  - - -  -  Fontaine  et al. 1998 [442] 
Poland 2000-2001  128  Chronically  infected  51.5  51.5  -  - -  Horban  et al. 2002 [438] 
Greece  2002-2003  101  Newly  diagnosed  8.9 5.0 4.0  0 
Hellenic Multi-
centre study on 
HIV-resistance
Paraskevis et al. 2005 [439] 
Denmark 2000  97  Newly  diagnosed  2.1  2.1  0  0  -  Jorgensen  et al. 2003 [437] 
Belgium  2000  83  Recently  infected  7.2 6.3 3.8 1.2  -  Derdelinckx  et al. 2004 [452] 
Notes: - denotes unknown information. 
TDR = transmitted drug resistance. 
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TDR mutations (%)  Country Recruitment  period No. of 
patients 
Selected patients 
Any NRTI  NNRTI    PI 
Name of study  Authors, year 
Switzerland  1996-1998  82  With acute infection  11.0  -  -  -  -  Yerly et al. 1999 [352] 
Slovenia 2000-2004  77  Newly  diagnosed  3.9  3.9  0  0  -  Babic  et al. 2006 [456] 
UK 1994-2000  69  Recently  infected  14.5  -  -  -  -  Fox  et al. 2006 [445] 
Germany 1996-1999 64  Recent  seroconverters  -  9.4  4.7 
German 
Seroconverter 
Study 
Duwe et al. 2001 [457] 
1995 12  -  25  0 
1996 14  -  21.5  0 
1997 18  -  5.6  11.1 
France 
1998 4 
With acute infection 
- 0 0 
- Tamalet  et al. 2000 [458] 
-  38  With acute infection  5.3  2.6  0  2.6 
Italy 
- 24  Chronically  infected  8.3  8.3  0  0 
- Re  et al. 2004 [459] 
Italy 1998-2003  61  Acute and chronically 
infected  16.4 -  -  0  -  Torti  et al. 2004 [460] 
1997-1999 31  25.8  -  -  - 
Spain 
2000-2001 26 
Acute and recent 
seroconverters  3.8 -  -  - 
- De  Mendoza  et al. 2002 [461] 
Notes: - denotes unknown information. 
TDR = transmitted drug resistance. 
 
 
156 
Other research found estimates ranging from as little as 2.1% to 51.5% [437,438].  This 
wide range could be due to many factors including differences in geographical location, 
study period, study population, study design, sampling methods, definitions of 
resistance, timing of the sampling and sequencing methods [337,462].  For example, 
the 51.5% prevalence of TDR was observed in Poland by Horban et al. (2002) over the 
period 2000-2001 [438].  Patients were all recruited in the Warsaw area and were 
predominantly IDUs who had a history of needle-sharing.  This may have spread the 
same drug-resistant HIV strain across this population.  The high frequency of 
zidovudine (ZDV) resistance mutations may be attributed to the widespread use of ZDV 
monotherapy in the 1990s, encouraging the selection of ZDV-resistant strains in the 
HIV infected population, which could then be transmitted.  In addition, the study used a 
high sensitivity genotypic assay that may have picked up on minor resistant strains. 
 
In this analysis, the majority of the study population (at least 81.9%) were chronically 
infected patients with similar findings to those found in a number of studies that also 
looked at chronic infections [348,436,440,443,460].  For example, in the I.Co.N.A. 
study, an overall prevalence of 10.1% TDR was observed in 415 patients enrolled from 
1997 onwards in Italy, using the 2003 IAS-USA figures of drug resistance mutations to 
define TDR [348].  In 363 patients enrolled in the French Odyssee study in 2000, TDR 
prevalence was found to be 12.0%, also using the 2003 IAS-USA list of mutations 
[443].  Prevalence of TDR may be lower in chronically infected patients compared to 
newly infected as the resistant virus may revert back to wild-type due to its reduced 
fitness [433]. 
 
5.4.1.3 Factors associated with detection of transmitted drug resistance 
The prevalence of TDR remained fairly stable over the years 1996-2004 in this 
analysis, after an initially high prevalence in 1994-1995.  In a multivariable analysis 
adjusting for HIV-1 subtype, geographical region, hepatitis C status and viral load at the 
date of plasma sample analysed, there appeared to be no significant differences in any 
two-year period compared to 1996-1997.  Other research has reported conflicting 
trends over time.  Increases in TDR over calendar time up to the year 2003 have been 
observed in a number of studies [388-393,447].  In a Californian study by Grant et al. 
(2002), NNRTI resistance rose from 0% in 1996-1997 to 13.2% in 2000-2001, and PI 
resistance from 2.5% to 7.7% in these same periods [392].  No increase was observed 
in NRTI resistance.  Cane et al. (2005) reported an increasing prevalence of resistance 
in the UK, over the years 1996-2003 in both high and medium resistance as defined by 
the Stanford algorithm [389].  In 1996-1997, the prevalence of high resistance to any 
drug was 11.0%, compared to 19.2% in 2002-2003.  This trend could be explained by 
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an increase in resistant strains in the HIV infected population following the increasing 
availability of ART.   
 
However, a study carried out in Madrid showed a decrease from 25.8% in 1997-1999 
to 3.8% in 2000-2001 in a sample of 57 acute or recent HIV seroconverters [461].  A 
decrease in TDR was also observed in the UK in 2004, which may be due to an 
increased use of successful initial regimens that achieve virological suppression.  This 
decreases the likelihood of resistant strains developing and therefore the chance of 
them being transmitted [394].  Furthermore, Yerly et al. (2004) found evidence that 
drug-resistant HIV, especially multidrug-resistant and HIV with the M184IV mutation, 
has a substantially reduced transmission capacity compared to wild-type [435].   
Therefore effective treatment in chronically infected patients may be reducing the 
transmission of resistant HIV in recently infected patients. 
 
A slightly higher prevalence of TDR was observed in patients infected with HIV-1 
subtype B compared to non-B subtypes in this analysis (12.5% versus 6.5%; p=0.096) 
but this difference was not statistically significant.  In the multivariable analysis, no 
significant difference was found in the odds of detection of TDR between A and B 
subtypes and a borderline significantly lower odds was found in patients infected with a 
subtype other than A or B, compared to B (p=0.066).  Due to the small number of non-
B subtypes included in the analyses (n=93), there may not have been enough power to 
detect a difference between HIV-1 subtypes, if it truly existed.  Jayaraman et al. (2006) 
also found a non-significant higher prevalence of TDR in HIV-1 subtype B compared to 
non-B (8.1% versus 3.0%; p=0.31) in 715 individuals [447].  Amongst 77 individuals in 
a Slovenian study by Babic et al. (2005), only 3 (4.8%) of 61 patients infected with HIV-
1 subtype B had TDR compared to none of 12 patients infected with a non-B subtype 
[456].  The CATCH study, which had a larger study population found a significantly 
higher prevalence of TDR in 1431 patients infected with HIV-1 subtype B compared to 
673 infected with a non-B virus (12.9% versus 4.8%; p<0.001) and this difference 
remained in a multivariable analysis [436].   
 
A significant difference was found in the odds of detecting TDR in patients from the 
South region compared to the North region after adjustment for calendar time, HIV-1 
subtype, hepatitis C status and viral load at the date of the plasma sample analysed.  
Epidemiological features such as drug exposure, adherence and treatment response at 
the population level may be responsible for this.  It is impossible to compare the 
findings from other research across regions of Europe because of the many differences 
in study periods, designs, sampling and sequencing methods, and definitions of 
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resistance, as already mentioned.  However, the CATCH study collected data from 
countries all across Europe in a consistent way and showed some variation in the rate 
of TDR from 0% (0 out of 8 patients) in Finland to 23% (14 out of 62 patients) in 
Germany [436]. 
 
5.4.1.4 Virological response to cART 
The results of the analyses investigating initial virological response to cART (a viral 
load less than 500 copies/mL at the first measurement six to twelve months after 
initiation of cART) were unable to show a significant difference in the odds of a 
virological response between patients with HIV-1 with full or intermediate resistance to 
at least one drug started compared to those fully susceptible, after adjustment for 
potentially confounding factors.  Due to the relatively small number of patients in the 
resistant group, the power of this analysis to detect a true difference was restricted and 
so more data are needed to draw a firm conclusion.  Although the finding was not 
significant, an inferior virological response to cART in patients with resistant HIV was 
observed, which supported results found in two US studies studies investigating time to 
virological suppression after initiation of therapy in recently infected patients [392,393].  
Three European studies also evaluated virological response in both chronically infected 
patients and patients with primary HIV infection and found that predicted virus 
susceptibility using genotypic sensitivity score interpretation systems was significantly 
associated with time to virological success [348,448,452].  A further European study 
could not find any difference in mean change in viral load or CD4 count at months six 
and twelve after starting therapy between patients with TDR and those without [458].  
 
In the sensitivity analysis investigating the alternative virological endpoint of a viral load 
less than 50 copies/mL instead of 500 copies/mL, the odds of a virological response 
were higher in the resistant group than in the susceptible group.  This result was also 
not significant and similarly to the results from the main analysis, could be due to 
chance.   
 
5.4.1.5 Immunological response to cART 
Investigating initial immunological response to cART (a 100 CD4 cells/mm
3 increase or 
more from baseline at the first measurement six to twelve months after initiation of 
cART) showed that after adjustment for potentially confounding factors, there were 
significantly increased odds of an immunological response in patients with HIV-1 with 
full or intermediate resistance to at least one drug started compared to those fully 
susceptible.  This remained after adjustment for change in viral load from baseline.  
However it was less pronounced (and non-significant) in a sensitivity analysis looking 
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at the alternative endpoint of a CD4 count increase of 50% or more from baseline.  
Fewer patients with resistant HIV achieved a 50% increase compared to a 100 
cells/mm
3 increase, which narrowed the difference between resistant and susceptible 
groups.  Therefore, although the proportion of immunological responders in the 
susceptible group was smaller, the CD4 increases experienced in this group were 
larger and mostly over 100 cells/mm
3. 
 
Studies in the UK found that patients with TDR had higher rates of CD4 cell decline 
before starting ART [445,463], however the immunological response following initiation 
of cART in these patients is unknown.  There is some evidence that patients who 
develop NNRTI and PI resistance on first-line therapy and experience virological failure 
will have better CD4 cell increases than non-responders without mutations.  This may 
be explained by a reduced viral fitness in resistant strains, which reduces 
immunological deterioration [464].  An analysis of nearly 2000 patients on ART found 
little evidence of differences in CD4 slope for a given viral load greater than 500 
copies/mL according to the presence of resistance, with the exception of certain NNRTI 
mutations that were found to be associated with greater CD4 count declines, but with 
large confidence intervals around the estimates [465]. 
 
The observed superior immunological response in patients with resistant HIV in this 
analysis may be due to chance as there were few patients in this group.  It may also be 
explained by the natural variability in CD4 counts.  To try to take this into account, 
average CD4 cell measurements at baseline and in months six to twelve were 
analysed, which still resulted in higher odds of immunological response in the resistant 
group compared to the susceptible group but the difference was smaller and not 
statistically significant.  Not all patients had CD4 counts measured frequently enough to 
be able to calculate average measurements, therefore variability could explain the 
results.  All known, measured factors found to be potentially confounding the response 
were adjusted for in multivariable analyses.  However, as the patients were from an 
observational study, unmeasured or unknown confounding variables may have biased 
the findings [209]. 
 
5.4.2 Limitations  of  analysis 
The main limitation of the analyses in this chapter was the limited statistical power due 
to only a small number of patients having TDR.  This made it difficult to detect true 
differences in response to therapy and more data are required to make conclusions 
with any certainty. 
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A further limitation of this analysis was that the average time from HIV positive 
diagnosis to earliest resistance test was more than three years.  Although EuroSIDA 
aims to collect all prior treatment data, when a patient is enrolled, it cannot be ruled out 
that errors with dates may have occurred, which could potentially mean undisclosed 
drug exposure.  To try and ensure only truly ART-naïve patients were included, plasma 
samples were required to be dated at least a month before starting ART.  If the patient 
had more than one plasma sample available before starting therapy that had been 
analysed for genotypic resistance, results were cumulated to obtain the best estimate 
of the extent of mutated virus populations present in the individual [466].  As routine 
assays can only detect mutations in the dominant virus, this gives a more conservative 
estimate of prevalence as mutations found in later tests are likely to have been present 
at transmission but were just not detected.        
 
The centres involved in EuroSIDA tend to be highly specialised and consequently may 
have more clinical experience with HIV and earlier access to new treatments than 
centres not included, therefore the cohort may not be completely representative of 
European clinics in general.  However as patients are enrolled consecutively, this 
should capture a broad representation of patients regularly seen and because of the 
large numbers of clinics in the study, this may be more representative than any one 
clinic cohort. 
 
5.4.3 Implications  of  findings 
The observed finding that virological response rate was not significantly different 
according to whether or not patients were infected with resistant HIV implies that 
resistance testing in ART-naïve patients may not be necessary.  However as already 
mentioned, the power to detect true differences was limited and these results should be 
treated with caution.  Although a significantly higher immunological response rate was 
observed in patients with resistant HIV, which is the opposite to what was expected, i.e. 
that drug resistance would result in an inferior response to cART, this result may be 
explained by variability in CD4 counts or unmeasured confounders.   
 
5.4.4 Further  research 
These analyses would benefit from a larger number of patients to achieve the statistical 
power to detect true differences.  As the EuroSIDA genotypic resistance database 
continues to expand, more patients may be available who meet the inclusion criteria.  
However, as resistance testing in ART-naïve patients becomes more widespread, more 
patients will receive treatment guided by test results and therefore the number of 
patients starting treatment with resistance to one or more drugs in their regimen may 
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not increase greatly.  As mentioned in Chapter 4 (section 4.4.4), collaborations of 
studies can be ideal for expanding datasets in order to be able to address certain 
research questions.  The ongoing collaboration known as EuroCOORD (The European 
Coordinating Committee for the Integration of Ongoing Coordination Actions Related to 
Clinical, Virological and Epidemiological HIV Research), integrating five projects 
including EuroSIDA, may provide a suitable study population for this and is planning to 
investigate TDR.  The disadvantages of collaboration studies are the variability across 
projects in factors such as the type of data collected, the frequency of data updates 
and the quality of the data collected.   
 
If a larger dataset was available, another aspect that could be investigated further is to 
establish whether or not there is an interaction between TDR and cART regimen 
started.  Due to lack of power, it was not possible to look at this in detail in this 
analysis.  A significant interaction would imply that patients with TDR might do better 
on certain regimens than on others.  An increased number of patients could provide the 
power to stratify analyses by type of TDR, i.e. NRTI, NNRTI or PI-associated or type of 
cART regimen. 
  
5.4.5 Conclusions 
The patients included in this study were selected based on availability of plasma 
samples whilst ART-naïve and were not selected based on suspicion of drug 
resistance.  The choice of samples analysed for genotypic resistance reflect the 
inclusion criteria for various studies in EuroSIDA and so may not be representative of 
the EuroSIDA cohort as a whole.  The prevalence of TDR was found to be in line with 
many other studies from across Europe and there was no evidence of significant 
differences in prevalence over calendar time or between HIV-1 subtypes after 
adjustment for potentially confounding variables.  There was some evidence of 
significantly higher odds of TDR in the South geographical region compared to the 
North, which may be due to drug exposure and adherence levels at the population 
level.   
 
There was no evidence of a significant difference in the odds of achieving a successful 
virological response to first-line cART in patients infected with HIV with full/intermediate 
resistance to at least one drug started compared to those with HIV susceptible to all 
drugs started, after adjustment for potentially confounding factors, although the 
response rate was slightly lower in the resistant group.  A significantly higher 
immunological response rate was observed in the resistant group, which may be 
explained by a reduced viral fitness in drug-resistant strains decreasing CD4 cell 
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depletion but could be a result of the natural variability in the data.  The number of 
patients with resistant HIV was small so the power of the analyses to detect true 
differences was limited.  This has identified the need for a larger dataset to be able to 
draw conclusions with more certainty, which could arise from a collaboration of projects 
and the pooling of resources. 
 
A manuscript of this analysis was published by the Journal of Acquired Immune 
Deficiency Syndrome in July 2008  and can be found in Appendix VIII. 
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Chapter 6. Comparison of genotypic resistance profiles 
and virological response between patients starting 
nevirapine and efavirenz 
6.1 Introduction 
As detailed in Chapter 1 (section 1.7.4), cART regimens containing two NRTIs and 
either an NNRTI or a ritonavir (RTV)-boosted PI are currently recommended by the 
IAS-USA Panel and the Department of Health and Human Services (DHHS) Panel as 
first-line regimens due to their frequently observed efficacy and convenience [40,41].  
Regimens containing the NNRTI, efavirenz (EFV), have become the standard-of-care 
comparator in clinical trials and have consistently proven to be an optimal choice for 
achieving viral suppression [185,290,291,467].  The other main NNRTI currently in use 
is nevirapine (NVP), which is recommended for pregnant women and can be used as 
an alternative for men and women with low pre-treatment CD4 counts and for patients 
who cannot tolerate the central nervous system toxicity of EFV [40,41].  For patients 
with high pre-treatment CD4 counts, there is evidence of an increased risk of serious 
symptomatic hepatic events associated with NVP use (in men with CD4 counts more 
than 400 cells/mm
3 and in women with CD4 counts more than 250 cells/mm
3) therefore 
it should only be used for these patients if the benefits outweigh the risks [468,469]. 
 
6.1.1  Use of NNRTIs in resource-limited settings 
To assist in the scale-up of ART in resource-limited settings, in 2002, the WHO 
published treatment guidelines to help develop standardised ART programmes to 
reach as many people in need of therapy as possible [470].  They recommended that 
developing countries should select a first-line regimen consisting of two NRTIs plus 
either an NNRTI, a PI or abacavir (ABC).  Due to the cost and risk of hypersensitivity 
reaction, triple NRTI regimens containing ABC were almost never selected.  Cost was 
also the main reason for PI-containing regimens being kept as secondary options [471].  
NNRTIs proved to be a popular selection due to their low cost, availability of fixed-dose 
combinations, lack of requirement for a cold chain (storage and transportation of the 
drug at the correct temperature to maintain potency) and drug availability.   
 
In 2006, the WHO carried out a survey in resource-limited countries to investigate the 
uptake of ART and predict future demand.  Across 23 countries that returned the 
questionnaires (representing 53% of relevant patients in developing countries), the 
majority of patients receiving first-line regimens started an NVP-based regimen; 61% 
received stavudine (d4T) plus lamivudine (3TC) plus NVP and 16% received 
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zidovudine (ZDV) plus 3TC plus NVP [472].  A further 17% received an EFV-based 
regimen; 9% received ZDV plus 3TC plus EFV and 8% received d4T plus 3TC plus 
EFV.  Even though the price of EFV has dropped substantially in the past two years, 
NVP remains the much cheaper option, which explains the widespread uptake of this 
drug in ART programmes in many developing countries [473].   
 
6.1.2 Nevirapine  versus  efavirenz 
A number of studies have compared the efficacy of these two NNRTIs.  Virological 
outcomes of NNRTI-based regimens containing either NVP or EFV were compared in 
patients mostly experienced in NRTIs and PIs in a previous EuroSIDA analysis by 
Phillips et al. (2001) [300].  This analysis showed that patients starting NVP were twice 
as likely to experience virological failure than patients starting EFV (relative hazards 
(RH): 0.49; 95% CI: 0.33-0.74; p<0.001), after adjustment for baseline characteristics 
including CD4 count and viral load, previous ART and number of drugs in the regimen.  
The finding was in line with results from a number of other observational studies [301-
304].  For example, the I.Co.N.A. study showed the RH of virological failure to be 2.08 
(95% CI: 1.37-3.15; p<0.001) for NVP compared to EFV [303].  Also, a recent analysis 
presented at CROI 2007 (14th Conference on Retroviruses and Opportunistic 
Infections) showed that South African patients starting a NVP-based regimen were 
43% more likely to experience virological failure than those starting an EFV-based one 
[301].   
 
Although this may have reflected differences in the effectiveness of the two drugs in 
this setting, as the patients were not randomised to starting either drug there may have 
been unmeasured confounding variables that biased the results.  The 2NN large-scale 
randomised clinical trial making a similar comparison in ART-naïve patients did not find 
a significant difference (at the 5% level) between NVP and EFV, but found slightly less 
treatment failure in those starting EFV compared to those starting NVP (38%; 95% CI: 
33-43%; and 44%; 95% CI: 39-49% respectively; p=0.091) [299].  However, the study 
was powered to investigate equivalence of the two drugs in treatment failure (assumed 
if the 95% CI of the difference was within the 10% of zero) and the results did not 
demonstrate this.   
 
A number of other studies also did not find a significant difference between the 
outcomes of patients starting the two NNRTIs, including the NNRTI substudy of the 
FIRST-CPCRA 058 trial, a randomised open-label pilot study in Spain and 
observational, non-randomised cohort studies in Italy, India and Thailand [474-478].  
Although randomised controlled trials have not found a significant difference in 
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virological outcome between patients starting the two drugs, the reasons for the inferior 
outcome in patients starting NVP compared to EFV found in observational studies 
remain unclear.  
 
6.1.3 NNRTI  resistance 
In contrast to the patients included in 2NN, most of the patients in the previous 
EuroSIDA analysis had already virologically failed other antiretroviral drugs, raising the 
possibility that the differences in outcome could be explained by differences in HIV 
ART resistance to other drugs used as part of the NNRTI-containing regimen.  The 
subsequent development of the EuroSIDA genotypic resistance database has allowed 
a re-investigation of this question to assess whether potential differences in prevalence 
of resistance to both the NNRTI component of the regimen and the NRTI backbone in 
the two groups could be a source of bias.  This chapter covers the findings from this 
analysis.   
 
Drug resistance is associated with virological failure in patients undergoing treatment 
[16,317,318].  NNRTIs have a low genetic barrier for resistance and only one HIV RNA 
point mutation is needed for high-level NNRTI resistance to develop [40,479].  A recent 
study by Harrigan et al. (2007) showed that certain mutations might cause intermediate 
phenotypic resistance: A98G and V179D for NVP resistance, and Y181C and V179D 
for EFV resistance [480].  There are also studies that have demonstrated a role for 
mutations in another region of HIV RNA, the connection domain (residues 316-427), in 
conferring resistance to NNRTIs [481,482].   
 
Conversely, there is evidence that some HIV RNA mutations in the RT gene may 
encourage increased susceptibility (hypersusceptibility) to NNRTIs [481,482].  For 
example, the M41L, M184V, L210W and T215Y mutations were found to be associated 
with a better virological outcome in patients treated with EFV-containing regimens 
[483].    
 
6.1.4  Motivation and aims for chapter 
The question of whether the two NNRTIs are equally effective at achieving virological 
suppression is very important as although EFV is proven to be a reliable option and is 
recommended to be used in first-line therapy, there are circumstances where NVP is 
preferred, e.g. if the patient is pregnant or has a low CD4 count.  NVP is also 
extensively used in the developing world due to its convenience and low cost.  The 
main aim of this chapter was therefore to re-investigate virological outcomes in patients 
starting NVP- and EFV-containing regimens for the first time in EuroSIDA.  Using the 
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new information collected in the genotypic resistance database, it was possible to 
adjust the analyses for ART resistance present at initiation of treatment to see if this 
could explain the previous finding of an inferior response in patients starting NVP.  A 
further aim was to look at the prevalence of ART resistance at time of virological failure 
and compare resistance profiles between the two groups. 
 
6.2 Methods 
6.2.1 Inclusion  criteria 
The EuroSIDA dataset used for the analyses in this chapter was the update completed 
in July 2007, including data on 14,282 patients with follow-up to (median date of last 
visit) July 2006.  Inclusion criteria for the current analyses were as in the previous 
EuroSIDA analysis [300].  All patients were required to be under follow-up at or after 
July 1997, the date that EFV was first used in patients in the study.  They were 
required to have started a regimen containing either NVP or EFV (not both) after July 
1997, with no previous NNRTI experience and with a viral load and CD4 count 
measured within six months before starting the regimen.  They were also required to 
have at least two viral load measurements after the date of starting the NNRTI.   
 
Finally, to investigate the effect of ART resistance present at the time of treatment 
initiation, patients needed to have genotypic resistance test results available from a test 
performed on a blood plasma sample taken within one year before starting the NNRTI 
regimen.  The majority of these tests were performed retrospectively using sequence 
analysis of viral RNA extracted from the plasma samples that were stored in the central 
EuroSIDA laboratories.  Some resistance test results were obtained from tests carried 
out at the clinical sites.  The methods by which this information is collected in 
EuroSIDA were previously detailed in Chapter 2 (section 2.1.3). 
 
6.2.2 Statistical  methods 
6.2.2.1 Definitions 
Baseline was defined as the date of starting the NNRTI-containing regimen.  Genotypic 
resistance profiles were described at baseline (most recent resistance test results 
within a year before treatment initiation) and at time of virological failure (most recent 
test results at least two weeks after treatment initiation and up to one year after time of 
virological failure as defined below).  At time of failure, resistance profiles were also 
determined in a subset of patients who were still receiving an NNRTI at the time of the 
test.  In addition, as some patients had more than one set of genotypic resistance test 
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results available, resistance profiles were examined where all previous test results 
were cumulated.   
 
Genotypic resistance was interpreted using both the IAS-USA 2006 figures of HIV-1 
drug resistance mutations [484] with resistance defined as at least one NRTI, NNRTI or 
major PI mutation, and using three algorithms that produce genotypic sensitivity scores 
to measure sensitivity to the drugs in the regimen: Rega Version 7.1 [349], ANRS July 
2006 [350] and Stanford University (HIVdb) Version 4.2.9 [351]. 
 
6.2.2.2 Time to virological failure following initiation of NNRTI regimen 
Time to virological failure following initiation of an NNRTI-containing regimen was 
investigated using Kaplan-Meier methodology and Cox proportional hazards models, 
with virological failure defined as two consecutive viral loads more than 500 copies/mL 
after starting the regimen.  If the baseline viral load was more than 500 copies/mL, 
these values were required to have been measured at least six months after initiation.  
Time of virological failure was defined as the first of these two measurements.  For 
patients who did not experience virological failure, the follow-up time was right 
censored at the time of the penultimate available viral load measurement.   
 
A multivariable model was developed to compare patients starting NVP and those 
starting EFV, stratified by the clinical centre in which patients were seen and adjusting 
for factors that could potentially affect the outcome.  These were chosen a priori in the 
research paper by Phillips et al. (2001) [300] based on experience from previous 
analyses.  Additional potential confounders were investigated, including demographics 
and use of specific drugs, as was stratification by the prior number of drugs used, 
geographical region (defined in Chapter 2, section 2.1.5) and calendar year of starting 
the regimen.  Furthermore, the effect of baseline genotypic drug resistance was 
analysed.   
 
6.2.2.3 Sensitivity analyses 
Sensitivity analyses were carried out using left censoring at the time of enrolment into 
EuroSIDA for those who were enrolled after starting the NNRTI-containing regimen and 
using right censoring at time of discontinuation of the NNRTI for those who 
discontinued.  Analyses were also repeated in a subset of patients who were ART-
naïve at baseline and in a subset of only the patients who had genotypic resistance 
tests carried out on stored plasma samples in the central EuroSIDA laboratories as 
opposed to at the clinical sites.   
 
168 
Multivariable linear regression models were also used to analyse changes in viral load 
and CD4 count between baseline and the last measurement six to twelve months 
following treatment initiation.  Patients with no measurements during this time were 
excluded and for undetectable viral loads, the value taken was the level of detection 
minus one (e.g. for undetectable viral load less than 50 copies/mL, viral load was taken 
to be 49).   
 
Finally, a multivariable logistic regression model was also developed to investigate 
virological success defined as a viral load less than 50 copies/mL at the first 
measurement six to twelve months after initiation of the regimen.  Patients were 
required to have this measured using an assay with a level of detection as low as 50 
copies/mL and so any patients with missing values were excluded.  Patients were also 
required to have a baseline viral load of at least 50 copies/mL. 
 
6.3 Results 
6.3.1 Patient  numbers 
A total of 5301 NNRTI-naïve patients fulfilled the original inclusion criteria, of whom 
2435 (45.9%) started NVP and 2866 (54.1%) started EFV.  Baseline genotypic 
resistance test results were available for 759 (14.3%) patients.  Amongst these, 618 
(81.4%) patients had stored plasma samples taken within a year before starting 
treatment, from which HIV RNA was subsequently tested for genotypic resistance in 
the central EuroSIDA laboratories.  The remaining 141 (18.6%) patients had resistance 
tests carried out at the clinical sites.  Figure 6.1 displays the subsets of patients 
investigated in these analyses.   
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Figure 6.1: Patient numbers in analyses according to inclusion criteria. 
  
 
 
6.3.2  Patient characteristics at date of NNRTI initiation 
6.3.2.1 Resistance test results available versus not 
Table 6.1 shows a comparison of the patient characteristics at the date of NNRTI 
initiation between the 759 patients with resistance test results available (either from 
retrospective analysis of samples or resistance tests performed at clinical sites) and the 
4542 patients who did not.  Patients with resistance tests on average started their 
regimens earlier (median: May 1999 versus August 2000; p<0.001), had lower baseline 
CD4 counts (median: 237 versus 321 cells/mm
3; p<0.001) and higher baseline viral 
loads (median: 4.3 versus 3.6 log10copies/mL; p<0.001).  Less patients with resistance 
tests were ART-naïve at the start of the regimen (13.0% versus 18.6%; p<0.001) and 
slightly more started NVP (51.3% versus 45.1%; p=0.002). 
 
Resistance test results available
within year before starting NNRTI
n=389
At least two viral loads
after starting NNRTI regimen
n=2435
No previous NNRTI experience,
had baseline viral load and CD4 counts
n=2532
Started NVP after July 1997
n=3333
Resistance test results available
within year before starting NNRTI
n=370
At least two viral loads
after starting NNRTI regimen
n=2866
No previous NNRTI experience,
had baseline viral load and CD4 counts
n=3065
Started EFV after July 1997
n=4157
Under follow-up at/after July 1997
n=12572
EuroSIDA patients
(July 2007 dataset)
n=14282
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Table 6.1: Patient characteristics at start of NNRTI-containing regimen according to 
whether or not baseline genotypic resistance test results were available. 
  
                       Total  Resistance test results 
available 
Resistance test results 
not available  p 
n %      
All    5301 100.0  759  14.3  4542  85.7 - 
Male  4042 76.2  612  80.6 3430 75.5  0.002
HIV  exposure  group         <0.001
  MSM  2384 45.0 1992 43.9  392  51.6  - 
 IDU  1049  19.8  910  20.0  139  18.3  - 
  Heterosexual  1496 28.2 1337 29.4  159  20.9  - 
  Other  372 7.0 303 6.7  69  9.1  - 
Previous AIDS  1756  33.1  297  39.1  1459  32.1  <0.001
ART-naïve  919  17.8 97 13.0  822  18.6  <0.001
Started NVP instead 
of EFV  2435 45.9  389  51.3 2046 45.1  0.002
Median (IQR)          
Date started NNRTI  Jun 00  (Feb 99- 
Mar 02)  May 99  (Jun 98- 
Feb 01)  Aug 00  (Apr 99- 
Jul 02)  <0.001
Age  (years)  40 (35-47) 40 (35-47) 40 (34-47)  0.138
CD4 count 
3
        
Baseline
  304 (179-480) 237 (140-365) 321 (186-498)  <0.001
 
Nadir
  148  (58-245) 99 (30-197)  155  (63-251)  <0.001
Viral load (log10copies/mL)         
Baseline
  3.8 (2.2-4.8) 4.3 (3.6-4.9) 3.6 (1.9-4.7)  <0.001
 
Max ever
  4.8 (4.1-5.4) 5.1 (4.6-5.6) 4.8 (4.0-5.3)  <0.001
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
MSM = men who have sex with men; IDU = injecting drug use; NVP = nevirapine; EFV = efavirenz; 
IQR = interquartile range. 
 
 
6.3.2.2 Nevirapine versus efavirenz 
Table 6.2 displays the patient characteristics at the date of initiation of the NNRTI-
containing regimen in the 759 patients with baseline resistance test results available.  A 
total of 389 (51.3%) patients started NVP and 370 (48.7%) started EFV for the first 
time.  NVP patients on average started their regimens earlier than EFV patients 
(median: August 1998 versus May 2000; p<0.001) and had resistance test results 
available earlier (median: May 1998 versus December 1999; p<0.001).   
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Table 6.2: Patient characteristics at start of NNRTI-containing regimen in patients with 
baseline resistance test results according to whether they started nevirapine or 
efavirenz. 
  
                       Total NVP  EFV  p 
n %    
All    759 100.0  389  51.3  370  48.7 - 
Male  612 80.6  323  83.0  289  78.1  0.086
HIV  exposure  group          0.277
 MSM  392 51.6  210  54.0  182  49.2 - 
 IDU  139  18.3 72 18.5 67 18.1  - 
 Heterosexual  159  20.9 70 18.0 89 24.1  - 
 Other  69  9.1 37 9.5 32 8.6  - 
Previous AIDS  297 39.1  158  40.6  139  37.6  0.390
HIV-1 subtype identified  707 93.1  365  93.8  342  92.4  0.466
 B*
  641 90.7  333  91.2  308  90.1  0.592
 Non-B*  66  9.3 32 8.8 34 9.9  - 
Median (IQR)           
Date started NNRTI  May 99  (Jun 98- 
Feb 01)  Aug 98  (Feb 98- 
Oct 99)  May 00  (Mar 99- 
Apr 02)  <0.001
Date of plasma sample  Dec 98  (Jan 98- 
Oct 00)  May 98  (Sep 97- 
Apr 99)  Dec 99  (Aug 98-
Dec 01)  <0.001
Age (years)  40  (35-47) 40 (34-47) 41 (36-47)  0.459
CD4 count (cells/mm
3)            
Baseline
  237  (140-365) 230 (131-349) 240 (146-377)  0.262  
Nadir
  99 (30-197) 102 (30-204) 98 (30-188)  0.376
Viral load (log10copies/mL)         
Baseline
  4.3  (3.6-4.9) 4.3 (3.7-4.9) 4.3 (3.5-4.9)  0.566  
Max ever
  5.1  (4.6-5.6) 5.1 (4.6-5.6) 5.1 (4.6-5.5)  0.970
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
*Percentage of HIV-1 B/non-B subtypes amongst those with subtype identified. 
MSM = men who have sex with men; IDU = injecting drug use; NVP = nevirapine; EFV = efavirenz; 
IQR = interquartile range. 
 
Table 6.3 gives details of the antiretroviral drugs started as part of the NNRTI-
containing regimen, as well as prior experience of ART.  The majority of patients 
started three or four drugs in the regimen (86.8%).  In both the NVP and EFV groups, 
d4T and 3TC were the most commonly used NRTIs in the regimens.  More patients in 
the NVP group started a PI as well as the NNRTI (59.6% versus 50.8%; p=0.015) and 
less were ART-naïve prior to starting the regimen (9.5% versus 16.5%; p=0.004).  
Patients starting NVP were more likely to have previous experience of NRTIs than 
patients starting EFV (90.5% versus 83.2%; p=0.003).  Previous use of PIs was similar 
between the groups (76.6% versus 75.4%; p=0.698). 
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Table 6.3: Use of antiretroviral drugs in patients with baseline resistance test results 
according to whether they started nevirapine or efavirenz. 
  
                       Total NVP  EFV  p 
All    759 100.0 389 51.3 370 48.7  -
Antiretroviral drugs in regimen, n %        
Total drugs in regimen          0 . 1 7 8
  1-2 37  4.9 24 6.2 13 3.5  - 
  3-4 659  86.8 336 86.4 323 87.3  - 
  ≥ 5  63  8.3 29 7.5 34 9.2  - 
NRTI(s) in regimen  728  95.9 372 95.6 356 96.2  0.683
ZDV  157  20.7 76 19.5 81 21.9  0.423
ddI  256  33.7 134 34.4 122 33.0  0.668
d4T  357  47.0 219 56.3 138 37.3  <0.001
3TC  378  49.8 189 48.6 189 51.1  0.492
ABC  167  22.0 44 11.3  123  33.2  <0.001
PI(s) in regimen  420 55.3  232  59.6  188  50.8  0.015
IDV  93  12.3 47 12.1 46 12.4  0.883
RTV  184  24.2 80 20.6  104  28.1  0.015
NFV  181 23.8  111  28.5  70  18.9  0.002
ART use prior to start of regimen, n %        
ART-naïve   98  12.9  37 9.5 61  16.5  0.004
Previous NRTI use  660  87.0  352  90.5  308  83.2  0.003
ZDV 630  83.0  336  86.4  294  79.5  0.011
ddI 379  49.9  198  50.9  181  48.9  0.585
d4T  491 64.7  254  65.3  237  64.1  0.721
3TC  611 80.5  322  82.8  289  78.1  0.105
ddC  260 34.3  158  40.6  102  27.6  <0.001
Previous PI use  577  76.0  298  76.6  279  75.4  0.698
IDV  399 52.6  207  53.2  192  51.9  0.716
RTV  314 41.4  145  37.3  169  45.7  0.019
SQV (hard gel)  188  24.8 70 18.0  118  31.9  <0.001
NFV  294 38.7  158  40.6  136  36.8  0.275
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
Specific NRTIs/PIs only shown where proportion of patients is more than 10%. 
NVP = nevirapine; EFV = efavirenz; ZDV = zidovudine; ddI = didanosine; d4T = stavudine;  
3TC = lamivudine; ABC = abacavir; ddC = zalcitabine; IDV = indinavir; RTV = ritonavir; NFV = nelfinavir; 
SQV = saquinavir. 
 
 
6.3.3  Baseline genotypic HIV drug resistance 
6.3.3.1 Prevalence of baseline IAS-USA resistance mutations 
Figure 6.2 displays IAS-USA viral mutations associated with drug resistance detected 
at the start of the NNRTI-containing regimens.  In general, there were similar 
proportions of patients with resistant HIV in those starting NVP and those starting EFV.   
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Figure 6.2: IAS-USA drug resistance mutations detected at start of NNRTI-containing regimen according to whether patients started nevirapine or 
efavirenz. 
Note: P values obtained from Chi-squared tests comparing patients starting nevirapine (NVP) and efavirenz (EFV). 
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Overall, 595 (78.4%) had at least one major mutation (82.3% NVP versus 74.3% EFV; 
p=0.008).  Of these, 569 (75.0%) had at least one NRTI resistance mutation (80.5% 
NVP versus 69.2% EFV; p<0.001), 26 (3.4%) had an NNRTI resistance mutation (3.1% 
NVP versus 3.8% EFV; p=0.597) and 385 (50.7%) had a major PI resistance mutation 
(48.3% NVP versus 53.2% EFV; p=0.176).  NVP patients had a higher prevalence of 
the M184I/V (61.7% versus 53.0%), the L210W (31.6% versus 25.1%) and the 
T215F/Y (56.3% versus 47.6%) mutations than EFV patients.  They also had a lower 
prevalence of the I84V mutation (7.5% versus 12.4%).  There were no differences in 
prevalence of the A98G, V179D or Y181C mutations, which may confer intermediate 
phenotypic resistance. 
 
6.3.3.2 Baseline resistance using interpretation algorithms 
Using the Rega algorithm to interpret resistance, 460 (64.3%) patients had HIV with 
resistance (full or intermediate) to at least one drug in the regimens they were starting: 
256 (68.6%) NVP patients and 204 (59.5%) EFV patients (p=0.011).  A total of 27 
(3.6%) patients had NNRTI resistance: 13 (3.3%) NVP patients (11 with full resistance, 
2 with intermediate) versus 14 (3.8%) EFV patients (10 with full, 4 with intermediate) 
(p=0.743).  Median genotypic sensitivity scores calculated according to the Rega 
algorithm were 2.5 (IQR: 1.5-3.0) for patients starting NVP and 3.0 (IQR: 2.0-3.0) for 
patients starting EFV (p<0.001).   
 
Results varied slightly according to which algorithm was used.  Overall 429 (56.5%) 
patients were found to have full or intermediate resistance according to ANRS and 550 
(72.5%) according to Stanford.  A similar level of NNRTI resistance was found using 
ANRS: 27 (3.6%) patients (all with full resistance), but a higher level was found using 
the Stanford algorithm: 66 (8.7%) patients (24 with full, 42 with intermediate).  Both 
showed similar levels of NNRTI resistance between patients starting NVP and EFV.  
 
6.3.4  Virological failure after starting NNRTI regimen: time to two 
consecutive viral loads greater than 500 copies/mL  
6.3.4.1 Main analysis in full set of 5301 patients 
Virological failure was first analysed in the 5301 NNRTI-naïve patients who fulfilled the 
original inclusion criteria regardless of whether baseline resistance test results were 
available.  A total of 2319 (43.7%) experienced virological failure: 1373 (56.4%; 95% 
CI: 54.5-58.4%) of the 2435 patients starting NVP and 946 (33.0%; 95% CI: 31.3-
34.8%) of the 2866 starting EFV (p<0.001).  Of these 2319 virological failures, 517 
(22.3%) started the regimen with a baseline viral load of less than or equal to 500 
copies/mL (22.3% NVP versus 22.3% EFV; p=0.992).  Median times between viral load 
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measurements after starting the NNRTI-containing regimen were similar for NVP and 
EFV (3.7 months (IQR: 2.9-5.0 months) and 3.6 months (IQR: 2.8-5.1 months) 
respectively; p=0.551) therefore it was unlikely that frequency of measurements was a 
source of bias explaining these differences.   
 
Using a Cox proportional hazards model stratified by clinical centre and after 
adjustment for number of previous NRTIs and PIs, previous AIDS diagnosis, year 
started NNRTI, CD4 count (baseline and nadir), viral load (baseline and maximum 
ever) and number of NRTIs and PIs in the regimen, it was found that patients starting 
EFV were 35% less likely to virologically fail their regimen than those starting NVP, 
which was highly significant (RH: 0.65; 95% CI: 0.59-0.72; p<0.001).  Figure 6.3 
displays univariable and multivariable results. 
 
Figure 6.3: Relative hazards and 95% confidence intervals of virological failure (two 
viral loads greater than 500 copies/mL) following initiation of an efavirenz-containing 
regimen compared to a nevirapine-containing regimen. 
 
No. of patients 
included in 
each analysis: 
All Left  censored  Right  censored  at 
NNRTI 
discontinuation 
ART-naïve    
NVP patients  2435  2244  2435  330   
% vl failure  56.4  54.4  24.1  33.9   
EFV patients  2866  2705  2866  617   
% vl failure  33.0  31.7  15.8  17.0   
  
Notes: Multivariable analyses adjusted for number of previous NRTIs and PIs, previous AIDS diagnosis, 
year started NNRTI, baseline CD4 count, CD4 nadir, baseline viral load, maximum viral load ever and 
number of NRTIs and PIs in the regimen.  
vl = virological; RH = relative hazards; NVP = nevirapine; EFV = efavirenz. 
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6.3.4.2 Sensitivity analyses in 5301 patients  
A total of 1280 (24.2%) patients started the NNRTI-containing regimen before 
enrolment into EuroSIDA and so were left censored in a sensitivity analysis.  Of these, 
352 patients were enrolled either after virological failure or after their penultimate viral 
loads and were therefore excluded from the analysis.  This left 4949 (93.4%) patients 
(2244 starting NVP and 2705 starting EFV), of which 2078 (42.0%) experienced 
virological failure (1221 (54.4%) of those starting NVP and 857 (31.7%) starting EFV). 
 
In a further sensitivity analysis, additional right censoring was applied to 1954 (36.9%) 
patients who discontinued the NNRTI before virological failure or their penultimate viral 
load measurement.  A total of 1040 patients discontinued before virological failure and 
therefore were not counted as virological failures in this analysis.  This left 1279 
patients who experienced virological failure (588 (24.1%) of those starting NVP and 
452 (15.8%) of those starting EFV).  The results from both these analyses, in addition 
to repeating the analysis in a subset of 947 (17.9%) ART-naïve patients, gave 
consistent findings to those of the main analysis.   
 
6.3.4.3 Main analysis in subset of 759 patients with baseline resistance test results 
This analysis was then repeated in the subset of 759 patients with baseline resistance 
test results available.  A total of 287 (73.8%; 95% CI: 69.7-78.4%) of the 389 NVP 
patients and 168 (45.4%; 40.6-50.7%) of the 370 EFV patients experienced virological 
failure (p<0.001).  Of these 455 virological failures, 24 (5.3%) started the regimen with 
a baseline viral load of less than or equal to 500 copies/mL (6.6% NVP versus 3.0% 
EFV; p=0.093).  The median times between viral load measurements after starting the 
regimen were similar (3.0 months (IQR: 2.0-4.1 months) for NVP and 3.0 months (IQR: 
2.3-4.3 months) for EFV; p=0.601) therefore it was unlikely that frequency of 
measurements was a source of bias explaining these differences.  In particular, in 
those who experienced virological failure, the median time between the two 
consecutive measurements more than 500 copies/mL was 2 months (95% CI: 1-4 
months) in the NVP group and 2 months (95% CI: 2-4 months) in the EFV group 
(p=0.748).  Figure 6.4 displays a Kaplan-Meier plot of the percentage of patients with 
virological failure by time from start of the NNRTI-containing regimen.      
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Figure 6.4: Kaplan-Meier estimate of the percentage of patients with baseline 
resistance test results available and with virological failure (two viral loads greater than 
500 copies/mL) by time from start of NNRTI regimen, according to use of nevirapine or 
efavirenz. 
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NVP  382 373 339  195 148 132  121  114   
EFV  367 357 343  257 233 212  198  183   
 
Notes: NVP = nevirapine; EFV = efavirenz. 
 
A total of 275 (36.2%) patients discontinued the NNRTI they started on within the first 
year of the regimen.  NVP was discontinued more than EFV (40.1% versus 32.2%; 
p=0.023).  Reasons for discontinuation were specified in 202 (73.5%) patients.   
Treatment failure was the reason given for 24.4% of discontinuations (29.5% NVP 
versus 17.7% EFV).  Hypersensitivity reaction accounted for a further 8.7% (13.5% 
NVP versus 2.5% EFV), toxicity predominantly in the nervous system accounted for 
6.9% (2.6% NVP versus 12.6% EFV) and patient/physician choice for 19.6% (12.2% 
NVP versus 29.4% EFV).  The remaining reasons included abnormal fat redistribution, 
concern over cardiovascular disease, toxicities in the gastro-intestinal tract, abdomen 
and liver, and other toxicities not specified.  Of the 156 patients discontinuing NVP 
during the first year, 7.7% switched to EFV and 17.3% switched to a PI-based regimen 
within a month of stopping.  Of the 119 patients discontinuing EFV, 16.8% switched to 
NVP and 15.1% switched to a PI within a month. 
 
A univariable Cox proportional hazards model showed that patients starting EFV were 
51% less likely to virologically fail their regimen than those starting NVP (RH: 0.49; 
No. at risk 
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95% CI: 0.39-0.62; p<0.001).  After adjustment for the same variables as mentioned 
above, the result remained similar (RH: 0.52; 95% CI: 0.40-0.67; p<0.001).  Figure 6.5 
displays these results.  Other potential confounding variables were investigated: 
gender, age, HIV exposure group, ethnicity, hepatitis B/C coinfection status, time from 
CD4 nadir, time from HIV positive diagnosis, HIV-1 subtype, specific drugs in the 
regimen and duration of previous use of drugs.  Adjustment for these also did not affect 
the findings.  Results were similar when stratifying by the prior number of drugs taken 
(RH: 0.60; 95% CI: 0.49-0.75; p<0.001), region of Europe (RH: 0.59; 95% CI: 0.47-
0.73; p<0.001) and by calendar year of starting the regimen (RH: 0.56; 95% CI: 0.45-
0.70; p<0.001). 
 
Patients with HIV with baseline NNRTI resistance mutations (defined according to IAS-
USA) were twice as likely to experience virological failure than those without NNRTI 
mutations (multivariable RH: 1.96; 95% CI: 1.18-3.24; p=0.009), those with NRTI-
resistant HIV were 49% more likely (multivariable RH: 1.49; 95% CI: 1.09-2.06; 
p=0.014) and those with PI-resistant HIV were 21% more likely (multivariable RH: 1.21; 
95% CI: 0.94-1.54; p=0.139).  However, adjustment of the multivariable model for this 
information did not explain the difference in virological failure between EFV and NVP 
(RH: 0.51; 95% CI: 0.39-0.66; p<0.001).  Figure 6.5 displays these results. 
 
An alternative model adjusting for the Rega genotypic sensitivity score, i.e. number of 
active drugs in the regimen excluding the NNRTI, as well as for NNRTI resistance, was 
also developed.  It was found that for each increase of one active drug (NRTI or PI) in 
the regimen, there was a 24% decreased chance of virological failure (multivariable 
RH: 0.76; 95% CI: 0.68-0.86; p<0.001).  There was no significant difference between 
patients with NNRTI-resistant HIV and those without (multivariable RH: 1.31; 95% CI: 
0.80-2.15; p=0.283).  This model also did not result in a change in the RH of virological 
failure in patients starting EFV compared to NVP (RH: 0.50; 95% CI: 0.39-0.65; 
p<0.001) (Figure 6.5).  Using the ANRS and Stanford algorithms instead of Rega gave 
similar findings and the RH for EFV versus NVP remained the same for both (RH: 0.51; 
95% CI: 0.39-0.66; p<0.001; and RH: 0.50; 95% CI: 0.39-0.65; p<0.001; respectively).   
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Figure 6.5: Relative hazards and 95% confidence intervals of virological failure (two viral loads greater than 500 copies/mL) following initiation of an 
NNRTI-containing regimen. 
  
Univariable  EFV versus NVP  
Multivariable EFV  versus  NVP   
EFV versus NVP 
NNRTI resistance versus none 
NRTI resistance versus none 
Multivariable adjusted 
for IAS-USA resistance 
PI resistance versus none 
EFV versus NVP 
No. active non-NNRTI drugs (per extra drug) 
Multivariable adjusted 
for Rega algorithm 
resistance 
NNRTI resistance versus none 
  
 
Notes: Multivariable analyses adjusted for number of previous NRTIs and PIs, previous AIDS diagnosis, year started NNRTI, baseline CD4 count, CD4 nadir, baseline viral 
load, maximum viral load ever and number of NRTIs and PIs in the regimen. 
NVP = nevirapine; EFV = efavirenz; RH = relative hazards; CI = confidence interval. 
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6.3.4.4 Sensitivity analyses in 759 patients 
Sensitivity analyses using the multivariable model adjusting for the Rega score and 
NNRTI resistance were carried out on the 759 patients with resistance test results 
available.  A total of 26 (3.4%) patients were left censored at the date of enrolment into 
EuroSIDA, giving a multivariable RH (EFV versus NVP) of 0.51 (95% CI: 0.39-0.65; 
p<0.001).  A total of 291 (38.3%) patients discontinued the NNRTI they started (at any 
time) and so were right censored at the time of discontinuation.  This gave a 
multivariable RH of 0.62 (95% CI: 0.44-0.88; p=0.007).  Taking only 618 patients 
whose resistance test results came from retrospective analysis of prospectively stored 
plasma samples in the central EuroSIDA laboratories resulted in a multivariable RH of 
0.53 (95% CI: 0.41-0.71; p<0.001).  It was found that patients whose results came from 
tests carried out in the clinical centres were almost three times as likely to start EFV 
than NVP in a logistic regression analysis after adjusting for other explanatory variables 
(OR: 2.73; 95% CI: 1.77-4.21; p<0.001).  Finally in a subset of 98 patients who were 
previously ART-naïve, the multivariable RH was 0.22 (95% CI: 0.04-1.18; p=0.215).     
 
6.3.5  Response to NNRTI regimen: change in viral load and CD4 count at 
months six to twelve 
Linear regression was then used to analyse change in viral load and CD4 count from 
baseline to the last measurement six to twelve months after starting the regimen.  A 
total of 711 (93.7%) of the 759 patients had viral loads measured during this time and 
those on EFV-containing regimens had a viral load reduction on average 0.65 
log10copies/mL greater than those on NVP-containing regimens (p<0.001) after 
adjustment for the same variables as in the main analysis.  CD4 counts were also 
measured in 711 (93.7%) patients during this six month period and after adjustment, 
those in the EFV group had a CD4 count increase of on average 26 cells/mm
3 higher 
than those in the NVP group (p=0.042).  After adjustment for the change in viral load, 
changes in CD4 count were similar between the two groups: 9 cells/mm
3 higher in the 
EFV group compared to the NVP group (p=0.474). 
 
6.3.6  Virological response to NNRTI regimen: viral load less than 50 
copies/mL at months six to twelve 
Finally logistic regression was used to compare virological success rates between 
those starting NVP and EFV.  A total of 632 patients were included who had their first 
viral load in the six to twelve month period after starting the NNRTI-containing regimen 
measured using an assay with a lower limit of detection of 50 copies/mL and also had a 
baseline viral load measurement of at least 50 copies/mL.  Virological suppression 
(less than 50 copies/mL at six to twelve months) was achieved by 72 (22.5%; 95% CI: 
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18.2-27.4%) of 320 NVP patients and 178 (57.1%; 95% CI: 51.9-62.9%) of 312 EFV 
patients (p<0.001).  A multivariable logistic regression model adjusting for the same 
variables as above, found that patients starting EFV were almost four times as likely to 
achieve virological suppression than those starting NVP (multivariable OR: 3.65; 95% 
CI: 2.37-5.62; p<0.001). 
 
6.3.7  Genotypic HIV drug resistance at time of virological failure 
6.3.7.1 Prevalence of IAS-USA resistance mutations at time of failure 
In total 131 (28.8%) of the 455 patients who experienced virological failure (amongst 
the 759 with a baseline resistance test) were still taking an NNRTI and had resistance 
test results available at the time of failure.  Prevalence of resistance was found to be 
similar between the NVP and EFV groups  (95.4% NVP versus 97.7% EFV; p=0.663).  
Overall, 117 (89.3%) patients had NRTI resistance, 112 (85.5%) had NNRTI resistance 
and 89 (67.9%) had major PI resistance (Figure 6.6).  The Y181C mutation was the 
most frequently observed in the NVP group (47.1%) and the K103N mutation in the 
EFV group (68.2%).   
 
6.3.7.2 New IAS-USA resistance mutations at time of failure compared to baseline 
A comparison with baseline results showed that between baseline and virological 
failure times, 55 (42.0%) patients developed a new NRTI resistance mutation (39.1% 
NVP versus 47.7% EFV; p=0.344), 111 (84.7%) developed a new NNRTI resistance 
mutation (83.9% NVP versus 86.4% EFV; p=0.712) and 36 (27.5%) developed a new 
PI resistance mutation (28.7% NVP versus 25.0% EFV; p=0.651).  The most common 
new NNRTI resistance mutations that developed were K103N (34.5% NVP versus 
65.9% EFV), V108I (10.3% NVP versus 20.5% EFV), Y181C (46.0% NVP versus 4.6% 
EFV) and G190A (35.7% NVP versus 9.1% EFV).  Logistic regression models were 
used to investigate whether the differences in development of mutations between those 
starting NVP and EFV were affected by the factors in the main analysis.  After 
adjustment for these factors including Rega score and NNRTI resistance, the 
significant differences in the detection of K103N, Y181C and G190A remained present 
between the two groups. 
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Figure 6.6: IAS-USA drug resistance mutations detected at time of virological failure following initiation of NNRTI-containing regimen in patients with 
resistance test results available whilst still on NNRTI, according to whether patients started nevirapine or efavirenz. 
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Note: P values based on comparison between patients starting nevirapine (NVP) and efavirenz (EFV). 
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6.4 Discussion 
The results from these analyses found that amongst 759 mostly NRTI/PI-experienced 
but NNRTI-naïve patients starting an NNRTI-containing regimen for the first time with a 
baseline genotypic resistance test result available, those starting EFV had a 50% 
reduced risk of virological failure compared to those starting NVP.  This was adjusted 
for demographics, previous ART, baseline NNRTI resistance and the predicted 
susceptibility to the other drugs included in the regimen.  NNRTI-resistant HIV was 
detected in 3.4% of patients at baseline with similar levels in both NVP and EFV 
groups.  Out of 131 patients still on an NNRTI and with resistance test results available 
at time of virological failure, NNRTI resistance was detected in 85.5% of patients and 
was similar between the groups, however different resistance profiles emerged.  After 
adjustment for the same factors as in the main analysis, the K103N mutation was more 
prevalent in those who failed on EFV and the Y181C and G190A mutations were more 
prevalent in those who failed on NVP. 
 
6.4.1  Interpretation of findings and previous research 
6.4.1.1 EuroSIDA 
The main findings match those from the previous EuroSIDA analysis, which found that 
patients starting EFV (n=739) had a 43% reduced risk of virological failure than those 
starting NVP (n=1174) [300].  At the time of that analysis, drug resistance data were 
not available therefore it was unknown as to whether baseline resistance profiles could 
explain the difference in virological outcome observed.  The findings in this chapter 
suggest that although patients with at least one IAS-USA NNRTI resistance mutation at 
baseline or a lower number of fully active drugs in the regimen (as defined by the 
Rega, ANRS or Stanford algorithms) were more likely to experience virological failure, 
neither of these factors confounds the association between the risk of virological failure 
and the use of NVP or EFV.  This result was consistent in a number of sensitivity 
analyses with the exception of a non-significant difference found between groups in the 
subset of 98 ART-naïve patients.  However, the results remained in favour of EFV and 
as the number of patients included was much lower, the power of the analyses to 
detect true differences was reduced.  Conversely, this could also reflect that possible 
differences in intrinsic virological efficacy between the two NNRTIs are less 
pronounced in patients harbouring fully susceptible virus. 
 
6.4.1.2 Other cohort studies 
The results also match findings from other observational cohort studies, which all 
considered many confounding factors but did not take into account baseline NNRTI 
resistance and so could not rule this out as potentially biasing the results [302-304].  
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Matthews et al. (2002) included 888 ART-naïve patients from two large London clinics, 
who started a cART regimen containing a PI, NVP or EFV and found a better initial 
virological response, measured as time to virological suppression less than 500 
copies/mL, for EFV compared to either of the alternatives [302].  The I.Co.N.A. study 
(n=694) found that patients starting NVP were twice as likely to experience virological 
failure (two consecutive measurements more than 500 copies/mL) than those starting 
EFV [303] and a US cohort study by Keiser et al. (2002) looking at 1078 ART-naïve 
patients found a 50% increased risk of virological failure (two consecutive 
measurements more than 400 copies/mL) for NVP versus EFV [304].  
 
Some other observational studies found no difference in response to NNRTI-based 
regimens.  A retrospective observational cohort study found no significant difference in 
time to virological or immunological response between ART-naïve patients starting 
NVP and EFV but with small patient numbers (n=53) [476].  Another prospective 
observational survey compared 287 patients treated with EFV to 258 treated with NVP 
over an 18-month period.  This also found comparable virological and immunological 
responses, however in a subset of 154 ART-naïve patients, those treated with EFV 
showed a virological advantage at three to twelve months [477].  An Indian cohort of 
1111 ART-naïve patients found equivalent CD4 cell increases between patients 
starting two NRTIs plus either NVP or EFV [475].   
 
Table 6.4 summarises the findings of previous research from both observational 
studies and clinical trials. 
 
6.4.1.3 Randomised clinical trials 
The question was also addressed in a large randomised clinical trial, the 2NN study 
[299].  A composite measurement of treatment failure, including virological failure, 
disease progression and therapy change was investigated in 1216 ART-naïve patients 
starting NVP once daily, NVP twice daily, EFV, or NVP plus EFV.  In the primary 
analysis, a comparison of NVP twice daily (n=387) versus EFV (n=400) found a non-
significant but slightly lower proportion of treatment failure at week 48 in those starting 
EFV (37.8%; 95% CI: 33.0-42.7%) compared to those starting NVP (43.7%; 95% CI: 
38.7-48.8%; p=0.091).  However, a sensitivity analysis excluding 28 patients who were 
randomised to either of these groups but who never started their treatment found a 
significant difference between them (7.7%; 95% CI: 0.8-14.6%; p=0.030).  
Furthermore, the study was powered to investigate equivalence of the two drugs but 
failed to demonstrate this.   
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Table 6.4: Previous research investigating virological response to nevirapine-containing versus efavirenz-containing regimens. 
Authors, year  Type of study (name of 
study) 
Patient numbers on 
each NNRTI  Main outcomes  Conclusions 
Phillips et al. 
2001 [300] 
Observational cohort 
(EuroSIDA) 
1174 NVP, 739 EFV 
(NNRTI-naïve) 
Time to virological failure defined as 
two consecutive values > 500 copies/mL after starting 
the regimen (> 6 months after start of the regimen if 
baseline viral load was > 500 copies/mL). 
Patients starting EFV had a significantly 
reduced risk of virological failure than those 
starting NVP in multivariable analysis. 
Matthews et al. 
2002 [302]  Observational cohort  237 NVP, 167 EFV, 484 
PIs (ART-naïve) 
Analysis 1: Time to first undetectable viral load (< 500 
copies/mL) after cART initiation. 
Analysis 2: Composite failure endpoint – failed to 
achieve viral load < 500 copies/mL within 6 months or 
who achieved this but then experienced viral load 
rebound (two consecutive viral load measurements of > 
500 copies/mL), both before 6 months. 
Patients starting EFV were significantly more 
likely to achieve an undetectable viral load and 
had a significantly reduced risk of virological 
failure than those starting NVP in multivariable 
analyses. 
Cozzi-Lepri et al. 
2002 [303] 
Observational cohort 
(I.Co.N.A.) 
460 NVP, 234 EFV 
(NNRTI-naïve) 
Time to virological failure defined as 
two consecutive values > 500 copies/mL after starting 
the regimen (> 6 months after start of the regimen if 
baseline viral load was > 500 copies/mL). 
Patients starting EFV had a significantly 
reduced risk of virological failure than those 
starting NVP in multivariable analysis. 
Núñez et al. 2002 
[478]  Randomised pilot study  36 NVP, 31 EFV (ART-
naïve) 
Endpoint: viral load < 50 copies/mL 48 weeks after 
starting cART regimen. 
No significant difference in virological 
response between patients starting the two 
NNRTIs was found. 
Keiser et al. 2002 
[304]  Observational cohort  523 NVP, 555 EFV 
(ART-naïve) 
Time to virological failure defined as two consecutive 
counts of viral load > 400 copies/mL in those who 
previously had undetectable viral load or the failure to 
achieve viral load < 400 copies/mL. 
Patients starting EFV had a significantly 
reduced risk of virological failure than those 
starting NVP in multivariable analysis. 
Manfredi et al. 
2004 [477]  Observational cohort 
258 NVP, 287 EFV (154 
ART-naïve, 298 ART-
experienced but NNRTI-
naïve, 103 on salvage 
regimens) 
Mean decrease in viral load at 3, 6, 9, 12, 15 and 18 
months after starting cART regimen. 
Comparable efficacy between NVP and EFV in 
ART-experienced patients and patients on 
salvage therapy.  Increased drop in viral load 
in ART-naïve patients starting EFV over NVP 
between months 3-12. 
Notes: NVP = nevirapine; EFV = efavirenz. 
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Authors, year  Type of study (name of 
study) 
Patient numbers on 
each NNRTI  Main outcomes  Conclusions 
Manosuthi et al. 
2004 [476]  Observational cohort 
24 NVP, 29 EFV (ART-
naïve with advanced 
infection) 
Time to virological success defined as undetectable 
viral load < 400 copies/mL after cART initiation. 
No significant difference in virological success 
rates was found between patients starting NVP 
and EFV in multivariable analysis. 
Van den Berg-
Wolf et al. 2006 
[474] 
Randomised substudy 
of clinical trial (FIRST-
CPCRA 058) 
117 NVP, 111 EFV 
(ART-naïve) 
Endpoint: viral load < 50 copies/mL 8 months after 
starting regimen or death. 
No significant difference in virological response 
between patients starting the two NNRTIs was 
found. 
Nachega et al. 
2007 [301]  Observational cohort  999 NVP, 1822 EFV  Endpoint: sustained viral load < 400 copies/mL 
throughout follow-up. 
Patients starting EFV were more likely to 
achieve 100% suppression than those starting 
NVP in multivariable analysis. 
Van Leth et al. 
2004 [299] 
Randomised clinical trial 
(2NN) 
220 NVP once daily, 
387 NVP twice daily, 
400 EFV, 111 EFV plus 
NVP (ART-naïve) 
Composite treatment failure endpoint: a decline of 
< 1 log10 copies/mL in viral load within first 12 weeks or 
two consecutive measurements ≥ 50 copies per mL 
from week 24 onwards, CDC grade C event from 8 
weeks onwards or death, and therapy change. 
No significant difference in treatment failure 
between patients receiving NVP twice daily 
and patients receiving EFV was found. 
Notes: NVP = nevirapine; EFV = efavirenz. 
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A substudy of the FIRST-CPCRA 058 trial randomised patients to receiving NVP or 
EFV and compared them in terms of rate of virological failure (more than 50 copies 
after eight months or death) in an intention-to-treat analysis.  No significant difference 
between NVP and EFV in the 228 ART-naïve patients was found (42.8 and 41.2 per 
100 person years respectively; p=0.590) but virological failure on NVP was associated 
with more drug resistance [474].  Recently, the group reported that using an ultra-deep 
genetic sequencing method (which can detect minor HIV populations at 1-3% levels), 
as opposed to standard methods, could detect low abundant drug-resistant HIV.  It was 
shown that patients with low abundant NNRTI-resistant variants were at significantly 
greater risk of virological failure than those without [485]. 
 
A Spanish pilot randomised study in 67 ART-naïve patients also found no significant 
difference in virological response but acknowledged that a much larger sample size is 
needed to detect any true difference [478].  
 
6.4.2 Limitations 
Although a large number of known, measured confounding variables were considered 
for this analysis, including the new information EuroSIDA has collected on genotypic 
drug resistance, as the data were from an observational study as opposed to from a 
randomised clinical trial, there may still be some unmeasured or unknown variables 
that may have biased the comparison, including neuropsychological issues that are not 
collected in routine clinical care.  For example, patients suffering from depression may 
be less adherent to their regimens resulting in a poorer virological response rate [486] 
and may also be more likely to receive NVP due to the neurological side effects of EFV 
[40,41].  EuroSIDA has recently (in January 2008) started collecting data on patient 
adherence based on any comments on the patient notes that may indicate their level of 
adherence: ‘<70%’ (‘poor’, ‘inadequate’, ‘not good’ or ‘intermittent’), ‘anything in 
between’ or ‘>95%’ (‘perfect’, ‘full’, ‘excellent’).  However, at present this information is 
scarce and no patients included in this analysis had it available.  Differences in 
toxicities between the two drugs may have influenced adherence and it was found that 
in patients discontinuing either NNRTI, there were different reasons for discontinuation 
between NVP and EFV groups.  
 
Specific drug resistance mutations do not necessarily occur independently from each 
other and so comparisons between patients starting NVP and EFV carry an increased 
risk that significant results could be due to chance.  Adjustments can be made to the p 
values (such as the Bonferroni correction) to compensate for multiple testing.  These 
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comparisons were made in this chapter to report the proportions of each mutation and 
conclusions were not drawn from the p values.  
 
6.4.3 Implications  of  findings 
6.4.3.1 Nevirapine versus efavirenz 
As both EFV and NVP are two of the most widely used drugs across the world, it is 
important to conduct more randomised trials comparing the virological efficacy of the 
two drugs.  If evidence is found that NVP is inferior to EFV, then this implies that 
developing countries (where NVP is commonly used [473]) are using a second-rate 
drug.  Although the introduction of the alternative NNRTI etravirine (TMC-125) will 
become a useful alternative option in clinical care, especially in the management of 
failure patients, access to this drug will be limited worldwide for some time yet.   
 
6.4.3.2 NNRTI resistance 
In this analysis, similar high levels of NNRTI resistance were found in patients treated 
with NVP and EFV by the time of virological failure suggesting that the drugs emitted 
selection pressure, which indicates that patients had actually adhered to their 
regimens.  The Y181C mutation was the most frequently observed in plasma samples 
from patients who failed a NVP-based regimen (46.0%) and the K103N mutation in 
samples from patients who failed an EFV-based regimen (51.4%), which supports 
other research [487-489].  It has implications for future therapy options as the K103N 
mutation has been linked to high-level cross-resistance to first-line EFV and NVP but 
there is evidence that it does not cause cross-resistance to TMC-125 and that Y181C 
alone only confers very limited resistance to TMC-125 when it is not accompanied by 
any other NNRTI related mutation [490-492]. 
 
However another bias for explaining the differences observed between NVP and EFV 
that cannot be ruled out is the possible impact of mutations in the connection domain 
(C-domain, residues 316-427) of HIV RNA.  It has recently been demonstrated that 
N348I decreases susceptibility to NVP (7.4 fold) and EFV (2.5 fold) and enhances 
NNRTI resistance in the context of K103N [481].  Mainly N348I confers decreased 
susceptibility to ZDV and NVP and is more likely to be selected with ZDV and NVP 
treatment.  Another mutation in the C-domain, E399G, has also been shown to slightly 
increase EFV resistance (3.6 fold) and significantly reduce viral replication capacity 
when associated with other mutations in the NNRTI binding pocket (L100I, V106I, 
V179D and F227C) [482].  However, the clinical impact of the C-domain mutations has 
not been assessed at the clinical level, therefore until these results are available, C-
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domain mutations cannot be ruled out as a possible explanation for the differences 
observed in this study and the discordances seen between different trials. 
 
6.4.4 Further  research 
As already mentioned, another potential confounder not addressed to date is the 
existence of resistance mutations in the connection domain of HIV RNA (C-domain, 
residues 316-427).  An investigation to determine the effect of pre-treatment mutations 
in both the connection and RNAseH reverse transcriptase domains on the virological 
outcome of first-line NNRTI-based cART has been proposed in EuroSIDA (the Connect 
project).  As more plasma samples become available, this study also proposes to look 
at the effect of on-treatment suboptimal plasma NNRTI levels.   
 
It would be useful to focus the analysis on ART-naïve patients only, as most future 
clinical use of these drugs will be in this group.  This may be possible in future updates 
of the dataset, however at present, there are few ART-naïve patients in the EuroSIDA 
dataset who fit the inclusion criteria of these analyses. 
 
6.4.5 Conclusions 
In this analysis, it was found that NVP was associated with an inferior virological 
outcome compared to EFV in NNRTI-naïve (but generally NRTI/PI experienced) 
patients confirming findings previously reported from EuroSIDA.  This difference does 
not appear to be explained by baseline drug resistance or number of active drugs in the 
regimen but could be linked to the different resistance profiles emerging over the 
course of treatment in those starting NVP compared to EFV.  However this is not a 
randomised comparison and the observational studies that have found similar findings 
may all have similar biases that could explain the results.  As results suggesting a 
difference in the efficacy of the two drugs consistently point towards an inferior 
virological response in NVP patients and as both drugs are widely used worldwide, it is 
important for more randomised trials to be carried out in both ART-naïve and NRTI/PI 
experienced patients to help to draw a reliable conclusion. 
 
A manuscript of this analysis was published by AIDS in January 2008 and can be found 
in Appendix IX. 
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Chapter 7. Toxicity of antiretroviral therapy: safety of 
abacavir 
7.1 Introduction 
This thesis has so far examined the factors affecting virological and immunological 
response to therapy by investigation of different subsets of EuroSIDA patients.  A 
further response to ART that patients may experience is toxicity that can be potentially 
life threatening.  Toxicity is a major reason for non-adherence to ART, which can in turn 
lead to virological and immunological failure [191-195,197], and may also result in 
treatment discontinuation, switches or interruptions [204,493].  This chapter focuses on 
the reasons for discontinuation of one NRTI, abacavir (ABC).  
 
7.1.1  Toxicities of antiretroviral drugs 
In Chapter 1 (section 1.6), the different classes of antiretroviral drugs available and 
their associated toxicities were discussed.  Toxicities can be mild to severe in intensity, 
sometimes even fatal and some are drug- or class-specific.  Early adverse effects 
(occurring within the first three to six months of treatment) tend to be mild to moderate 
conditions, such as headaches, nausea, diarrhoea and insomnia, which can be 
managed with advice and palliative drugs [215,216].    As treatment options are limited 
by the number of drugs available, it is beneficial to preserve options for as long as 
possible therefore drugs should only be discontinued or switched if the side effects 
cannot be controlled or lead to a reduced quality of life or lack of adherence.  One of 
the exceptions is hypersensitivity reaction (HSR), which usually occurs within the first 
six weeks and is life threatening if the drug responsible is not discontinued [234,494]. 
 
Later complications after long-term ART exposure occur much less frequently but can 
lead to permanent disability, stigmatising body changes or death.  Examples of long-
term adverse events associated with antiretroviral use include lactic acidosis, 
hepatotoxicity, peripheral neuropathy and lipodystrophy [223,224,231,241,495].  These 
conditions are likely to result in treatment modification or interruption.  
 
Some individuals may be more susceptible to adverse drug effects than others.  For 
example, patients who are co-infected with hepatitis B or C have an increased risk of 
hepatotoxicity (liver damage) after starting ART compared with those who are not 
[226,227,230].  Other factors that may increase risk of adverse effects are the 
concurrent use of other medicines that can also have toxic effects, certain individual 
conditions such as alcoholism, and use of combinations of drugs that may interact with 
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each other to increase dose related toxicities, e.g. use of tenofovir (TDF) with 
didanosine (ddI) leads to increased plasma concentrations of ddI, which increases the 
risk of ddI-associated pancreatitis [40,496].  
 
Although the main aim of ART is to achieve and maintain virological suppression, 
enabling recovery of the immune system, it is important that the regimen is selected not 
only for its efficacy, but also for its safety based on knowledge of the patient’s 
conditions, concomitant medications and history of drug intolerance.  It is 
recommended by current guidelines that ART should be changed if toxicities or 
intolerance develop that cannot be managed or treated.  If one drug can be identified 
that is likely to be causing the toxic effect, it is virologically safe to switch only that drug 
to another within the same drug class.  If acute toxicities occur such as rash, hepatic 
dysfunction and fever, then it is recommended that all drugs be stopped [40,41]. 
 
7.1.2 Abacavir 
Abacavir (ABC) was first approved for use as an anti-HIV drug by the US Food and 
Drug Administration (FDA) in 1998 [220], followed by the European Medicines Agency 
(EMEA) in 1999 [216].  Treatment guidelines recommend the use of ABC as an 
alternative option rather than a preferred option because of the risk of HSR [40-42].  
For those starting ABC as part of a first-line regimen, it is suggested that ABC be taken 
as part of an NRTI backbone for efavirenz (EFV), nevirapine (NVP), atazanavir (ATV), 
fosamprenavir (fAPV), fosamprenavir/ritonavir (fAPV/r), indinavir/ritonavir (IDV/r), 
lopinavir/ritonavir (LPV/r), nelfinavir (NFV), or saquinavir/ritonavir (SQV/r) with either 
lamivudine (3TC), which is co-formulated under the brand names Epzicom (in the USA) 
or Kivexa (in Europe), or with emtricitabine (FTC).  Only in cases where there are 
concerns over toxicities, drug interactions or complexity of regimen, ABC may be used 
in a first-line triple NRTI regimen, which has the advantages of fewer drug interactions, 
low pill burden as it can be taken in a twice-daily fixed-dose combination pill (Trizivir, 
also containing zidovudine (ZDV) and 3TC) and avoidance of the side effects 
associated with PIs and NNRTIs [40-42].  However, randomised clinical trial data 
suggests that this regimen may be virologically inferior to an EFV-based regimen [185] 
and to an IDV-based regimen in patients with high baseline viral loads [307], therefore 
this regimen is only recommended in occasional circumstances.   
  
The adverse effects of ABC are commonly appetite loss, headaches, malaise, nausea, 
vomiting and diarrhoea, which often improve within a few weeks of taking the drug 
[215,216].  As detailed in Chapter 1 (section 1.6.2.1), potentially fatal toxic effects that 
have been reported in patients taking NRTIs, including ABC, are lactic acidosis and 
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severe liver problems.  Other complications include lipodystrophy, increased 
cholesterol and triglycerides in the blood and diabetes.  However, the most dangerous 
potential side effect of taking ABC is HSR, which is detailed below.  
 
7.1.3 Hypersensitivity  reaction 
HSR occurs in approximately 4-8% of patients starting the drug [40,41,234-236].  The 
majority of cases occur within six weeks of starting the drug with a median time to 
onset of 11 days [235,497], although symptoms have been reported up to 318 days 
after initiation [497].  HSR is characterised by fever, rash, neurologic symptoms 
(fatigue, malaise, headache), gastro-intestinal symptoms (nausea, vomiting, diarrhoea), 
musculoskeletal symptoms (myalgias, body aches) and respiratory symptoms 
(coughing, wheezing,  pharyngitis) [234-236,495].  If the drug is not discontinued 
immediately there is the risk of death [40,495,498] and potentially fatal symptoms may 
reoccur within hours if the drug is restarted [499,500].  However, as patients are 
advised to stop immediately if symptoms arise, reported incidence of fatal HSR is 
fortunately rare.  A recent study reported no HSR related deaths in over 11,500 
patients exposed to either Ziagen (ABC as a single tablet) or Trizivir [501].  The study 
also found no differences in the frequency of ABC HSR between patients starting either 
formulation. 
 
The HLA (human leukocyte antigen) genes in human DNA regulate the immune 
response to foreign antigens.  In particular, a genetic polymorphism in the HLA-B 
region may be linked to ABC metabolism [502].  The allele HLA-B*5701 has been 
found to be strongly associated with ABC related HSR and is more prevalent in 
Caucasian individuals, which could account for differences in observed rates of HSR 
between ethnic groups [502-506].  In particular, the presence of HLA-B*5701, HLA-
DR7 and HLA-DQ3 was found to have a positive predictive value of 100% and absence 
of this combination had a negative predictive value of 97% [507].  Prospective genetic 
screening for HLA-B*5701 prior to prescribing ABC has been shown to dramatically 
reduce the incidence of ABC related HSR [503,505,506,508-512].  Despite the fact that 
the test has been found to be highly predictive, its implementation in clinical practice 
has been impeded by the fact that high-resolution HLA genotyping is expensive, 
performed in specialised immunology laboratories and has long turnaround times [511].  
Cost-effective, rapid and sensitive molecular tests have more recently been developed 
that can easily be incorporated into routine patient management and may remove the 
barriers to widespread use of genetic screening prior to ABC prescription [506,512]. 
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In clinical practice, diagnosis of HSR may be difficult as it includes a combination of 
non-specific symptoms.  Patients who exhibit symptoms consistent with HSR may be 
given a skin patch test to immunologically confirm whether or not they are a true HSR 
case.  To date, 100% of patch test positive patients identified worldwide have been 
HLA-B*5701 positive [509,513].  Recent findings from the PREDICT-1 study provided 
evidence that the presence of HLA-B*5701 was a necessary condition for ABC HSR 
and that withholding the drug from these patients would eliminate the reaction [506].  It 
also highlighted the problem of clinical over-diagnosis of HSR, which results from 
physicians not being able to risk missing any potential true cases of HSR.  Further 
factors that have been linked to an increased risk of HSR include female gender, 
higher CD8 cell count at initiation of ABC (CD8 cells are another type of T lymphocyte 
with a CD8 receptor) and ABC use during primary HIV infection.  Factors linked to a 
decreased risk are previous treatment experience and more advanced disease 
[494,514-516]. 
 
Other antiretroviral drugs have also been linked to HSR in a small number of patients: 
ZDV [517], zalcitabine (ddC) [518], delavirdine (DLV) [519], EFV [520], fAPV [521] and 
in particular NVP [522,523].  Risk of mortality through NVP hypersensitivity is increased 
by hepatitis C co-infection  [523].  In addition there have been cases of HSR following 
initiation of the antimicrobial drugs cotrimoxazole [524], dapsone [525] and sulfadiazine 
[526], which are used to prevent and treat HIV related opportunistic infections such as 
Pneumocystis jiroveci pneumonia and toxoplasmosis. 
 
7.1.4  Motivation and aims for chapter 
EuroSIDA collects prospective longitudinal data from a large, heterogeneous 
population in centres across Europe, which provides the opportunity to compare 
incidence of ABC related HSR across different patient subsets.  The aims of these 
analyses were to investigate the incidence of ABC discontinuation, particularly as a 
result of HSR, according to: the line of therapy within which ABC was received (first, 
second, third or subsequent regimens), geographical region, calendar time, and co-
formulation of ABC (as part of Kivexa or as either the single formulation, Ziagen, or as 
part of Trizivir).  Incidence of HSR within these patient subsets has not previously been 
evaluated in a large cohort study and is important to identify patients most at risk and to 
monitor trends.  The rate of death associated with ABC HSR was also determined.     
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7.2 Methods 
7.2.1 Inclusion  criteria 
The EuroSIDA dataset used for these analyses, as in Chapter 5, was the update 
completed in February 2008, providing information on 14,310 patients with follow-up to 
(median date of last visit) January 2007.  The inclusion criteria required patients to 
have initiated Ziagen, Trizivir or Kivexa for the first time after January 1999 (the date at 
which EuroSIDA started collecting data on reasons for discontinuation of therapy) 
during prospective follow-up, i.e. those who started ABC after enrolment into EuroSIDA 
and before the date of their last visit at the clinical centre.   
 
7.2.2 Statistical  methods 
7.2.2.1 Definitions 
The EuroSIDA forms provide a list of reasons for discontinuation of antiretroviral drugs 
from which sites are asked to indicate the most appropriate based on physician 
assessment, with just one reason chosen per drug stopped (see follow-up form in 
Appendix IV).  Only the first ABC discontinuation was considered and baseline was 
defined as the date of first starting the drug.   
 
7.2.2.2 Incidence of discontinuation of ABC 
Incidence of ABC discontinuation was assessed using a person-year analysis with 
person-years of follow-up (PYFU) defined from the date of starting ABC to the earliest 
of the last follow-up visit, death or until ABC was discontinued for any reason.  The 
incidence of ABC discontinuation due to HSR (as reported on the EuroSIDA forms) 
was assessed in the three months after initiating ABC treatment with follow-up time to 
the earliest of three months, death or ABC discontinuation. 
 
Univariable Poisson regression models were used to identify factors that could 
potentially affect the incidence of HSR related discontinuation within three months of 
starting ABC.  Factors investigated were: gender, age, HIV exposure group (defined as 
‘men who have sex with men (MSM)’, ‘injecting drug use (IDU)’, ‘heterosexual’ or 
‘other’), ethnicity (defined as ‘white’ or ‘other’), baseline viral load, CD4 count (baseline 
and nadir), hepatitis B/C coinfection status, prior AIDS diagnosis, whether or not 
patients were ART-naïve at baseline and concurrent use of other drugs that may cause 
HSR.  The potential interactions between hepatitis C status and both HIV exposure 
group and NVP use were also investigated.  A multivariable Poisson regression model 
was then developed adjusting for the factors found to be significant (p<0.1) in the 
univariable models and also including the following factors: whether patients started 
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ABC as part of a first-line regimen (containing at least one PI, one NNRTI or ABC), 
second-line regimen (containing a new PI, a new NNRTI or ABC and started at least 
one month after initiation of the first), third-line or subsequent regimen; geographical 
region the patients were seen in (defined as ‘South’, ‘Central West’, ‘North’ and ‘East’, 
as described in Chapter 2, section 2.1.5); and calendar time of starting ABC, which was 
divided into two-year periods (‘1999-2000’, ‘2001-2002’, ‘2003-2004’ and ‘2005’ 
onwards).  A further factor analysed in a separate model was whether a patient started 
ABC for the first time as part of the co-formulation Kivexa, or whether they started 
either ABC as Ziagen or as part of Trizivir.  As Kivexa was first introduced in January 
2004, only patients who started ABC after this time were included in this particular 
analysis. 
 
7.2.2.3 Rate of deaths 
As mentioned in Chapter 2 (section 2.1.2), EuroSIDA requests that all deaths are 
recorded on the follow-up forms with cause of death chosen from a list provided (see 
follow-up form in Appendix IV).  A fatal case of HSR was defined as a death that 
occurred either on ABC therapy or within one month of discontinuing ABC with the 
cause of death stated as HSR, or as a death that occurred within one month of 
discontinuing ABC with the reason for discontinuation stated as HSR.  Incidence of 
HSR related death was assessed during the follow-up time from ABC initiation to the 
earliest of the last follow-up visit, death or if ABC was discontinued, one month after 
discontinuation (for any reason).  Non-HSR related deaths that occurred whilst on ABC 
or within one month of stopping the drug were investigated further.     
 
7.3 Results 
7.3.1 Patient  numbers 
A total of 3278 (22.9%) patients fulfilled the inclusion criteria with a median follow-up 
time of 1.4 years (range: 0.0-8.5) and a total follow-up time of 6803 person-years from 
the date of ABC initiation.  Amongst these patients who started ABC, there were 2101 
(64.1%) discontinuations.  The remaining 1177 (35.9%) patients continued on ABC 
therapy to the end of their available follow-up time.  A total of 193 (9.2%) of ABC 
discontinuations were reported to be associated with HSR, of which 167 (86.5%) had 
reported HSR within three months of initiation, accounting for 5.1% of all patients 
starting ABC therapy.  Figure 7.1 displays the subsets of patients investigated in these 
analyses.   
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Figure 7.1: Patient numbers in analyses according to inclusion criteria. 
  
 
7.3.2  Patient characteristics at date of abacavir initiation 
Table 7.1 shows a comparison of the patient characteristics at date of ABC initiation 
between the 1177 patients who continued on ABC therapy in the available follow-up 
time, the 193 patients who discontinued ABC due to HSR and 1908 patients who 
discontinued due to a reason not reported as HSR.  Patients who continued ABC 
started treatment most recently, followed by those who discontinued due to HSR and 
then those who discontinued for another reason (medians: June 2004, June 2001 and 
January 2001 respectively; p<0.001).  More patients who discontinued ABC were IDUs 
(p<0.001), had lower baseline CD4 counts (p<0.001) and higher baseline viral loads 
(p<0.001).  Slightly more patients who discontinued ABC due to HSR were Caucasian 
(95.3%;  p=0.011), were hepatitis C positive (28.0%; p<0.001) and were ART-naïve 
(5.7%; p=0.007).  They were also more likely to have started NVP at the same time as 
ABC (7.8%; p=0.042).  There were similar proportions of patients across the three 
groups starting other drugs that have been linked to HSR, i.e. EFV, APV and 
cotrimoxazole.   
 
Continued on ABC throughout
available follow-up time
n=1177
Discontinued within
3 months of initiation
n=167
Due to hypersensitivity
reaction
n=193
Due to other reason
n=1908
Discontinued ABC
n=2101
Initiated ABC therapy after January 1999
during prospective follow-up
n=3278
EuroSIDA patients
(February 2008 dataset)
n=14310
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Table 7.1: Patient characteristics at start of abacavir therapy according to continuation of abacavir therapy, discontinuation of abacavir due to 
hypersensitivity reaction or discontinuation of abacavir due to another reason. 
    Total  Continuation of ABC  Discontinuation due to HSR Discontinuation due to other 
reason  p 
All n, %  3278 100.0 1177 35.9 193 5.9 1908 58.2 -
Male  2539  77.5 937  79.6 141 73.1  1461  76.6  0.047 
MSM 1507  46.0  591  50.2  80  41.5 836 43.8  <0.001 
IDU 672  20.5  192  16.3  51  26.4  429  22.5  - 
Heterosexual 861  26.3  306  26.0  48  24.9  507  26.6  - 
HIV exposure group 
 
Other 238  7.3 88  7.5 14 7.3  136  7.1 - 
White  ethnicity  3026  92.3  1066  90.5 184 95.3  1776  93.1  0.011 
Previous AIDS  1197  36.5  412  35.0  59  30.6  726  38.1  0.049 
Negative  2561  78.1 976  82.9 143 74.1  1442  75.6  <0.001 
Positive  206  6.3 58  4.9 14 7.0  134  7.0 -  Hepatitis B status 
Unknown 511  15.6  143  12.2  36  18.7  332  17.4  - 
Negative  1950  59.5 785  66.7 103 53.4  1062  59.5  <0.001 
Positive 717  21.9  228 19.4  54  28.0  435  22.8  -  Hepatitis C status 
Unknown 611  18.6  164  13.9  36  18.7  411  21.5  - 
NVP  183  5.6 51  4.3 15 7.8  117  6.1  0.042 
EFV 511  15.6  165  14.0  33  17.1  313  16.4  0.173 
APV 108  3.3  32  2.7  3  1.6 73 3.8  0.093 
Concurrent use of drugs  
that may cause HSR 
Cotrimoxazole 42  1.3  14  1.2  3  1.6  25  1.3  0.903 
ART-naïve at start of ABC  96  2.9 42  3.6 11 5.7  43  2.3  0.007 
Median (IQR)                
Date started ABC  Oct 01 (Apr 00-Jun 04) Jun 04  (Jul 01-Feb 06) Jun 01  (Jan 00-Feb 06) Jan 01  (Jan 00-Sep 02) <0.001 
Age (years)  41  (37-48)  42  (37-49) 41 (37-48)  41  (36-48)  0.005 
Baseline
(1)  357  (211-544) 394  (239-586) 327 (226-480)  336  (190-520)  <0.001 
CD4 count (cells/mm
3) 
Nadir
(2)  127  (50-215) 134  (51-218) 136 (63-200)  121  (46-214)  0.114 
Viral load (log10copies/mL) Baseline
(3)  2.8 (1.7-4.4)  2.1  (1.7-4.0)  3.1  (1.7-4.4)  3.3  (1.7-4.6)  <0.001 
Notes: P values obtained from Chi-squared, Fisher’s Exact and Kruskal-Wallis tests. 
Median CD4 counts and viral loads based on measurements from 
(1)3138 patients, 
(2)3276 patients, 
(3)3090 patients. 
ABC = abacavir; HSR = hypersensitivity reaction; MSM = men who have sex with men; IDU = injecting drug use; NVP = nevirapine; EFV = efavirenz; APV = amprenavir;  
IQR = interquartile range. 
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Figure 7.2 displays the types of ABC-containing regimens started in the three groups. 
Patients who continued on ABC therapy throughout their follow-up time were more 
likely to have started it as part of an NRTI backbone for a PI, RTV-boosted PI or NNRTI 
regimen.  More patients who discontinued ABC due to a reason other than HSR started 
the drug in a triple NRTI regimen.  The patients who discontinued ABC due to HSR 
were more likely to have started a more non-conventional regimen and had the 
smallest proportion of triple NRTI regimens.  Overall there was a significant difference 
in the type of regimen started between the three groups (p<0.001). 
 
Figure 7.2: Type of abacavir-containing regimen according to continuation of therapy, 
discontinuation due to hypersensitivity reaction or discontinuation due to another 
reason. 
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Note: ABC = abacavir; HSR = hypersensitivity reaction; RTV = ritonavir. 
 
 
7.3.3  Reasons for discontinuation of abacavir 
For patients who discontinued ABC, the reasons for discontinuation as reported on the 
EuroSIDA follow-up forms and the median duration of ABC therapy from initiation to the 
time when the drug was discontinued according to reason, are displayed in Table 7.2.  
As expected from the literature, HSR was experienced very soon after starting ABC 
with a median time to HSR related discontinuation of 1.0 month (IQR: 0.3-1.2 months).  
A further 344 (16.4%) discontinued due to treatment failure with median time on ABC of 
16.0 months (IQR: 8.4-29.0 months).  Other reasons for ABC discontinuation reported 
in 317 (15.1%) patients were clinical fat abnormalities, dyslipidaemia, toxicities and 
structured treatment interruption.  A further 285 (13.5%) patients had other known 
causes, not specified in the list.  Finally, 607 (28.9%) had the reason for ABC 
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discontinuation as patient or physician’s choice and 357 (17.0%) had an unknown 
reason.  As the median times to discontinuation for these groups were over a year 
(13.0 months (IQR: 4.2-32.5 months) and 18.0 months (IQR: 5.3-40.6 months) 
respectively), it is unlikely that these patients experienced HSR. 
 
Table 7.2: Reasons for discontinuation of abacavir.  
Reason for discontinuation  Patients  Duration of ABC therapy at 
discontinuation (months), 
 n  %  median  (IQR) 
All 2101  64.1  12.1  (3.0-29.4) 
      
Hypersensitivity reaction  193  9.2  1.0 (0.3-1.2) 
Treatment failure (virological, immunological and/or 
clinical failure) 
344 16.7  16.0  (8.4-29.0) 
Clinical fat abnormalities  45  2.1  31.7 (16.2-45.1) 
Dyslipidaemia 9  0.4  28.1  (15.7-33.3) 
Toxicity, predominantly from abdomen/G-I tract  102  4.9  3.6 (1.1-12.0) 
Toxicity, predominantly from nervous system  24  1.1  4.6 (2.0-23.3) 
Toxicity, predominantly from kidneys  4  0.2  22.4 (15.6-29.2) 
Toxicity, predominantly from the endocrine system  5  0.2  10.0 (10.0-10.7) 
Toxicity, haematological  10  0.5  6.5 (3.1-19.0) 
Toxicity, hyperlactataemia or lactic acidosis  3  0.1  7.0 (0.5-9.0) 
Toxicity, not mentioned above  74  3.5  3.0 (1.0-8.0) 
Patient’s wish, not specified above  291  13.9  8.5 (2.5-18.6) 
Physician’s decision, not specified above  316  15.0  20.7 (9.1-44.7) 
Structured treatment interruption  41  2.0  16.9 (8.2-33.0) 
Other causes, not specified above  283  13.5  19.0 (7.3-38.0) 
Unknown 357  17.0  18.0  (5.3-40.6) 
Notes: ABC = abacavir; G-I = gastro-intestinal; IQR = interquartile range. 
 
7.3.4  Incidence of abacavir discontinuation and hypersensitivity reaction 
7.3.4.1 Overall incidence of abacavir hypersensitivity reaction 
The incidence of ABC discontinuation for any reason (including HSR) was 30.9 (95% 
CI: 29.6-32.2) per 100 PYFU, and for HSR specifically was 2.8 (95% CI: 2.4-3.2) per 
100 PYFU.  The incidence of ABC discontinuation due to HSR within three months was 
22.1 (95% CI: 18.7-25.4) per 100 PYFU during 757 PYFU. 
 
7.3.4.2 Incidence according to the line of therapy in which abacavir was received 
A total of 252 (7.7%) patients started ABC as part of a first-line regimen, 952 (29.0%) 
started it as part of a second regimen, 1081 (33.0%) as part of a third and 993 (30.3%) 
as part of a fourth or subsequent regimen.  The highest incidence of ABC 
discontinuation for any reason was in those who started ABC as part of a 
fourth/subsequent regimen (p=0.002).  Incidence of HSR related discontinuation within 
the first three months was highest in those who started ABC as part of a first-line 
regimen (p=0.002).  Table 7.3 displays the incidences of ABC discontinuation due to 
any reason and due to HSR only, according to the line of therapy within which ABC 
was received, as well as the proportions of patients in each group.   
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Table 7.3: Abacavir discontinuation due to any reason or due to hypersensitivity reaction within three months according to the line of therapy within 
which abacavir was received. 
Discontinued due to HSR in 3 months:  Number of patients 
who started ABC 
Discontinued ABC due to 
any reason n (%)  of all those who 
discontinued n (%) 
of all those started 
ABC, % 
Any discontinuation:
incidence per 100 
PYFU  (95% CI) 
Total 
PYFU 
Discontinuation due 
to HSR in 3 months: 
incidence per 100 
PYFU (95% CI) 
PYFU up to 
3 months 
Overall: n=3278  2101 (64.1)  167 (7.9)  5.1  30.9 (29.6-32.2)  6803  22.1 (18.7-25.4)  757 
First-line: n=252  171 (67.9)  27 (15.8)  10.7  32.3 (27.5-37.2)  529  48.8 (30.4-67.2)  55 
Second-line: n=952  585 (61.5)  44 (7.5)  4.6  27.4 (25.1-29.6)  2138  19.9 (14.0-25.7)  222 
Third-line: n=1081  714 (66.1)  52 (7.3)  4.8  31.5 (29.2-33.8)  2266  21.0 (15.3-26.7)  248 
Fourth-line/later: n=993  631 (63.5)  44 (7.0)  4.4  33.7 (31.1-36.4)  1870  19.0 (13.4-24.6)  232 
p value 0.095
(1)  0.001
(1) <0.001
(1) 0.002
(2)  - 0.002
(2)  - 
Notes: P values obtained from 
(1)Chi-squared tests and 
(2)univariable Poisson regression models. 
ABC = abacavir; HSR = hypersensitivity reaction; PYFU = person-years of follow-up; CI = confidence interval. 
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7.3.4.3 Incidence according to geographical region within EuroSIDA 
A total of 929 (28.3%) patients were from the South region, 938 (28.6%) were from the 
Central West, 1164 (35.5%) were from the North and 247 (7.5%) were from the East.  
Overall there was no significant difference in incidence of discontinuation due to any 
reason and incidence of discontinuation due to HSR between regions (p=0.797 and 
p=0.114 respectively), however the North region appeared to have a lower incidence of 
HSR related discontinuation than the other regions.  Results are shown in Figure 7.3. 
 
Figure 7.3: Abacavir discontinuation due to any reason or due to hypersensitivity 
reaction within three months according to geographical region within EuroSIDA. 
 
 South  Central  West  North  East  p 
n  929  938 1164 247  - 
Discontinued due to 
any reason, n (%)  593 (63.8)  659 (70.3)  715 (61.4)  134 (54.3)  <0.001 
Discontinued due to HSR:         
of all discontinued,  
n (%)  54 (9.1)  53 (8.0)  45 (6.3)  15 (11.2)  0.127 
of all started, %  5.8  5.7  3.9  6.1  0.126 
Total PYFU  1861  2130  2372  440  - 
PYFU up to 3 
months  216 214 271 57  - 
 
Notes: P values obtained from Chi-squared tests and univariable Poisson regression models. 
HSR = hypersensitivity reaction; PYFU = person-years of follow-up; CI = confidence interval. 
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7.3.4.4 Incidence according to date of initiation of abacavir 
A total of 1245 (38.0%) patients started ABC in 1999-2000, 863 (26.3%) in 2001-2002, 
450 (13.7%) in 2003-2004 and 720 (22.0%) in 2005 or later.  Incidence of ABC 
discontinuation for any reason was similar over the time periods 1999-2000 and 2001-
2002, followed by a slight increase in the years 2003-2004 and a drop in 2005 
onwards, giving an overall significant difference (p=0.014).  Incidence of ABC 
discontinuation due to HSR within the first three months of ABC treatment remained 
similar over the years until 2005 onwards when a sharp decrease to 11.4 cases per 
100 PYFU during 166 PYFU was observed, also giving an overall significant difference 
(p=0.004), shown in Figure 7.4.  
  
Figure 7.4: Abacavir discontinuation due to any reason or due to hypersensitivity 
reaction within three months according to date of initiation of abacavir. 
  
  1999-2000 2001-2002 2003-2004  2005  onwards  p 
n 1245  863  450  720  - 
Discontinued due to 
any reason, n (%)  1012 (81.3)  631 (73.1)  282 (62.7)  176 (24.4)  <0.001 
Discontinued due to HSR:         
of all discontinued,  
n (%)  67  (6.6) 54  (8.6) 27  (9.6)  19  (10.8) 0.126 
of  all  started,  %  5.4 6.3 6.0  2.6  0.006 
Total PYFU  3169  2010  736  424  - 
PYFU up to 3 
months  287 200 104  135  - 
 
Notes: P values obtained from Chi-squared tests and univariable Poisson regression models 
HSR = hypersensitivity reaction; PYFU = person-years of follow-up; CI = confidence interval. 
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7.3.4.5 Incidence according to formulation of abacavir 
A total of 928 (28.3%) previously ABC-naïve patients started ABC from January 2004 
onwards, the date when Kivexa was first introduced into clinical practice.  Of these, 342 
(36.9%) patients started Kivexa.  Overall, 305 (32.9%) patients discontinued ABC, of 
which 27 (8.9%) discontinuations occurred within three months and were associated 
with HSR.  Incidence of discontinuation due to any reason was significantly higher in 
the non-Kivexa group: 38.6 (95% CI: 33.9-43.3) cases per 100 PYFU during 676 PYFU 
compared to 13.1 (95% CI: 9.3-17.0) cases per 100 PYFU during 335 PYFU in the 
Kivexa group (p<0.001).  There was also a significant difference in incidence of 
discontinuation due to HSR within three months: 16.2 (95% CI: 9.4-23.0) cases per 100 
PYFU during 136 PYFU in the non-Kivexa group, compared to 6.3 (95% CI: 2.0-14.6) 
cases per 100 PYFU during 80 PYFU in the Kivexa group (p=0.036).   
 
7.3.4.6 Multivariable incidence rate ratios 
In univariable models, female gender, positive hepatitis C coinfection status, lack of 
prior AIDS diagnosis and a lower baseline CD4 cell count were significantly associated 
with incidence of ABC discontinuation due to HSR within three months.  The concurrent 
use of drugs such as NVP, EFV, APV and cotrimoxazole that can cause HSR, started 
at the same time as ABC, were investigated to check that symptoms arising from one 
of these drugs had not been misdiagnosed as ABC HSR.  However none were found to 
be significantly associated with HSR related ABC discontinuation.  Ethnicity was also 
not found to be associated with this, although the incidence rate was lower in those 
with non-white ethnicity compared to those with white ethnicity as expected from the 
literature, with an incidence rate ratio (IRR) of 0.66 (95% CI: 0.34-1.30; p=0.230).  A 
multivariable model was then developed that contained the above factors significantly 
associated with HSR in univariable analyses (p<0.1), as well as whether ABC was a 
component of a first, second, third or subsequent regimen, geographical region and 
calendar time when ABC was started.  Figure 7.5 displays the adjusted incidence rate 
ratios (IRRs) and 95% CIs from this model. 
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Figure 7.5: Multivariable incidence rate ratios and 95% confidence intervals of abacavir discontinuation due to hypersensitivity reaction within three 
months. 
 
Note: ABC = abacavir; IRR = incidence rate ratio; CI = confidence interval; 
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This multivariable model provided evidence that the incidence of ABC discontinuation 
due to HSR amongst patients starting ABC as part of a first-line regimen was twice that 
observed amongst those starting ABC in a second-line regimen (IRR: 2.04; 95% CI: 
1.24-3.38; p=0.005).  Incidence of HSR was similar across regions although was higher 
in all regions compared to the North.  There was also evidence that amongst patients 
starting ABC in 2005 onwards, the incidence of HSR related discontinuation was 
almost half that observed amongst patients starting ABC in 1999-2000 (IRR: 0.54; 95% 
CI: 0.32-0.92; p=0.024). 
 
A multivariable model was developed containing the same variables as before, but with 
date started ABC adjusted for instead of time period, and with the addition of whether 
patients received Kivexa or Ziagen/Trizivir.  After adjustment, there was evidence of a 
significantly lower incidence of ABC discontinuation due to HSR within three months in 
those starting Kivexa compared to those starting Ziagen/Trizivir (IRR: 0.33; 95% CI: 
0.13-0.88; p=0.027).   
 
7.3.5  Rate of death associated with abacavir hypersensitivity reaction 
There were no fatal cases of HSR registered during 6969 PYFU; no patients died on 
ABC therapy or within a month of stopping the drug with HSR recorded as the cause of 
death, and no patients discontinued ABC therapy due to HSR and died within one 
month of discontinuation.  A total of 111 (3.4% of all those who started ABC) patients 
died on ABC therapy or within one month of a non-HSR related discontinuation.  Of 
these, 55 had specific non-HSR related causes of death recorded and of the remaining 
56 patients, 33 had a previous AIDS diagnosis and 36 had extensive treatment 
experience and had received at least two or three PI/NNRTI-containing regimens prior 
to the ABC regimen.  Amongst these 111 patients, 15 died within three months of 
starting ABC.  The investigators classified 13 of these 15 deaths as being due to 
specific and mainly AIDS related causes, rather than as a result of HSR.  The two 
remaining patients had unknown causes of death but both died with low CD4 counts of 
106 cells/mm
3 (measured two months before date of death) and 120 cells/mm
3 
(measured 16 days before date of death).  The characteristics of all 111 patients who 
died are summarised in Table 7.4, as well as characteristics of the subgroup of 15 
patients who had received less than three months of ABC therapy at the time of death.   
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Table 7.4: Characteristics at time of death of patients who died on abacavir therapy or 
within one month after abacavir discontinuation. 
 
All  ABC treatment < 3 
months 
n (%)  111 (3.4)*  15 (0.5)*
 
Cause of death:  AIDS related  24 (21.6)  6 (40.0) 
  Cardiovascular disease  15 (13.5)  2 (13.3) 
  Liver failure/hepatitis  10 (9.0)  1 (6.7) 
  Lactic acidosis  2 (1.8)  0 (0.0) 
  Suicide  2 (1.8)  0 (0.0) 
  Renal failure  1 (0.9)  0 (0.0) 
  Pancreatitis  1 (0.9)  0 (0.0) 
 Other  36  (32.4)  4  (26.7) 
 Unknown  20  (18.0)  2  (13.3) 
Prior AIDS    62 (55.9)  9 (60.0) 
ABC started as part of:  First PI/NNRTI/ABC regimen  9 (8.1)  1 (6.7) 
  Second regimen after starting first  31 (27.9)  4 (26.7) 
  Third regimen  38 (34.2)  6 (40.0) 
  Fourth or later regimen  33 (29.7)  4 (26.7) 
No. drugs in regimen  1-2  4 (3.6)  2 (13.3) 
(excluding ABC)  3  48 (43.2)  4 (26.7) 
 4-5  51  (45.9)  9  (60.0) 
Median (IQR)    
Date of death  Oct 02 
(Jan 01-Sep 04) 
May 00 
(Nov 99-Jan 02) 
Duration on ABC (months)  18 (8-37)  1 (0-2) 
CD4 count (cells/mm
3)  227 (84-361)  90 (33-175) 
Viral load (log10 copies/mL)  2.3 (1.7-4.4)  4.6 (2.7-5.3) 
Notes: *Proportion of 3278 patients who started abacavir. 
ABC = abacavir; IQR = interquartile range.    
 
 
7.4 Discussion 
The results from these analyses found that amongst 3278 HIV-1 infected patients who 
started ABC across Europe, the incidence rate of ABC discontinuation for any reason 
(including HSR) was 30.9 (95% CI: 29.6-32.2) per 100 PYFU.  The incidence of ABC 
discontinuation due to HSR within three months was 22.1 (18.7-25.4) per 100 PYFU 
and this occurred in 5.1% of patients who started the drug.   
 
HSR was the most common named toxicity reported in patients who discontinued ABC, 
although the main reason for discontinuation was treatment failure.  The main findings 
were that in a multivariable model adjusting for potentially confounding factors, there 
were significantly higher incidence rates of HSR (within three months) when ABC was 
started in a first-line regimen compared to a second-line regimen and in the time period 
2005 onwards compared to earlier years.  The geographical region that patients were 
seen in was not associated with HSR incidence after adjustment.  Patients starting 
Kivexa compared to those starting Ziagen or Trizivir were observed to have a lower 
incidence of ABC discontinuation due to HSR but the person-years available in the 
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subgroup of patients starting Kivexa were limited.  Finally, there were no deaths that 
were attributed to HSR in the one-month period after discontinuation of the drug. 
 
7.4.1  Interpretation of findings and previous research 
The overall incidence of HSR in patients starting ABC found in this dataset was in line 
with the 4-8% found in other studies [40,41,234-236].  HSR was assessed by 
physicians in each clinical centre based on the interpretation of clinical symptoms.  It is 
unknown as to whether or not the results of skin patch tests were used as well.  Patch 
tests appear to correlate well with immunological and genetic testing and may be useful 
in defining true HSR, however their use in diagnosis remains experimental at present 
[509,512,513].  The incidences reported in this analysis therefore indicate a practical 
“real life” approach to the diagnosis of HSR and possibly reflect clinical diagnosis rather 
than true HSR.  Recent discussion at the 4th IAS Conference 2007, Sydney, Australia, 
identified the difficulties in diagnosing HSR correctly and the consequences of 
misclassification in studies [527]. 
 
7.4.1.1 Incidence of hypersensitivity reaction according to the line of therapy 
In this analysis, the adjusted HSR incidence rate was found to be twice as high when 
ABC was started as part of a first-line regimen compared to a second-line regimen.  
This supports research by Symonds et al. (2002) that showed a 42% decreased odds 
of HSR in patients with prior treatment experience in a multivariable model [516].   
Patients starting therapy for the first time may be more likely to be clinically diagnosed 
with suspected HSR, which may not reflect the incidence of true HSR cases in this 
group.  New patients may be more likely to report all symptoms experienced due to 
anxiety about starting treatment whereas more experienced patients may not mention 
the more minor symptoms.  Physicians may also be more cautious with new patients 
who have no previous history of ART.  This may result in physicians misdiagnosing 
HSR more often in patients starting first-line therapy to ensure that no true HSR cases 
are missed.   
 
HLA-B*5701 is linked to ABC related HSR in many studies [502-506].    The HLA 
human genes help in the body’s immune defence by allowing CD8 cells to recognise 
cells infected by pathogens [528].  It is also well-established that HLA-B*5701 is 
associated with long-term non-progression of HIV [528-530].  HIV infected individuals 
who do not experience disease progression may start therapy later and hence this 
allele may be under-represented in the groups of patients starting ABC as part of a 
second-, third- or fourth-line regimen.  This could be another explanation for the 
increased incidence of HSR in the group starting ABC in a first-line regimen.  HLA-
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B*5701 is more often found in Caucasian patients than in non-Caucasians and 
therefore ethnicity could be a marker for the presence of this allele [502,504,505].  The 
frequency has been found to be 5-8% in Caucasians, 4-7% in Hispanics, less than 1% 
in Asians and rare in Sub-Saharan Africans [531,532].  However the analyses in this 
chapter found no significant association between white ethnicity and risk of HSR and 
so ethnicity was ruled out as a potential confounder in this dataset.  This may be due to 
limited power as there were very few non-Caucasians included in the study population.  
Just 7.7% of patients who met the inclusion criteria were non-Caucasian.   
 
7.4.1.2 Incidence of hypersensitivity reaction according to geographical region 
There was no evidence of a significant regional difference in ABC discontinuation due 
to HSR within the first three months in this analysis.  The frequency of HLA-B*5701 is 
known to vary across different populations and differences in frequency have been 
found across Europe [511,531,532].  Therefore, a possible explanation for this finding 
is that in areas of low prevalence of the allele, there may be more cases of clinical 
over-diagnosis of suspected HSR resulting in an overall similar incidence of ABC HSR 
between regions.  
 
7.4.1.3 Incidence of hypersensitivity reaction according to date started abacavir  
A significantly higher incidence rate of HSR was found in earlier years compared to the 
time period 2005 onwards.  A reason for this could be that more clinics are using 
prospective genetic screening, which has been shown to effectively reduce the 
incidence of HSR by preventing the prescription of ABC to those at high-risk 
[503,505,506,508-512].  A study looking at an ethically mixed French HIV infected 
population showed that introducing prospective screening reduced the incidence of 
ABC related HSR from 12% to 0% [505].  Rauch et al. (2006) also found a significant 
drop in the incidence of true HSR (confirmed by skin patch tests) in 260 ABC-naïve 
patients from the Western Australian HIV Cohort Study, from 8% before the 
introduction of screening, to 2% after its implementation [508].  The development of 
low-cost, rapid, accurate tests may have allowed more widespread use of genetic 
screening in more recent years [533,534].  Another reason for the decrease observed 
in 2005 could be that as HSR symptoms are now better documented, HSR may be 
more recognisable and therefore correctly identified more frequently, reducing the 
chance of over-diagnosis.  If symptoms were misclassified as HSR in earlier years, this 
could explain the decrease in recent years.   
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7.4.1.4 Incidence of hypersensitivity reaction according to formulation of abacavir  
A decreased incidence of ABC discontinuation due to HSR within three months was 
observed in patients starting Kivexa compared to those starting Ziagen or Trizivir.  The 
Trizivir Epidemiology Study found no differences in the frequency of ABC HSR 
between patients starting either Ziagen or Trizivir [501].  However, to date there have 
been no studies that have compared the incidence of HSR between patients starting 
Kivexa and other formulations of ABC.  In this analysis, all known, measured variables 
that potentially may have confounded the results were investigated but a difference 
remained after adjustment.  This may be due to the relatively small number of person-
years available for the Kivexa group and the small number of events during this time 
and so these results should be treated with caution.   
 
7.4.1.5 Hypersensitivity reaction related deaths 
Severe ABC related HSRs, which can lead to death, are rare but have been reported in 
a few case studies [498-500].  In this analysis, there were no reports of patients who 
discontinued ABC due to HSR and then died within one month.  Patients who died on 
ABC therapy or within a month after stopping due to a reason not recorded as HSR 
mostly had advanced disease with known non-HSR causes of death.  Of patients who 
died within three months of starting ABC, only two had unknown causes of death.   
However as recent CD4 counts at time of death were low for these patients, it is likely 
that immunodeficiency was the cause of death.  This suggests that any patients with 
severe reactions to ABC were taken off the drug promptly to prevent fatality. 
 
7.4.2 Limitations 
The main limitation of the analyses in this chapter was that the incidence rates can only 
reflect clinical diagnosis of HSR, rather than cases confirmed to be immunologically 
“true”.  However, it is interesting to observe these trends across the different patient 
subsets defined in this chapter, to identify patients more likely to be given a diagnosis 
of HSR.  No standardised guidelines were used to define HSR and cases of HSR were 
not reviewed centrally, therefore reporting bias between centres cannot be ruled out.  
Some centres may be more likely to be cautious about stopping ABC treatment if they 
suspect HSR than others, which may be a source of confounding.  Furthermore, the 
follow-up forms only collect one reason for discontinuation per drug.  As some patients 
may experience more than one toxicity, it is possible that HSR is not always reported.  
The forms also allow ‘patient’s wish’ and ‘physician’s decision’ as reasons for 
discontinuation, which could result in misclassification.   
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Another limitation is that EuroSIDA does not collect information on genetic screening.  
Thus, it is unknown as to whether or not patients were tested for HLA-B*5701 and 
prescribed ABC according to results.  There is also no information on CD8 cell count, 
which was identified by Easterbrook et al. (2003) as a factor associated with HSR (i.e. 
the higher the baseline CD8 count, the higher the risk of HSR) [494].   
 
Although it is assumed in this study that all deaths are recorded on the follow-up forms, 
it is possible that some were missed.  Causes of death could also be misclassified or 
coded differently in different centres.  The introduction of the CoDe (“Coding of Death 
in HIV”) project in cohort studies (details at www.cphiv.dk) has helped to standardise 
the approach to collecting and reviewing causes of death. 
 
7.4.3 Implications  of  findings 
The results of these analyses identified that HSR diagnoses occurred more frequently 
in patients starting ABC in a first-line regimen than in later regimens, which may not 
necessarily reflect the situation when looking at true cases of HSR.  Clinical over-
diagnosis may prevent patients who would benefit from ABC use from continuing to 
take the drug but is preferable to the risk of fatality from HSR that accompanies 
continued use.  The wider use of prospective genetic screening may allow physicians 
to assess individual patients’ risk of HSR more accurately.  The decrease in incidence 
of ABC related HSR observed in recent years could indicate that this is becoming the 
case and that with a greater awareness of the factors that are associated with this 
reaction, doctors are able to avoid prescribing ABC to those most at risk.   
 
7.4.4 Further  research 
Further data that would be useful to collect is whether or not genetic screening was 
used prior to prescribing ABC, whether or not skin patch tests were used to confirm 
HSR and all reasons for discontinuation per drug, rather than just one reason.  This 
would establish more clearly the extent of true HSR and whether or not physicians had 
prior knowledge of genetic factors that would affect the risk of HSR.  It would be helpful 
to have more details about patients who discontinued ABC due to patient or physician 
choice as symptoms experienced may have led the patient or physician to decide to 
stop the drug; these symptoms may have been early signs of HSR. 
 
As the incidence of HSR related discontinuation of ABC only decreased in 2005 
onwards in these analyses and was observed to be fairly stable over calendar time 
before then, it would be interesting to continue to monitor HSR incidence over the next 
few years to see if the incidence rate continues to drop.  It would also be interesting to 
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investigate whether these trends are observed in each geographical region, which 
would require a larger study population. 
 
Further analyses could also compare the short and long-term reasons for 
discontinuation of other drugs to ABC and look at the factors affecting this.  Some 
patients may be more likely to stop any regimen in the first three months and the 
factors associated with this may not be ABC-specific. 
 
7.4.5 Conclusions 
Incidence of ABC discontinuation due to HSR appears to be higher in patients starting 
ABC as part of first-line therapy, which may be explained by increased clinical over-
diagnosis.  It has decreased in recent years, suggesting that prospective genetic 
screening, improved patient care and awareness of the symptoms of HSR may have 
prevented the use of this drug for high-risk patients.  There appears to be a similar rate 
of ABC discontinuation due to HSR across Europe.  Patients starting the co-formulation 
drug, Kivexa, which was introduced in January 2004, appear to have a decreased risk 
to those starting ABC as the single tablet, Ziagen, or as part of Trizivir, however limited 
data are available for the use of Kivexa and so results remain preliminary.  There were 
no reported deaths due to ABC HSR in this analysis. 
 
A manuscript of this analysis was published by Antiviral Therapy in July 2008 and can 
be found in Appendix X.  
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Chapter 8. Conclusions 
Since combination antiretroviral therapy (cART) was introduced into clinical practice 
across North America and Western Europe in 1995-1996, mortality and morbidity rates 
in HIV infected individuals have been reduced significantly [118-121,139,140,179].   
Antiretroviral drugs inhibit HIV from successful replication, which protects the immune 
system from further damage and allows restoration of the key target host cells, CD4 
cells [40,41,182-186].  This protects the body from opportunistic infections that can 
lead to AIDS or death [187].   
 
Factors strongly associated with a successful response to therapy include a potent and 
tolerable regimen [180,181,185,202-205,290], good adherence (more than 95%) [192] 
and low levels of HIV drug resistance [16,318,319].  The aims of this thesis were to 
investigate specific factors potentially associated with virological and immunological 
responses to cART, including HIV drug resistance and tolerability of a specific drug, in 
a large observational cohort study of HIV-1 infected individuals. 
 
8.1 Summary  of main findings 
8.1.1  Virological response to first-line combination antiretroviral therapy 
across geographical regions and over calendar time  
In Chapter 3, differences in virological response rate were analysed across 
geographical regions within calendar time periods, corresponding to when patients 
started a cART regimen for the first time, and also over calendar time within each 
region.  Multivariable analyses were carried out on ART-naïve patients to eliminate 
patients with a history of ART use who may have accumulated HIV drug resistance that 
would confound the results.  As it is now common for patients to start cART for the first 
time from ART-naïve, these results are widely applicable to newly diagnosed HIV 
infected individuals across Europe.   
 
One of the purposes of these analyses was to explore whether or not patients starting 
therapy for the first time in different regions had similar chances of responding 
successfully and to see if this had been the case in different time periods.  Another was 
to monitor trends in virological response over time within each region to see if 
improvements in patient care and management were reflected in response rates 
throughout Europe.  Analyses were adjusted for type of cART regimen to see if there 
was an additional effect of calendar time or region after accounting for differences in 
regimen.   
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The results showed some variation between regions of EuroSIDA in virological 
response to first-line cART.  This was most apparent in early-cART years (1996-1997) 
when the East region had a comparatively inferior response rate and Central West had 
the highest rate.  In mid-cART (1998-1999) and late-cART (2000-2004) years, 
virological response rate in the East region was still generally lower than other regions, 
however response rates were more similar across all regions than in the earlier years.  
This suggests that the standard of patient care, toxicity management, patient 
information and availability of new potent antiretroviral drugs have become more 
uniform across Europe since the introduction of cART and fits in with previous 
EuroSIDA findings that showed a decrease in regional variation of the type of cART 
regimen received over calendar time [383].   
 
Another finding was that there were significant improvements in virological response in 
all EuroSIDA regions, but especially in East Europe, where a large-scale HIV epidemic 
has been growing rapidly since the mid-1990s [83].  These improvements may be 
explained by better patient adherence to their treatment due to improved toxicity 
management and clinical support, and increased access to new antiretroviral drugs.  
Previous research has also found improvements in virological response over calendar 
time [379-382].  These increases in virological response observed in ART-naïve 
patients suggest that transmitted HIV drug resistance has not yet had a clinically 
significant impact and may even be decreasing in the population.  Recent data have 
suggested this is the case in the UK [394].  This question was further researched in 
Chapter 5 of this thesis and no significant trends over time were observed.   
 
These results highlight the key role of a study like EuroSIDA to monitor trends and 
potentially signal variability in type of care and treatment outcomes across Europe. 
 
8.1.2  HIV-1 subtypes and virological and immunological response to 
combination antiretroviral therapy 
HIV-1 is classified into a number of genetically distinct subtypes, A-D, F-H, J and K, as 
well as circulating recombinant forms including the most common CRF01_AE and 
CRF02_AG strains [344,355,399,401].  Subtype B is largely predominant across North 
America and Western Europe.  As antiretroviral drugs have historically been designed 
based on biological and clinical trial data from these regions, it is uncertain as to 
whether patients infected with strains more prevalent elsewhere in the world will 
respond as successfully as those infected with subtype B. 
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Chapter 4 investigated the prevalence of HIV-1 subtypes in EuroSIDA patients who 
had the information available and found that of the patients selected for inclusion in 
these analyses, the majority (86.5%) were infected with subtype B as expected.   
Subtypes A, C, CRF01_AE and CRF02_AG were the next most prevalent strains.   
Virological and immunological response to cART were compared between patients 
infected with B and non-B subtypes in multivariable analyses and no significant 
differences were found, which supports findings from previous research [422-429].   
However, the power to detect true differences was limited due to the small number of 
patients infected with a non-B virus.  Comparison of A, C and ‘other’ subtypes with B 
subtype showed slightly higher odds of a virological response in patients infected with 
C or ‘other’ and borderline significantly lower odds in those infected with A, which could 
explain the overall result of no difference between B and non-B subtypes.  It is 
recognised that a larger sample size is needed in order to gain the power to draw firm 
conclusions, which could be obtained by combining data from a collaboration of 
studies.  With a larger dataset, it may be possible to analyse specific non-B subtypes in 
more detail. 
 
If the finding of no significant difference in response to cART between HIV-1 B and 
non-B is to be taken as true, this suggests that the genetic distinctions and also 
differences observed in resistance development between subtypes [399,406,411,413-
417] do not seem to have a clinically significant impact on overall response rates.   
Results from studies such as this have important implications for the resource-limited 
setting where the majority of patients have non-B HIV-1 subtypes and are receiving the 
same antiretroviral drugs as patients treated in the Western world.  
 
8.1.3  Transmitted drug-resistant HIV-1 and association with virological 
and immunological response to first-line combination antiretroviral 
therapy 
Transmitted drug resistance (TDR) is a potential problem for patients starting therapy 
for the first time as it could hinder the chances of successful viral suppression.  In 
Chapter 5, the prevalence of TDR in ART-naïve EuroSIDA patients was investigated 
across different patient subsets.  Overall 11.4% of patients with genotypic resistance 
test results available from tests performed retrospectively, on plasma samples stored 
prospectively whilst ART-naïve, were infected with a resistant strain.  This was in line 
with the estimates reported by other European studies [348,436,440,443,460].  No 
evidence was found to support a significant difference in the odds of detecting TDR 
over calendar time, between HIV-1 subtypes B versus non-B, or between Central West 
and East geographical regions compared to the North region within EuroSIDA, in 
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multivariable analyses.  Significant higher odds of TDR were found in the South region 
compared to the North.   
 
Previous research showed conflicting findings in whether or not TDR was on the 
increase or decline [388-394,447,461].  The increase observed in a number of studies 
could be explained by the wider accessibility to ART leading to an increase in the 
selection of drug-resistant strains.  It could also be due to increasing high-risk 
behaviour in patients on treatment [388-393].  However the most recent data from the 
UK showed a decrease that may be explained by improved virological control in 
patients on therapy, management of treatment failure and the fact that the most 
infectious HIV infected people are not receiving ART [394].   
 
Virological and immunological response to first-line cART was compared between 
patients infected with HIV with full/intermediate resistance to at least one drug started 
and those with HIV susceptible to all drugs started in multivariable analyses.  No 
significant difference was found in the odds of virological suppression, although there 
was a non-significant trend towards decreased odds in patients with resistant HIV.  The 
analyses had limited power due to the relatively small number of patients in this group.  
Significantly increased odds of immunological response were found in patients with 
TDR, which could be explained by a reduced viral fitness in resistant strains that may 
reduce immunological deterioration [464], but could likely be a result of the natural 
variability in the data.  As with the analyses in Chapter 4, these analyses would benefit 
from a larger dataset.  The collaboration of studies known as EuroCOORD is planning 
to investigate TDR in the near future.  
 
8.1.4  Comparison of genotypic resistance profiles and virological 
response between patients starting nevirapine and efavirenz 
At present, the two most commonly used NNRTIs in clinical practice across the world 
are nevirapine (NVP) and efavirenz (EFV).  Given their high potency and low cost 
these are the drugs recommended by the World Health Organisation for use in first-line 
ART in resource-limited settings [471,473].  Previous findings from a number of cohort 
studies, including a previous EuroSIDA analysis of mostly NRTI/PI-experienced 
patients, have highlighted an inferior virological response in patients starting NVP for 
the first time compared to EFV [300-304].  In contrast, a large randomised clinical trial 
of ART-naïve patients (known as 2NN) found no significant difference in treatment 
failure in their main analysis, although the study failed to demonstrate equivalence after 
being powered to investigate this.  Also, results from a sensitivity analysis excluding a 
small number of patients who were randomised to either of the groups, but who never 
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started their treatment, did find results supporting those from the observational studies 
[299]. 
 
As at the time of the previous EuroSIDA analysis, resistance data were not available, it 
was uncertain as to whether or not a different prevalence of pre-existing resistance in 
patients starting NVP or EFV may have confounded the comparison.  In Chapter 6, the 
analysis was repeated taking into account the new genotypic resistance data from tests 
performed retrospectively on stored plasma samples.  The results were found to be 
consistent with previous findings showing that those starting EFV had a 50% reduced 
risk of virological failure compared to those starting NVP.  In addition to controlling for 
demographics, previous ART and baseline NNRTI resistance, this more recent analysis 
was also adjusted for the predicted susceptibility to the drugs included in the regimen 
besides NVP and EFV.  NNRTI-resistant HIV was detected in 3.4% of patients at 
baseline with similar levels in both NVP and EFV groups.   
 
Different resistance profiles emerged over the course of treatment in the two groups.  
NNRTI resistance was detected in the majority (85.5%) of patients at time of virological 
failure and was similar between the groups.  Resistance profiles were compared in 
those who were still on an NNRTI at time of virological failure and with resistance test 
results available.  The K103N mutation was found to be more prevalent in those who 
failed on EFV and the Y181C and G190A mutations were more prevalent in those who 
failed on NVP, consistent with previous research [487-489]. 
 
Since this was not a randomised comparison, there may still be unmeasured 
confounding variables that may have biased the results.  These may be common to all 
the observational studies that found similar results, therefore this highlights the need 
for more randomised trials to compare the virological efficacy of NNRTIs in both 
NRTI/PI experienced patients as well as ART-naïve patients.  Although the 2NN 
randomised study concluded that there was no significant difference in the risk of 
treatment failure between patients starting NVP and EFV, the risk was higher in those 
starting NVP and it could be argued that this was of borderline statistical significance 
(significantly higher at the 10% level although not at the 5% level) and should be 
investigated further. 
 
As far as future prospectives in the observational setting are concerned, there is a plan 
to extend the sequencing to other regions of HIV RNA to definitely rule out the possible 
confounding due to a different prevalence of pre-existing resistance not detected by 
standard sequencing of the RT region (the Connect project within EuroSIDA).    
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8.1.5  Toxicity of antiretroviral therapy: safety of abacavir 
As briefly mentioned above, access to tolerable treatment is one of the key 
components for therapy success as toxicities are a major reason for non-adherence 
and may also result in treatment discontinuation, switches or interruptions 
[197,204,493].  Chapter 7 investigated a toxicological response to therapy, focusing on 
the reasons for discontinuation of one NRTI, abacavir (ABC), in particular the 
potentially fatal adverse effect, hypersensitivity reaction (HSR).  Incidence of 
discontinuation and specifically discontinuation due to HSR was compared across 
different patient subsets, which is important to identify patients most at risk and to 
monitor trends in a large heterogeneous population across Europe. 
 
Amongst patients who started ABC, HSR was the most commonly named toxicity 
reported in patients who discontinued.  It was found that 5.1% discontinued due to HSR 
within three months of initiation in line with other studies [40,41,234-236].  Incidence of 
ABC discontinuation due to HSR was found to be significantly higher in patients 
starting ABC as part of first-line therapy than in those starting the drug in a second-line 
regimen, which may be explained by increased clinical over-diagnosis and not 
necessarily true cases of HSR.  The HLA-B*5701 allele, which has been linked to ABC 
related HSR in many studies [502,503,507,508], is also associated with long-term non-
progression of HIV [528-530].  Therefore, genetically susceptible patients carrying this 
allele may have been under-represented in the groups starting ABC in 
second/third/fourth line regimens as they may start therapy later.   
 
Incidence decreased in recent years, suggesting that prospective genetic screening for 
the HLA-B*5701 haplotype, improved patient care and awareness of HSR may have 
prevented the use of this drug for high-risk patients.  Similar rates of discontinuation of 
ABC due to HSR were observed across EuroSIDA regions.  Patients starting the co-
formulation drug, Kivexa (introduced in January 2004), appear to have a decreased risk 
to those starting ABC as the single tablet, Ziagen, or as part of Trizivir, however limited 
data are available for the use of Kivexa and so results remain preliminary.  There were 
no reported deaths due to ABC HSR in this analysis, suggesting that any patients with 
severe reactions were taken off the drug early enough to prevent fatality.   
 
Recently the use of ABC has been also associated with an increased risk of myocardial 
infarction in the D:A:D study [533].  These findings were unexpected and the biological 
mechanisms by which the risk is increased are at present unknown.  The US Food and 
Drug Administration (FDA) and European Medicines Agency (EMEA) are both 
reviewing the safety data on ABC in relation to myocardial infarction [534].     
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8.2  Main limitations of analyses 
The research questions addressed in this thesis were investigated using data from a 
large prospective observational cohort, which carries the general limitations of all 
observational studies.  Analyses are adjusted to take into account potentially 
confounding factors that may bias the results, however as previously discussed in 
Chapter 1 (section 1.6.1) there may be unmeasured or unknown factors that cannot be 
adjusted for and so bias cannot be ruled out, only minimised.  Randomised controlled 
trials are the gold standard for comparisons of drug interventions, as factors that may 
affect the outcome should be balanced between groups resulting in unbiased 
comparisons.  Chapter 6 comparing NVP and EFV would benefit from trial data to 
address this question.  However, it is not possible to conduct trials to compare naturally 
occurring subsets of patients, e.g. patients infected with different HIV-1 subtypes, and 
so for this type of research question, observational study data are required.  The 
benefits of observational studies are the longer follow-up time collected for patients, the 
lack of strict inclusion/exclusion criteria that can result in quite a specialised selection of 
patients, and the opportunity to study long-term or rare effects of treatment. 
 
One of the main limitations throughout this thesis was the lack of statistical power for 
certain analyses due to limited numbers of patients in certain subsets.  In Chapter 3, 
there were few EuroSIDA patients starting cART in 1996-1997 in East Europe due to 
the fact that EuroSIDA started collecting data from East European countries later than 
the rest of Europe.  The small number of non-B HIV-1 subtypes limited the analyses in 
Chapter 4 and there were few patients starting cART with TDR in Chapter 5.   
Collaborative studies are a good way to pool data in order to maximise power, although 
a disadvantage is the variability across the different datasets in frequency and quality 
of data collection, as well as the specific information collected.      
 
A further question when interpreting the results is how representative the patients 
included in EuroSIDA are of the general European population.  Although many clinics 
across Europe are represented in EuroSIDA, those not included may differ in terms of 
clinician experience, treatment decisions and availability of ART.  Patients were 
entered into the study consecutively within the seven cohorts within EuroSIDA, which 
should give a good representation of patients attending each clinic.  Due to the large 
number of clinics, it could be argued that the sample is broadly representative of 
centres across Europe and more so than any one clinic cohort.   
 
A further general limitation of the dataset analysed in this thesis is the fact that there 
are missing values.  Data can be missing for a variety of unknown reasons and it is 
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possible that if merely excluded, this could bias the results.  EuroSIDA is a prospective 
observational study but attempts to collect complete treatment histories when a patient 
is enrolled.  Retrospective collection of data is likely to result in missing values.   
Patients may be too ill to travel to a clinic for a follow-up visit, which could mean that 
patients not responding to treatment are excluded from analyses, when there may be a 
common reason as to why they are not responding.  Two common methods of dealing 
with missing viral loads or CD4 counts were considered throughout, i.e. excluding the 
patients with missing values or counting the missing values as treatment failures.   
Conclusions were drawn having evaluated the results based on the main analysis as 
well as sensitivity analyses to allow for potential biases in the choice of statistical 
method.   
 
8.3  Overall implications of findings 
This thesis investigated trends in response to ART to identify factors that could affect a 
patient’s chance of a successful response.  This is useful for many reasons.   
Improvements in virological response, the lack of an increase in transmitted drug 
resistance and the decrease in the incidence of the potentially fatal toxicity of ABC 
HSR over calendar time, indicate that treatment strategies, physician knowledge and 
awareness of the effects of treatment, clinical support and toxicity management have 
all contributed to the success of ART and the increasing standard of HIV patient care 
across Europe.  Genetic variability of the virus has not yet proved to be a significant 
factor in the chance of responding to treatment, however it is recognised that this 
needs to continue to be monitored as studies investigating this have been fairly small-
scale or lacking in the power to make statistical comparisons.  There appears to be 
evidence of a difference between the two main NNRTIs used worldwide, which if true, 
could potentially have major implications for treatment policy.  At present, NVP is a 
popular choice for first-line therapy in developing countries due to its low cost, 
availability and ease of taking.  Results from EuroSIDA, as well as a number of other 
studies, suggest that this could be a second-rate treatment compared with EFV.   
However the studies may be biased by unmeasured or unknown confounding factors. 
 
8.4 Further  research 
This thesis covers issues that are currently of interest in HIV research, namely, recent 
trends in response to cART, the genetic variability of the virus including drug 
resistance, a comparison of two frequently used antiretroviral drugs and an adverse 
effect of another drug commonly prescribed in clinical practice.  Over the next few 
years, it is important to continue to monitor trends in response to treatment and in HIV 
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drug resistance, and observational cohort studies present the ideal setting to study a 
large heterogeneous population over a long period of time.  This thesis has identified 
the need for more randomised controlled trials to compare the two most widely used 
NNRTIs, NVP and EFV.  The newer NNRTIs such as etravirine (TMC-125) and others 
currently being developed or in the trial stage, may prove to be useful alternative 
options in the future.  During the preparation of this thesis, a number of new drugs have 
been approved by the FDA and the EMEA, including TMC-125, a PI (darunavir), an 
entry inhibitor (maraviroc), as well as a drug from a new drug class (an integrase 
inhibitor, raltegravir).  There are also further new drug classes in the experimental 
stage [215], which has provided hope for patients on salvage therapy who have 
extensive ART experience and possibly multi-drug resistance.  Monitoring the response 
to therapy, including any adverse reactions, over the coming years in patients starting 
these new drugs is essential to guide physicians in terms of appropriate prescription of 
treatment. 
 
Understanding more about the genetic diversity of the virus is important to ensure that 
the drugs being developed have universal efficacy.  Travel and migration are on the 
increase, which means that different strains of the virus are spreading worldwide.   
There is still a lot to learn about drug resistance and the combinations of genetic 
mutations that may predict whether or not a patient will have a successful response to 
treatment.  The genetic interpretation systems currently in use are constantly updated 
based on the latest research.   
 
This thesis concentrated on virological and immunological endpoints.  Ideally, it is 
clinical endpoints (AIDS and death) that are ultimately important and should be studied.  
Realistically, as treatment and patient management are improving all the time and 
keeping infected individuals alive for longer, they are fortunately becoming increasingly 
rare, making it difficult to study these endpoints.  With a much larger dataset, it may be 
possible to investigate them in some analyses.   
 
As discussed above, one of the main limitations of some of the analyses in this thesis 
was the lack of statistical power to detect true differences between groups of interest.  
This thesis would benefit from further HIV RNA sequence data in order to evaluate HIV 
drug resistance and to determine subtype.  This is an area that is being expanded in 
EuroSIDA and in the future, these analyses may be repeated in order to draw 
conclusions with more certainty.  At present, EuroSIDA is also recruiting patients for an 
eighth cohort, which will provide an additional 2500 patients, including 1250 in East 
European countries.  It also provides data for the D:A:D study and is a part of the 
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ongoing collaborative studies, EuroCOORD (The European Coordinating Committee 
for the Integration of Ongoing Coordination Actions Related to Clinical, Virological and 
Epidemiological HIV Research), COHERE (Collaboration of Observational HIV 
Epidemiological Research Europe) and the ART Cohort Collaboration. 
 
8.5 Concluding  remarks 
This thesis has compared a variety of different responses to antiretroviral therapy 
across subsets of a large heterogeneous HIV infected population across Europe (and a 
minority from Israel and Argentina).  The main aim was to study a number of factors 
potentially associated with outcomes of therapy that have not been previously 
investigated in a large prospective cohort study with such a substantial amount of data 
collected, including analyses based on the link between the clinical data and the 
increasingly growing EuroSIDA genotypic resistance database.  The continued 
expansion of EuroSIDA will allow more powerful analyses in the future with stricter 
inclusion criteria and will permit further stratifications of variables of interest for more 
detailed analyses.  It is hoped that these findings will contribute to research in 
monitoring trends in response to therapy and help to provide insight into association 
with the vast genetic variability of the virus.   
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Appendix I. International AIDS Society (IAS)-USA. 
Update of the drug resistance mutations in HIV-1: 
Spring 2008 
Reprinted with permission from the International AIDS Society–USA. Johnson VA, 
Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 
Spring 2008. Topics  in  HIV Medicine. 2008; 16(1): 62-68. ©2008, IAS-USA. Updated 
information [add: “(and thorough explanatory notes)” if the user notes are not reprinted] 
is available at www.iasusa.org. 
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Update	of	the	Drug	Resistance	Mutations	in	HIV-1:		
Spring	2008
Victoria A. Johnson, MD, Françoise Brun-Vézinet, MD, PhD, Bonaventura Clotet, MD, PhD, 
Huldrych F. Günthard, MD, Daniel R. Kuritzkes, MD, Deenan Pillay, MD, PhD, Jonathan M. 
Schapiro, MD, and Douglas D. Richman, MD
This Spring 2008 version of the Inter-
national AIDS Society–USA (IAS-USA) 
Drug Resistance Mutations Figures up-
dates the figures published in this jour-
nal  in  August/September  2007.1  The 
authors  comprise  the  IAS-USA  Drug 
Resistance Mutations Group, an inde-
pendent,  volunteer  panel  of  experts 
charged with the goal of delivering ac-
curate, unbiased, and evidence-based 
information on these mutations to HIV 
clinical practitioners. As for all IAS-USA 
panels, a rotation procedure is in place   
whereby 1 or 2 panel members peri-
odically step down from panel partici-
pation and new members join. These 
rotations are designed to ensure that 
all  IAS-USA  expert  panels  remain  di-
verse in member affiliations and areas 
of expertise. 
The figures are designed for practi-
tioners to use in identifying key muta-
tions associated with viral resistance to 
antiretroviral drugs and in making ther-
apeutic decisions. Updates are posted 
periodically  at  www.iasusa.org.  Care 
should be taken if using this list of mu-
tations in surveillance or epidemiologic 
studies of transmission of drug-resistant 
virus. Some amino acid substitutions, 
particularly minor mutations, represent 
polymorphisms  that  in  isolation  may 
not reflect prior drug selective pressure 
or reduced drug susceptibility. 
The mutations listed have been iden-
tified by 1 or more of the following crite-
ria: (1) in vitro passage experiments or 
validation of contribution to resistance 
by using site-directed mutagenesis; (2) 
susceptibility  testing  of  laboratory  or 
clinical isolates; (3) genetic sequencing 
of viruses from patients in whom the 
drug  is  failing;  (4)  correlation  studies 
between genotype at baseline and vi-
rologic response in patients exposed to 
the drug. The group reviews data that 
have been published or have been pre-
sented at a scientific conference. 
Drugs that have been approved by 
the US Food and Drug Administration 
(FDA) as well as any drugs available in 
expanded access programs are includ-
ed. They are listed in alphabetic order 
by drug class. User notes provide ad-
ditional information as necessary. Al-
though the Drug Resistance Mutations 
Group works to maintain a complete 
and current list of these mutations, it 
cannot  be  assumed  that  the  list  pre-
sented here is exhaustive. Readers are 
encouraged  to  consult  the  literature 
and experts in the field for clarification 
or more information about specific mu-
tations and their clinical impact. 
In the context of making clinical de-
cisions regarding antiretroviral therapy, 
evaluating the results of HIV genotypic 
testing includes: (1) assessing whether 
the pattern or absence of a pattern in 
the  mutations  is  consistent  with  the 
patient’s antiretroviral therapy history; 
(2)  recognizing  that  in  the  absence 
of drug (selection pressure), resistant 
strains may be present at levels below 
the limit of detection of the test (ana-
lyzing stored samples, collected under 
selection pressure, could be useful in 
this setting); and (3) recognizing that 
virologic  failure  of  the  first  regimen 
typically  involves  HIV-1  isolates  with 
resistance to only 1 or 2 of the drugs 
in the regimen (in this setting, resis-
tance  most  commonly  develops  to 
lamivudine or the nonnucleoside ana-
logue  reverse  transcriptase  inhibitors 
[NNRTIs]). The  absence  of  detectable 
viral resistance after treatment failure 
may result from any combination of 
the following factors: the presence of 
drug-resistant  minority  viral  popula-
tions,  nonadherence  to  medications, 
laboratory  error,  drug-drug  interac-
tions  leading  to  subtherapeutic  drug 
levels,  and  possibly  compartmental 
issues, indicating that drugs may not 
reach optimal levels in specific cellular 
or tissue reservoirs. 
Revisions	to	the	Figures	for	the	
Spring	2008	Update
In  addition  to  minor  formatting  and 
color alterations, revisions to the fig-
ures include removal of the “expanded 
access”  indication  for  etravirine  be-
cause the drug was approved by the 
US FDA in early 2008. A new etravirine 
mutation, V179T, has been added to 
the figure bar, and user note 13 has 
been revised to reflect new informa-
tion concerning etravirine mutations. 
Also, the expanded access indication 
for raltegravir has been removed be-
cause the drug was approved by the 
US FDA in late 2007.
Comments?
The  IAS-USA  Drug  Resistance  Mut-
ations Group welcomes comments on 
the mutations figures and user notes.
Author Affiliations: Dr Johnson (Group Chair), Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham 
School of Medicine, Birmingham, AL; Dr Brun-Vézinet, Hôpital Bichat-Claude Bernard, Paris, France; Dr Clotet, Fundacio irsiCAIXA and HIV 
Unit, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; Dr Günthard, University Hospital, Zurich, Switzerland; Dr Kuritzkes, Brigham 
and Women’s Hospital and Harvard Medical School, Boston, MA; Dr Pillay, Department of Infection, University College London, and Centre for 
Infections, Health Protection Agency, United Kingdom; Dr Schapiro, Sheba Medical Center, Tel Aviv, Israel;  Dr Richman (Group Vice-Chair), San 
Diego Veterans Affairs Medical Center and the University of California San Diego, CA.
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MUTATIONS IN THE REVERSE TRANSCRIPTASE GENE ASSOCIATED WITH RESISTANCE TO REVERSE TRANSCRIPTASE INHIBITORS
Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (nRTIs)1
Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)1,12
Multi-nRTI Resistance: 69 Insertion Complex2 (affects all nRTIs currently approved by the US FDA)
Multi-nRTI Resistance: 151 Complex3 (affects all nRTIs currently approved by the US FDA except tenofovir)
Multi-nRTI Resistance: Thymidine Analogue-associated Mutations4,5 (TAMs; affect all nRTIs currently approved 
by the US FDA)
Abacavir6
Didanosine7,8
Emtricitabine
Lamivudine
Stavudine4,5,9,10
Tenofovir11
Zidovudine4,5,9,10
Etravirine13
Efavirenz
Nevirapine
M
41
L
M
41
L
D
67
N
K
65
R
L
74
V
K
65
R
K
65
R
K
65
R
K
65
R
L
74
V
Y
115
F
M
184
V
M
184
V
I
M
184
V
I
A
62
V
A
62
V
V
75
I
F
77
L
F
116
Y
Q
151
M
K
70
R
K
70
R
M
41
L
D
67
N
K
70
R
K
70
E
M
41
L
D
67
N
K
70
R
L
210
W
T
215
Y
F
K
219
Q
E
L
210
W
T
215
Y
F
K
219
Q
E
L
210
W
T
215
Y
F
K
101
E
P
V
106
I
K
103
N
V
106
M
V
108
I
G
190
S
A
G
190
S
A
L
100
I
L
100
I
A
98
G
V
90
I
Y
181
C
I
Y
188
L
K
103
N
V
106
A
M
V
108
I
G
190
A
L
100
I
Y
181
C
I
Y
188
C
L
H
P
225
H
K
219
Q
E
L
210
W
T
215
Y
F
K
219
Q
E
U
69
Insert
Y
181
C
I
V
V
179
D
F
T
225 Special Contribution – Spring 2008 Resistance Mutations Update   Volume 16 Issue 1   March/April 2008
MUTATIONS IN THE PROTEASE GENE ASSOCIATED WITH RESISTANCE TO PROTEASE INHIBITORS14,15,16,17
Atazanavir
+/– ritonavir18
Fosamprenavir/
ritonavir
Darunavir/
ritonavir19
Indinavir/
ritonavir20
Lopinavir/
ritonavir21
Nelfinavir20,22
Saquinavir/
ritonavir
Tipranavir/
ritonavir23
L
10
I
F
V
C
G
16
E
K
20
R
M
I
T
V
L
24
I
V
32
I
L
33
I
F
V
L
33
F
E
34
Q
M
36
I
L
V
M
46
I
L
G
48
V
F
53
L
Y
D
60
E
I
62
V
I
54
L
V
M
T
A
I
64
L
M
V
A
71
V
I
T
L
G
73
C
S
T
A
V
82
A
T
F
I
I
93
L
M
I
85
V
L
90
M
I
84
V
L
10
V
I
13
V
K
20
M
R
L
33
F
E
35
G
M
36
I
M
46
L
I
47
V
K
43
T
I
54
A
M
V
Q
58
E
H
69
K
T
74
P
V
82
L
T
N
83
D
L
90
M
I
84
V
L
10
I
R
V
L
24
I
G
48
V
I
62
V
I
54
V
L
A
71
V
T
G
73
S
V
77
I
V
82
A
F
T
S
L
90
M
I
84
V
N
88
S
L
10
F
I
D
30
N
M
36
I
M
46
I
L
A
71
V
T
V
77
I
V
82
A
F
T
S
L
90
M
I
84
V
N
88
D
S
I
50
L
L
10
F
I
R
V
K
20
M
R
L
24
I
V
32
I
L
33
F
M
46
I
L
I
47
V
A
F
53
L
I
54
V
L
A
M
T
S
L
63
P
A
71
V
T
G
73
S
V
82
A
F
T
S
L
90
M
I
84
V
I
50
V
L
10
I
R
V
K
20
M
R
L
24
I
V
32
I
M
36
I
M
46
I
L
I
54
V
A
71
V
T
G
73
S
A
V
77
I
V
82
A
F
T
L
90
M
I
84
V
L
10
F
I
R
V
V
32
I
M
46
I
L
I
47
V
I
54
L
V
M
G
73
S
V
82
A
F
S
T
L
90
M
I
84
V
I
50
V
V
11
I
V
32
I
I
47
V
I
54
M
L
G
73
S
L
76
V
L
76
V
L
89
V
I
84
V
I
50
V
L
76
V
L
76
V
MUTATIONS IN THE INTEGRASE GENE ASSOCIATED WITH RESISTANCE TO INTEGRASE INHIBITORS
Raltegravir26
N
155
H
MUTATIONS IN THE ENVELOPE GENE ASSOCIATED WITH RESISTANCE TO ENTRY INHIBITORS 
Enfuvirtide24
Maraviroc25
Q
148
H
K
R
G
36
D
S
V
38
A
M
E
Q
39
R
Q
40
H
N
42
T
N
43
D
I
37
V
See User Note
90 54
L U
M
Amino acid, wild-type
Amino acid position
Major (boldface type;
protease only)15
Amino acid substitution conferring resistance
Minor (lightface type;
protease only)15
Insertion
MUTATIONS
Amino acid abbreviations: A, alanine; C, cysteine; D, aspar-
tate;  E,  glutamate;  F,  phenylalanine;  G,  glycine;  H,  histidine;   
I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; 
P,  proline;  Q,  glutamine;  R,  arginine;  S,  serine;  T,  threonine;   
V, valine; W, tryptophan; Y, tyrosine.
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User	Notes
1. Numerous nucleoside (or nucleotide) ana-
logue  reverse  transcriptase  inhibitor  (nRTI) 
mutations,  such  as  the  M41L,  L210W,  and 
T215Y mutations, may lead to viral hyper-
susceptibility to the nonnucleoside analogue 
reverse  transcriptase  inhibitors  (NNRTIs)  in 
nRTI-treated  individuals.  The  presence  of 
these  mutations  may  improve  subsequent 
virologic response to NNRTI-containing regi-
mens in NNRTI treatment-naive individuals 
(Shulman et al, AIDS, 2004; Demeter et al, 
11th CROI, 2004; Haubrich et al, AIDS, 2002; 
Tozzi,  J	Infect	Dis,  2004;  Katzenstein  et  al, 
AIDS, 2003). NNRTI hypersusceptibility can 
be  conferred  by  2  distinct  phenotypes:  in-
creased enzyme susceptibility to NNRTI (eg, 
V118I/T215Y) or decreased virion-associated 
levels  of  reverse  transcriptase  (eg,  H208Y/
T215Y and V118I/H208Y/T215Y). The viruses 
that contained less reverse transcriptase rep-
licated less efficiently than those with wild-
type levels of reverse transcriptase. (Clark et 
al, Antivir	Ther, 2006). The clinical relevance 
of all these mutations has not been assessed.
2. The 69 insertion complex consists of a 
substitution at codon 69 (typically T69S) and 
an insertion of 2 or more amino acids (S-S, S-
A, S-G, or others). The 69 insertion complex 
is associated with resistance to all nRTIs cur-
rently approved by the US FDA when present 
with 1 or more thymidine analogue-associ-
ated mutations (TAMs) at codons 41, 210, or 
215 (Miller et al, J	Infect	Dis, 2004). Some 
other amino acid changes from the wild-type 
T at codon 69 without the insertion may also 
be associated with broad nRTI resistance. 
3.  Tenofovir  retains  activity  against  the 
Q151M complex of mutations (Miller et al, J	
Infect	Dis, 2004).
4.  Multi-nRTI  resistance  mutations,  also 
known  as  nucleoside  analogue-associated 
mutations (NAMs), are associated with re-
sistance  to  numerous  nRTIs.  The  M41L, 
D67N, K70R, L210W, T215Y/F, and K219Q/
E are known as TAMs. TAMs are a subset of 
NAMs  that  are  selected  by  the  thymidine 
analogues  zidovudine  and  stavudine  and 
are  associated  with  cross-resistance  to  all 
nRTIs  currently  approved  by  the  US  FDA 
(Larder et al, Science, 1989; Kellam et al, 
Proc	Natl	Acad	Sci	USA, 1992; Calvez et al, 
Antivir	Ther, 2002; Kuritzkes et al, J	Acquir	
Immune	Defic	Syndr, 2004). Mutations at the 
C-terminal  reverse  transcriptase  domains 
(amino acids 293–560) outside of regions 
depicted on the figure bars may prove to 
be important for HIV drug resistance. Muta-
tions in the connection (A371V) and RNase 
H  (Q509L)  domains  of  reverse  transcrip-
tase are coselected on the same genome as 
TAMs and increase significantly zidovudine 
resistance when combined with TAMs. They 
also increase, although to a much lesser ex-
tent, cross-resistance to lamivudine, abaca-
vir, and tenofovir but not to stavudine or di-
danosine (Brehm et al, Antivir	Ther, 2006). 
When  the  polymerase  domain  contains 
TAMs, mutations in the connection domain 
(E312Q, G335C/D, N348I, A360I/V, V365I, 
and A376S) increase resistance to zidovu-
dine from 11-fold to as much as 536-fold 
over wild-type reverse transcriptase (Niko-
lenko et al, Proc	Natl	Acad	Sci	USA, 2007). 
Three mutations (N348I, T369I, and E399D) 
in the reverse transcriptase C-terminus are 
associated with the increased resistance to 
zidovudine and to NNRTIs. Mutations at this 
level could modulate NNRTI resistance by 
affecting dimerization of p66/p51 heterodi-
mers (Gupta et al, Antivir	Ther, 2006). Since 
the clinical relevance of these mutations has 
not been demonstrated, they are not depict-
ed on the figure bars.
5.  The  E44D  and  the  V118I  mutations  in-
crease the level of resistance to zidovudine 
and stavudine in the setting of TAMs, and 
correspondingly increase cross-resistance to 
the other nRTIs. The significance of E44D or 
V118I when each occurs in isolation is un-
known (Romano et al, J	Infect	Dis, 2002; Wal-
ter et al, Antimicrob	Agents	Chemother, 2002; 
Girouard et al, Antivir	Ther, 2002).
6. The M184V mutation alone does not ap-
pear to be associated with a reduced viro-
logic response to abacavir in vivo (Harrigan 
et al, J	Infect	Dis, 2000; Lanier et al, Antivir	
Ther, 2004). When present with 2 or 3 TAMs, 
M184V contributes to reduced susceptibility 
to abacavir and is associated with impaired 
virologic response in vivo (Lanier et al, Antivir	
Ther, 2004). The M184V plus 4 or more TAMs 
resulted in no virologic response to abacavir 
in vivo (Lanier et al, Antivir	Ther, 2004).
7. The K65R mutation may be selected by 
didanosine and is associated in vitro with 
decreased susceptibility to the drug (Winters 
et  al,  Antimicrob	Agents	Chemother,  1997). 
The impact of the K65R mutation in vivo is 
unclear.
8. The presence of 3 of the following—M41L, 
D67N, L210W, T215Y/F, and K219Q/E—has 
been associated with resistance to didano-
sine (Marcelin et al, Antimicrob	Agents	Chemo-
ther, 2005). The K70R and M184V mutations 
are not associated with a decreased virologic 
response to didanosine in vivo (Molina et al, 
J	Infect	Dis, 2005).
9. The presence of the M184V mutation ap-
pears to delay or prevent emergence of TAMs 
(Kuritzkes et al, AIDS, 1996). This effect may 
be overcome by an accumulation of TAMs or 
other mutations. The clinical significance of 
this effect of M184V is not known.
10. The T215A/C/D/E/G/H/I/L/N/S/V substitu-
tions are revertant mutations at codon 215, 
conferring increased risk of virologic failure 
of zidovudine or stavudine in antiretroviral-
naive patients (Riva et al, Antivir	Ther, 2002; 
Chappey et al, Antivir	Ther, 2003; Violin et 
al, AIDS, 2004). In vitro studies and prelimi-
nary clinical studies suggest that the T215Y 
mutant  may  emerge  quickly  from  one  of 
these mutations in the presence of zidovu-
dine or stavudine (Garcia-Lerma et al, J	Virol, 
2004; Lanier et al, Antivir	Ther, 2002; Riva et 
al, Antivir	Ther, 2002).
11.  The  K65R  mutation  is  associated  with 
a  reduced  virologic  response  to  tenofovir 
The  International  AIDS  Society–USA  (IAS–USA)  Drug  Resistance  Mutations  Group 
reviews new data on HIV drug resistance to maintain a current list of mutations 
associated  with  clinical  resistance  to  HIV.  This  list  includes  mutations  that  may 
contribute to a reduced virologic response to a drug. 
The mutations listed have been identified by 1 or more of the following criteria: (1) 
in vitro passage experiments or validation of contribution to resistance by using site-
directed mutagenesis; (2) susceptibility testing of laboratory or clinical isolates; (3) 
genetic sequencing of viruses from patients in whom the drug is failing; (4) correlation 
studies between genotype at baseline and virologic response in patients exposed to 
the drug. In addition, the group reviews only data that have been published or have 
been presented at a scientific conference. Drugs that have been approved by the US 
Food and Drug Administration (US FDA) as well as any drugs available in expanded 
access programs are included (listed in alphabetical order by drug class). User notes 
provide additional information as necessary. Although the Drug Resistance Mutations 
Group works to maintain a complete and current list of these mutations, it cannot be 
assumed that the list presented here is exhaustive. Readers are encouraged to consult 
the literature and experts in the field for clarification or more information about 
specific mutations and their clinical impact. 
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in vivo (Miller et al, J	Infect	Dis, 2004). A re-
duced response occurs in the presence of 3 
or more TAMs inclusive of either M41L or 
L210W (Miller et al, J	Infect	Dis, 2004). Slight-
ly increased treatment responses to tenofovir 
in vivo were observed if M184V was present 
(Miller et al, J	Infect	Dis, 2004).
12.  The  long-term  virologic  response  to 
sequential  NNRTI  use  is  poor,  particularly 
when 2 or more mutations are present (Anti-
nori et al, AIDS	Res	Hum	Retroviruses, 2002; 
Lecossier et al, J	Acquir	Immune	Defic	Syndr, 
2005). The K103N or Y188L mutation alone 
prevents      the      clinical       utility        of 
efavirenz     and    nevirapine    (Antinori et 
al, AIDS	Res	Human	Retroviruses, 2002). The 
V106M mutation is more common in HIV-
1 subtype C than in subtype B, and confers 
cross-resistance  to  all  currently  approved 
NNRTIs (Brenner et al, AIDS, 2003; Cane et 
al, J	Clin	Microbiol, 2001).
13.  Virologic  response  was  seen  in  clini-
cal  trials  despite  the  presence  of  single 
mutations. The impact of most mutations 
depends  on  the  simultaneous  presence 
of  Y181C;  Y181C  has  impact  only  when 
present with 1 or more of these mutations 
(Vingerhoets et al, Antivir	Ther, 2007). The 
presence  of  V179D/F/T,  Y181V,  or  G190S 
at  study  baseline  was  associated  with  a 
decreased  virologic  response  to  etravirine 
(etravirine package insert). The presence of 
3 or more baseline mutations (V90I, A98G, 
L100I,  K101E/P,  V106I,  V179D/F,  Y181C/I/ 
V, G190A/S) resulted in a reduced virologic 
response  to  etravirine  that  was  similar  to 
placebo (Picchio et al, CROI, 2008). How-
ever, the presence of K103N does not af-
fect etravirine response (etravirine package 
insert).  Correlations  between  detection  of 
etravirine mutations and subsequent viro-
logic response will likely undergo revision 
with the accumulation of more phenotypic 
susceptibility data and genotypic results in 
treatment-experienced individuals.
14.  The  same  mutations  usually  emerge 
whether or not PIs are boosted with low-
dose  ritonavir,  although  the  relative  fre-
quency of mutations may differ. Data on the 
selection of mutations in antiretroviral-naive 
patients in whom a boosted PI is failing are 
very limited. Numerous mutations are often 
necessary  to  significantly  impact  virologic 
response to a boosted PI. Although numbers 
vary for the different drugs, 3 or more muta-
tions are often required. 
15.  Resistance  mutations  in  the  protease 
gene are classified as either “major” or “mi-
nor,” if data are available.
Major mutations in the protease gene 
are defined in general either as those 
selected  first  in  the  presence  of  the 
drug; or those shown at the biochemi-
cal or virologic level to lead to an alter-
ation in drug binding or an inhibition 
of viral activity or viral replication. Ma-
jor mutations have an effect on drug 
susceptibility  phenotype.  In  general, 
these mutations tend to be the prima-
ry contact residues for drug binding.
Minor  mutations  generally  emerge 
later  than  major  mutations  and  by 
themselves do not have a significant 
effect on phenotype. In some cases, 
their effect may be to improve repli-
cative fitness of the virus containing 
major  mutations.  However,  some 
minor mutations are present as com-
mon polymorphic changes in HIV-1 
nonsubtype B clades, such as K20I/R 
and M36I in protease.
16.  Ritonavir  is  not  listed  separately  as  it 
is currently used at therapeutic doses as a 
pharmacologic booster of other PIs. At high-
er doses tested previously in humans, ritona-
vir administered as monotherapy produces 
mutations similar to those produced by indi-
navir (Molla, Nature	Med, 1996).
17.  HIV-1  Gag  cleavage  site  changes  can 
cause  PI  resistance  in  vitro.  It  has  been 
observed that mutations in the N-terminal 
part  of  gag  (MA:  E40K;  L75R;  K113E  and 
CA: M200I; A224A/V), outside the cleavage 
site, contribute directly to PI resistance by 
enhancing  the  overall  Gag  processing  by 
wild-type protease (Nijhuis et al, PLoS	Med, 
2007). The clinical relevance of these muta-
tions has not been assessed.
18. In most patients in whom an atazanavir/
ritonavir-containing  regimen  was  failing 
virologically,  accumulations  of  the  follow-
ing  13  mutations  were  found  (L10F/I/V, 
G16E,  L33F/I/V,  M46I/L,  I54L/V/M/T,  D60E, 
I62V,  A71I/T/L,  V82A/T,  I84V,  I85V,  L90M, 
and  I93L). Seven mutations were retained in 
an atazanavir score (L10F/I/V,  G16E, L33F/I/
V, M46I/L,  D60E, I84V, I85V); the presence 
of 3 or more of these mutations predicts a 
reduced virologic response at 3 months, par-
ticularly when L90M  was present (Vora et al, 
AIDS, 2006; http://www.hivfrenchresistance.
org/2006/tab2.html). A different report (Ber-
toli et al, Antivir	Ther, 2006) found that the 
presence of 0, 1, 2, or greater than or equal 
to 3 of the following mutations was associat-
ed with 92%, 93%, 75%, and 0% virologic re-
sponse to atazanavir/ritonavir: L10C/I/V, V32I, 
E34Q, M46I/L, F53L, I54A/M/V, V82A/F/I/T, 
I84V; presence of I15E/G/L/V, H69K/M/N/Q/
R/T/Y, and I72M/T/V improved the chances of 
response. For unboosted atazanavir, the pres-
ence of 0, 1, 2, or greater than or equal to 
3 of the following mutations was associated 
with 83%, 67%, 6%, and 0% response rates: 
G16E, V32I, K20I/M/R/T/V, L33F/I/V, F53L/Y, 
I64L/M/V, A71I/T/V, I85V, I93L/M. 
19. Darunavir (formerly TMC-114), boosted 
with ritonavir, was approved by the US FDA 
in June 2006. Resistance data are therefore 
still  preliminary  and  limited.  HIV  RNA  re-
sponse to boosted darunavir correlated with 
baseline susceptibility and the presence of 
multiple  specific  PI  mutations.  Reductions 
in response were associated with increasing 
numbers of the  mutations indicated in the 
bar. Some of these mutations appear to have 
a  greater  effect  on  susceptibility  than  oth-
ers (eg, I50V versus V11I). Further study and 
analysis in other populations are required to 
refine and validate these findings. 
20.  The  mutations  depicted  on  the  chart 
bar  cannot  be  considered  to  be  compre-
hensive  since  little  relevant  research  has 
been reported in recent years to update the 
resistance and cross-resistance patterns for 
this drug.
21. In PI-experienced patients, the accumula-
tion of 6 or more of the mutations indicated 
on the bar is associated with a reduced vi-
rologic response to lopinavir/ritonavir (Mas-
quelier  et  al,  Antimicrob	Agents	Chemother, 
2002; Kempf et al, J	Virol, 2001). The product 
information states that accumulation of 7 or 
8 mutations confers resistance to the drug. 
In contrast, in those in whom lopinavir/rito-
navir is their first PI used, resistance to this 
drug at the time of virologic rebound is rare. 
However,  there  is  emerging  evidence  that 
specific mutations, most notably I47A (and 
possibly I47V) and V32I are associated with 
high-level resistance (Mo et al, J	Virol, 2005; 
Friend et al, AIDS, 2004; Kagan et al, Protein	
Sci, 2005).
22. In some nonsubtype-B HIV-1, D30N is 
selected less frequently than other PI muta-
tions (Gonzalez et al, Antivir	Ther, 2004).
23. Accumulation of more than 2 mutations 
at positions 33, 82, 84, and 90 correlates 
with reduced virologic response to tiprana-
vir/ritonavir, although an independent role 
for L90M was not found. Detailed analyses 
of data from phase II and III trials in PI-ex-
perienced patients identified mutations as-
sociated with reduced susceptibility or viro-
logic  response.  These  include:  L10V,  I13V, 
K20M/R,  L33F,  E35G,  M36I,  K43T,  M46L, 
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I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, 
N83D, and I84V. Accumulation of these mu-
tations is associated with reduced response. 
Subsequent genotype-phenotype and geno-
type-virologic response analyses determined 
some mutations have a greater effect than 
others (eg, I84V versus I54M). Refinement 
and clinical validation of these findings are 
pending (Baxter et al, J Virol, 2006; Mayers 
et al, Antivir	Ther, 2004; Hall et al, Antivir	
Ther,  2003;  McCallister  et  al,  Antivir	Ther, 
2003;  Parkin  et  al,  CROI,  2006;  Bacheler 
et al, European HIV Drug Resistance Work-
shop, 2006).
24.  Although  resistance  to  enfuvirtide  is 
associated primarily with mutations in the 
first heptad repeat (HR1) region of the gp41 
envelope gene, viruses that are wild type in 
the  depicted  HR1  region  vary  500-fold  in 
susceptibility.  Such  pretreatment  suscepti-
bility differences were not associated with 
differences in clinical responses (Labrosse et 
al, J	Virol, 2003). Furthermore, mutations or 
polymorphisms in other regions in the enve-
lope (eg, the HR2 region or those yet to be 
identified) as well as coreceptor usage and 
density  may  affect  susceptibility  to  enfu-
virtide (Reeves et al, Proc	Natl	Acad	Sci	USA, 
2002; Reeves et al, J	Virol, 2004; Xu et al, 
Antimicrob	Agents	Chemother,  2005).  Thus, 
testing  to  detect  only  the  depicted  HR1 
mutations may not be adequate for clinical 
management  of  suspected  failure  (Reeves 
et al, J	Virol, 2004; Menzo et al, Antimicrob	
Agents	Chemother, 2004; Poveda et al, J	Med	
Virol, 2004; Sista et al, AIDS, 2004; Su, Anti-
vir	Ther, 2004). 
25. Maraviroc activity is limited to patients 
with only CCR5 (R5)-using virus detectable; 
CXCR4 (X4)-CCR5 mixed tropic viruses and 
X4-using viruses do not respond to maravi-
roc treatment. Some cases of virologic fail-
ure during maraviroc therapy are associated 
with outgrowth of X4 virus that pre-exists as 
a minority population below the level of as-
say detection. Mutations in the HIV-1 gp120 
molecule that allow the virus to bind to R5 
receptors in the presence of drug have been 
described  in  viruses  from  some  patients 
whose virus remained R5 at the time of vi-
rologic failure. A number of such mutations 
have  been  identified,  and  the  phenotypic 
manifestation  of  this  drug  resistance  is  a 
reduction in the maximal percentage inhi-
bition (MPI) rather than the increase in the 
50% inhibitory concentration (IC50; defined 
by fold increase) that is characteristic of re-
sistance  to  other  classes  of  antiretrovirals. 
The resistance profile for maraviroc is too 
complex to be depicted on the figures. The 
frequency and rate at which maraviroc resis-
tance mutations emerge are not yet known.
26. Raltegravir failure was associated with inte-
grase mutations in 2 distinct genetic pathways 
defined by 2 or more mutations including: (1) 
a signature (major) mutation at either Q148H/
K/R or N155H; and (2) 1 or more minor mu-
tations unique to each pathway. Minor muta-
tions described in the Q148H/K/R pathway 
include L74M + E138A, E138K, or G140S. 
The most common mutation pattern in this 
pathway  is  Q148H  +  G140S;  this  Q148H 
+ G140S pattern exhibits the greatest loss 
of drug susceptibility. Mutations described in 
the N155H pathway include this primary mu-
tation plus either L74M, E92Q, T97A, E92Q 
+ T97A, Y143H, G163K/R, V151I, or D232N 
(Hazuda et al, Antivir	Ther, 2007).
(continued from page 62)
Please  send  your  evidence-based 
comments,  including  relevant  ref-
erence  citations,  to  the  IAS-USA  at 
resistance2008“at”iasusa.org  or  by 
fax  at  415-544-9401.  Please  include 
your name and institution.
Reprint	Requests
The Drug Resistance Mutations Group 
welcomes interest in the mutations fig-
ures as an educational resource for prac-
titioners and encourages dissemination 
of the material to as broad an audience 
as possible. However, permission is re-
quired to reprint the figures and no al-
terations in the content can be made. 
If  you  wish  to  reprint  the  mutations 
figures, please send your request to the 
IAS-USA via e-mail or fax (see above). 
Requests  to  reprint  the  material 
should  include  the  name  of  the  pub-
lisher  or  sponsor,  the  name  or  a  de-
scription  of  the  publication  in  which 
you  wish  to  reprint  the  material,  the 
funding  organization(s),  if  applicable, 
and the intended audience of the publi-
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adaptations of the material should in-
clude the former, plus a detailed expla-
nation of how the adapted version will 
be changed from the original version 
and, if possible, a copy of the proposed 
adaptation. To ensure the integrity of 
the mutations figures, IAS–USA policy 
is to grant permission for only minor, 
preapproved adaptations of the figures 
(eg, an adjustment in size). Minimal ad-
aptations  only  will  be  considered;  no 
alterations of the content of the figures 
or user notes will be permitted. Please 
note  that  permission  will  be  granted 
only for requests to reprint or adapt the 
most current version of the mutations 
figures as they are posted on the Web-
site (www.iasusa.org). Because scientif-
ic understanding of HIV drug resistance 
evolves rapidly and the goal of the Drug 
Resistance Mutations Group is to main-
tain  the  most  up-to-date  compilation 
of mutations for HIV clinicians and re-
searchers, publication of out-of-date fig-
ures is counterproductive. If you have 
any questions about reprints or adapta-
tions, please contact us.
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Appendix II. Rega Version 7.1. Algorithm for the use of  
genotypic HIV-1 resistance data: 8 May 2007  
Reprinted with permission from the authors. Van Laethem K, Deforche K, Geretti AM, 
Camacho R and Vandamme A-M. Algorithm for the use of genotypic HIV-1 resistance 
data. Rega v7.1 ©, Leuven, 8 May 2007.  
http://www.kuleuven.be/rega/cev/links/rega_algorithm/Rega_HIV1_Rules_v7.1.pdf. 
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The rules include and score mutations for which in vitro phenotypic drug resistance or in vivo therapy response data have been reported, or for which retrospective associations with drug experience have been described. Some of the mutations do not necessarily 
result in high-level phenotypic resistance. Instead, they have been identified as key mutations along a pathway leading to high-level resistance (e.g., T215 revertants) or have proved to be predictive of therapy failure. Where supported by reliable evidence, the 
antagonistic or synergistic interaction effects of combinations of mutations are also incorporated (e.g., M184IV and TAMs). Three levels of interpretation criteria are applied: for HIV-1, criteria to consider an isolate as resistant, intermediately resistant or susceptible. 
 
Genotypic susceptibility scores (GSS) are assigned to the three susceptibility levels for each drug class or individual drug. Although the same rules apply to each PI and its respective PI/r, different GSS are assigned to the boosted and un-boosted drug. 
 
GSS resistant  intermediate  resistant  susceptible 
NRTI - NtRTI 
NNRTI 
Etravirine 
PI 
PI/r 
EI 
0 
0 
0 
0 
0 
0 
0.5 
0.25 
0.5 
0.5 
0.75 
0.25 
1 
1 
1 
1 
1.5 
1 
 
Target GSS for the entire treatment combination regimen are proposed. Resistance development is expected when therapy changes with GSS below the target are installed. 
 
Clinical situation  Target GSS 
Therapy-naive persons with indications of transmitted drug resistance 
Therapy-naive and therapy-experienced persons 
Therapy-experienced persons with limited treatment options 
≥3.5 
≥3 
≥2 
 
 
  Criteria to consider an isolate resistant a,b,c Criteria to consider an isolate intermediately resistant  a,b,c
NRTI 
 
zidovudine  [at least 1 mutation of (T69X-XX,Q151M)] 
or [at least 4 mutations of  (M41L,D67GN,T69AN,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR)] 
or [3 mutations of (M41L,L210W,T215Y) and not M184IV and not L74V] 
or [at least 3 mutations of (D67GN,K70R,T215F, K219EQ)] 
[2 or 3 mutations of (M41L,D67GN,T69AN,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR)] 
or [T215FY and not M184IV] 
didanosine  at least 1 mutation of (T69DGN,T69X-XX,Q151M) 
or [M184IV and at least 1 mutation of (K65RN,L74IV)] 
or [at least 5 mutations of (M41L,D67N,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR)] 
at least 1 mutation of (K65NR,L74IV,V75T) 
or [3 or 4 mutations of (M41L,D67N,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR)] 
stavudine  [at least 1 mutation of (∆67,T69X-XX,V75AMST,Q151M)] 
or [at least 4 mutations of  (M41L,D67N,T69ADGN,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR)] 
or [3 mutations of (M41L,L210W,T215Y)] 
[2 or 3 mutations of (M41L,D67N,T69ADGN,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR)] 
or [T215FY and not M184IV] 
232lamivudine M184IV 
or (K65NR and Q151M) 
[at least 1 mutation of (∆67,T69X-XX,K65NR,Q151M)] 
or {[at least 1 mutation of (E44AD,V118I)] 
and [at least 3 mutations of (M41L,D67N,T69AN,K70R,L210W,T215FY,K219EHNQR)]} 
abacavir  [at least 1 mutation of (∆67,T69G)] 
or [at least 2 mutations of (K65NR,T69X-XX,L74IV,Y115F,Q151M,M184IV)] 
or {(T69X-XX or Q151M) and [at least 3 mutations of (M41L,D67N,K70R,L210W,T215ACDEGHILNSVFY, 
K219EHNQR)]} 
or {[at least 1 mutation of (K65NR,L74IV,Y115F,M184IV)] 
and [at least 4 mutations of (M41L,D67N,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR]} 
[1 mutation of (T69X-XX,Q151M)]  
or [1 mutation of (K65NR,L74IV,Y115F,M184IV)] 
and [2 or 3 mutations of (M41L,D67N,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR]} 
or [at least 3 mutations of (M41L,D67N,K70R,L210W,T215ACDEGHILNSVFY,K219EHNQR)] 
emtricitabine M184IV 
or (K65NR and Q151M) 
[at least 1 mutation of (∆67,T69X-XX,K65NR,Q151M)] 
or {[at least 1 mutation of (E44AD,V118I)] 
and [at least 3 mutations of (M41L,D67N,T69AN,K70R,L210W,T215FY,K219EHNQR)]} 
NtRTI   
tenofovir  [at least 1 mutation of (K65NR,T69X-XX)] 
or [at least 5 mutations of (M41L,D67N,K70R,L210W,T215ACDEGHILNSVYF,K219EHNQR)] 
[at least 1 mutation of (70EG,Q151M)] 
or [K65NR and M184IV] 
or [3 mutations of (M41L,L210W,T215Y)] 
or [at least 4 mutations of (M41L,D67N,K70R,L210W,T215ACDEGHILNSVYF,K219EHNQR)] 
NNRTI 
 
nevirapine  [at least 1 mutation of (L100I,K101P,K103HNST,V106AM,Y181CIV,Y188CHL,G190ACEQSTV,M230L)] 
or [at least 4 mutations of (A98G,K101EQ,K103R,V106I,V108I,V179D,H221Y,F227L,K238T,Y318F)] 
[2 or 3 mutations of (A98G,K101EQ,V106I,V108I,V179D,H221Y,F227L,K238T,Y318F)] 
or (K103R and V179D) 
delavirdine  [at least 1 mutation of (L100I,K103HNT,V106AM,Y181CIV,Y188L,G190E,M230L,P236L)] 
or [at least 2 mutations of (K101P,K103S,Y188CH,G190Q,Y318F)] 
or [1 mutation of (K101P,K103S,Y188CH,G190Q,Y318F) and at least 2 mutations of 
(A98G,K101EQ,K103R,V106I,V108I,V179D,F227L)] 
or [at least 4 mutations of (A98G,K101EQ,K103R,V106I,V108I,V179D,F227L)] 
[1 mutation of (K101P,K103S,Y188CH,G190Q,Y318F)] 
or [2 or 3 mutations of (A98G,K101EQ,V106I,V108I,V179D,F227L)] 
or (K103R and V179D) 
efavirenz  [at least 1 mutation of (K103HN,V106M,Y181C,Y188L,G190CEQSTV,M230L)] 
or [at least 2 mutations of (L100I,K101P,K103ST,V106A,Y181IV,Y188CHF,G190A,P225H)] 
or [1 mutation of (L100I,K101P,K103ST,V106A,Y181IV,Y188CHF,G190A,P225H) 
and at least 2 mutations of (A98G,K101EQ,K103R,V106I,V108I,V179D,H221Y,F227L,K238T,Y318F)] 
or [at least 4 mutations of (A98G,K101EQ,K103R,V106I,V108I,V179D,H221Y,F227L,K238T,Y318F)] 
[1 mutation of (L100I,K101P,K103ST,V106A,Y181IV,Y188CHF,G190A,P225H)] 
or [2 or 3 mutations of (A98G,K101EQ,V106I,V108I,V179D,H221Y,F227L,K238T,Y318F)] 
or (K103R and V179D) 
etravirine  (V179DEFI and Y181CV) 
or [at least 1 mutation of (Y181I,F227C,M230L) and at least 1 mutation of (L100I,K101ENP,E138K,V179DEFI,Y181CV, 
Y188L,G190ES)] 
or [at least 1 mutation of (Y181I,F227C,M230L) and at least 2 mutations of (A98G,K101QR, 
K103N,V106AM,V108I,Y188CFH,G190ACQTV,H221Y,P225H,F227L,L234I,P236L,K238T,Y318T)] 
or [at least 3 mutations of (L100I,K101ENP,E138K,V179DEFI,Y181CV, Y188L,G190ES)] 
or [at least 2 mutations of (L100I,K101ENP,E138K,V179DEFI,Y181CV,Y188L,G190ES) and at least 2 mutations of 
(A98G,K101QR,K103N,V106AM,V108I,Y188CFH,G190ACQTV,H221Y,P225H,F227L,L234I,P236L,K238T, Y318T)] 
or [at least 1 mutation of (L100I,K101ENP,E138K,V179DEFI,Y181CV,Y188L,G190ES) and at least 4 mutations of 
(A98G,K101QR,K103N,V106AM,V108I,Y188CFH,G190ACQSTV,H221Y,P225H,F227L,L234I,P236L,K238T, Y318T)] 
or [at least 6 mutations of (A98G,K101QR,K103N,V106AM,V108I,Y188CFH,G190ACQTV, 
H221Y,P225H,F227L,L234I,P236L,K238T,Y318T)] 
[1 mutation of (Y181I,F227C,M230L)] 
or [2 mutations of (L100I,K101ENP,E138K,V179DEFI,Y181CV, Y188L,G190ES)] 
or [1 mutation of (L100I,K101ENP,E138K,V179DEFI,Y181CV,Y188L,G190ES) and at least 2 mutations of 
(A98G,K101QR,K103N,V106AM,V108I,Y188CFH,G190ACQTV,H221Y,P225H,F227L,L234I,P236L,K238T,Y318T)] 
or [4 or 5 mutations of (A98G,K101QR,K103N,V106AM,V108I,Y188CFH,G190ACQTV,H221Y,P225H, 
F227L,L234I,P236L,K238T,Y318T)] 
233PId   
saquinavir/r  score is at least 3.5 
[add 1.5 to the score for every mutation in the following list: 48MV,54AST,84AC,90M; 
add 1 to the score for every mutation in the following list: 24I,53L,54V,71V,84V,88DS,89V; 
add 0.5 to the score for every mutation in the following list: 10F,20T,46IL,48A,50V,54LM,58E,71I,73STC, 74SP,89T; 
add 0.25 to the score for every mutation in the following list: score 0.25: 10IV,11I,20IMRV,62V,71T,74A,82AIFLMST,89I; 
distract 0.5 from the score for every mutation in the following list: 50L] 
score is at least 2  
[add 1.5 to the score for every mutation in the following list: 48MV,54AST,84AC,90M; 
add 1 to the score for every mutation in the following list: 24I,53L,54V,71V,84V,88DS,89V; 
add 0.5 to the score for every mutation in the following list: 10F,20T,46IL,48A,50V,54LM,58E,71I,73STC, 74SP,89T; 
add 0.25 to the score for every mutation in the following list: score 0.25: 10IV,11I,20IMRV,62V,71T,74A,82AIFLMST,89I; 
distract 0.5 from the score for every mutation in the following list: 50L] 
indinavir/r  score is at least 3 
[add 1.5 to the score for every mutation in the following list: 46IL,54AST,82AT,84A; 
add 1 to the score for every mutation in the following list: 10F,24I,32I,48MV,54V,76V,82FMS,88S,90M; 
add 0.5 to the score for every mutation in the following list: 20T,32X-X,43T,48A,54LM,66F,71I, 73STC,74P,84CV,88D, 
89TV,95F; 
add 0.25 to the score for every mutation in the following list: score 0.25: 10IV,20IMRV,35DGN,43R,62V,71TV,74AS, 
82I,89I; 
distract 0.5 from the score for every mutation in the following list: 50L] 
score is at least 2 
[add 1.5 to the score for every mutation in the following list: 46IL,54AST,82AT,84A; 
add 1 to the score for every mutation in the following list: 10F,24I,32I,48MV,54V,76V,82FMS,88S,90M; 
add 0.5 to the score for every mutation in the following list: 20T,32X-X,43T,48A,54LM,66F,71I, 73STC,74P,84CV,88D, 
89TV,95F; 
add 0.25 to the score for every mutation in the following list: score 0.25: 10IV,20IMRV,35DGN,43R,62V,71TV,74AS, 
82I,89I; 
distract 0.5 from the score for every mutation in the following list: 50L] 
nelfinavir  score is at least 2.5 
[add 1.5 to the score for every mutation in the following list: 30N,54AST,84AC,88S,90M; 
add 1 to the score for every mutation in the following list: 54V,82ATF,88D; 
add 0.5 to the score for every mutation in the following list: 10F,20T,23I,24I,32I,43T,46IL,48AV, 
54LM,58E,66F,71I,73STC,74P,82LMS,84V,89TV,93M; 
add 0.25 to the score for every mutation in the following list: 
10IV,20IMRV,33FI,35DGN,43R,62V,64V,71TV,74AS,82I,89I; 
distract 0.5 from the score for every mutation in the following list: 50L; 
distract 0.25 from the score for every mutation in the following list: 70R] 
score is at least 1.5 
[add 1.5 to the score for every mutation in the following list: 30N,54AST,84AC,88S,90M; 
add 1 to the score for every mutation in the following list: 54V,82ATF,88D; 
add 0.5 to the score for every mutation in the following list: 10F,20T,23I,24I,32I,43T,46IL,48AV, 
54LM,58E,66F,71I,73STC,74P,82LMS,84V,89TV,93M; 
add 0.25 to the score for every mutation in the following list: 
10IV,20IMRV,33FI,35DGN,43R,62V,64V,71TV,74AS,82I,89I; 
distract 0.5 from the score for every mutation in the following list: 50L; 
distract 0.25 from the score for every mutation in the following list: 70R] 
fosamprenavir 
(/r) 
score is at least 3.5 
[add 1.5 to the score for every mutation in the following list: 32X-X,50V,84AC; 
add 1 to the score for every mutation in the following list: 47AV,48M,54MTV,76V,82F,84V; 
add 0.5 to the score for every mutation in the following list: 10F,20T,24I,32I,33F,43T,46IL,48A,54AL,58E,82AMST,89TV; 
add 0.25 to the score for every mutation in the following list: 10IV,20IRMV,33I,43R,48V,82I,89I,90M; 
distract 0.5 from the score for every mutation in the following list: 50L] 
score is at least 2 
[add 1.5 to the score for every mutation in the following list: 32X-X,50V,84AC; 
add 1 to the score for every mutation in the following list: 47AV,48M,54MTV,76V,82F,84V; 
add 0.5 to the score for every mutation in the following list: 10F,20T,24I,32I,33F,43T,46IL,48A,54AL,58E,82AMST,89TV; 
add 0.25 to the score for every mutation in the following list: 10IV,20IRMV,33I,43R,48V,82I,89I,90M; 
distract 0.5 from the score for every mutation in the following list: 50L] 
lopinavir/r  score is at least 4 
[add 1.5 to the score for every mutation in the following list: 32X-X,47A,54AT; 
add 1 to the score for every mutation in the following list: 47V,48M,50V,54SV,76V,82FS,84A; 
add 0.5 to the score for every mutation in the following list: 10F,20T,24FI,32I,33F,43T,46IL,48AV,53L,54LM, 71I,73STC, 
82ALMT,84V,88D,90M; 
add 0.25 to the score for every mutation in the following list: 10IV,20IMRV,33I,43R,64MV,71TV,77ATV,82I; 
distract 0.5 from the score for every mutation in the following list: 50L] 
score is at least 2.5 
[add 1.5 to the score for every mutation in the following list: 32X-X,47A,54AT; 
add 1 to the score for every mutation in the following list: 47V,48M,50V,54SV,76V,82FS,84A; 
add 0.5 to the score for every mutation in the following list: 10F,20T,24FI,32I,33F,43T,46IL,48AV,53L,54LM, 71I,73STC, 
82ALMT,84V,88D,90M; 
add 0.25 to the score for every mutation in the following list: 10IV,20IMRV,33I,43R,64MV,71TV,77ATV,82I; 
distract 0.5 from the score for every mutation in the following list: 50L] 
atazanavir(/r)  score is at least 3.5 
[add 1.5 to the score for every mutation in the following list: 48V,50L,54AT; 
add 1 to the score for every mutation in the following list: 20T,47V,54V,74P,82T,84V,88DS,90M; 
add 0.5 to the score for every mutation in the following list: 10F,24I,32I,46IL,54LM,58E,71IL,73ACFST,82ALMSF,85V; 
add 0.25 to the score for every mutation in the following list: 10IV,20IMRV,33FI,71TV,74AS,82I] 
score is at least 2 
[add 1.5 to the score for every mutation in the following list: 48V,50L,54AT; 
add 1 to the score for every mutation in the following list: 20T,47V,54V,74P,82T,84V,88DS,90M; 
add 0.5 to the score for every mutation in the following list: 10F,24I,32I,46IL,54LM,58E,71IL,73ACFST,82ALMSF,85V; 
add 0.25 to the score for every mutation in the following list: 10IV,20IMRV,33FI,71TV,74AS,82I] 
234tipranavir/r  score is at least 5 
[add 1.5 to the score for every mutation in the following list: 47V,54A,82T,84V; 
add 1 to the score for every mutation in the following list: 11L,32I,33FM,38W,41T,54S,73T,82L; 
add 0.5 to the score for every mutation in the following list: 10F,20T,43T,45I,46IL,54MVT,58E, 71ILF,73SC,82ACSFM, 
88DS,89VT,90M; 
add 0.25 to the score for every mutation in the following list: 
10IV,13V,20IMRV,33IV,35DGN,36I,41K,43R,69K,71TV,82I,89I; 
distract 0.5 from the score for every mutation in the following list: 50L; 
distract 0.25 from the score for every mutation in the following list: 57R] 
score is at least 3 
[add 1.5 to the score for every mutation in the following list: 47V,54A,82T,84V; 
add 1 to the score for every mutation in the following list: 11L,32I,33FM,38W,41T,54S,73T,82L; 
add 0.5 to the score for every mutation in the following list: 10F,20T,43T,45I,46IL,54MVT,58E, 71ILF,73SC,82ACSFM, 
88DS,89VT,90M; 
add 0.25 to the score for every mutation in the following list: 
10IV,13V,20IMRV,33IV,35DGN,36I,41K,43R,69K,71TV,82I,89I; 
distract 0.5 from the score for every mutation in the following list: 50L; 
distract 0.25 from the score for every mutation in the following list: 57R] 
darunavir/r  score is at least 5 
[add 1.5 to the score for every mutation in the following list: 50V; 
add 1 to the score for every mutation in the following list: 76V,84ACV; 
add 0.5 to the score for every mutation in the following list: 32I,33F,47AV; 
add 0.25 to the score for every mutation in the following list: 11I,32L,33IMV,34V,35GN,41IT,46IL,54LM,70E,73ACFSTV, 
74E,82L,85V,89ITV] 
score is at least 3 
[add 1.5 to the score for every mutation in the following list: 50V; 
add 1 to the score for every mutation in the following list: 76V,84ACV; 
add 0.5 to the score for every mutation in the following list: 32I,33F,47AV; 
add 0.25 to the score for every mutation in the following list: 11I,32L,33IMV,34V,35GN,41IT,46IL,54LM,70E,73ACFSTV, 
74E,82L,85V,89ITV] 
EI   
enfuvirtide  at least 2 mutations of (G36DESV,V38AEM,Q40H,Q41R,N42DEHKQT,N43DKQS,L44MV,L45MPQ)  1 mutation of (G36DESV,V38AEM,Q40H,Q41R,N42DEHKQT,N43DKQS,L44MV,L45MPQ) 
 
a T69X-XX, X whatever amino acid. ∆67, deletion of amino acid 67. A, alanine; R, arginine; N, asparagine; D, aspartic acid; C, cysteine; Q, glutamine; E, glutamic acid; G, glycine; H, histidine; I, isoleucine; L, leucine; K, lysine; M, methionine; F, phenylalanine; P, 
proline; S, serine; T, threonine; W, tryptophan; Y, tyrosine and V, valine. b If more mutations are present at a certain position (e.g. T215Y and T215F), they are only counted as one mutation in the rules. c If none of the criteria to consider an isolate resistant towards a 
particular drug are full-filled, proceed to the criteria to consider an isolate intermediately resistant. If none of the latter criteria are full-filled, the isolate can be scored susceptible to that particular drug. d r, PI boosted with baby dose of ritonavir. NRTI, nucleoside 
reverse transcriptase inhibitor; NtRTI, nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; EI, entry inhibitor. 
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Appendix III. The EuroSIDA study group  
(National co-ordinators in parenthesis). 
Argentina: (M Losso), A Duran, Hospital JM Ramos Mejia, Buenos Aires.  
Austria: (N Vetter), Pulmologisches Zentrum der Stadt Wien, Vienna. 
Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk. 
Belgium: (N Clumeck), S De Wit, B Poll, Saint-Pierre Hospital, Brussels; R 
Colebunders, Institute of Tropical Medicine, Antwerp. 
Bulgaria: (K Kostov), Infectious Diseases Hospital, Sofia. 
Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb. 
Finland: (M Ristola), Helsinki University Central Hospital, Helsinki. 
Czech Republic: (L Machala), H Rozsypal, Faculty Hospital Bulovka, Prague; D 
Sedlacek, Charles University Hospital, Plzen. 
Denmark: (J Nielsen), J Lundgren, T Benfield, O Kirk, Panum Institute, Copenhagen; J 
Gerstoft, T Katzenstein, A-B E Hansen, P Skinhøj, Rigshospitalet, Copenhagen; C 
Pedersen, Odense University Hospital, Odense; L Oestergaard, Skejby Hospital, 
Aarhus. 
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; J Smidt, Nakkusosakond 
Siseklinik, Kohtla-Järve. 
France: (C Katlama), Hôpital de la Pitié-Salpétière, Paris; J-P Viard, Hôpital Necker-
Enfants Malades, Paris; P-M Girard, Hospital Saint-Antoine, Paris; JM Livrozet, Hôpital 
Edouard Herriot, Lyon; P Vanhems, University Claude Bernard, Lyon; C Pradier, 
Hôpital de l'Archet, Nice; F Dabis, Unité INSERM, Bordeaux.  
Germany: (J Rockstroh), Universitäts Klinik Bonn; R Schmidt, Medizinische 
Hochschule Hannover; J van Lunzen, O Degen, University Medical Center Hamburg-
Eppendorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, 
Hamburg; S Staszewski, JW Goethe University Hospital, Frankfurt; J Bogner, 
Medizinische Poliklinik, Munich; G. Fätkenheuer, Universität Köln, Cologne.  
Greece: (J Kosmidis), P Gargalianos, G Xylomenos, J Perdios, Athens General 
Hospital; G Panos, A Filandras, E Karabatsaki, 1st IKA Hospital; H Sambattakou, 
Ippokration Genereal Hospital, Athens.  
Hungary: (D Banhegyi), Szent Lásló Hospital, Budapest. 
Ireland: (F Mulcahy), St. James's Hospital, Dublin.  
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; S Pollack, G Hassoun, 
Rambam Medical Center, Haifa; S Maayan, Hadassah University Hospital, Jerusalem. 
Italy: (A Chiesi), Istituto Superiore di Sanità, Rome; R Esposito, I Mazeu, C Mussini, 
Università Modena, Modena; C Arici, Ospedale Riuniti, Bergamo; R Pristera, Ospedale 
Generale Regionale, Bolzano; F Mazzotta, A Gabbuti, Ospedale S Maria Annunziata, 
Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, Rome; A Chirianni, E 
Montesarchio, M Gargiulo, Presidio Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; 
G Antonucci, F Iacomi, P Narciso, C Vlassi, M Zaccarelli, Istituto Nazionale Malattie 
Infettive Lazzaro Spallanzani, Rome; A Lazzarin, R Finazzi, Ospedale San Raffaele, 
Milan; M Galli, A Ridolfo, Osp. L. Sacco, Milan; A d’Arminio Monforte, Istituto Di Clinica 
Malattie Infettive e Tropicale, Milan.  
Latvia: (B Rozentale), P Aldins, Infectology Centre of Latvia, Riga.  
Lithuania: (S Chaplinskas), Lithuanian AIDS Centre, Vilnius.  
Luxembourg: (R Hemmer), T Staub, Centre Hospitalier, Luxembourg.  
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Netherlands:  (P Reiss), Academisch Medisch Centrum bij de Universiteit van 
Amsterdam, Amsterdam.  
Norway: (J Bruun) A Maeland, V Ormaasen, Ullevål Hospital, Oslo.  
Poland: (B Knysz), J Gasiorowski, Medical University, Wroclaw; A Horban, Centrum 
Diagnostyki i Terapii AIDS, Warsaw; D Prokopowicz, A Wiercinska-Drapalo, Medical 
University, Bialystok; A Boron-Kaczmarska, M Pynka, Medical Univesity, Szczecin; M 
Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, 
Medical University, Gdansk.  
Portugal: (F Antunes), E Valadas, Hospital Santa Maria, Lisbon; K Mansinho, Hospital 
de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.  
Romania: (D Duiculescu), Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes, 
Bucarest.  
Russia: (A Rakhmanova), Medical Academy Botkin Hospital, St Petersburg; E 
Vinogradova, St Petersburg AIDS Centre, St Peterburg; S Buzunova, Novgorod Centre 
for AIDS, Novgorod.  
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Belgrade. 
Slovakia: (M Mokráš), D Staneková, Dérer Hospital, Bratislava.  
Spain:  (J González-Lahoz), V Soriano, L Martin-Carbonero, P Labarga, Hospital 
Carlos III, Madrid; B Clotet, A Jou, J Conejero, C Tural, Hospital Germans Trias i Pujol, 
Badalona; JM Gatell, JM Miró, Hospital Clinic i Provincial, Barcelona; P Domingo, M 
Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona.  
Sweden: (A Karlsson), Karolinska University Hospital, Stockholm; PO Persson, 
Karolinska University Hospital, Huddinge; L Flamholc, Malmö University Hospital, 
Malmö.  
Switzerland:  (B Ledergerber), R Weber, University Hospital, Zürich; P Francioli, M 
Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B Hirschel, E Boffi, 
Hospital Cantonal Universitaire de Geneve, Geneve; H Furrer, Inselspital Bern, Bern; 
M Battegay, L Elzi, University Hospital Basel.  
Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for AIDS, Kiev.  
United Kingdom: (S Barton), St. Stephen's Clinic, Chelsea and Westminster Hospital, 
London; AM Johnson, D Mercey, Royal Free and University College London Medical 
School, London (University College Campus); A Phillips, MA Johnson, A Mocroft, 
Royal Free and University College Medical School, London (Royal Free Campus); M 
Murphy, Medical College of Saint Bartholomew's Hospital, London; J Weber, G 
Scullard, Imperial College School of Medicine at St. Mary's, London; M Fisher, Royal 
Sussex County Hospital, Brighton; R Brettle, Western General Hospital, Edinburgh. 
Virology group: B Clotet (Central Coordinators) plus ad hoc virologists from 
participating sites in the EuroSIDA Study.  
Steering Committee: F Antunes, B Clotet, D Duiculescu, J Gatell, B Gazzard, A 
Horban, A Karlsson, C Katlama,  B Ledergerber (Chair), A D’Arminio Montforte, A 
Phillips, A Rakhmanova, P Reiss (Vice-Chair), J Rockstroh.  
Coordinating centre staff: J Lundgren (project leader), O Kirk, A Mocroft, N Friis- 
Møller, A Cozzi-Lepri, W Bannister, M Ellefson, A Borch, D Podlevkareva, C Holkmann 
Olsen, J Kjær, L Peters, J Reekie. 
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Appendix IV. The EuroSIDA December 2006 follow-up 
form  
 
 
238December 2006 / Center/patient code EuroSIDA dataset 25 form
Date of completion of this form (dd-mm-yyyy) Completed by (investigator's initials)
Section A. Demography
Date of Birth (dd-mm-yyyy):
      -      -      
Gender: 1=male, 2=female
Section B1. Basic clinical information (if dead see also section H)
Height (999cm = unknown) cm
Enrollment weight (999.0=unknown) kg
(if dead, present visit = time of death, see section H)
Most recently measured weight kg
Time of measurement (dd-mm-yyyy)
Not available (x) (section F and/or G should be completed)
Time of AIDS diagnosis (dd-mm-yyyy) if applicable
Last follow-up recorded in database
Present visit (dd-mm-yyyy)
First seen at the department
      -      -      
      -      -      
      -      -      
Systolic and diastolic blood pressure:
Not done
Date of measurement 
(dd-mm-yyyy)
      -      -      
Value Unit
/
Most recent measurement since last follow-up:
Yes No Unknown Smoking status:
Is the patient currently a cigarette smoker? 
Was the patient a cigarette smoker at last follow-up?
If NO - has he/she ever smoked cigarettes?
Have any first degree relatives (genetic mother, father, brother, sister) 
experienced myocardial infarction or stroke before the age of 50 years? 
Please fill out if blank:
If Pregnancy, outcome:  Spontaneous abortion
Medical abortion
Birth of HIV+ 
child
Birth of HIV- child
Birth of child with unknown HIV stat
Still pregnant
For women: Pregnancy in 2006? 
239Center/patient code Section B2. Clinical events
Have any of the following serious events occured since last follow-up?: 
(Please see diagnosis definitions in the instructions)
If yes, date of event:
Unknown No Yes (dd-mm-yyyy)
Cardiovascular events*:
Carotic endarterectomy*:       -      -      
Coronary angioplasty/stenting*:       -      -      
Coronary artery by-pass grafting*:       -      -      
Myocardial infarction*:       -      -      
Stroke*:       -      -      
Metabolic events:
Diabetes Mellitus*:       -      -      
Lipodystrophy:
Is the patient experiencing loss of fat from 
extremities, buttocks or face?
Is the patient experiencing accumulation of fat in 
abdomen, neck, breasts or other defined location?
Other organ events:
Avascular necrosis in the femural head (by imaging):       -      -      
Bone fracture (specify location:______________________________):       -      -      
Hepatic encephalopathy (stage III or IV ) :       -      -      
      -      -       Pancreatitis (symtoms + objective evidence):
Renal disease, end stage (dialysis/transplantation):       -      -      
* Please complete relevant DAD case report forms
Section C. Laboratory values
Date of measurement 
(dd-mm-yyyy) Value Unit
Fasting Most recently measured: Not done
Serum total cholesterol:       -      -      
Serum HDL cholesterol:       -      -      
Serum triglycerides:       -      -      
Peak value since last visit for:
Peak plasma glucose:       -      -      
Most recently reported s-creatinine value:       -      -      
ALL measured s-creatinine values since last follow-up:
Date of measurement 
(dd-mm-yyyy) Unit Value
Date of measurement 
(dd-mm-yyyy) Value Unit
      -      -             -      -      
      -      -             -      -      
      -      -             -      -      
240Section C. Laboratory values Center/patient code
Date of measurement 
(dd-mm-yyyy) Value Unit Most recently measured since last follow-up:
Haemoglobin level:       -      -      
Platelet count:       -      -      
ALT value:       -      -      
AST value:       -      -      
INR value:       -      -      
Bilirubin value:       -      -      
S-lactate (not LDH) value:       -      -      
Peak value since last follow-up for:
S-lactate value (not LDH):       -      -      
S-amylase value:       -      -      
Value Value Date of measurement 
(dd-mm-yyyy)
Date of measurement 
(dd-mm-yyyy)
Two most recently reported 
CD4 cell counts:       -      -             -      -      
CD4 cell counts measured 
since last follow-up:
      -      -             -      -      
      -      -             -      -      
      -      -             -      -      
Two most recently reported  
HIV-RNA values:
Date of measurement 
(dd-mm-yyyy)
Value Below level of 
detection (X)
Detection 
limit
Assay
(see list)
Please note that values reported below level of 
detection have been registered as detection limit 
minus 1
eg. Below 200 would be recorded as 199
      -      -      
      -      -      
HIV-RNA values measured 
since last follow-up:
Assay:
1 - Roche
2 - Roche ultrasensitive
3 - NASBA
4 - Chiron/bDNA
9 - Other, please specify:________________
      -      -      
      -      -      
      -      -      
      -      -      
      -      -      
      -      -      
5 - TaqMan
Date (dd-mm-yyyy)
Last HIV-subtyping performed:
Type Not done
Method used:
Last HIV resistance testing, 
if performed since last follow-up:  -      -      
 -      -      
Last HCV-subtyping performed:  -      -      
If a test was performed - please attach a copy of the resistance test report when returning the form
Hepatitis virology/serology
HBV antibody test
HBVsAg
HBV-DNA
HCV antibody test
HCV-RNA
Last reported
Date Result
Most recent test (if  any later than the last recorded)
Date Positive Negative Unknown Value Unit
      -      -      
      -      -      
      -      -      
      -      -      
      -      -      
-
-
-
-
-
241Section D. Antiretroviral treatment within the last 5 year Center/patient code
1. Has the patient ever received antiretrovirals?  
If yes, please update this section which should include all data on antiretrovirals used within the last 5 years. (go to section E for other treatment)
If no, index X [  ]
*If stopped drug 
since last visit, 
Ongoing treatment First time 
of initiation
Most recent ended treatment
  b. reason for 
discontinuation
a.last date of 
stopping
On drug at 
present visit
On drug at 
last visit
Latest date of 
start Reason 
Date of 
stop
Date of 
start
indexed by X indexed by X
2.  Previous and/or present 
antiretroviral therapy from 
within the last 5 years
                                     
3.  All initiated and/or restarted antiretroviral therapy since last follow-up 
Please use the list of codes below or write full drug name for any drugs not listed
                                     
      -      -             -      -       _________________
      -      -             -      -       _________________
      -      -             -      -       _________________
_________________       -      -             -      -      
4.  Has any comment(s) on adherence to ART been 
made in the patient records since last follow-up?
No Yes - 
please give date of 
comment(s) to the right:
Date of comment
(dd-mm-yyyy)
      -      -      
      -      -      
      -      -      
"<70%", "poor", "inadequate", 
"not good", "intermittent"
anything 
inbetween
">95%", "perfect", 
"full", "excellent"
TEN: Tenofovir
PBT: Participant in blinded trial
NRTIs:
ABC: Abacavir
AZT: Zidovudine
3TC: Lamivudine
D4T: Stavudine
DDI: Didanosine
EMT: Emtricabine
NNRTIs:
EFV: Efavirenz
ETV: Etravirine (TMC-125)
PIs:
AMP: (Fos-)Amprenavir
AZV: Atazanavir
DAV: Darunavir (TMC-114)
IDV: Indinavir
LPV: Lopinavir/r 
NFV: Nelfinavir
RTV: Ritonavir
SQH: Saquinavir hard gel capsule
TPV: Tipranavir
Combination drugs:
COM: Combivir (AZT/3TC)
KIV: Kivexa (3TC/ABC)
LPV: Kaletra (LPV/RTV)
TRP: Atripla (TEN/EMT/EFV)
TRU: Truvada (TEN/EMT)
TZV: Trizivir  (AZT/3TC/ABC)
ENF: Enfurvirtide (Fuzeon/T20)
Other:
NVP: Nevirapine
Integrase inhibitors:
Fusion inhibitors:
Please specify full name
MAR: Maraviroc
*Reason for discontinuation: 
1: Treatment failure ( i.e. virological, 
immunological and/or clinical failure)
2: Abnormal fat redistribution
3: Concern of cardiovascular disease
4: Hypersensitivity reaction
5: Toxicity, predominantly 
from abdomen/GI tract
6: Toxicity, predominantly 
from nervous system
 7: Toxicity, predominantly
from kidneys
 8: Toxicity, predominantly
from the endocrine system
90: Toxicity, not mentioned above
91: Patient's wish/decision, not specified above
92: Physician's decision, not specified above
94: Other causes, not specified above
93: STI - Structured Treatment Interruption
99: Unknown 
3.1: Dyslipidaemia
3.2: Cardiovascular disease
5.1: Toxicity - GI tract
5.2: Toxicity - Liver
5.3: Toxicity - Pancreas
 8.1: Diabetes
 9: Haematological toxicity
10: Hyperlactataemia/
lactic acidosis
PIs:
2421. Has the patient ever received drugs to prevent
(both primary prophylaxis and maintenance therapy) or treat infections?     
Section E1. Treatment against infections Center/patient code
 If no, index X [  ]
If  yes, complete this section (For drugs against opportunistic infections, only those used after enrollment in EuroSIDA).  
Most recent ended treatment 2. Previous and/
or present therapy                               Date of 
stop
Date of 
start
If not on drug at pres. visit 
indicate date of stopping
(dd-mm-yyyy)
On drug at 
present visit 
(indexed by X)
On drug at last 
clinical visit 
(indexed by X)
Latest date of start
(dd-mm-yyyy)
First time of 
treatment
Nothing previously reported
3. All initiated and/or restarted antiretroviral therapy since last follow-up 
Please use the list of codes below or write full drug name for any drugs not listed                          
            -      -             -      -       ___________________________________ 
      -      -             -      -       ___________________________________ 
Immunomodulating therapy
IL2: Interleukin 2
GCSF: G-CSF
INTF: Interferon
PINT: Peg-Interferon
HCV drugs
RIBA: Ribavirin     
PCP/TOXO drugs                                                            
ATOV: Atovaquone          
BACT: Bactrim (cotrimoxazole)                                                                              
CLIN: Clindamycin                                                                                            
DAPS: Dapsone                           
PENT: Pentamidine neb./inj.
PYRI: Pyrimethamine
SULP: Sulphadiazine
Mycobacterium  drugs
ISON: Isoniazide
ETHA: Ethambutole
PYRA: Pyrazinamide
RIFA: Rifabutine
RIFM: Rifampicine
CLAR: Clarithromycin/azithromycin
HBV and CMV/HSV drugs
GANC: Ganciclovir
FOSC: Foscarnet
CONA: Continous Acyclovir
ADEF: Adefovir dipivoxil
CIDO: Cidofovir
Fungal drugs
AMPH: Amphotericin B, i.v.
FLUC: Fluconazole
ITRA: Itraconazole
KETO: Ketoconazole
CASP: Caspofungin 
VORI: Voriconazole    
INTF: Interferon
Mycobacterium  drugs
Section E2. Treatment related to risk of cardiovascular disease
1. Has the patient ever received medication related to risk of cadiovascular disease?  If no, index X [  ]
If  yes, complete this section .  
2. Previous and/
or present treatment
First time of 
treatment
Most recent ended treatment
Date of 
start
Date of 
stop
Latest date of 
start
(dd-mm-yyyy)
On drug at last 
clinical visit 
(indexed by X)
On drug at 
present visit 
(indexed by X)
If not on drug at pres. visit 
indicate date of stopping
(dd-mm-yyyy)
Anabolic steroids/
appetite stimulants:
      -      -             -      -       - - -
ACE inhibitors:       -      -             -      -       - - -
Antihypertensive agents, 
others:
      -      -             -      -       - - -
Anti platelets:       -      -             -      -       - - -
Insulin or derivatives hereof:       -      -             -      -       - - -
Lipid lowering agents:       -      -             -      -       - - -
Oral antidiabetic agents:       -      -             -      -       - - -
2431. Any previous or new severe opportunistic infections (including AIDS defining)?
Section F1. Severe opportunistic infections Center/patient code
If no index X  [  ]
If  yes, complete this section 
2. Previously reported:
Way of diagnosis (tick box)
Autopsy Presumptive Definitive
Time of onset 
(dd-mm-yyyy)
Nothing previously reported
3. New severe opportunistic infections:
___________________________________        -      -      
      -      -       ___________________________________     
DEM: AIDS dementia complex  
BCNE: Bacterial pneumonia, recurrent (>2 episodes within 1 year)  
CANO: Candidiasis, oesophageal
CRCO: Cryptococcosis, extrapulm.
CRSP: Cryptosporidosis (duration > 1 month)
CMVR: Cytomegalovirus (CMV) chorioretinitis
CMVO: CMV - other location, specify 
HERP: Herpes simplex virus ulcers (duration >1 month) 
or  pneumonitis/esophagitis
HIST: Histoplasmosis, extrapulm.
WAST: HIV wasting syndrome
ISDI: Isosporiasis diarrhoea  (duration >1 month)
LEIS: Leishmaniasis, visceral
MCDI: Microsporidosis diarrhoea (duration >1 month)
MC: Mycobact. avium complex (MAC)  or Kansasii, extrapulm.
MCP: Mycobact. tuberculosis, pulm.
MCX: Mycobact. tuberculosis, extrapulm.
MCPO: Mycobact. pulm., other type, specify 
MCXO: Mycobact. extrapulm., other type, specify 
PCP: Pneumocystis jiroveci pneumonia (PCP)
LEU: Progressive multifocal  leucoencephalopathy
SAM: Salmonella bacteriaemia (non-typhoid) (>2 episodes)
TOX: Toxoplasmosis, brain
FBLS: Focal brain lesion   
1. Any previous or new other severe infections?
Section F2. Other severe infections
If no index X  [  ]
If  yes, complete this section 
2. Previously reported:
Way of diagnosis (tick box)
Autopsy Presumptive Definitive
Time of onset 
(dd-mm-yyyy)
Nothing previously reported
3. New severe infections:
Please use codes below or write the full type for any severe infection not listed
___________________________________        -      -      
___________________________________        -      -      
BACT: Bacteremia
PNEU: Pneumonia
MENI: Meningitis PERI: Peritonitis
ENDO: Endocarditis OSTI: Ostitis
PYEL: Pyelonephritis
Please specify full name for 
any other severe infections
2441. Any new AIDS defining malignancies?
Section G1. AIDS defining malignancies Center/patient code
If no index X  [  ]
If  yes, complete this section 
2. Previously reported:
Way of diagnosis (tick box)
Autopsy Presumptive Definitive
Time of onset 
(dd-mm-yyyy)
Nothing previously reported
3. New AIDS defining malignancies:
      -      -       ___________________________________ 
      -      -       ___________________________________ 
KS: Kaposi´s sarcoma  Non-Hodgkin lymphoma: NHLB: Burkitt (Classical or Atypical)
NHLI: Diffuse large B-cell lymphoma (Immunoblastic or Centroblastic)
NHLU: Unknown/other histology 
NHLP: Primary brain lymphoma (at diagnosis, involvement of the  central 
nervous system without other organ affection -  regardless of histology)
CRVC: Cervical cancer
1. Any new non-AIDS defining cancers?
Section G2. Non-AIDS defining cancers
If no index X  [  ]
If  yes, complete this section 
2. Previously reported:
Way of diagnosis (tick box)
Autopsy Presumptive Definitive
Time of onset 
(dd-mm-yyyy)
Nothing previously reported
3. New non-AIDS defining cancers:
Please use codes below or write the full type for any cancer not listed
      -      -       ___________________________________ 
      -      -       ___________________________________ 
ANUS: Anus cancer
BLAD: Bladder cancer
BRCA: Breast cancer
COLO: Colon cancer
COTC: Connective tissue cancer
KIDN: Kidney cancer
Leukemia:
LIPC: Lip cancer
LUNG: Lung cancer
MULM: Multiple myeloma
PENC: Penile cancer
PROS: Prostate cancer
RECT: Rectum cancer
STOM: Stomach cancer
TESE: Testicular seminoma
UTER: Uterus cancer
HDL: Hodgkin lymphoma
CERV: Cervical dysplasia/carcinoma in situ
ALL: Acute lymphoid
AML: Acute myeloid
CLL: Chronic lymphoid
CML: Chronic myeloid
MALM: Malignant melanoma
MESC: of squamuos cell carcinoma
MEAC: of adenocarcinoma
MEOC: of other cancertype
Metastasis:
LIVR: Liver cancer
Section H. For patients who died
1. Time of death (dd-mm-yyyy)       -      -      
2. Presumed ilness causing terminal condition, index (X) 
(1) Myocardial Infarction
(2) Stroke
(3) Other cardiovascular disease
(4) Symptoms caused by mitochondrial toxicity
(5) Complications to diabetes mellitus
(6) Pancreatitis
(7) Liver failure
(8) HIV-related
(90) Other, specify: __________________________
(99) Unknown
(4.1) Lactic Acidosis
(8.1) AIDS defining event (which? __________________________)
(8.2) Invasive bacterial infection
(9) Renal Failure 
(10) Suicide
(11) Drug overdose
(7.1) Hepatitis related
(7.2) Liver failure not related to hepatitis or mitochondrial toxicity
Please complete the case report form for the CoDe project 
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Appendix V. Statistical methods 
This appendix gives a formal description of the statistical ideas presented throughout 
this thesis.  For more details, see An Introduction to Statistical Modelling by W.J. 
Krzanowski,  Modelling Binary Data by D. Collett and Modelling Survival Data in 
Medical Research by D. Collett [371,372,535].  Statistical models can be described in 
terms of a systematic component and a random component.  Choice of an appropriate 
model depends upon the prior beliefs of the underlying probability distribution of the 
response variable and how the response can be related to other explanatory variables.  
The systematic component is made up of explanatory variables and parameters, i.e. 
constant values that are the coefficients in the equation, which define the relationship 
with the response.  The random component is a random variable that takes values from 
a defined probability distribution to take account of individual deviation from the 
systematic component.  Most commonly, these two components are combined together 
additively to form a model.  For n observed values of a response variable Y, the ith 
observation in the model can be written as: 
yi = ηi + εi,   i = 1, 2, …, n 
where ηi is the systematic component and εi is the random component. 
 
Logistic regression 
The logistic regression model is one of a family of models called generalised linear 
models (GLMs).  These are linear in terms of the parameters in the model, so that for 
every unit change in any parameter, the response variable experiences the same 
change in value.  A GLM assumes that the response variable has a probability 
distribution from the exponential family (including a wide range of distributions) and 
relates the expected value of the response for the ith observation, μi, to the systematic 
component, ηi, via a link function.   
 
Logistic regression models are used for binary data where data can be grouped or 
ungrouped.  All the data in this thesis were ungrouped, i.e. each observation was for 
one individual and so this is the model that is described below.  The response variable 
Yi for the ith observation has a binomial probability distribution, Yi ~ B(1, pi) with pi = the 
probability of a ‘success’.  It is this probability that is predicted in the model using a 
logistic link function: 
logit(pi) = loge(pi/(1-pi)) = β0 + β1x1i + β2 x2i +… + βn xni 
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where {x1i, x2i,…, xni} are the ith observations on n explanatory variables {X1i, X2i,…, 
Xni}, 
{β0,  β1,  β2,…,  βn} are the parameters measuring the effects of the explanatory 
variables, 
exp(β0) is the odds of the outcome in patients with zero values for each of the 
explanatory variables, 
exp(βj) is the odds ratio of the outcome in patients with xj = 1 compared to xj = 0. 
 
This link function transforms the probability p from taking values in the interval (0,1) to  
(-∞,∞).  An unconstrained model is better to avoid the possibility of predicting 
impossible values outside of the range and so ensures that the predicted probability is 
between zero and one. 
 
Cox proportional hazards regression model 
The basic model for time to event (survival) data is the Cox proportional hazards 
regression model, which relates the survival time to an event of interest to a set of 
explanatory variables.  It does not assume a particular distribution for the survival times 
and so is a semi-parametric model.  If the actual survival time of an individual is t, 
which is a value of the random variable T that can take any non-negative value, then 
the survivor function can be defined as: 
S(t) = P(T > t) = 1 – F(t) 
where F(t) = P(T ≤ t) is the probability distribution function.  The probability density 
function, f(t), is the derivative of F(t) and gives the probability of the event of interest 
per unit of time t.  However, it is more convenient to think in terms of the probability that 
an individual who has survived until time t will experience an event in the next small 
interval of time between t and t + δt.  This is conditional on survival up to time t and is 
the instantaneous risk of developing the event defined by the hazard function: 
h(t) = 
0 δt lim

 {P(t ≤ T < t + δt │T ≥ t) /δt} 
Assuming proportional hazards at all time points, the predicted hazard for a particular 
individual i is: 
hi(t) = h0(t)Ψi 
where  h0(t) is called the baseline hazard and Ψi is a linear predictor consisting of 
explanatory variables.  To ensure that this is a positive value, the exponential is taken: 
Ψi = exp(β1x1i + β2 x2i +… + βn xni) 
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where {x1i, x2i,…, xni} are the ith observations on n explanatory variables {X1i, X2i,…, 
Xni}, 
{β0,  β1,  β2,…,  βn} are the parameters measuring the effects of the explanatory 
variables. 
 
This is a log-linear model from which hazard ratios (or relative hazards) can be 
estimated.  For individuals i and k with covariate values xi = {x1i, x2i,…, xni} and xk = {x1k, 
x2k,…, xnk}, the relative hazards is given by: 
hi(t)/ hk(t) = exp(β(xi – xk)) 
As it is independent of t, the value is constant over time and the hazards for the two 
individuals are therefore proportional. 
 
Poisson regression 
The Poisson regression model is also a generalised linear model used for count data.  
The response variable Yi for the ith observation has a Poisson probability distribution, 
Yi ~ P(μi) with μi = the expectation of Yi (the mean average), E(Yi).  A log-linear link 
function is used: 
log (μi) = β0 + β1x1i + β2 x2i +… + βn xni 
where {x1i, x2i,…, xni} are the ith observations on n explanatory variables {X1i, X2i,…, 
Xni}, 
{β0,  β1,  β2,…,  βn} are the parameters measuring the effects of the explanatory 
variables. 
 
Linear regression 
The linear regression model is used when the data are normally distributed with Yi ~ 
N(μi, σ
2) with μi = the expectation of Yi, E(Yi) and σ
2
, the variance of Yi.  A simple linear 
link function is used: 
μi = β0 + β1x1i + β2 x2i +… + βn xni 
where {x1i, x2i,…, xni} are the ith observations on n explanatory variables {X1i, X2i,…, 
Xni}, 
{β0,  β1,  β2,…,  βn} are the parameters measuring the effects of the explanatory 
variables. 
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Estimating the parameters 
For all the above models, the parameters β = {β0, β1, β2,…, βn} are estimated via the 
method of maximum likelihood estimation, which selects values that make the data the 
most likely to have occurred.  For a sample x1, x2,…, xn of n values from a particular 
probability distribution with unknown parameter θ, the multivariate probability density 
function associated with the observed data is the likelihood function: 
L(θ) =  fθ(x1, x2,…, xn| θ) 
The method of maximum likelihood estimation finds the value of θ that maximises L(θ).  
This requires iterative computational procedures such as the Newton-Raphson method.   
 
Confidence intervals and testing for significance 
In large samples the distribution of the parameters β can be approximated to a normal 
distribution.  Therefore, confidence intervals and hypothesis tests for β can be 
performed in the usual way.  Given a parameter estimate βj and a standard error for 
this estimate (the square root of the estimated variance), a 95% confidence interval 
(CI) can be calculated as:  
βj ± (1.96 x standard error of βj) 
A Wald test is used to compare the value of βj divided by its standard error to a 
standard normal distribution in order to obtain a p value.  If the p value is less than 
0.05, it is conventionally accepted that there is enough evidence to reject the null 
hypothesis of no significant difference from zero. 
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Appendix VI. Regional changes over time in initial 
virologic response rates to combination antiretroviral 
therapy across Europe 
Removed due to copyright restrictions.  See Bannister WP, Kirk O, Gatell JM, Knysz B, 
Viard J-P, Mens H, D’Arminio Monforte A, Phillips AN, Mocroft A and Lundgren J for 
the EuroSIDA Study. Regional changes over time in initial virologic response rates to 
combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr 2006; 
42:229-237. 
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Appendix VII. HIV-1 subtypes and response to 
combination antiretroviral therapy in Europe  
Reprinted with permission from Antiviral Therapy. Bannister WP, Ruiz L, Loveday C, 
Vella S, Zilmer K, Kjær J, Knysz B, Phillips AN, Mocroft A and Lundgren J for the 
EuroSIDA Study. HIV-1 subtypes and response to combination antiretroviral therapy in 
Europe. Antivir Ther 2006; 11:707-715. 
260Background: Combination antiretroviral therapy (cART)
may vary in ability to suppress viral load and increase
CD4
+ T-cell count in people infected with different HIV-
1 subtypes, possibly due to differences in resistance
development. Antiretroviral drugs have predominantly
been developed in Western Europe/North America on the
basis of the most prevalent subtype, B. However, non-B
subtypes are increasingly spreading worldwide. 
Objective: To compare virological and immunological
response to cART between patients infected with B and
non-B subtypes across Europe.
Design: EuroSIDA prospective, observational cohort with
11,928 HIV-1-infected patients.
Methods: Response to cART was analysed in patients with
subtypes determined pre-cART, via multivariable logistic
regression on the first measurements 6–12 months after
starting cART. A virological response was defined as a
viral load <500 copies/ml and immunological response as
a CD4
+ T-cell count increase of ≥100 cells/mm
3.
Results: Forty-five percent of patients were antiretro-
viral naive at initiation of cART. Virological suppression
was achieved by 58% of 689 subtype-B-infected
patients and 66% of 102 non-B-infected patients
(P=0.159). After adjustment for potential confounders,
there was no significant difference in odds of
achieving virological suppression (non-B compared
with B; odds ratio [OR]: 1.05, 95% confidence interval
[CI]: 0.58-1.93, P=0.866). An immunological response
was achieved by 43% of 753 B-infected patients and
48% of 114 non-B-infected patients (P=0.334). After
adjustment, there was no significant difference in odds
of an immunological response (OR: 1.17, 95% CI:
0.73–1.87, P=0.524).
Conclusions: There was no evidence of significant
differences in virological or immunological response to
cART between patients infected with HIV-1 B and
non-B subtypes.
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HIVs are a genetically diverse group of retroviruses
[1–6]. HIV-1 is the predominant form of the virus
worldwide [7], classified into three groups according
to its genetic structure [2,3,8,9]. The major group, ‘M’,
represents the vast majority of all infections [4,7] and
has nine distinct subtypes: A–D, F–H, J and K [9–11],
as well as 19 circulating recombinant forms (CRFs)
[12–16]: CRF01–CRF19.
It has been suggested that certain HIV-1 subtypes
may be more susceptible to evolving mutations associ-
ated with antiretroviral resistance than others
[10,11,17–22] and there is evidence that resistance is
associated with a poorer virological response to
antiretroviral therapy [23–25]. Historically, antiretro-
viral drugs have mostly been designed in North
America and Western Europe [11], where subtype B is
the most prevalent strain [26]. Consequently, they have
been developed based on the biological and clinical
findings of their effects on patients largely infected
with this strain [10,20], even though, in 2000, subtype
B was estimated to contribute to just 12.3% of the
worldwide epidemic [26]. Non-B subtypes, which are
widespread in Africa, Asia and much of Eastern
Europe [26], are increasingly spreading worldwide
through travel and migration [4]. This highlights the
importance of researching response to antiretroviral
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261therapy in patients infected with different subtypes. So
far, the limited research in this area has generally found
no striking differences [27–35].
The aims of these analyses were to compare both
virological and immunological response with combina-
tion antiretroviral therapy (cART) between patients
infected with HIV-1 B and non-B subtypes across Europe.
Methods
Patients
The EuroSIDA study is a prospective, observational
cohort of 11,928 HIV-1-infected patients in 83 centres
across 28 European countries, Israel and Argentina [36].
It comprises six cohorts of consecutive HIV-1-infected
patients with pre-booked clinic appointments, aged 16
or over, from May 1994 onwards. For Cohort I–III,
eligible patients were those with a CD4
+ T-lymphocyte
count of <500 cells/mm
3 in the previous 4 months. This
restriction was removed for Cohorts IV–VI.
Information was provided on a standardized data
collection form at baseline and every 6 months there-
after. Follow-up is to May 2005. Data collected
includes all CD4
+ T-cell counts and viral loads
measured since the last follow-up and starting and
stopping dates of all antiretroviral drugs and prophy-
lactic drugs used against opportunistic infections. All
dates of diagnosis of AIDS-defining illnesses are also
recorded, using the 1993 clinical definition of AIDS
from the Centers for Disease Control [37]. Members
of the coordinating office visit all centres to facilitate
correct patient selection and to verify the information
provided against case notes for a proportion 
of patients.
Patients were eligible for analyses if they started
combination antiretroviral therapy (cART), defined as
at least three antiretroviral drugs including a protease
inhibitor (PI), a non-nucleoside reverse transcriptase
inhibitor (NNRTI), or abacavir (ABC), with no
previous PI/NNRTI/ABC experience, before May 2004
allowing for the potential of at least 1 year’s follow-up,
and had pre-cART test results available determining
the subtype they were infected with.
Subtype determination
HIV-1 subtypes in EuroSIDA were primarily ascertained
using plasma samples analysed in central virology labo-
ratories. Phylogenetic analysis on genetic sequences of
reverse transcriptase and protease was used to deter-
mine subtype in all but a few cases where sequences
were incomplete and serology methods had been used.
Phylogenetic trees were constructed as neighbour-
joining trees based on Kimura 2-parameter distances.
In the absence of plasma samples, clinics could provide
paper copies of resistance test results including subtype
determination, conducted in local laboratories. If these
were also not available, any subtype assignment in the
patients’ case notes reported on the EuroSIDA follow-up
forms was taken.
Statistical methods
χ
2 and Kruskal–Wallis tests were used to test the signif-
icance of differences in demographics between patients
infected with B versus non-B subtypes. All tests were
two-sided and a P<0.05 was taken to be statistically
significant. Resistance mutations were defined
according to IAS-USA October/November 2005 [38].
SAS software version 8.2 (SAS Institute, Cary, NC,
USA, 1999–2001) was used for all analyses.
Response to cART was analysed via logistic regression
on the first measurements 6–12 months after initiation
of cART. A virological response was defined as a viral
load <500 copies/ml and immunological response as a
CD4
+ T-cell count increase of ≥100 cells/mm
3 from the
start of cART (baseline) to be consistent with previous
EuroSIDA analyses [39,40]. For analyses of virological
response, patients were required to have an unsup-
pressed baseline viral load of ≥500 copies/ml and for
immunological response, patients needed a baseline
CD4
+ T-cell count, measured within 6 months prior to
starting cART. In the main analysis, patients with
missing values in the period 6–12 months after cART
were defined as virological/immunological failures to
maximize the number of patients included. A sensitivity
analysis was conducted excluding these patients
instead. All analyses were intent-to-treat in the sense
that no adjustments were made for stopping or
changing any component of the regimen.
Multivariable models were developed to investigate
the effects of subtype on virological/immunological
response and were adjusted for potentially
confounding variables found to be significant (P<0.10)
in univariable analyses. A stepwise selection method
was used to confirm final model selection. Variables
investigated included baseline viral loads and CD4
+ T-
cell counts, hepatitis B/C coinfection status, prior AIDS
diagnosis, previous antiretroviral experience, current
regimen, demographics, how subtype was determined
and whether or not tested for resistance.
Sensitivity analyses with stricter inclusion criteria
were conducted on subsets of antiretroviral-naive
patients, patients with subtypes determined by phylo-
genetic analysis, patients who had their subtypes iden-
tified post-1999 due to subtype-specific problems with
viral load assays before then [41–43] (for virological
response only) and patients who started cART after
enrollment into EuroSIDA. Alternative definitions of
virological and immunological response were also
investigated (a viral load <50 copies/ml and a CD4
+
T-cell count increase of 25% from baseline).
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262Results
Demographics
Of the 11,928 EuroSIDA patients, 8,200 (69%)
started cART with no previous NNRTI/PI/ABC expe-
rience and the potential for at least 1 year’s follow-up.
Figure 1 displays a description of the patients
included. Pre-cART subtype results were available for
939 (11%) of these. Compared with the 7,261 (89%)
excluded patients, those with known subtypes had
higher median baseline CD4
+ T-cell counts (228
cells/mm
3 compared with 185 cells/mm
3,  P<0.001),
higher viral loads (4.7 compared with 4.5 log10
copies/ml,  P<0.001), less previous AIDS diagnoses
(22% compared with 30%, P<0.001) and less
previous antiretroviral experience (55% compared
with 63%, P<0.001).
Overall the analyses included 812 (86%) patients
infected with subtype B, 23 (2%) with A, 42 (4%)
with C and 62 (7%) with any other subtype,
including 16 with CRF01_AE and 14 with
CRF02_AG. Table 1 compares the demographics
between the 812 infected with B and the 127 (14%)
infected with non-B virus at the time of starting
cART. There were similar proportions of antiretro-
viral-naive patients: 45% of B-infected and 42% of
non-B-infected (P=0.481), and similar median base-
line CD4
+ T-cell counts: 230 cells/mm
3 for B-infected
and 210 cells/mm
3 for non-B-infected (P=0.881).
Viral loads were slightly higher for B-infected: 4.7
log10  copies/ml compared with 4.5 log10  copies/ml
(P=0.045).
Resistance test results were available within 1 year
before starting cART for 533 (57%) patients of whom
466 (87%) were infected with subtype B. Overall 218
(41%) patients had at least one IAS-USA NRTI
resistance mutation, 35 (7%) had a major PI resistance
Antiviral Therapy 11:6 709
HIV-1 subtypes and response to cART in Europe
EuroSIDA patients
n=11,928
Started cART with no previous
experience of NNRTIs/Pls/ABC
n=8,330
Potential for 1 year’s
follow-up after starting cART
n=8,200
Subtype determined before
starting cART
n=939
Virological response:
baseline viral load 
≥500 copies/ml
n=791
Missing viral loads
6–12 months after
cART = excluded
n=721
Missing viral loads
6–12 months after cART 
= virological failures
n=791
Missing CD4+ T-cell counts
6–12 months after cART 
= excluded
n=796
 
Missing CD4+ T-cell counts
6–12 months after cART 
= immunological failures
n=867
Immunological response:
baseline CD4+ T-cell count
n=867
Figure 1. Patient numbers in analyses according to inclusion criteria
ABC, abacavir; cART, combination antiretroviral therapy; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhbitors.
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Table 1. Demographics at date of starting cART according to HIV-1 subtype B versus non-B
Total B Non-B
n % n % n % P-value
All 939 100.0 812 86.5 127 13.5 –
Source of subtype ID –
Phylogenetic analysis 729 77.6 656 80.8 73 57.5 <0.001
Other 210 22.4 156 19.2 54 42.5 –
Serology methods 6 0.6 6 0.7 0 0.0 –
Local lab results 30 3.2 21 2.6 9 7.1 –
EuroSIDA follow-up 174 18.5 129 15.9 45 35.4 –
Male 725 77.2 666 82.0 59 46.5 <0.001
HIV transmission mode <0.001
Homosexual/bisexual 467 49.7 457 56.3 10 7.9 –
IDU 179 19.1 170 20.9 9 7.1 –
Heterosexual 223 23.7 128 15.8 95 74.8 –
Other 70 7.5 57 7.0 13 10.2 –
Ethnicity <0.001
White 783 83.4 725 89.3 58 45.7 –
Other 156 16.6 87 10.7 69 54.3 –
Region 0.045
South 110 11.7 98 12.1 12 9.4 –
Central West 229 24.4 189 23.3 40 31.5 –
North 514 54.7 444 54.7 70 55.1 –
East 86 9.2 81 10.0 5 3.9 –
Previous AIDS 206 21.9 184 22.7 22 17.3 0.177
Hepatitis B status 0.582
Negative 662 70.5 574 70.7 88 69.3 –
Positive 68 7.2 56 6.9 12 9.4 –
Unknown 209 22.3 182 22.4 27 21.3 –
Hepatitis C status 0.013
Negative 418 44.5 351 43.2 67 52.8 –
Positive 153 16.3 143 17.6 10 7.9 –
Unknown 368 39.2 318 39.2 50 39.4 –
cART regimen 0.786
Single PI  532 56.7 461 56.8 71 55.9 –
Boosted PI 78 8.3 67 8.3 11 8.7 –
Single NNRTI 185 19.7 157 19.3 28 22.0 –
Other 144 15.3 127 15.6 17 13.4 –
Antiretroviral naive 419 44.6 366 45.1 53 41.7 0.481
Successful resistance test 
within 1 year pre-cART 533 56.8 466 57.4 67 52.8 0.327
NRTI resistance* 218 40.9 192 41.2 26 38.8 0.709
PI resistance* 35 6.6 27 5.8 8 11.9 –
NNRTI resistance* 24 4.5 17 3.6 7 10.4 -
Median (interquartile range) –
GSS score according to  3.0 3.0–3.0 3.0 3.0–3.0 3.0 2.5–3.0 0.155
Rega algorithm (v6.4)*
Date started cART regimen Jan ‘98 Apr ‘97 to Dec ‘99 Feb ‘98 Apr ‘97 to Dec ‘99 Nov ‘97 Mar ‘97 to Mar ‘00 0.607
Date pre-cART subtype test May ‘97 Jul ‘96 to Dec ‘98 May ‘97 Jul ‘96 to Dec ‘98 Apr ‘97 Jul ‘96 to Sep ‘98 0.752
Age, years 37 32–45 37 32–45 35 32–43 0.124
CD4
+ T-cell count, cells/mm
3
Baseline 228 113–333 230 113–333 210 116–330 0.881
Nadir 172 87–260 171 87–260 176 84–257 0.843
Viral load, log10 copies/ml
Baseline 4.7 4.0–5.2 4.7 4.0–5.2 4.5 3.8-5.0 0.045
Maximum ever 5.0 4.5–5.4 5.0 4.5–5.4 4.9 4.4–5.2 0.017
*In a subset of patients with a successful resistance test within 1 year pre-combination antiretroviral therapy (cART). GSS, genotypic sensitivity score; IDU,
intravenous drug user; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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264mutation and 24 (5%) had an NNRTI resistance
mutation. Genotypic sensitivity score (GSS), as
defined by the Rega algorithm version 6.4, was also
compared in this subset. The median scores in both
groups were 3.0, P=0.155.
Virological response to cART
Table 2 displays the results of analysing virological
response to cART in patients infected with B versus
non-B subtypes. Patients with baseline viral loads
missing or <500 copies/ml were excluded leaving 791
patients. Of these, 721 had a viral load measurement
in the period 6–12 months after starting cart (median
time to first measurement: 7 months, interquartile
range [IQR]: 6–8 months, for both B-infected and
non-B-infected patients, P=0.779) and a further 47
patients had a subsequent measurement recorded
after 12 months. Counting patients with missing
values during this period as virological failures gave
a total of 469 (59%) patients out of 791 who
achieved virological suppression (<500 copies/ml):
402 (58%) of 689 B-infected compared with 67
(66%) of 102 non-B-infected patients, P=0.159.
Within the non-B subtypes, 8 (47%) of 17 patients
Antiviral Therapy 11:6 711
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Table 2. ORs and 95% CIs of virological and immunological response for HIV-1 subtype B versus non-B
B Non-B
% Reference % Univariable  Multivariable
n responders OR n responders OR (% CI) P-value OR (% CI) P-value
Virological response*
Main analysis,  689 58 1.00 102 66 1.37 0.160 1.05 0.866
missing=failure (0.88–2.11) (0.58–1.93)
Sensitivity analyses, 
missing=failure
AR-naive 326 71 1.00 46 72 1.04 0.903 1.09 0.849
(0.53–2.07) (0.44–2.70)
Subtypes by  573 59 1.00 58 62 1.15 0.613 1.22
phylogenetic analysis (0.66-2.01) (0.58-2.56) 0.597
Subtypes post-1999 139 63 1.00 35 83 2.80 0.033 3.51 0.098
(1.09–7.20) (0.80–15.47)
Excluding 565 62 1.00 72 67 1.23 0.437 1.13 0.730
retrospective data  (0.73-2.06) (0.56-2.29)
Endpoint viral load  689 29 1.00 102 42 1.76 0.010 1.39 0.330
<50 copies/ml (1.15–2.69) (0.72–2.67)
Excluding missing 629 64 1.00 92 73 1.51 0.096 1.28 0.476
(0.93–2.46) (0.65–2.54)
Immunological response
†
Main analysis,  753 43 1.00 114 48 1.21 0.335 1.17 0.524
missing=failure (0.82–1.80) (0.73–1.87)
Sensitivity analyses, 
missing=failure
AR-naive 353 48 1.00 49 55 1.31 0.383 1.35 0.401
(0.72–2.38) (0.67–2.75)
Subtypes by  623 43 1.00 65 48 1.21 0.470 1.27 0.425
phylogenetic analysis  (0.72–2.02) (0.70–2.31)
Excluding 614 44 1.00 85 49 1.26 0.317 1.34 0.285
retrospective data  (0.80–1.99) (0.78–2.31)
Endpoint 25% CD4
+ 753 57 1.00 114 61 1.20 0.387 1.28 0.333
T-cell increase (0.80–1.79) (0.78–2.09)
Excluding missing 691 47 1.00 105 52 1.21 0.334 1.17 0.537
(0.82–1.80) (0.72–1.90)
*Multivariable analyses adjusted for baseline maximum ever viral load (log10 copies/ml), baseline CD4
+ T-cell nadir (log2 cells/mm
3), time from CD4
+ T-cell nadir,
hepatitis B and C coinfection status, calendar year of starting combination antiretroviral therapy (cART) regimen, type of regimen, number of new drugs in regimen,
whether or not antiretroviral (AR) naive at baseline, age, transmission risk group, region of clinical centre visited and ethnicity. 
†Multivariable analyses adjusted for
baseline viral load (log10 copies/ml), baseline CD4
+ T-cell nadir (log2 cells/mm
3), time from CD4
+ T-cell nadir, calendar year of starting cART regimen, type of regimen,
number of new drugs in regimen, whether or not AR naive and transmission risk group. CI, confidence interval; OR, odds ratio.
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265infected with subtype A, 25 (66%) of 38 patients
with C and 34 (72%) of 47 patients with ‘Other’
achieved virological suppression, P=0.152.
Before adjustment for potentially confounding
variables, the data showed no evidence of a significant
difference between the odds of achieving virological
suppression in non-B-infected compared with
B-infected patients (odds ratio [OR]: 1.37, 95%
confidence interval [CI]: 0.88–2.11, P=0.160). A
multivariable model adjusting for baseline maximum
ever viral load, CD4
+ T-cell nadir, time from CD4
+ T-
cell nadir, hepatitis B and C coinfection, calendar year
of starting cART, type of regimen, number of new
drugs in regimen, whether or not antiretroviral-naive
at baseline, age, transmission risk group, region of
clinical centre visited and ethnicity also showed no
significant difference (OR: 1.05, 95% CI: 0.58–1.93,
P=0.866). Unadjusted and adjusted ORs are displayed
in Figure2. Further investigation into A, C and
‘Other’ subtypes showed adjusted ORs (95% CIs) of
0.32 (0.10–1.00; P=0.051), 1.07 (0.45–2.54;
P=0.879) and 1.64 (0.73–3.67; P=0.233), respec-
tively. Interactions between type of cART regimen and
subtype were also considered. The power for this was
limited; however, the interaction between
PI-containing versus other regimens and subtype was
not found to be significant.
All sensitivity analyses gave results consistent with
those from the main analyses (results shown in
Table 2).
Immunological response to cART
The results of analysing immunological response to
cART in patients infected with B versus non-B are
also displayed in Table 2. Patients with missing base-
line CD4
+ T-cell counts were excluded, leaving 867
patients. Of these, 796 had a CD4
+ T-cell count 6–12
months after starting cART (median time to first
measurement: 7 months, IQR: 6–8 months, for both
B-infected and non-B-infected patients, P=0.973) and
a further 47 patients had a subsequent measurement
recorded after 12 months. Counting patients with
missing values during this period as immunological
failures gave a total of 382 (44%) patients out of 867
who experienced a successful immunological
response: 327 (43%) of 753 B patients and 55 (48%)
of 114 non-B patients (P=0.334). Of the non-B
subtypes, 7 (35%) of 20 patients infected with
subtype A, 18 (46%) of 39 patients with C and 30
(55%) of 55 patients with ‘Other’ experienced an
immunological response (P=0.346).
Before adjustment for potentially confounding
variables, there was no evidence of a significant differ-
ence in the odds of experiencing an immunological
response between non-B-infected and B-infected
patients (OR: 1.21, 95% CI: 0.82–1.80, P=0.335). A
multivariable model adjusting for baseline viral load,
baseline CD4
+ T-cell nadir, time from CD4
+ T-cell
nadir, hepatitis B and C coinfection, calendar year of
starting cART, type of regimen, number of new drugs
in regimen, whether or not antiretroviral-naive at
baseline, age and transmission risk group again found
no significant difference (OR: 1.17, 95% CI:
0.73–1.87,  P=0.524). Unadjusted and adjusted ORs
are again displayed in Figure 2. ORs (95% CIs) for A,
C and ‘Other’ subtypes compared to B were 0.64
(0.24–1.72; P=0.375), 1.06 (0.52–2.18; P=0.871) and
1.54 (0.83–2.86; P=0.168), respectively. Interactions
between type of cART regimen (PI-containing versus
other) and subtype were again considered; however,
they were not found to be significant.
Sensitivity analyses also gave consistent results as
those from the main analyses (results shown in Table 2).
Discussion
In this cohort of HIV-1-infected patients from across
Europe, a comparison of patients infected with B and
non-B subtypes showed that after adjustment for
potentially confounding variables, there was no
evidence of significant differences in virological or
immunological response to cART. Relatively few
patients were infected with non-B subtypes, but further
investigation suggested that there were generally no
significant differences between patients infected with
A, C or ‘Other’ subtypes, compared with those with B.
WP Bannister et al.
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Figure 2. ORs of virological response (<500 copies/ml) and
immunological response (100 CD4
+ T-cell increase) after
starting cART according to HIV-1 subtype B versus non-B
cART, combination antiretroviral therapy; ORs, odds ratio.
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266However, due to the small numbers, the possibility that
some differences do exist cannot be excluded.
The findings are consistent with previous research
[27–35]. For example, Bocket et al. 2005 [28]
compared time to virological suppression between
317 B-infected and 99 non-B-infected antiretroviral-
naive patients in a French cohort and found no
significant difference. A retrospective case–control
study of 50 B-infected and 50 non-B infected patients
starting cART looked at both initial and long-term
virological response, finding no significant differ-
ences [33]. Analyses such as this have implications
for increasing the availability of drugs in developing
countries (where non-B subtypes dominate) [22], for
future drug development and for potential vaccine
development [3,7,44].
There is evidence that the frequency and pattern of
drug-resistance mutations differ between subtypes,
which could suggest that differences in virological,
immunological and clinical outcomes would be
expected [10,11,18,21,22]. The results from these
analyses imply that any differences in drug resistance
development between subtypes have not impacted
greatly on patients’ response to therapy.
The limitations of this study should be recognized
when interpreting these results. The patients in this
analysis were from an observational study and hence
were not randomized to groups, so there may be
unmeasured or unknown confounding variables.
However, all measured potentially confounding vari-
ables were investigated or adjusted for in analyses to
limit their influence on the results. The reason for
patients having their subtypes determined may also
introduce a bias. It is likely that subtypes were mostly
determined at the same time as a resistance test and
some patients may have been selected for testing if they
were virologically or immunologically failing on a
regimen. To limit the impact of this, patients were only
included if their subtypes were determined prior to
starting cART so that any who were tested for
resistance (and also had their subtype determined) due
to failing on cART were excluded.
The results from sensitivity analyses were found to
be consistent with those of the main analyses. One
analysis investigated another conventional way of
dealing with missing values (exclusion) [45]. The
reasons for these missing values are unknown, but
some could be due to the varying frequency of
measurements. This was the motivation for using a
binary endpoint, as unlike a time to event endpoint, it
was relatively robust to the number of measurements
available. Another analysis took patients who had their
subtypes identified after 1999 only, as earlier assays
were identified as having problems measuring
accurately in non-B subtypes [41–43]. A subset
excluding patients with retrospective data was also
analysed; that is, those who started cART before being
enrolled into EuroSIDA. Patients from this subset were
excluded, as they had already survived a period of time
up to enrollment; therefore, they may have been more
likely to have a successful response to therapy than
those starting cART after enrollment.
In summary, the findings from these analyses
showed no evidence of significant differences in viro-
logical or immunological response to cART between
B-infected and non-B-infected patients. Those
infected with non-B subtypes did not show a detri-
mental outcome compared with patients infected
with B, as suggested by differences in resistance
development found in other research. The continued
expansion of the EuroSIDA resistance database and
the exclusive use of phylogenetic analysis to deter-
mine subtypes will allow more sensitive analyses in
the future with increased power to detect any true
differences. Increasingly we will be able to focus on
individual non-B subtypes and on responses to
particular regimens.
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Background: The aim of the study was to investigate the 
incidence of abacavir-related hypersensitivity   reaction (HSR) 
and associated deaths in EuroSIDA HIV-1-infected patients.
Methods: Poisson regression models were developed to 
compare incidence of abacavir discontinuation accord-
ing to the line of therapy within which abacavir was 
received, geographical regions, calendar time and drug 
formulation  (abacavir/lamivudine  combination  tablet 
versus abacavir as a single drug or abacavir/zidovudine/
lamivudine combination).
Results: Of 3,278 patients that started abacavir, 2,101 
(64.1%) discontinued. Of these, 167 (5.1%) discontin-
ued abacavir within 3 months due to HSR with an inci-
dence of 22.1 (95% confidence interval [CI] 18.7–25.4) 
per 100 person-years of follow-up. After adjustment for 
gender, prior AIDS, hepatitis C serostatus, baseline CD4+ 
T-cell count, region and calendar time, HSR incidence 
was significantly higher in those starting abacavir in a 
first-line regimen compared with second-line (incidence 
rate  ratio  [IRR]  2.04  [95%  CI  1.24–3.38];  P=0.005). 
There  was  no  significant  difference  between  regions. 
HSR  incidence  from  2005  onwards  was  significantly 
lower  compared  with  1999–2000  (IRR  0.54  [95%  CI 
0.32–0.92]; P=0.024). There was a lower observed inci-
dence in patients starting abacavir/lamivudine compared 
with other formulations (IRR 0.33 [95% CI   0.13  –0.88]; 
P=0.027), however, available data were limited.
Conclusions: Incidence of abacavir-related HSR is higher 
in patients starting abacavir in first-line therapy, which 
could indicate increased over-diagnosis. HSR incidence 
has decreased in recent years, which might reflect the 
wider  availability  of  genetic  screening  and  improved 
awareness of symptoms. There were no reported deaths 
due to abacavir HSR.
Hypersensitivity reaction (HSR) occurs in approximately 
4–8% of patients starting abacavir generally within 6 
weeks of initiation [1–5]. It is characterized by fever, rash, 
neurological, gastrointestinal, musculoskeletal and respi-
ratory symptoms [1,4–6] and if the drug is not discontin-
ued immediately there is a risk of death [3,6,7]. Poten-
tially fatal symptoms may reoccur within hours if the 
drug is restarted [8,9]. However, as patients are advised 
to stop immediately if symptoms arise, reported incidence 
of fatal HSR is fortunately rare. A recent study reported 
no HSR-related deaths in over 11,500 patients exposed 
to either Ziagen® (abacavir as a single tablet) or Trizivir® 
(abacavir, lamivudine and zidovudine) [10]. This study 
also found no differences in the frequency of abacavir 
HSR between patients starting either formulation.
The genetic allele HLA-B*5701 has been found to be 
strongly  associated  with  abacavir-related  HSR  and  is 
more prevalent in Caucasian individuals, which could 
account for differences in observed rates of HSR between 
ethnic  groups  [11–15].  In  particular,  the  presence  of 
HLA-B*5701, HLA-DR7 and HLA-DQ3 was found to 
have a positive predictive value of 100% and absence of 
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this combination had a negative predictive value of 97% 
[16].  Prospective  genetic  screening  for  HLA-B*5701 
prior to prescribing abacavir has been shown to dramat-
ically reduce the incidence of abacavir-related HSR, but 
is not widely available to all patients [11,14,15,17–21]. 
In clinical practice, diagnosis of HSR can be difficult 
as it includes a combination of non-specific symptoms. 
Patients  who  exhibit  symptoms  consistent  with  HSR 
may be given a skin patch test to immunologically con-
firm whether or not they are a true HSR case [19,21]. 
Recent findings from the PREDICT-1 study provided 
evidence that the presence of HLA-B*5701 was a neces-
sary condition for abacavir HSR and that withholding 
the drug from these patients would eliminate the reac-
tion [15]. The findings also highlighted the problem of 
clinical over-diagnosis of HSR that results from physi-
cians not being able to risk missing any potential true 
cases of HSR. Further factors that have been linked to 
an increased risk of HSR include female gender, higher 
CD8+ T-cell counts at initiation of abacavir and abacavir 
use  during  primary  HIV  infection  [22–24].  Factors 
linked to a decreased risk include previous treatment 
experience and more advanced disease [22,25].
EuroSIDA  collects  prospective  longitudinal  data 
from  a  large,  heterogeneous  population  in  centres 
across  Europe,  which  provides  the  opportunity  to 
compare  incidence  of  abacavir-related  HSR  across 
different patient subsets. The objective of these analy-
ses was to investigate the incidence of abacavir dis-
continuation, particularly as a result of HSR, accord-
ing to the line of therapy within which abacavir was 
received (first, second, third or subsequent regimens), 
geographical  region,  calendar  time  and  coformula-
tion of abacavir (as part of the combination tablet, 
Kivexa®  [abacavir/lamivudine]  or  as  part  of  either 
the combination tablet Trizivir® or as Ziagen®). The 
incidence of HSR within these patient subsets has not 
previously been evaluated in a large cohort study and 
is important to identify patients most at risk and to 
monitor  trends.  The  rate  of  death  associated  with 
abacavir HSR was also determined.
Methods
Patients
The  EuroSIDA  study  is  a  prospective,  observational 
cohort of 14,310 HIV-1-infected patients in 93 centres 
across Europe, Israel and Argentina. The study has been 
described in detail previously [26]. In brief, patients were 
enrolled into seven cohorts from May 1994 onwards 
and median follow-up time was to January 2007. Infor-
mation is collected on a standardized data collection 
form every 6 months, including all CD4+ T-cell counts 
and viral loads measured since the last follow-up and 
starting and stopping dates of all antiretroviral drugs. 
The forms (available at www.cphiv.dk) provide a list of 
reasons for discontinuation of antiretroviral drugs from 
which sites are asked to indicate the most appropri-
ate reason (with one reason chosen per drug stopped) 
on the basis of the physician’s assessment. EuroSIDA 
also requests that all deaths are recorded on the forms 
with the cause of death selected from a list provided. 
To ensure correct patient selection and to verify that 
accurate data is supplied, members of the coordinating 
office visit all centres to check the information provided 
against case notes for all patients with clinical events 
and 10% of randomly selected patients per year.
Patients were included in the analyses if they initiated 
abacavir as Ziagen®, Trizivir® or Kivexa® for the first 
time during prospective follow-up after 1 January 1999 
(the date at which EuroSIDA started collecting data on 
reasons for discontinuation of therapy).
Statistical methods
Patient characteristics were compared using χ2 tests and 
Fisher’s exact tests for categorical data and Kruskal–
Wallis tests for continuous data. Only the first abacavir 
discontinuation with a corresponding reason was con-
sidered and baseline was defined as the date that the 
drug  was  first  started.  Incidence  of  abacavir  discon-
tinuation  was  assessed  using  a  person-year  analysis 
with person-years of follow-up (PYFU) measured from 
the date of starting abacavir to the earliest of the last 
follow-up visit, death or until abacavir was discontin-
ued for any reason. The incidence of abacavir HSR was 
assessed in the 3 months after initiating abacavir treat-
ment with follow-up time to the earliest of 3 months, 
death  or  abacavir  discontinuation.  No  standardized 
guidelines were used to define HSR and cases of HSR 
were not reviewed centrally. Diagnosis was based on 
physician assessment.
Univariable Poisson regression models were used to 
identify factors that could potentially affect incidence of 
HSR-related discontinuation within 3 months of starting 
abacavir. Factors investigated were gender, HIV exposure 
group, ethnicity, prior AIDS diagnosis, hepatitis B/C coin-
fection serostatus, CD4+ T-cell count, nadir CD4+ T-cell 
count and viral load at date of starting abacavir (base-
line), whether or not patients were previously antiretrovi-
ral-naive, age and concurrent use of other drugs that may 
cause HSR. The potential interactions between hepatitis C 
status and both HIV exposure groups and nevirapine use 
were also investigated. A multivariable Poisson regression 
model was then developed adjusting for the factors found 
to be significant (P-value <0.1) in the univariable models. 
The model also included factors such as whether patients 
started abacavir as part of a first-line regimen (containing 
at least one protease inhibitor [PI], non-nucleoside reverse 
transcriptase inhibitor [NNRTI] or abacavir), second reg-
imen (containing a new PI, a new NNRTI or abacavir 
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and started at least 1 month after initiation of the first), 
third or subsequent regimen; other factors included were 
the geographical region of EuroSIDA the patients were 
seen in (categorized into South, Central West, North and 
East, as described in a previous analysis [27]) and calen-
dar time of starting abacavir, which was divided into two-
year periods (1999–2000, 2001–2002, 2003–2004 and 
2005 onwards). A further factor considered in a separate 
model was whether a patient started abacavir for the first 
time as part of the coformulation Kivexa® or whether 
they started abacavir as the single drug Ziagen® or as part 
of Trizivir®. As Kivexa® was first introduced in January 
2004, only patients who started abacavir after this time 
were included in this particular analysis.
All tests were two-sided and a P-value of <0.05 was 
taken to be statistically significant. SAS software ver-
sion 9.1 (SAS Institute, Cary, NC, USA) was used for 
all analyses.
Results
Patient numbers
A total of 3,278 (22.9%) patients fulfilled the inclusion 
criteria with a median follow-up time of 1.4 years (range 
0.0–8.5)  and  a  total  follow-up  time  of  6,803  person-
years. Among the patients who started abacavir, there 
were  2,101  (64.1%)  discontinuations,  of  which  193 
(9.2%) were associated with HSR. As expected from the 
literature, HSR was experienced very soon after starting 
abacavir with a median time to HSR-related discontinu-
ation of 1 month (interquartile range [IQR] 0.3–1.2). A 
further 344 (16.4%) patients discontinued due to treat-
ment failure with a median time on abacavir treatment of 
16 months (IQR 8.4–29.0). Other reasons for discontinu-
ation reported by 317 (15.1%) patients included clinical 
fat abnormalities, dyslipidaemia, toxicities and structured 
treatment interruption. A further 285 (13.5%) patients 
had other causes, not specified in the list. Finally, 607 
(28.9%) had the reason for discontinuation as patient 
or physician’s choice and 357 (17.0%) had an unknown 
reason. As the median times to discontinuation for these 
groups were over a year (13.0 months [IQR 4.2–32.5] 
and  18.0  months  [IQR  5.3–40.6],  respectively),  it  is 
unlikely that these patients experienced HSR.
Patient characteristics at date of abacavir initiation
Table 1 shows a comparison of the patient characteris-
tics at date of abacavir initiation between 1,177 patients 
who  continued  on  abacavir  therapy  in  the  available 
follow-up time, 193 patients who discontinued abacavir 
due to HSR and 1,908 patients who discontinued due to 
a reason not reported as HSR. Patients who continued 
abacavir throughout their follow-up time started treat-
ment most recently, followed by those who discontin-
ued due to HSR and then those who discontinued for 
another reason (medians June 2004, June 2001 and Jan-
uary 2001, respectively, P<0.001). Patients who discon-
tinued abacavir were more likely to be intravenous drug 
users (P<0.001) than those who continued on the drug, 
had lower baseline CD4+ T-cell counts (P<0.001) and 
higher baseline viral loads (P<0.001). A higher percent-
age of patients who discontinued abacavir due to HSR 
were Caucasian (95.3%, P=0.011), hepatitis C positive 
(28.0%, P<0.001), antiretroviral-naive (5.7%, P=0.007) 
and were less likely to start abacavir in a triple nucle-
oside  reverse  transcriptase  inhibitor  (NRTI)  regimen 
(11.9%, P<0.001). They were also more likely to have 
started nevirapine at the same time as abacavir (7.8%, 
P=0.042).  There  were  similar  percentages  of  patients 
across the three groups starting other drugs that have 
been linked to HSR, that is, efavirenz, amprenavir and 
cotrimoxazole.
Incidence of abacavir discontinuation and abacavir-
related HSR
The incidence of abacavir discontinuation for any reason 
(including HSR) was 30.9 (95% confidence interval [CI] 
29.6–32.2) per 100 PYFU and for HSR specifically the 
incidence was 2.8 (95% CI 2.4–3.2) per 100 PYFU. To 
avoid including patients who may have been misclassi-
fied as experiencing HSR, 167 patients (86.5% of the 
193 reported to have discontinued abacavir due to HSR) 
who discontinued abacavir due to HSR within the first 3 
months of abacavir treatment were investigated further. 
This accounted for 5.1% of all patients starting the drug. 
The incidence of abacavir discontinuation due to HSR 
within 3 months was 22.1 (95% CI 18.7–25.4) per 100 
PYFU during 757 PYFU.
Incidence according to the line of therapy within 
which abacavir was received
A total of 252 (7.7%) patients started abacavir as part 
of a first-line regimen, 952 (29.0%) started it as part of 
a second regimen, 1,081 (33.0%) as part of a third and 
993 (30.3%) as part of a fourth or subsequent regimen 
(Table 2). The highest incidence of abacavir discontinu-
ation for any reason was in those who started abacavir 
as part of a fourth/subsequent regimen (P=0.002). Inci-
dence of HSR-related discontinuation within the first 
3 months was highest in those who started abacavir as 
part of a first-line regimen (P=0.002).
Incidence according to EuroSIDA region
A total of 929 (28.3%) patients were from the South 
region,  938  (28.6%)  were  from  the  Central  West, 
1,164 (35.5%) were from the North and 247 (7.5%) 
were from the East (Figure 1). Overall there was no 
significant  difference  in  incidence  of  discontinuation 
due  to  any  reason  and  incidence  of  discontinuation 
due to HSR between regions (P=0.797 and P=0.114, 
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respectively), however, the North region appeared to 
have a lower incidence of HSR-related discontinuation 
than the other regions.
Incidence according to date of initiation of abacavir
A  total  of  1,245  (38.0%)  patients  started  abacavir 
between 1999 and 2000, 863 (26.3%) between 2001 
and 2002, 450 (13.7%) between 2003 and 2004 and 
720 (22.0%) from 2005 onwards (Figure 2). Incidence of 
abacavir discontinuation for any reason was similar over 
1999–2000 and 2001–2002 followed by a slight increase 
during 2003–2004 and a drop from 2005 onwards, giv-
ing an overall significant difference (P=0.014). Incidence 
of abacavir discontinuation due to HSR within the first 3 
months of abacavir treatment remained similar over the 
years until 2005 onwards when a sharp decrease to 11.4 
cases per 100 PYFU during 166 PYFU was observed, 
giving an overall significant difference (P=0.004).
    Continuation   Discontinuation   Discontinuation due 
Characteristic  Total  of abacavir  due to HSR  to other reason  P-value
All patients, n (%)  3,278 (100.0)  1,177 (35.9)  193 (5.9)  1,908 (58.2)  –
Male gender, n (%)  2,539 (77.5)  937 (79.6)  141 (73.1)  1,461 (76.6)  0.047
HIV exposure
   Male homosexual intercourse, n (%)  1,507 (46.0)  591 (50.2)  80 (41.5)  836 (43.8)  <0.001
   Heterosexual intercourse, n (%)  861 (26.3)  306 (26.0)  48 (24.9)  507 (26.6)  –
   Intravenous drug use, n (%)  672 (20.5)  192 (16.3)  51 (26.4)  429 (22.5)  –
   Other, n (%)  238 (7.3)  88 (7.5)  14 (7.3)  136 (7.1)  –
White ethnicity, n (%)  3,026 (92.3)  1,066 (90.5)  184 (95.3)  1,776 (93.1)  0.011
Previous AIDS  1,197 (36.5)  412 (35.0)  59 (30.6)  726 (38.1)  0.049
Hepatitis B status
   Negative, n (%)  2,561 (78.1)  976 (82.9)  143 (74.1)  1,442 (75.6)  <0.001
   Positive, n (%)  206 (6.3)  58 (4.9)  14 (7.0)  134 (7.0)  –
   Unknown, n (%)  511 (15.6)  143 (12.2)  36 (18.7)  332 (17.4)  –
Hepatitis C status
   Negative, n (%)  1,950 (59.5)  785 (66.7)  103 (53.4)  1,062 (59.5)  <0.001
   Positive, n (%)  717 (21.9)  228 (19.4)  54 (28.0)  435 (22.8)  –
   Unknown, n (%)  611 (18.6)  164 (13.9)  36 (18.7)  411 (21.5)  –
Type of regimen
   Single PI plus ≥2 NRTIs, n (%)  281 (8.6)  92 (7.8)  21 (10.9)  168 (8.8)  <0.001
   Ritonavir-boosted PI plus
    ≥2 NRTIs, n (%)  687 (21.0)  326 (27.7)  39 (20.2)  322 (16.9)  –
   Single NNRTI plus ≥2 NRTIs, n (%)  917 (28.0)  392 (33.3)  51 (26.4)  474 (24.8)  –
   Triple NRTI, n (%)  722 (22.0)  182 (15.5)  23 (11.9)  517 (27.1)  –
   Other, n (%)  671 (20.5)  185 (15.7)  59 (30.6)  427 (22.4)  –
Concurrent use of drugs 
that may cause HSR
   Nevirapine, n (%)  183 (5.6)  51 (4.3)  15 (7.8)  117 (6.1)  0.042
   Efavirenz, n (%)  511 (15.6)  165 (14.0)  33 (17.1)  313 (16.4)  0.173
   Amprenavir, n (%)  108 (3.3)  32 (2.7)  3 (1.6)  73 (3.8)  0.093
   Cotrimoxazole, n (%)  42 (1.3)  14 (1.2)  3 (1.6)  25 (1.3)  0.903
Antiretroviral-naive at start of
abacavir, n (%)  96 (2.9)  42 (3.6)  11 (5.7)  43 (2.3)  0.007
Median date of abacavir start (IQR)  Oct 01  Jun 04  Jun 01  Jan 01  <0.001
  (Apr 00–Jun 04)  (Jul 01–Feb 06)  (Jan 00–Feb 06)  (Jan 00–Sep 02)
Median age, years (IQR)  41 (37–48)  42 (37–49)  41 (37–48)  41 (36–48)  0.005
Median CD4+ T-cell count (IQR)
   At baseline, cells/mm3*   357 (211–544)  394 (239–586)  327 (226–480)  336 (190–520)  <0.001
   At nadir, cells/mm3†  127 (50–215)  134 (51–218)  136 (63–200)  121 (46–214)  0.114
Median viral load (IQR)
   At baseline, log10 copies/ml‡  2.8 (1.7–4.4)  2.1 (1.7–4.0)  3.1 (1.7–4.4)  3.3 (1.7–4.6)  <0.001
Table 1. Patient characteristics at start of abacavir therapy according to continuation of abacavir therapy, discontinuation of 
abacavir due to hypersensitivity reaction or discontinuation of abacavir due to another reason
Median CD4+ T-cell counts and viral loads were based on measurements from *3,138 patients, †3,276 patients or ‡3,090 patients. P-values were obtained from χ2, 
Fisher’s exact and Kruskal–Wallis tests. HSR, hypersensitivity reaction; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside 
reverse transcriptase inhibitor; PI, protease inhibitor.
8_Bannister.indd   690 22/7/08   14:39:09
296Abacavir hypersensitivity reaction
Antiviral Therapy 13.5 691
Incidence according to use of Kivexa®
A  total  of  928  (28.3%)  previously  abacavir-naive 
patients started abacavir in January 2004 onwards, 
the date when the coformulation drug Kivexa® was 
first  introduced  into  clinical  practice.  Of  these  928 
patients, 342 (36.9%) started Kivexa®. Overall, 305 
(32.9%) patients discontinued abacavir, of which 27 
(8.9%)  discontinuations  occurred  within  3  months 
and were associated with HSR. Incidence of discon-
tinuation due to any reason was significantly higher 
(P<0.001) in the non-Kivexa® group (38.6 [95% CI 
33.9–43.3]  cases  per  100  PYFU  during  676  PYFU) 
compared with the Kivexa® group (13.1 [95% CI 9.3–
17.0] cases per 100 PYFU during 335 PYFU). There 
was also a significant difference (P=0.036) in incidence 
of discontinuation due to HSR within 3 months (16.2 
[95% CI 9.4–23.0] cases per 100 PYFU during 136 
PYFU) in the non-Kivexa® group compared with the 
Kivexa® group (6.3 [95% CI 2.0–14.6] cases per 100 
PYFU during 80 PYFU).
Multivariable incidence rate ratios
In univariable models, female gender, positive hepatitis 
C coinfection serostatus, lack of prior AIDS diagnosis 
and  a  lower  baseline  CD4+  T-cell  count were  signifi-
cantly associated with incidence of abacavir discontinu-
ation due to HSR within 3 months of treatment. The 
concurrent use of drugs such as nevirapine, efavirenz, 
amprenavir  and  cotrimoxazole  that  can  cause  HSR, 
started at the same time as abacavir, were investigated 
to check that symptoms arising from one of these drugs 
had not been misdiagnosed as abacavir HSR. However, 
none  were  found  to  be  significantly  associated  with 
HSR-related  abacavir  discontinuation.  Ethnicity  was 
also found to be unassociated with HSR-related abacavir 
discontinuation. However, the HSR incidence rate was 
lower in those with non-white ethnicity compared with 
those with white ethnicity, as expected from the litera-
ture, with an incidence rate ratio (IRR) of 0.66 (95% CI 
0.34–1.30; P=0.230). A multivariable model was then 
developed that contained the above factors significantly 
associated with HSR in univariable analyses, as well as 
whether abacavir was a component of a first, second, 
third or subsequent regimen, geographical region and 
calendar time when abacavir was started. Figure 3 dis-
plays the adjusted IRRs and 95% CIs from this model.
The  multivariable  model  provided  evidence  that 
the incidence of abacavir discontinuation due to HSR 
among patients starting abacavir as part of a first-line 
regimen was twice that observed among those starting 
abacavir in a second-line regimen (IRR 2.04 [95% CI 
1.24–3.38]; P=0.005). Incidence of HSR was similar 
across regions, although it was lowest in the North. 
There was also evidence that among patients starting 
abacavir from 2005 onwards, the incidence of HSR-
related discontinuation was almost half that observed 
among  patients  starting  abacavir  between  1999  and 
2000 (IRR 0.54 [95% CI 0.32–0.92]; P=0.024).
A multivariable model was developed containing the 
same variables as before, but adjusting for the abacavir 
start date instead of the time period and with the addi-
tion of whether patients received Kivexa® or Ziagen®/
Trizivir®. After adjustment, there was evidence of a sig-
nificantly  lower  incidence  of  abacavir  discontinuation 
due to HSR within 3 months in those starting Kivexa® 
compared  with  those  starting  Ziagen®/Trizivir®  (IRR 
0.33 [95% CI   0.13  –0.88]; P=0.027).
Rate of death associated with abacavir HSR
There were no fatal cases of HSR registered (defined 
as patients who discontinued abacavir therapy due to 
HSR and died within 1 month of discontinuation). A 
      Discontinued abacavir  Any    Discontinuation due
  Discontinued    due to HSR in 3 months  discontinuation    to HSR in 3 months
Number of patients  abacavir due to  Of all those who  Of all those  incidence per 100  Total  incidence per 100  PYFU up to
who started abacavir  any reason, n (%)  discontinued, n (%)  started abacavir, %  PYFU (95% CI)  PYFU  PYFU (95% CI)  3 months
Overall n=3,278  2,101 (64.1)  167 (7.9)  5.1  30.9 (29.6–32.2)  6,803  22.1 (18.7–25.4)  757
As first-line therapy  171 (67.9)  27 (15.8)  10.7  32.3 (27.5–37.2)  529  48.8 (30.4–67.2)  55
n=252
As second-line  585 (61.5)  44 (7.5)  4.6  27.4 (25.1–29.6)  2,138  19.9 (14.0–25.7)  222
therapy n=952
As third-line  714 (66.1)  52 (7.3)  4.8  31.5 (29.2–33.8)  2,266  21.0 (15.3–26.7)  248
therapy n=1,081
As fourth-line therapy  631 (63.5)  44 (7.0)  4.4  33.7 (31.1–36.4)  1,870  19.0 (13.4–24.6)  232
or later n=993
P-value  0.095*  0.001*  <0.001*  0.002†  –  0.002† –
Table 2. Abacavir discontinuation due to any reason or due to hypersensitivity reaction within 3 months according to the line of 
therapy within which abacavir was received
P-values obtained from *χ2 tests and †univariable Poisson regression models. CI, confidence interval; HSR, hypersensitivity reaction; PYFU, person-years of follow-up.
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total of 111 (3.4%) patients died on abacavir therapy 
or within 1 month of a non-HSR related discontinua-
tion. Of these, 55 had specific non-HSR-related causes 
of death recorded and of the remaining 56 patients, 33 
had a previous AIDS diagnosis and 36 had received at 
least two or three PI/NNRTI-containing regimens prior 
to the abacavir regimen. Among these 111 patients, 15 
died within 3 months of starting abacavir. The investi-
gators classified 13 of these 15 deaths as due to specific 
and mainly AIDS-related causes rather than as a result 
of HSR. Non-AIDS-related causes of death included 
myocardial infarction and complications in hepatitis 
infection. The two remaining patients had unknown 
causes of death, but both died with low CD4+ T-cell 
counts of 106 cells/mm3 and 120 cells/mm3.
Discussion
In  this  cohort  of  3,278  HIV-1-infected  patients  who 
started abacavir across Europe, the incidence rate of 
abacavir  discontinuation  for  any  reason  (including 
HSR) was 30.9 (95% CI 29.6–32.2) per 100 PYFU. 
In line with the 4–8% incidence found in other stud-
ies  [1–5],  the  incidence  of  abacavir  discontinuation 
due to HSR within 3 months was 22.1 (18.7–25.4) per 
100 PYFU and this occurred in 5.1% of patients who 
n
Discontinued abacavir
due to any reason, n (%)
Discontinued due to HSR:
of all discontinued, n (%)
Discontinued due to HSR:
of all started, %
Total PYFU
PYFU up to 3 months
South
929
593 (63.8)
54 (9.1)
5.8
1,861
216
Central West
938
659 (70.3)
53 (8.0)
5.7
2,130
214
North
1,164
715 (61.4)
45 (6.3)
3.9
2,372
271
East
247
134 (54.3)
15 (11.2)
6.1
440
57
P-value
–
<0.001
0.127
0.126
–
–
25
20
15
10
5
0
30
35
40
45
50
I
n
c
i
d
e
n
c
e
 
p
e
r
 
1
0
0
 
P
Y
F
U
 
(
9
5
%
 
c
o
n
f
i
d
e
n
c
e
 
i
n
t
e
r
v
a
l
)
Discontinuation due to
HSR within 3 months
Any discontinuation P=0.797
P=0.114
Figure 1. Abacavir discontinuation due to any reason or due to hypersensitivity reaction within 3 months according to EuroSIDA region
HSR, hypersensitivity reaction; PYFU, person-years of follow-up.
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started the abacavir treatment. This analysis assessed 
the incidence of HSR across different patient subsets 
in a heterogeneous population from centres all across 
Europe with a standardized data collection and check-
ing system, as well as investigating the factors associ-
ated with abacavir-related HSR, which is important to 
identify patients with the highest risk.
One of the main findings was that the adjusted HSR 
incidence  rate  was  found  to  be  twice  as  high  when 
abacavir was started as part of a first-line regimen com-
pared with a second-line regimen. This supports research 
that showed a 42% decreased risk in patients with prior 
treatment  experience  [25].  Patients  starting  therapy 
for the first time might be more likely to be clinically 
diagnosed with suspected HSR, however, this might not 
reflect the incidence of true HSR cases. New patients 
could be more likely to report all symptoms experienced 
due to anxiety about starting treatment, whereas more 
experienced patients might not mention the more minor 
symptoms. This could result in physicians misdiagnos-
ing HSR more often in patients starting first-line therapy 
to ensure that no true HSR cases are missed.
It is well-established that the HLA-B*5701 allele is 
associated  with  long-term  non-progression  of  HIV 
n
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Figure 2. Abacavir discontinuation due to any reason or due to hypersensitivity reaction within 3 months according to date of 
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[28–30] and is linked to abacavir-related HSR in many 
studies [11–15]. Therefore, patients with this allele may 
be under-represented in the groups starting abacavir in 
second-,  third-  and  fourth-line  therapy,  which  could 
explain the increased incidence in the group starting a 
first-line regimen. It is more often found in Caucasian 
patients than in non-Caucasians [12–14], however, no 
significant association between white ethnicity and risk 
of HSR was found in this analysis and so ethnicity was 
ruled out as a potential confounder. This could be due to 
limited data as there were few non-Caucasians who dis-
continued due to HSR in this study (9 patients, 4.7%).
There was no evidence of a significant regional differ-
ence in abacavir discontinuation due to HSR within the 
first 3 months in this analysis. The frequency of HLA-
B*5701 is known to vary across different populations 
and differences in frequency have been found across 
Europe [31]. Therefore, a possible explanation for this 
finding is that in areas of low prevalence of the allele, 
there could be more cases of clinical over-diagnosis of 
suspected HSR resulting in an overall similar incidence 
of abacavir HSR between regions.
A significantly higher incidence rate of HSR was found 
in earlier years compared with 2005 onwards. A reason 
for this could be that more clinics are using prospective 
genetic screening, which has been shown to effectively 
reduce the incidence of HSR by preventing the prescrip-
tion of abacavir to those at high risk [11,14,15,17–21]. 
Also, as HSR symptoms are now better-documented, it 
could be more recognizable and therefore correctly iden-
tified more frequently, reducing the chance of over-diag-
nosis. If symptoms were misclassified as HSR in earlier 
years, this could explain the decrease in recent years.
A  decreased  incidence  of  abacavir  discontinuation 
due to HSR within 3 months was observed in patients 
starting Kivexa® compared with those starting Ziagen® 
or Trizivir®. All known, measured variables that could 
potentially confound  the results were investigated but a 
difference remained after adjustment. This could be due 
to the relatively small number of person-years available 
for the Kivexa® group and the small number of events 
during  this  time.  Therefore,  these  results  should  be 
treated with caution.
Severe abacavir-related HSRs, which can lead to death, 
are rare but have been reported in a few case studies 
[7–9]. In this analysis, there were no reports of patients 
who discontinued abacavir due to HSR and then died 
within 1 month. Patients who died on abacavir therapy 
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Figure 3. Multivariable incidence rate ratios and 95% confidence intervals of abacavir discontinuation due to hypersensitivity 
reaction within 3 months
HSR, hypersensitivity reaction; IRR, incidence rate ratios; PYFU, person-years of follow-up. 
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or within 1 month after stopping mostly had advanced 
disease with known non-HSR causes of death. This sug-
gests that any patients with severe reactions to abacavir 
were taken off the drug promptly to prevent fatality.
The main potential limitation of these analyses is that 
there could be bias in the reporting of reasons of discon-
tinuation. The definition of HSR is unclear as it includes 
a  combination  of  clinical  symptoms.  The  incidences 
reported in this analysis are therefore made on the basis 
of a practical ‘real life’ approach to the diagnosis of HSR 
and could possibly reflect clinical diagnosis rather than 
true HSR. Examination of the data did not show any 
major differences in reported HSR between centres, sug-
gesting that reporting bias across centres was minimal 
(results  not  shown).  Furthermore,  the  EuroSIDA  fol-
low-up forms only collect one reason for discontinuation 
per drug and some patients may experience more than 
one toxicity, which could mean that HSR is not always 
reported. The forms also allow ‘patient’s wish’ and ‘phy-
sician’s decision’ as reasons for discontinuation, which 
could result in misclassification of HSR.
Another limitation is that EuroSIDA does not collect 
information on genetic screening. Thus, it is unknown 
if patients were tested for HLA-B*5701 and prescribed 
abacavir according to results. There is also no informa-
tion on CD8+ T-cell count so it was not possible to look 
at any association between this and HSR. Although it is 
assumed in this study that all deaths are recorded on the 
follow-up forms, it is possible that some were missed. 
Causes of death could also be misclassified or coded dif-
ferently in different centres. The introduction of the CoDe 
(‘Coding  of  Death  in  HIV’)  project  in  cohort  studies 
(details at www.cphiv.dk) has helped to standardize the 
approach to collecting and reviewing causes of death.
In summary, incidence of abacavir discontinuation 
due to HSR appears to be higher in patients starting 
abacavir as part of first-line therapy, which might be 
explained by increased clinical over-diagnosis. Incidence 
of abacavir HSR has decreased in recent years, suggest-
ing that prospective genetic screening, improved patient 
care and awareness of the symptoms of HSR may have 
prevented the use of this drug for high-risk patients. 
There appears to be a similar rate of abacavir discon-
tinuation due to HSR across Europe. Patients starting 
the coformulation drug Kivexa® which was introduced 
in January 2004, appear to have a decreased risk to 
those  starting  Ziagen®  or  Trizivir®;  however,  limited 
data are available for the use of Kivexa® and so results 
remain preliminary. There were no reported deaths due 
to abacavir HSR in this analysis.
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